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Abstract 
The design, synthesis and biological evaluation of novel steroidal inhibitors of 17 β-
Hydroxysteroid dehydrogenase type 1 which converts estrone into the highly potent 
estrogen, estradiol, is described. This isozyme has been implicated as a new drug 
target against hormone-dependent tumours which are stimulated by increased levels 
of estradiol. 
Initial targets were planned, around modifications of the steroidal estrone / estradiol 
core, utilising Mannich, Friedel-Crafts and amide coupling chemistry. When the 
biological activity of these compounds was evaluated in a cell-based 17β-HSD1 
assay, significant inhibitory action was observed. The most potent compound was 
(13S)-3-hydroxy-13-methyl-2-(morpholinomethyl)-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 128 with an IC50 of 723 nM, 128 was 
also shown to be selective for 17βSHD1 over 17β-HSD2 and does not display any 
cytotoxicity at 50 µM over a 96 hour period in estrogen receptor positive and 
estrogen receptor negative cells. 
A C16 extended linked and reverse amide series were synthesised, for which design 
was based upon STX1040 1 the most potent inhibitor in the literature. The most 
biologically active compound was N-(((13S,16R,17S)-2-ethyl-3,17-dihydroxy-13-
methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-3-yl)acetamide 186 with a percentage inhibition of 81% at 10 
µM. Similar biological activities were observed for the rest of this series, however 
these values are approximately 20% lower than those observed for STX1040 1. 
Quantities of H6-17β-HSD1 were successfully synthesised and purified for use in 
development of a novel MTS/PES recombinant protein assay, to assess the inhibitory 
potential of the novel steroidal compounds described and their modes of binding with 
the active site of 17β-HSD1. For these experiments it can be tentatively concluded 
that STX1040 1 acts a mixed site inhibitor for both the E2 and co-factor binding sites 
and the 2-substituted Mannich compound 127 acts as a competitive inhibitor for the 
E2 binding site and a non-competitive inhibitor for the co-factor binding site, 
however further experimentation is required to confirm these preliminary results.  
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Chapter 1 
Introduction 
1.1 Hormone Dependent Cancers 
With the development of new medicines designed to fight off disease and infections, 
the average life expectancy of people within developed countries has almost doubled 
since the mid-nineteenth century. Whilst these medical advances have led to an 
improvement in the quality of life for most people, therefore people being diagnosed 
with cancer is becoming more common. Cancer occurs predominantly in older 
people, with 64% of cases diagnosed in people aged 65 and over, and more than a 
third of cases in people aged 75 and over. In the UK, over 280,000 people were 
diagnosed with cancer in 2004. Four types; breast, lung, bowel (colorectal) and 
prostate, account for over half of all new cases of cancer.
1
 Of all human cancers, 
40% are steroid hormone sensitive, (namely breast, prostate, ovarian and uterine 
cancers).
1
  
1.2 Breast Cancer Statistics 
Breast cancer is now the most commonly diagnosed cancer in the UK, with nearly 
46000 women and around 300 men diagnosed each year with the disease.
2
 One in 
nine women in the UK will develop breast cancer at some point in their life. Over the 
last twenty years breast cancer rates have increased by over 50% and over four out of 
five of all breast cancer cases in the UK are in women over the age of 50, most men 
diagnosed with breast cancer are over the age of 60.
1,3
 It is known that only one in 
twenty of breast cancers are due to inherited faults in known breast cancer genes, e.g. 
BRCA2, which lead to a high risk of developing the disease.
2 
1.3 Current Breast Cancer Treatments 
Once the staging of the cancer has been determined there are a number of treatment 
options available for early breast cancer. Local treatments, surgery and radiotherapy, 
aim to remove the cancer from the breast and auxiliary lymph nodes. Systemic 
treatments e.g. chemotherapy, endocrine therapy and biological therapies, for 
example Herceptin, enter the blood stream and circulate throughout the body to 
destroy any cancer cells which might have metastisised from the original site. Most 
patients with early breast cancer will be offered surgery. However, sometimes 
patients have other significant illnesses or conditions that mean surgery is not a 
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suitable option. In this situation the patient might be offered endocrine or biological 
therapy. 
1.3.1 Endocrine Therapy 
Endocrine therapy is usually less toxic than chemotherapy but the patients’ response 
to treatment tends to be slower in onset. Endocrine therapy is appropriate for 
approximately 70% of patients who have hormone receptor positive advanced breast 
cancer.
3
 To determine this, a clinical pathologist will measure whether or not breast 
cancer cells are hormone sensitive. This is known as an estrogen receptor (ER) test. 
Although not used in combination with chemotherapy e.g. cisplatin, endocrine 
therapy is in certain circumstances combined with biological therapy, although high 
quality evidence to justify this is lacking. Many patients will have received adjuvant 
endocrine therapies with either tamoxifen or an aromatase inhibitor for primary 
breast cancer prior to developing advanced breast cancer and some patients may 
relapse whilst still taking them. There is currently no evidence on the most 
appropriate endocrine treatment for patients who have received prior treatment with 
aromatase inhibitors.
3
 Other endocrine therapies include ovarian ablation for 
premenopausal women and fulvestrant (Figure 1) for postmenopausal women.  
 
Figure 1: Selective Estrogen Receptor modulators that are currently in the clinic 
1.4 Estrogen and Androgen Biosynthetic Pathway 
The androgen and estrogen biosynthetic pathway is an attractive and challenging area 
for research into the discovery of potential new medicines to combat the two major 
hormone dependant cancers: breast and prostate. There are many different enzymes 
involved in the biosynthesis of both dihydrotestosterone (DHT) and estradiol (E2) 
from their less active forms, testosterone (T) and estrone (E1). These enzymes 
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include: steroid sulphatase, 3β-hydroxysteroid dehydrogenase (3β-HSD types 1 and 
2), 5α-Steroid reductase (5α-SR types 1 and 2) and several members of the 17β-
hydroxysteroid dehydrogenase family.
4
 (Figure 2) 
3β-HSDs are a group of steroidogenic enzymes. The main steroidogenic isoform, 3β-
HSD1, catalyzes the conversion of pregnonolone to progesterone, the conversion of 
17-hydroxypregnenolone to 17-hydroxyprogesterone and the conversion of 
dehydroepiandrosterone (DHEA) to androstenedione (Δ4-dione). 3β-HSD1 is mainly 
expressed in the gonads and adrenal cortex.
5
   
Human 5α-SR is a NADPH dependent enzyme which occurs as two isozymes with 
similar molecular weights but only 50% sequence homology. These isozymes exhibit 
different pH rate profiles: 5α-SR1 predominates in skin and 5α-SR2 predominates in 
the prostate and genital skin.
6
 5α-Dihydrotestosterone (DHT), formed from 
testosterone (T) by 5α-SR1 and 5α-SR2, is the main intracellular androgen in the 
prostate, and stimulates the growth of hormone-dependent prostate tumours via its 
interaction with the androgen receptor.
7
  
 
Figure 2: Biosynthetic pathway of Estrogens and Androgens 
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HSDs play a pivotal role in the local production of steroid hormones in target tissues 
(intracrine modulation). It has been stated that the intracrine formation of steroid 
hormones is of relevance to the aetiology of steroid dependent breast and prostate 
cancer. A number of enzymes play a key role in the local production of estradiol (E2) 
in the breast. Estrone (E1) is formed from DHEA via a series of enzyme catalysed 
reactions by 3β-HSD/ketosteroid isomerase (KSI) and cytochrome P450 aromatase 
(CYP arom).
8
 Most of this E1 can be stored locally in the breast as in active estrone 
sulphate, which can then be converted by estrogen sulphatase back into the weak 
estrogen estrone.
9
 Once this free estrone is formed it will be reduced by 17β-HSD1 
into the potent estrogen estradiol which then can interact with the ER to accelerate 
cell proliferation. The ability of the 17β-HSDs to be able to convert androgens and 
estrogens to both active and inactive forms makes this particular family of enzymes a 
very attractive therapeutic target. 
1.5 Estrogen Receptor (ER) 
Estrogen receptors (ERs) are proteins within breast cancer cells to which estrogen 
binds and then helps the cancer cells to grow. The ER is a protein that is present in 
nearly two thirds of breast tumours. The ER is also a protein that integrates signals 
from numerous cell signalling pathways.
10
 Estrogenic hormones act via the ER and 
this makes the ER the most widely targeted protein in breast cancer therapy. The 
most well known drugs for targeting the ER are selective ER modulators (SERMs). 
SERMs are composed of a broad range of compounds. Compounds such as 
fulvestrant block estrogen action in all tissues, whereas other compounds such as 
tamoxifen (Figure 1) are mixed agonistsantagonists that show distinctive tissue 
selectivity in blocking or stimulating estrogen responses.
10
 Studies have shown that 
there are risks associated with long term use of SERMs one of these is that there can 
be an increased risk of developing endometrial cancer, uterine cancer, strokes and 
blot clots. However some women are prepared to take this risk as they are far 
outweighed by the potential benefits of using SERMs for breast cancer treatment.  
Although SERMs are very useful in breast cancer prevention and treatment they are 
not effective in all ER positive breast tumours and resistance can often develop as 
well as undesired side-effects such as venous thromboembolism.  
The ER exists in two forms: ER-α and ER-β; these two different forms are encoded 
by different genes on different chromosomes. Both of these forms belong to the large 
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nuclear steroid/thyroid hormone receptor family of ligand dependant transcription 
factors. Like the majority of the other members of the family, the ERs have a 
modular architecture of four domains, the N-terminal A/B domain containing the 
ligand-independent transcription activation function-1 (AF-1), the C (DNA-binding) 
domain, the D (hinge) domain, and the C terminal E/F (ligand-binding) domain 
containing the ligand-dependent transcription activation function-2 (AF-2).
11
 While 
ER-α and ER-β have nearly identical DNA binding domains, these receptor subtypes 
have only 56% amino acid sequence identity in their hormone binding domains and 
differ even more markedly (only 21% amino acid identity) in their N-terminal 
activation function-1 (AF1) regions.
10
 These differences in identity suggest that there 
should be different ligands that would have differing levels of potency or efficacy for 
each of the two ERs. Estrone has only a low affinity for the ER and has to undergo 
pre-receptor activation by 17β-HSD1 to reduce it to E2 in order to bind with the ER 
with high affinity (Figure 1).
12
 For this reason 17β-HSD1 is a very attractive 
potential target for the treatment of breast cancer. 
1.6 17β-HSDs 
It has been reported that there are 15 types of 17β-HSDs known.13-28 The 17β-HSDs 
belong to two protein superfamilies: the short-chain dehydrogenase/reductase (SDR) 
protein superfamily and the aldo-ketoreductase (AKR) protein superfamily. All of 
the 17β-HSDs with the exception of 17β-HSD5 belong to the SDR protein 
superfamily and 17β-HSD6 and 9 have only been identified in rodents. Six of the 
isozymes have been structurally characterised, namely, 1, 4, 5, 10, 11 and 14. Both 
the oxidative and reductive reactions in vitro, in vivo they have preferred 
directionality and can therefore be classified into two categories: a) oxidative 
enzymes (17β-HSD2, 4, 6, 8, 9, 10, 11, 13 and 14), which catalyse the NADP+ 
dependent oxidation in vivo and therefore the inactivation of steroids, and b) 
reductive enzymes (17β-HSD1, 3, 5, 7 and 15), which catalyze the NADPH 
dependent reduction of ligands in vivo forming active steroid hormones.
29
 Although 
most of the isozymes are capable of catalysing SDRs constitute a large family of 
oxidoreductases, present in all forms of life. The SDRs are mainly multimeric 
enzymes with a monomer molecular mass of ~32 kDa of typically about 250-300 
amino acid residues. The enzymes of the SDR family are non-metallo 
oxidoreductases that exhibit only 15-30% sequence identity.
30-32
 Despite low 
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sequence identity there are two regions present in these enzymes that are highly 
conserved. The first of these highly conserved regions contains a Tyr-X-X-X-Lys (X 
is any amino acid) catalytic motif. The second of these regions is an area of 
alternating α-helices and β-strands, known as a Rossmann fold.31 The Rossmann fold 
is responsible for creating the co-factor, nicotinamide adenine dinucleotide 
(NADPH), binding region.
30
 Despite this structural conservation, substrate 
specificities among family members are diverse and for some 17β-HSDs substrates 
such as fatty acids or bile acids are preferred over sex steroids. Herein the main 
points in the literature with regard to 17β-HSD1 and 17β-HSD3 shall be described, 
as these are the enzymes upon which this research is based. 
1.6.1  17β-HSD1 
17β-HSD1 is the primary enzyme responsible for catalysing the reduction of the 
carbonyl at the 17 position (Figure 3) of the in active estrogen E1 to the highly active 
estrogen E2 using NADPH as a co-factor. 17β-HSD1 is also responsible to a lesser 
extent for the reduction of androstenedione to testosterone.  
 
Figure 3: Numbering system of the steroid backbone for E1 
17β-HSD1 was the first of the 17β-HSDs to be cloned and have its structure 
elucidated.
33, 34
 The core of the structure is a seven stranded, parallel β-sheet (βA to 
βG), surrounded by six parallel α-helices (αB to αG), three on each side of the β-
sheet. The first structure of 17β-HSD1 has shown that the enzyme has the folding 
characteristics of a SDR, with Tyr155, Lys159 and Ser142 constituting the catalytic 
triad of the enzyme.
35
 The steroid binding site is a narrow hydrophobic tunnel that 
shows a high degree of complimentarity to the substrate.
36
 In humans, 17β-HSD1 is 
predominantly expressed in the cytosol of steroidogenic tissue particularly ovaries, 
breast and placental tissue.
30
 The proposed catalytic mechanism is shown in Figure 4 
and depicts the transfer of the Pro-S hydrogen of the NADPH co-factor to the natural 
substrate E1 and therefore, forming the natural product E2. 
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Figure 4: Hypothesised catalytic mechanism of 17β-HSD1. The substrate E1 is in 
blue, the co-factor NADPH is in red and the amino acids involved in either the 
stabilization of the ligands or the catalysis of the enzyme are shown in black and the 
residue is labelled.
37 
Although both 17β-HSD1 and 17β-HSD2 are present in healthy pre-menopausal 
women, several studies have indicated that the ratio of 17β-HSD1 to 17β-HSD2 is 
increased in the tumours of post-menopausal patients with hormone-dependent breast 
cancer.
38, 39
 This results in an increased level of E2 which exerts estrogenic effects by 
binding with the ER, which leads to a proliferative effect, in turn accelerating tumour 
growth.
6
 Hence, a specific 17β-HSD1 inhibitor would potentially lower the levels of 
E2 present in the mammary gland by competing with the natural substrate E1, and 
consequently the proliferative effects exhibited on hormone dependent breast cancer. 
Several studies have indicated that patients with tumours that have high 17β-HSD1 
expression have significantly shortened disease free survival.
40-42
 There is a lot of 
research into the discovery of novel inhibitors for this particular enzyme with many 
reversible and irreversible inhibitors having been reported in the literature.
4, 6, 43-47
 It 
has been shown that the University of Bath drug candidate, STX1040 1 (Figure 5), 
inhibited E1 stimulated proliferation of T-47D cells in vitro and significantly 
decreased tumour volumes and plasma E2 levels in vivo.
43
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Figure 5: Structure of STX1040, 2-Ethyl-16β-m-pyridyl methyl amido methyl 
estrone 1 
Day et al.
48
 and Laplante et al.
49
 have shown that in T-47D cells despite the low level 
expression of 17β-HSD1 mRNA (~3%), compared to other reductive isoforms 7 and 
12 (~50%), is responsible for the high transformation rate of E1 to E2. Laplante et al. 
have also shown that 17β-HSD1 is the only enzyme responsible for the formation of 
E2 in BT-20 and JEG-3 cell lines, and in HEK-293 cells 17β-HSD1 is the most 
effective enzyme for the conversion of E1 to E2 with an average 90% transformation 
after 24 h.
48, 49
 Demonstrating that inhibitors designed for 17β-HSD1 and not 
isoforms 7 or 12 may well have a future in the treatment of hormone dependent 
breast cancer. 
1.6.2  17β-HSD2 
17β-HSD2 catalyzes the NADPH dependent conversion of E2, T and 5α-
dihydrotestosterone to their less potent forms E1, Δ4-dione and 5α-androstenedione 
respectively. Its cDNA encodes for a predicted protein containing 387 amino acids 
with a molecular mass of 42.8 KDa. It is a member of the SDR protein superfamily 
and shares a sequence identity of approximately 20% with 17β-HSD1 cDNA.50 17β-
HSD2 is widely expressed in both adult and fetal tissues such as; placenta, uterus, 
liver, gastrointestinal and urinary tracts.
51-54
 Due to the fact that 17β-HSD2 is 
expressed in such a wide variety of tissues it has been suggested that its main role is 
to protect tissues from excessive steroid action.
55 
1.6.3  17β-HSD3 
17β-HSD3 catalyzes the NADPH dependent reduction of Δ4-dione to T in the gonads 
and is responsible for supplying around 50% of T in the prostate.  
The 17β-HSD3 isozyme is membrane bound and consists of 310 amino acids, with a 
molecular mass of ~34.5 KDa.
35
 17β-HSD3 is bound through an N-terminal 
transmembrane domain to the endoplasmic reticulum, and the hydrophobic nature 
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has thus far prohibited its structure determination and even soluble expression in cell 
lines that do not normally express 17β-HSD3.30 It uses NADH as a co-factor, and the 
equilibrium favours the reduction of Δ4-dione to T, which is then converted by 5α-
steroid reductase to the most potent androgen, DHT (Figure 2). This reaction occurs 
in the Leydig cells of the testis under the control of the pituitary hormones.
56
 
Crystallisation is difficult as the protein has to be removed from the membrane prior 
to crystallisation, which can alter the tertiary structure. Stabilisation of the protein 
tertiary structure by adding detergents is a method sometimes used to crystallise such 
proteins, but to this date this has not been successful for 17β-HSD3.57  
Currently, little is known about the mechanisms that control the expression of 17β-
HSD3 however specific mutations of this enzyme are identified in patients with male 
pseudohermaphroditism.
30
 These patients are phenotypically characterized by the 
lack of normal development of male reproductive organs,
16, 57
 thus proving that 17β-
HSD3 plays an essential role in the development of normal male genitalia. 
1.6.4  17β-HSD5 
The main biosynthesis of T occurs in the testes by 17β-HSD3. However T 
biosynthesis occurs to some extent in the prostate for which 17β-HSD5 is 
responsible. 17β-HSD5 is the only 17β-HSD that is a member of the AKR protein 
superfamily and is also known as AKR1C3, and shows a broad substrate specificity 
allowing it to display activity for 3α-HSD, 20α-HSD and prostaglandin 11-
ketoreductase (prostaglandin F synthase).
58, 59
 17β-HSD5 is highly expressed in the 
testes and extragonadal tissues such as basal cells of the prostate, adrenals and 
liver.
60
 It preferentially catalyzes the NADPH dependent reduction of Δ4-dione to T 
and to a lesser extent DHEA to Δ4-dione.61 17β-HSD5 consists of 323 amino acids 
with a molecular mass of ~ 30 KDa. The 17β-HSD5 binding site is spacious (~960 
Å
3
 or ~470 Å
3
 depending on the substrate) and flexible when compared to that on 
17β-HSD1 (~340 Å3). This flexibility of the binding site permits the docking of 
various steroids in different orientations, which in turn encompasses a wider range of 
activities as described earlier. It has been suggested that 17β-HSD5 is responsible for 
the biosynthesis of T in females as 17β-HSD3 is not present in the ovary, which is 
the location of androgen synthesis in women.
62
 As 17β-HSD5 is involved in the 
biosynthesis of androgens, along with 17β-HSD3, it is an emerging therapeutic area 
for the treatment of prostate cancer. The crystal structure of 17β-HSD5 has been 
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determined both alone and in complex with a variety of ligands providing an 
excellent basis for inhibitor development.
29 
1.6.5  17β-HSD7 
In humans 17β-HSD7 is expressed in steroidogenic tissues such as the testes or 
ovaries for non-pregnant women including the uterus, placenta, mammary glands, 
prostate liver, kidney as well as in neural tissue.
63  
It is responsible for catalysing the 
reduction of E1 to E2, and converts the potent androgen DHT to androstanediol (3β-
diol) an ER ligand.
64
 Unlike other mammals in which 17β-HSD7 is part of the 
pregnancy process,
65, 66
 its precise role within humans has yet to be determined. Due 
to its dual enzymatic activity and wide distribution it is believed that 17β-HSD7 acts 
as an intracrine regulator of steroid metabolism.
67 
However, this has yet to be proven 
and its predominant role in vivo is thought to be in cholesterol synthesis.
68 
1.6.6  17β-HSD12 
A study from Luu-The et al.
27
 suggested that 17β-HSD12, originally thought to be 
exclusively involved in fatty acid elongation may also be an important enzyme 
responsible for the conversion of E1 to E2.
69
 Results from a further study by the 
same group indicated that it is up-regulated in the tumours of breast cancer patients.
63
 
It has been shown that 17β-HSD12 is present in steroidogenic tissues such as breast, 
ovary and prostate but not to the same level of expression as in active lipid 
metabolizing tissues such as liver, kidney, heart and skeletal muscle as well as in the 
placenta and testis, further supporting its role as a regulator of fatty acid 
biosynthesis.
70
 Studies by Day et al.
48
 and Laplante et al.
49
 confirm that 17β-HSD1 
and not 17β-HSD12 is responsible for the high transformation rate of E1 to E2 in a 
variety of breast cancer cell lines. 
1.7 Inhibitors of 17β-HSD1 a Review of the Literature 
In recent years there has been a significant increase in the number of patents and 
publications concerning 17β-HSD1 inhibition, as the pharmaceutical industry has 
recognised the potential for development of 17β-HSD1 inhibitors as a treatment for 
hormone dependent breast cancer. The majority of known inhibitors in the literature 
are based upon modifications of the estrone steroid core. However there has been a 
concerted effort over the last couple of years in the research of non-steroidal 
inhibitors. As of this time there are no 17β-HSD1 inhibitors on the market. 
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Inhibitors of 17β-HSD1 should be selective against 17β-HSD2 and importantly 
should display no estrogenic effects. Activity against other E1 converting enzymes or 
antiestrogenic effects can be seen as a desired extra benefit. Good inhibitors should 
exhibit certain drug-like properties. Lipinski et al.
71
 describe a series of criteria that 
an orally active compound should have, these are; no more than five hydrogen bond 
donors or ten hydrogen bond acceptors. A molecular mass of less than 500 gmol
-1
 
and a partition co-efficient (log P) of less than five. If an inhibitor meets these 
criteria it is theoretically deemed to have the necessary properties required to have 
sufficient absorption and permeation in biological systems. A good 17β-HSD1 
inhibitor will have an IC50 value in the low nM range or a high percentage inhibition 
in µM test concentrations. 
In this review inhibitors with modifications of the E1 and E2 steroid core will be 
discussed first and non-steroidal inhibitors will be discussed afterwards. 
1.7.1 Steroidal Inhibitors of 17β-HSD1 
Steroids represent a broad class of naturally occurring compounds that play crucial 
roles in the homeostasis of biological systems. In humans, the different families of 
steroidal hormones, such as progestins, glucocorticoids, androgens and estrogens all 
originate from endogenous and exogenous cholesterol. The majority of 17β-HSD1 
inhibitors are based upon steroid structures, particularly the natural substrates of 17β-
HSD1 E1 and E2. The E1 and E2 scaffold can be conveniently used to investigate 
how substitution at varying positions of the steroid core affect the binding affinity of 
inhibitors and can then used to develop structure activity relationships (SAR). The 
following sections introduce steroidal 17β-HSD1 inhibitors, which are divided into 
classes based upon the position where the modification is attached to the steroidal 
core. 
1.7.1.1  Derivatives of E1 and E2 Substituted at C2 
Substituents at the C2 position of the E1 or E2 core were introduced to try and 
increase selectivity for 17β-HSD1 over 17β-HSD2 as well as reduce any possible 
estrogenic effects. Hillisch et al.
72
 and Gege et al.
73
 together with Schering have 
patented a series of 2-substituted E1 and 2-substituted D-homo E1 compounds as 
selective 17β-HSD1 inhibitors (Figure 6).  In a human recombinant 17β-HSD1 assay 
2-phenylethynylestrone, 2 and 2-phenylethylestrone, 3 showed good inhibitory 
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activity with an IC50 value of 56 nM and 47 nM respectively, this indicates that bulky 
substituents at the C2 position are well tolerated by the active site. Other 2-
substituted E1 derivatives showed good inhibitory data. The compound, 2-
chloroestrone, 4 showed promising activity with an IC50 value of 140 nM. The 
activity of 4 was improved by the addition of either C18 methyl, 5 or C16 fluorine, 6 
and 7 group. The stereochemistry of the C16 fluoro group plays an important role in 
how the inhibitor binds to the active site of 17β-HSD1. When the fluoro group points 
to the α-face of the steroid core the activity of the inhibitor, 7 marginally increases, 
however when the fluoro group points to the β-face of the steroid core the IC50 
increases from 140 nM to 35 nM which is the most potent inhibitor, 6 described 
amongst the 2-substituted estrone inhibitors.
72
 
 
Figure 6: Derivatives of E1 and E2 with varying substitution patterns on C2
72, 73 
Replacing the estrone core with a D-homoestrone core resulted in an increase in 
activity for the majority of the compounds.
73 
The D-homoestrone inhibitors with a 
halogen in the C2 position are very potent inhibitors, 8-10. The activity of the C2 
halogenated D-homoestrone series shows again that bulky groups are well tolerated 
within the active site. An interesting observation is that unlike in the native E1 series 
when a fluoro group is introduced alpha to the carbonyl the 2-chloro-17-β-fluoro 
compound 12 displays a lower activity and the 2-chloro-17-α-fluoro compound 11 
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has a higher activity. This is due to the change of position of the fluoro group within 
the active site. 
 
The best D-homoestrone inhibitors were the 2-substituted, 2-
phenylethyl-D-homoestrone 14 and 2-allyl-D-homoestrone 13 with IC50 values of 15 
nM and 24 nM respectively. For comparison the natural substrate E1 showed an IC50 
value of approximately 300 nM.  
No estrogenicity or selectivity data has been reported for either the E1 or the D-
homoestrone series. The C2 substitution is likely to reduce if not prevent any 
cytochrome P450 (CYP) 1A1, 1A2, 3A4 and 3A7 interaction with these compounds. 
The 2-position is a well-known major oxidative metabolic pathway, namely by 
hydroxylation, and the CYP isoforms stated earlier have a uniquely high activity for 
this position.
74 
1.7.1.2  Derivatives of E1 and E2 Substituted at C6 
Several groups have synthesised compounds based upon E1 and E2 with substituents 
at the 6-position of the steroid core. Allan et al.
75
 explain that their interest in the 6 
position of E1 arose after computational investigation of how E1 binds in the active 
site of 17β-HSD1 using the crystal structure of 17β-HSD1 with E2 and NADP (PDB 
code 1FDT).
76, 77
 Their investigation suggested that a small hydrogen bond acceptor 
at the 6 position could potentially capitalise on beneficial interactions with the 
hydroxyl group of Ser222. They decided that a carbonyl group would be of a 
sufficient size to make use of this potential interaction and subsequently synthesised 
6-oxo estrone 15 and two other oxidised forms 16 and 17 of previously reported 
potent inhibitors of 17β-HSD1 (Figure 7).78 
 
Figure 7: 6-Oxo derivatives of E1
75 
Presence of the 6-oxo substituent does not significantly enhance the activity of the 
compound compared to that of the natural substrate. These results show that the 6-
oxo substituent is well tolerated within the active site of 17β-HSD1 but does not 
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increase the binding affinity and therefore does not interact with the hydroxyl group 
of Ser222. 
The investigation into position 6 of the steroid core was expanded by the synthesis of 
oxime derivatives 16-17, with the aim of further investigating the SAR around 
position 6 by retaining a similar hydrogen bond acceptor. The oxime group was 
chosen because it could be easily introduced in one step without having to protect the 
3-hydroxyl to give the compounds in Figure 8. 
 
Figure 8: Oxime derivatives of 6-oxo E1 
The biological data for the oxime derivatives 18-19 shows that the oxime group is 
not well tolerated in the active site as 18 has an IC50 value of 1.90 µM that is 6 fold 
less active than the natural substrate E1. Compound 19 has a percentage inhibition at 
10 µM of 31%. Whether or not this reduction in binding affinity is due to the oxime 
groups in the 6 position or the 17 position cannot be conclusively determined. 
Poirier et al. have also reported the synthesis of 6-substituted E2 compounds. In their 
efforts to design potent inhibitors for 17β-HSD1 they developed a series of E2 based 
compounds containing a thia-alkanamide side chain at position 6
79-81
 based upon the 
pure antiestrogen 20, (Figure 9) which has a very moderate percentage inhibition at 1 
µM of 33% for 17β-HSD1 prepared from human placental cytosol.79 
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Figure 9: 6-Substituted E1 and E2 derivatives by Poirier et al.
83 
By moving the N-butyl-N-methyl alkyl amide side chain to C6 and optimising the 
side chain length to have five methylenes 21 instead of nine methylenes, the 
inhibitory activity was improved to give an IC50 value of 0.17 µM, twice as potent as 
E1. The compound with a 6β-side chain 29 is 70 fold more potent than the compound 
with a 6α-side chain 2879 showing that the orientation of the side chain is a key 
structural characteristic for the inhibition of 17β-HSD1 and shows that there is steric 
hindrance in the active site around C6 of the steroid scaffold. Compound 21 was 
unfortunately shown to display estrogenic activity.
82
 It was hypothesised that this 
activity was due to the instability of the thioether, where if cleaved yields estrogenic 
E2.
80
 From this hypothesis Tremblay et al.
80
 developed a series of inhibitors 22-27 
that potentially would be less liable to undergo modification by metabolising 
enzymes, by replacing the thioether with an ether. The biological activity of 22 was 
lower than that of the original thioether inhibitor 21 but the estrogenicity of the 
compound was considerably reduced.  It was also discovered that modifications of 
the 3-hydroxyl and the amide group of the initial lead compound 21 drastically 
reduced the biological activity of the inhibitors, therefore showing that the 3-
hydroxyl and amide group are key structural characteristics associated with 
biological activity. With regards to how these modifications altered the estrogenicity 
16 
 
of the compounds, the changing of the amide group did not alter the estrogenicity of 
the compound, but the alterations of the 3-hydroxyl showed a marked reduction in 
the estrogenicity of the inhibitors as was expected.
80
 Another strategy was developed 
for trying to reduce the estrogenicity of the lead compound 21, substitution at C2. 
Cadot et al.
81
 had limited success with this strategy due to instability of the thioether 
and only the 2-methoxy substituted compound 27 was tested. The effect of the group 
at C17 was also investigated in this work. For the 17-keto compounds it was 
observed that the biological activity was approximately 30% lower than that of the 
17β-alcohols, and the addition of the 2-methoxy group decreased the inhibitory 
activity by around 20%.
81
 Though structurally similar to the antiestogen 20 
compound 21 displayed a strong estrogenic effect in T-47D and MCF-7 cell lines.
80, 
81
 For compounds 22 and 24 the proliferative effect in T-47D cells was only seen at 
0.1 µM and 1.0 µM. As proposed the 2-methoxy substituted compound did not 
display any estrogenic activity on T-47D cells at 1.0 µM but a higher than normal 
cell growth was observed at lower concentrations.
81
 
1.7.1.3  Derivatives of E1 and E2 Substituted at C15 
Solvay Pharmaceuticals have patented C15 substituted E1 and 3-methoxy E1 
derivatives as 17β-HSD1 inhibitors.83, 84 These patents cover a series of compounds 
containing an amide, sulfonamide, urea, carbamate or hydroxyl side chain connected 
via an alkyl linker to C15 of the steroid backbone, and with additional substitution at 
C2. The biological activity of these compounds was assessed by using recombinant 
17β-HSD1 (rec17β-HSD1).83, 84 Messinger et al.85 focussed on the synthesis of E1 
derivatives based upon the hypothesis that the natural substrate should have a higher 
binding affinity for the active site of 17β-HSD1 than E2. Their decision to 
concentrate on C15 substitution was because substitution at C16 displays the 
undesired side-effect of being estrogenic.
85
 After analysis of the 17β-HSD1 X-ray 
crystal structure complexed with E2 occupying the active site (pdb code 1FDT)
76
 it 
was observed that the enzyme exhibits an opening towards the area located in the 
proximity of the steroid D ring. This opening is formed via the amino acids; Ser222, 
Leu219, Met193 as well as Tyr218, Leu96 and Gly198. It was reasoned that the 
position of these amino acids is highly flexible; due to the flexibility of the protein it 
is believed that substitutions on C16 can also penetrate the opening.
85 
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Figure 10: Selected examples of C15 substituted E1 derivatives patented by Solvay 
Pharmaceuticals
83, 84 
Archetypal inhibitor structures and their rec17β-HSD1 inhibitory activities are shown 
in Figure 10 and Table 1. The most potent of which is compound 37 displaying 87% 
and 93% inhibition at 100 nM and 1 µM concentrations respectively and having an 
IC50 of 4 nM. This set of data shows that for these types of inhibitor a large variety of 
side chains containing groups of differing polarity and size can be tolerated within 
the active site. Nevertheless some SAR rules can be established; 1) Compounds with 
a side chain length of 2 – 4 methylene units are generally preferred as demonstrated 
by the morpholino bearing side chain compounds 32-36. 2) A hydroxyl group at C3 
of the steroid core is not essential for the binding of these inhibitors. 3) 15α 
substitution can be well tolerated but these inhibitors tend to show a lower biological 
activity compared to the 15β compounds of a similar structure. The ability of 
compound 39 to inhibit 17β-HSD1 has been demonstrated in vivo in a nude mouse 
model.
86
 Inoculation of the mice with estrogen sensitive MCF-7 breast tumour cells, 
that expressed human 17β-HSD1 led to the growth of hormone dependent tumours. 
Subcutaneous administration of compound 32 (5 µM/kg/day) resulted in a 60% 
18 
 
reduction in size of the tumour compared to non-treated control animals. Less polar 
side chains show a tendency to reveal minor estrogenic activities, identified by 
estrogen receptor binding and uterine weight tests.
85 
Compound Recombinant 17β-HSD1 
 % Inhibition at 100 nM % Inhibition at 1 µM IC50 (nM) 
30 89 93 14 
31 42 85  
32 19 63  
33 27 79 194 
34 12 40  
35 17 68  
36 29 80  
37 87 93 4 
38 80 87 14 
39 77 89 26 
Table 1: C15 substituted E1 derivatives and their recombinant 17β-HSD1 inhibitory 
activity 
1.7.1.4  Derivatives of E1 and E2 Substituted at C16 
Interest in the C16 position was initiated by the discovery that E1 and E2 substituted 
with reactive halogenated functional groups, such as bromoacetoxy, were found to be 
irreversible inhibitors of 17β-HSD1.79 The bromoacetoxysteroids are traditionally 
used to affinity label the target enzyme.
87-89
 While such compounds have been 
extremely useful for the mapping of the active site of 17β-HSD190 they are 
ineffective as therapeutic reagents because of their high reactivity with nucleophiles. 
Despite the fact that these compounds could not be used for therapy these studies 
showed that C16 was a good location to introduce a modification for the inhibition of 
17β-HSD1. As stated earlier in this report, it was observed that the enzyme exhibits 
an opening towards the area located in the proximity of the steroid D ring. This 
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opening is formed via the amino acids; Ser222, Leu219, Met193 as well as Tyr218, 
Leu96 and Gly198. It was reasoned that the position of these amino acids is highly 
flexible and therefore expansion from C16 is an attractive option. From docking 
studies it is hypothesised that there is a possibility that a C16 side chain may interact 
with the co-factor binding site and therefore produce a dual site inhibitor. Poirier and 
co-workers had shown that large substituents at C16 of E2 were well tolerated,
91, 92
 
indicating that there is promise of developing a dual site hybrid inhibitor. The dual 
site inhibitors are very promising because these inhibitors can potentially interact 
with both the substrate (E1) and the co-factor (NADPH) binding sites, therefore 
making use of the binding energy of both moieties to produce an inhibitor that shows 
a very strong binding affinity for 17β-HSD1. Qui et al.93 were the first group to 
publish the structure of an E2-adenosine hybrid compound (Figure 11) in 2002. 
 
Figure 11: EM-1745 40 the first reported E2 adenosine hybrid inhibitor 
The E2 adenosine hybrid, EM-1745 40 show a strong biological activity against 17β-
HSD1 with an IC50 of 52 nM which was significantly improved over all previously 
available inhibitors and natural substrates,
93
 with the synthesis later described in 
2003.
94
 To optimise the affinity of each moiety with their respective binding sites, 
the hydroxyls of the steroid as well as the amine and secondary hydroxyl of the 
adenosine moiety must be free. Therefore the primary alcohol of the adenosine was 
retained for the formation of an ester bond with the C16 steroid side chain to give the 
lead compound EM-1745 40. As part of further research into this area Bérubé et al.
95
 
identified the synthesis of simplified hybrid inhibitors of 17β-HSD1 via cross-
metathesis and Sonogashira coupling reactions.
95
 Showing that hybrid inhibitors can 
be accessed in an efficient and rapid manner. Poirier et al.
96
 continued to explore the 
C16 substitution by investigating whether α / β substitution was optimal for 
biological activity and what the ideal spacer length was between the steroid and 
20 
 
adenosine moieties. Results from this research (Table 2) show that a β orientation 42-
46 is desired for optimal biological activity of the inhibitor with both the steroid and 
co-factor binding sites. A spacer length of 8 methylenes 46 was determined to be the 
ideal spacer length for the adenosine residue to interact efficiently with the co-factor 
binding site.
96 
 
Compound C16 Orientation Spacer length IC50 (nM) 
41 α 10 310 
42 β 10 120 
43 β 11 1000 
44 β 6 430 
45 β 7 93 
46 β 8 52 
Table 2: Modifications of the D ring substituent and their IC50 values as determined 
by a recombinant 17β-HSD1 assay100 
A protein crystal structure with EM-1745 40 occupying both the steroid and co-
factor binding sites at a resolution of 1.6 Å was reported by Qui et al.
97
 in 2002 (PDB 
code 1I5R) and several important observations have been noted: 1) The steroid core 
and adenine core of EM-1745 40 bind to 17β-HSD1 in a similar to that observed in 
the structure of 17β-HSD1-E2-NADP ternary complex. (PDB code 1FDT76) 2) The 
electron density is very strong in the steroid and adenine regions. 3) O17 of the 
steroid forms strong hydrogen bonds with amino acid residues that are observed in 
the 17β-HSD1-E2 complex (PDB code 1FDS80) (Figure 12).94   
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Figure 12: Schematic diagram of the most important hydrogen bonds between EM-
1745 40 (green) and certain amino acid residues (red) of 17β-HSD1. The hydrogen 
bonds are represented by dashed lines, and their lengths are given in Å.
96 
Two potential major drawbacks when using EM-1745 40 in intact cell assays or in in 
vivo models were identified and investigated in 2008 by Fournier et al.
97
 The first of 
which was that the inhibitor might not penetrate the cellular membrane, and the 
second was that the inhibitor might be metabolized, at the ester between the steroidal 
component and the adenosine component of the compound. When EM-1745 40 was 
tested in intact HEK-293 transfected cells, for which no exogenous co-factor is 
required, EM-1745 40 still retained some inhibiting power, albeit approximately 10 
fold lower than that observed in a homogenate of transfected HEK-293 cells at 0.1 
µM.
96
 Due to the fact that 17β-HSD1 catalyses the formation of E2 from E1 using 
NADPH as the co-factor the inhibitory activity of  EM-1745 40 was compared using 
NADPH and NADH as exogenous co-factor in a homogenous cell assay, and as 
expected the inhibitory activity of EM-1745 40 was lower when NADPH was used 
as the co-factor. The conclusions drawn from these experiments were that the lower 
inhibitory activity of EM-1745 40 in intact cells compared to a cell homogenate 
assay was not clear as to whether this could be attributed to the inhibitor being 
incapable of crossing the cellular membrane or the inhibitor being metabolised. What 
22 
 
could be determined was that EM-1745 40 is less efficient at inhibiting 17β-HSD1 
when NADPH was being used as the cofactor, as would be the case at physiological 
conditions.
97 
Therefore EM-1745 40 is not a very ‘drug like’ compound. It is known 
that E1 is a better substrate when compared to E2 for the reductive activity of 17β-
HSD1. It has been reported that the Michaelis-Menten constant (KM) of E1 is 0.03 
µM and 0.36 µM for the cofactors NADPH and NADH respectively. Whilst the KM 
for E2 is much greater at 4.6 µM and 1.7 µM for the cofactors NADP
+
 and NAD
+
 
respectively,
98
 indicating that E1 is a much better substrate for 17β-HSD1. In 
addition enzyme kinetics analysis of EM-1745 40 using a Lineweaver-burk plot 
shows that this inhibitor acts as a typical reversible competitive inhibitor 
93
 and so by 
taking this information into account it was hypothesised that a C17 hydroxy analogue 
47 of EM-1745 40 would provide an improved biological activity against 17β-HSD1. 
When tested against EM-1745 40 in a homogenated HEK-293 cell assay using 
NADH as a cofactor, it was discovered that 47 gave a lower percentage inhibition 
than EM-1745 40 by approximately 10% at 0.1 µM concentrations.
99
 This was 
unexpected result but after the biological evaluation of a number of other inhibitors 
differing only at C17 by either a ketone or hydroxyl, this result was once again 
observed. Nevertheless the biological activity of a larger sample set of inhibitors 
should be evaluated before any conclusions from this observation can be drawn. 
As an expansion of this work and to develop the SAR of C16 substituted inhibitors a 
series of simplified inhibitors were developed to investigate whether other aromatic 
groups could be used instead of an adenosine to improve the bioavailability of these 
inhibitors for 17β-HSD1.  These compounds were easily obtained from E1 via an 
aldol condensation using an aromatic aldehyde, followed by the stereoselective 
reduction of the carbonyl to an alcohol, and finally the double bond was 
stereoselectively reduced by catalytic hydrogenation to give 48 with a 16β orientated 
R group. (Figure 13) 
 
Figure 13: A simplified dual site inhibitor
100 
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One compound, 48, synthesised was of particular interest having an IC50 of 0.79 – 
1.0 µM. When this compound was docked into a 3D structure of 17β-HSD1 
complexed with E2, the steroid nucleus was shifted from the steroid binding site to 
enable the phenyl group to get closer to a hydrophobic pocket formed by Leu96 and 
Val196.
100
 To try and improve the drug like properties of these simplified 17β-HSD1 
inhibitors
101
 three strategies were utilised to try and reduce the estrogenic activity of 
these inhibitors. Their strategies were 1) replacing the hydroxyl group at C3 with a 
hydrogen. 2) Adding a methoxy group at C2, this arose from the use of 2-MeO-E2 
Panzem
®
, which had previously been demonstrated to reduce growth of many cancer 
cell lines.
102, 103
 3) Adding an alkylamide side chain at C7α known for its anti-
estrogenic properties.
105
 The chemical structure and inhibitory potency of these 
compounds are reported in Table 3.  
Compound Chemical structure 
% Inhibition at 0.1 / 1 / 
10 µM 
IC50 
(nM) 
49 
 
77 / 94 / 96 44 ± 7 
50 
 
24 / 44 / 79  
51 
 
37 / 69 / 81  
52 
 
4 / 45 / 61  
Table 3: Inhibitors of 17β-HSD1 and their potency in T-47D intact cells101 
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Results indicate that none of the compounds generated from these strategies were as 
potent as the parent compound 49 when tested in an intact T-47D cell assay and are 
noticeably less potent than compound EM-1745 40. The estrogenic activities of these 
compounds were in fact lower than 49 in both T-47D and MCF-7 cell assay which 
are both ER
 
positive cell lines. Compound 50 and 51 exert 31% and 21% less 
estrogenic activity than 49 at 0.1 µM. Compound 52 totally inhibits growth at 0.01 
µM and even brings cell density under that of the control level for both T-47D and 
MCF-7 cell lines suggesting that this compound is actually an anti-estrogen that 
displays some weak 17β-HSD1 activity.101 
During this period Potter et al. were also developing a variety of these hybrid 
compounds and they started with the addition of substituents of various sizes at C16 
conducted in a systematic manner, starting with the incorporation of small 
substituents such as, nitriles, alkyls and alkenyls. These inhibitors showed promising 
biological activity (Table 4).
75 
These compounds were accessed via condensation 
reactions of various aldehydes with E1. Ensuing reduction of the C17 ketone 
followed by hydrogenation of the alkene gave the 16β-alkyl derivatives 55 and 56.75, 
104
  
 
17β-HSD% inhibition at 10 µM75 Purified 17β-HSD1100 
 53 54 55 53 54 55 
R Type 1
a
 Type 2
b 
Type 1
a 
Type 2
b 
Type 1
a 
Type 2
b 
IC50 
(µM)
a 
IC50 
(µM)
a 
IC50 
(µM)
a 
H 70 10 64 20      
25 
 
a 82 31 84 27      
b 17 < 10 26 < 10   10-32 3.4-5.6 0.8-1.0 
c 34 25 77 < 10 84 37    
d 23 16 55 17 88 11 > 20 
9.3-
12.6 
2.4-5.5 
e 44 10 52 43 87 11 8.6-18 7.5-16 3.3-4.2 
f 72 13 72 81 41 25 > 40 7.0-14 4.0-5.7 
g       1.1-3.4   
h       3.8-4.0   
i     86 17    
j       
0.26-
0.33
 
14-32
 
0.72-
1.3 
a - Assessed in T-47D cells; b – Assessed in MDA-MB-231 cells 
Table 4: Inhibitory activities of various C16 substituted E1 derivatives in a purified 
17β-HSD1 assay and T-47D and MDA-MB-231 cancer cell based assays75, 100 
A wide range of inhibitory activities can be seen in Table 4 although certain 
compounds showed promising activity against 17β-HSD1 in T-47D cells and 
selectivity when compared to the percentage inhibition at 10 µM against 17β-HSD2 
in MDA-MB-231 cells. (Table 4) Compound 53 (R=H), a known 17β-HSD1 
alkylating agent,
106
 showed 70% inhibition of 17β-HSD1 at 10 µM and 10% 
inhibition of 17β-HSD2, compound 53a showed an improved inhibition of 82% for 
17β-HSD1 but was less selective than compound 53 with 31% inhibition of 17β-
HSD2. Reduction of the C17 ketone to yield the E2 derivatives 54 gave curious 
results. Compounds 53a and 54a showed similar inhibitory activities and selectivity 
to each other with this also being the case for compounds 53b and 54b. When the 
alkenyl substituent for compound 54 is changed from a phenyl group to varying 
pyridyl derivatives the inhibitory activity improves vastly with the largest increase 
being seen for the para substituted pyridyl compound, 54c 77% for 17β-HSD1 and < 
10% for 17β-HSD2. Compound 54c shows a promising IC50 value of 4.1 µM. 
26 
 
Generally the percentage inhibition of 17β-HSD1 was improved by the reduction of 
the E1 derivatives, 53a-f, to the E2 derivatives, 54c-f,i. Further investigation of C16 
substitution led to the synthesis of a series of C16β substituted compounds, 55. The 
results for this series of compounds showed more favourable inhibitory activity 
against 17β-HSD1 when compared to compounds 53 and 54, with inhibitions of 84% 
and over for compounds 55c-e at 10 µM. These results suggest that some flexibility 
of the C16 side chain might be important for binding of the inhibitor with the active 
site of 17β-HSD1. These results also show that bulky aryl substituents can be 
tolerated by the active site, but optimisation of these systems is needed to obtain a 
potent inhibitor.
75
  
As the biological activities of these compounds was deemed to be promising it was 
decided that a more flexible, functionalizable substituent at C16 was to be 
incorporated. To investigate this area of the active site two such linkers were initially 
investigated: 1) a carboxylic acid, 2) a methyl carboxylic acid. These carboxylic 
acids could then be readily reacted via an amide coupling reaction with a wide 
variety of commercially available amines, that were specifically chosen to include a 
range of electron accepting, electron donating, charge transfer, hydrophobic, 
hydrophilic and π-stacking properties, with the purpose to explore the SAR in the 
C16 area of the active site. 
 
Compound 
% Inhibition at 10 µM IC50 (µM) 
17β-HSD1a 17β-HSD2b 17β-HSD1a 
 R 56 57 58 56 57 58 56 57 
a OH 39 13 58 < 10 <10 < 10   
b   97 67  18 18  0.30 
c 
 
 90 63  < 10 11  1.5 
27 
 
d 
 
 84 76  < 10 13   
e 
 
 82 79  < 10 14   
f 
 
82 91 63 11 21 25  0.38 
g 
 
87 85   < 10    
h 
 
90 83  12 10  0.81  
i 
 
85 
 
 < 10    
 
j 
 
87        
k 
 
91 95  <10 26  0.51 0.037 
l 
 
 82   < 10   
 
m 
 
 58   14    
a - Assessed in T-47D cells; b – Assessed in MDA-MB-231 cells 
Table 5: Biological activities of C16 substituted derivatives of E1 and E2 as 
determined from T-47D and MDA-MB-231 cell based assays
104 
The biological activities of the carboxylic acid derivatives of E2 based inhibitors, 56-
58, are shown in Table 5. These inhibitors were tested as mixtures of 
diastereoisomers, for which the ratios of R and S were undetermined for the majority 
as it is described that only one set of peaks were observed in the 
1
H NMR. It can be 
seen that a large proportion of these inhibitors display good inhibition of 17β-HSD1 
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at 10 µM. For compounds 56g-k the aromatic amide moieties show greater 
percentage inhibition than the alkyl amide moieties. Indicating that there is 
potentially some form of beneficial π-π interaction between the aromatic moiety and 
the active site of 17β-HSD1. The most potent compound of this series was 56k with 
an IC50 value of 510 nM, all compounds from this series demonstrate good 
selectivity of 17β-HSD1 over 17β-HSD2.104 
The percentage inhibition values of 17β-HSD1 for the methyl carboxyl derivatives of 
E2, 59, are shown in Table 5. These analogues displayed reduced inhibitory activities 
when compared to that of the methyl carboxyl derivatives of E1, 58. Any conclusions 
made from the results derived from compounds, 58 can only be tentatively concluded 
as a more comprehensive library of compounds would have to be synthesised 
including amides with a wider variety of chemical properties.
104
  
The methyl carboxyl derivatives of E1 showed very promising inhibitory activity. 
The amides 57b-h and 57k-m showed excellent inhibitory activity of 17β-HSD1 as 
well as selectivity against 17β-HSD2. From the comparison of the percentage 
inhibition of 57l and 57m it can be deduced that there is an optimum distance for 
which the pyridyl moiety needs to be for beneficial interaction with the active site of 
17β-HSD1. The most potent inhibitor from this series is the compound 57k, which as 
reported in a preliminary paper 
110
 has an IC50 of 37 nM, making this compound one 
of the most potent inhibitors to described at this date.
104 
With a view to reducing the estrogenicity of compound 57k, synthesis of the 2-
methoxy and 2-ethyl analogues, 1 and 59was undertaken.
104
 Several 2-methoxy E1 
derivatives have been reported to display lower estrogenic effects when compared to 
their E1 counterparts
102, 107-108
 and 2-substituted E1 derivatives have also shown 
reduced estrogenicity.
107 
Vicker et al.
46
 described that in silico studies using the 
crystal structure (PDB code 3ERD
109
) of the ligand-binding domain of the human 
ERα have shown that compounds bearing a C2 substitution of the steroid nucleus do 
not fit well, as the 2-substituent disrupts key hydrophobic interactions in the ER-α 
steroid binding site.
46
 This therefore gives an in silico prediction that compounds 1 
and 59 would not be strongly estrogenic, as docking studies of the binding 
orientation in ER-α have proven predictive in the identification of ER-α selective 
agonists using the same crystal structure.
110
  Compounds 1 and 59 were synthesised 
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and identified as the most potent and selective inhibitors of 17β-HSD1 (Table 6) and 
were shown to be selective for 17β-HSD1 over 17β-HSD2.104 
 
Compound R1 R2 
IC50 (nM) 
against 
17β-HSD1a 
% 
Inhibition 
17β-HSD1a 
% 
Inhibition 
17β-HSD2b 
57k H 
 
37 97 26 
1 Et 
 
27 99 -5.0 
59 OMe 
 
290 96 0 
a - Assessed using T-47D cells; b - Assessed using MBA-MD-231 cells 
Table 6: A table showing the effect of A ring substitution upon the activity of C16 
substituted E1 derivatives as determined in T-47D and MD-MBA-231 cell based 
assays
104 
When compounds 57k and 1 were docked into 1FDT
76
 with E2 removed it could be 
seen that the steroid backbones are essentially overlaid, therefore forming the same 
hydrophobic interactions, with Leu149, Val225, Phe226 and Phe259, as the natural 
substrate E1. The 2-ethyl group of 1 is able to form an additional hydrophobic 
interaction with Leu262 and Phe259. It was also noted that the oxygen of the 
carbonyl in the amide side chain is 3.16 Å from the closest nicotinamide NH, 
indicating that there may be an interaction between the carbonyl on the 16-amide 
side chain and the nicotinamide amide moiety. The pyridyl nitrogen of the 16β side 
chain is 3.16 Å from a phosphate oxygen and could form a hydrogen bonding 
interaction.
104
 These additional interactions between compounds 57k and 1 and the 
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co-factor could potentially explain the vastly improved biological activity for 17β-
HSD1.  
When comparing the inhibitory activity of compounds 60, 61 and 1, (Table 7) IC50 
values of 3.62 µM, 165 nM and 27 nM respectively, and it can be seen that the 
binding region is sensitive to small changes in the structure of the inhibitor and also 
indicates the importance of the binding interactions between the inhibitors and the 
protein and / or co-factor binding sites. This observation is also demonstrated by the 
approximately 6 fold difference in activity between compounds 61 and 1 in which 
the nitrogen of the pyridyl ring has been moved from a meta to an ortho position. 
 
Compound R % Inhibition IC50 (µM) 
60 
 
45 3.62 
61 
 
89 0.165 
1 
 
94 0.027 
Table 7: A table showing how varying the position and number of nitrogen atoms 
present in the D ring moiety affects activity as determined in a T-47D cell based 
assay
104 
This extensive research by Lawrence et al.
104
 has confirmed that good inhibitory 
activity and selectivity for 17β-HSD1 against 17β-HSD2 can be obtained for 
compounds bearing a large and flexible side chain at C16 of E1 and E2. The 
inhibitory activity of these compounds were assessed using T-47D breast cancer 
cells, which represent the physiological conditions and show that these inhibitors are 
able to successfully pass through the cell membrane. 2-((13S,16R)-2-ethyl-3-
31 
 
hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-
phenan-thren-16-yl)-N-(pyridin-3-ylmethyl)acetamide, STX1040 1 is the most potent 
inhibitor of 17β-HSD1 reported to date and has the lowest reported IC50 value of 27 
nM obtained from a cell based assay.
43 
1.7.1.5  E ring modified steroids 
As an extension of the work by Lawrence et al.
104
 that led to the discovery of 1, the 
C16 position was further explored in combination with modifications at the C17 
position in the form of E ring steroidal based inhibitors. These E ring containing 
inhibitors have the benefit of being able to further explore the chemical space within 
the active site without the introduction of a chiral centre at the C16 position. It had 
been previously reported that heterocyclic analogues of E1 with a pyrazole or an 
isoxazole fused to the 16, 17-position on the D ring were competitive inhibitors of 
purified placental 17β-HSD1.111 It was hypothesised that the pyrazole E ring 
modification acts as a bioisostere for 16-(hydroxymethylene)estrones because of the 
plausible potential intramolecular hydrogen bonding (Figure 14).  
 
Figure 14: An example of bioisosterism
78 
Besides retaining the carbonyl isostere C=N at C17, the fused pyrazole ring system is 
also a desirable scaffold for chemical substitution with three different attachment 
positions for the rapid exploration of chemical space. Fischer et al.
78
 described the 
utilisation of the pyrazole based E ring for the synthesis of N1, N2 and C5ʹ 
substitiuted compounds as 17β-HSD1 inhibitors. Pyrazoles are attractive targets for 
synthesis because of the ease of access to a common pyrazole carboxylic acid 
intermediate for rapid modification. In a T-47D cell based assay the pyrazole 
compound as a mixture of N1H and N2H tautomers, had an IC50 value of 180 nM at 
10 µM concentration and displayed a percentage inhibition of 97%. In comparison 
the corresponding pyrazolone E ring compound
47
 and pyridine E ring compound
78
 
analogues displayed a slightly lower percentage inhibiton of 86 and 78% 
32 
 
respectively. A reduction in activity was also observed for the addition of a C6 
carbonyl to 62a.
47
 (Table 8) 
 
 R 
% Inhibition at 10 
µM (Compound 62) 
IC50 (µM) 
% Inhibition at 10 
µM (Compound 63) 
17β-HSD 17β-HSD 
Type 1
a 
Type 2
b 
Type 1 Type 1 Type 2 
a
c 
H 97 32 0.18   
b CH3 94 24 2.75 43 32 
c CH2CH(CH3)2 77 61  70 44 
d CH2CO2CH3 95 19 0.92 79 30 
e (CH2)2OCH3 95 48 0.53 83 55 
f (CH2)2CN 95 44 0.73   
64a CO2Et 94 7 1.85   
64b CH2OH 94 -1 0.95   
64c COOH 32 -6    
64d CF3 75 36    
a - Measured in T-47D cells; b - Measured in MDA-MB-231 cells; c - A mixture of N1H and N2H 
tautomers 
Table 8: A table to show how variation in the substitution pattern of the pyrazole 
affects the biological activity of this class of E ring modified steroids as measured in 
T-47D and MDA-MB-231 cells
 
In the N-alkylated pyrazole series all the N1 substituted compounds significantly 
inhibited 17β-HSD1, although the selectivity for 17β-HSD1 over 17β-HSD2 was 
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shown to be modest for the majority of the inhibitors from this series, for example 
62e has an IC50 value of 0.53 µM but displayed only 2 fold greater inhibitory activity 
for 17β-HSD1 over 17β-HSD2.78 This shows that the E ring modified scaffold is well 
tolerated by the active site of 17β-HSD1. A bulky hydrophobic group however was 
not well tolerated as displayed by 62h, which had the lowest percentage inhibition of 
the series. The N2 alkylated derivatives corresponding to their N1 analogues all 
showed a lower percentage inhibition and so are not as potent as the pyrazole N1 
derivatives. The C5' series produced compounds that were highly selective for 17β-
HSD1 over 17β-HSD2 and the alkylated compounds from this series demonstrated 
high percentage inhibition against 17β-HSD1 with compounds 64a and 64b both 
having a percentage inhibition of 94% and IC50 values of 1.85 µM and 0.95 µM 
respectively.
78 
Compounds 62d and 63d, the N-methoxyethyl derivatives, did not 
show any estrogenic activity up to 100 nM concentration, indicating that it is 
unlikely to bind to the ER.
78 
As part of further work into the investigation of a pyrazole template as a new 
scaffold for 17β-HSD1 inhibitors, previous studies had indicated that an amide side 
chain displayed beneficial interactions with the co-factor, and so this approach was 
used for the design of a new series of C5' inhibitors (Table 9). By applying this 
approach to the synthesis of new C5' compounds several new potent inhibitors were 
developed (Table 9). Compound 65b was found to be the most potent from this series 
with an IC50 of 300 nM.
47, 78 
Other compounds containing a pyridyl moiety in the 
side chain were found to be potent inhibitors of 17β-HSD1 as well as displaying 
good selectivity for 17β-HSD1 over 17β-HSD2. Primary aliphatic amides however 
showed only moderate activity against 17β-HSD1. To try and mimic STX1040 1 the 
most potent inhibitor of 17β-HSD1, an ethyl group was substituted onto the 2-
position of the steroid core, this led to a 2 fold decrease in activity for compound 66b 
compared to the most potent inhibitor 65g from this series.
46
 The addition of a 
sulfamate group to the 3-OH also led to decrease in activity by approximately 5 fold. 
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Compound R 
% Inhibition of 17β-HSD at 10 
µM 
IC50
a
 (µM) 
Type 1
a 
Type 2
b 
65a 
 
57 0  
65b 
 
50 -1  
65c 
 
80 61  
65d 
 
90 -4 2.3 
65e 
 
93 9 0.88 
65f 
 
92 28 0.78 
65g 
 
99 3 0.30 
66a 
 
  1.97 
66b 
 
  0.7 
35 
 
67a 
 
17   
67b 
 
20   
a – Measured in T-47D cells; b – Measured in MD-MBA-231 cells 
Table 9: A table to show the biological activities of steroidal E ring based inhibitors 
as determined in T-47D and MD-MBA-231 cell based assays
113 
A molecular modelling study of compound 65e and 66b in the active site of 17β-
HSD1-E2-NADP
+
 complex (PDB code 1FDT
76
) showed that the steroid cores of 
both compounds in the ligand binding pocket were overlaid and it was seen that they 
formed the same hydrophobic interactions as E2.
46, 78
 The hydrogen bond acceptor 
group in the side chain are in close proximity to the primary amide group of the 
nicotinamide group of the co-factor and may form favourable π-stacking interactions 
with this moiety. In compound 66b the ethyl group at the 2-position was located in a 
hydrophobic region and was said to be likely to interact with the amino acid residues; 
Met147, Leu149, Phe259 and Leu262.
46
 The phenol moiety was predicted to interact 
with His221 which was seen to be 1.8 Å away, this interaction was also observed for 
the substrate, and the nitrogens present in the pyrazole ring were shown to be 1.9-2.1 
Å away from the Pro-S of the NADP
+
. The meta-pyridyl moiety positioned itself 
towards the phosphate backbone between the two ribose rings of the co-factor,
46, 78
 
and so could potentially form further interactions with the co-factor and protein. This 
could explain why the compounds 65e-g bearing a pyridyl side chain are the most 
potent inhibitors from these series. Compound 62e was also docked into the crystal 
structure of the ligand binding domain in human ER-α (PDB code 3ERD109).  Poor 
docking scores indicated that 62e did not fit well in the active site and therefore 
suggests that this compound is not strongly estrogenic.
78 
1.7.2 Non-Steroidal Inhibitors 
The majority of the inhibitors that have been described for 17β-HSD1 are based upon 
modifications of the E1 and E2 steroid core. There has recently been a concerted 
effort by several groups to research the potential of non-steroidal inhibitors for 
activity against 17β-HSD1. Non-steroidal inhibitors have several advantages over 
36 
 
steroidal inhibitors in that non-steroidal compounds could have advantages of ease of 
synthesis, drug-likeness, selectivity and non-estrogenicity. Non-steroidal inhibitors 
also have the advantage of enabling a range of different pharmacophores to be 
assessed for their inhibitory potential for 17β-HSD1.  When studying the SAR of 
steroidal inhibitors some common structural features can be identified which aid 
binding at the active site. These include a phenol which can undergo bifurcated 
hydrogen bonding to His221 and Glu282, and a hydrophobic scaffold which inhabits 
the hydrophobic area in the active site. 
1.7.2.1  E1 skeleton mimics 
Vicker et al.
112
 synthesised a series of non-steroidal inhibitors that were designed to 
be mimics of compound 1 which has an IC50 of 27 nM. The reason for designing 
non-steroidal mimics of this compound was that non-steroidal inhibitors might 
provide compounds with an improved pharmacokinetic (PK) profile. The search for 
non-steroidal inhibitors of 17β-HSD1 began with the investigation into which 
possible scaffolds might be able to replace the E1 steroid core, whilst keeping the 
phenol and ketone functionalities on the E1 A and D rings, since these moieties are 
known to be important for binding. An investigation of biphenyl ethanone type 
systems with different linkers between the phenyl rings showed that those with just a 
C-C linker showed activity. (Table 10)
112
 These compounds were accessed by 
utilising the Suzuki coupling reaction between a boronic acid and a bromo-
substituted aromatic ring.
113
 Alignment studies showed that compound 68 is similar 
in length to E1, and a number of alignment and shape similarity studies were 
performed to investigate possible scaffolds. 
Compound Structure 
% 
Inhibition 
of 17β-
HSD1 at 
10 µM
a 
% 
Inhibition 
of 17β-
HSD2 at 
10 µM
b 
IC50
a
 
(µM)
 
68 
 
97  3.7 
37 
 
69 
 
Inactive   
70 
 
73 51 5.4 
71 
 
81 17 1.7 
72 
 
Inactive   
73 
 
86 48 2.0 
74 
 
Inactive   
75 
 
Inactive   
76 
 
89  15.6 
38 
 
77 
 
Inactive   
78 
 
51   
79 
 
71  8.3 
80 
 
24 12 3.7 
81 
 
Inactive   
82 
 
39  4.7 
83 
 
Inactive   
a – Measured in T-47D cells; b- Measured in MD-MBA-231 cells  
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Table 10: A table to show the biological activities of a series of non-steroidal E1 and 
E2 mimics as determined from a cell based assay
44 
The compounds shown in Table 10 were assessed for their ability to inhibit 17β-
HSD1 using T-47D human breast cancer cells. The results for the biphenyl ethanone 
series showed promising inhibition of 17β-HSD1, with compounds 68 and 80 
showing the best IC50 of 3.7 µM. It can be seen for all of the scaffolds that the 
methylation of the phenol results in the loss of biological activity. The addition of a 
2-ethyl group on the A ring was well tolerated for all of these compounds, however 
the selectivity of these compounds for 17β-HSD1 against 17β-HSD2 was shown to 
decrease when comparing compounds 68, 70 and 71, 73.
113 
The indanone series 
proved promising, with the most potent compound being the unsubstituted biphenyl 
indanone 71, with an IC50 value of 1.7 µM and is shown to be selective against 17β-
HSD2. The tetralone containing compounds displayed reduced activity compared to 
the indanone and the acetophenone series. This is a surprising result because the six 
membered homo D ring 2-substituted E1 derivatives are reported to be at least as 
active as the E1 scaffold itself.
72, 73
 As the acetophenone and indanone scaffolds were 
shown to be more active than the tetralone scaffold it was then decided that these 
scaffolds were to be used to synthesise mimics of compound 1, STX1040, it was 
decided to incorporate the ethyl substituent immediately, with the idea to avoid 
estrogenicity from the outset. As with the steroidal series
46
 the length of the chain 
and position of the nitrogen in the pyridyl ring were investigated and as with the 
steroidal series the meta pyridyl compounds, 80 and 82 with IC50 values of 3.7 and 
4.7 µM respectively displayed the best inhibitory activity compared to the ortho 
pyridyl compounds, 81 and 83, which were determined to be inactive at 10µM. 
These non-steroidal inhibitors are shown to be promising inhibitors of 17β-HSD1, 
however further investigation and optimisation is required. The inhibitory data for 
these compounds does indicate that compound 1 is being mimicked in the desired 
way.  
1.7.2.2  Phenylnaphthalene and phenylquinoline derivatives 
It was seen that the substrate binding pocket contained a hydrophobic tunnel with 
polar regions at each end, consisting of the polar amino acids His221 and Glu282 
forming hydrogen bonds with the 3-O of the A ring of the steroid and at one end of 
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the binding pocket Ser142 and Tyr155 forming hydrogen bonds with the 17-O of the 
D ring of the steroid. In front of the active site is an entry loop comprising of amino 
acids 188-201. This loop was deemed to be very flexible as these amino acids are not 
properly resolved in the crystal structure 1FDT
76
. This loop occupies two modes; in 
mode A the loop closes entry to the substrate binding pocket and in mode B the loop 
closes entry to the co-factor binding pocket. Bearing this information in mind 
Hartmann et al.
118
 synthesised a series of compounds that were designed to mimic 
the natural substrates E1 and E2. These compounds contained two polar terminal 
groups that are 10 – 13 Å apart, designed to mimic the 3-O on the A ring of the 
steroid and 17-O of the D ring of the steroid core. It was determined that to mimic 
the planar geometry of the steroid phenylnaphthalenes and phenylquinolines would 
be ideal non-steroidal scaffolds for this and would also satisfy the other criteria stated 
above.
44
  
A series of phenylnaphthalenes were synthesised and the position of the hydroxyls 
on the naphthalene and phenyl were investigated (Table 11). 
 
Figure 15: The numbering convention for the core structure of the phenylnaphthalene 
and phenylquinoline based compounds 
When the hydroxyls were located at position 1 on the naphthalene and position 3’ 
and 4’ on the phenyl only moderate biological activity was observed. By moving the 
hydroxyl on the naphthalene to position 2 and the hydroxyl of the phenyl to either 
position 2’, 3’ or 4’ only compound 84 with the phenyl hydroxyl at position 3’ 
displayed any activity in a recombinant placental 17β-HSD1 assay, with an IC50 of 
116 nM.
44, 114-115 
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Compound Structure % inhibition at 100 nM / 1 µM 
84 
 
91 / 94 
85 
 
ni / 55 
86 
 
ni / ni 
87 
 
26 / 61 
88 
 
ni / ni 
89 
 
14 / 42 
90 
 
ni / 45 
42 
 
91 
 
40 / 80 
92 
 
nt / 33 
93 
 
nt / 75 
94 
 
83 / 88 
95 
 
76 / 89 
ni – No Inhibition; nt – Not Tested 
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Table 11: A table displaying the biological activities for a series of 
phenylnaphthalenes as determined in a recombinant 17β-HSD1 assay118-120 
Compounds 85 and 86 were inactive, therefore highlighting that the position of the 
hydroxyls is very important for the inhibition of 17β-HSD1. Removal of the 
hydroxyl on the naphthalene core to give the monohydroxylated compound 87, 
drastically reduced the activity to 26% inhibition at 100 nM. Removal of the 
hydroxyl of the phenyl moiety resulted in a complete loss of activity,
115 
displaying 
that the presence of a hydroxyl at each end of the compound is very important for 
biological activity. It was reasoned that this was due to the hydroxyls being very 
important for the stabilisation of the compound within the active site of 17β-HSD1.  
It was hypothesised that substitution at positions 1 and / or 3 with a hydrogen bond 
acceptor or donor might enable the compounds to interact with the polar amino acids 
Tyr218 and Ser222. A number of compounds with an amide present at position 1 
show only moderate activity, 45% and 80% inhibition at 1 µM for compounds 90 
and 91 respectively, compared to 94% for the lead compound 84. Substitution in 
position 1 with a sulfone also exhibits moderate activity, 33% and 75% at 1 µM for 
compounds 92 and 93, which is lower than that seen for the lead compound 84.
114 
These results for percentage inhibition are all significantly lower than the lead 
compound 84 and so suggests that substitution at position 1 is not forming any 
favourable interactions with the active site. Substitution with electron rich moieties 
such as the halogen bromine 94 and a phenyl group 95 at position 1 gave compounds 
with an improved activity compared to the lead compound, with IC50 values of 40 
nM and 20 nM respectively.
114 
This increase in activity could be due to π–π stacking 
interactions, and does demonstrate that there is potential for substitution at position 1 
of the naphthalene core. It remains unclear however why 94 is more active than 95 
but the electronic effects of the bromine compared to the phenyl are offered as one 
explaination. These compounds show good selectivity for 17β-HSD1 over 17β-
HSD2 and also show low relative binding affinities for the ER-α and ER-β, 
highlighting their potential as therapeutic agents for hormone dependent breast 
cancer. It has also been shown that the lead compound 84 displays moderate 
metabolic stability against CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 in tests using rat 
liver microsomes, as well as moderate cell permeability in an assay using Caco-2 
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cells which exhibit the morphological and physiological properties of a human small 
intestine.
44 
It was hypothesised that the addition of a heteroatom into one of the rings of the 
compound could establish favourable interactions with the polar amino acids Tyr218 
and / or Ser222 which are located close to the C6 position on the B ring of the 
steroid.
 
To investigate this hypothesis compounds based upon a phenylquinoline core 
were synthesised. (Table 12)
44, 115
 The introduction of a nitrogen into the naphthalene 
moiety to give a quinolone gave rise to a dramatic decrease in activity, 24% and 14% 
at 100 nM for compounds 96 and 97 respectively.
120
  
Compound Structure % Inhibition @ 100 nM/1 µM 
96 
 
24 / 57 
97 
 
14 / 63 
Table 12: A table to show the biological activities of a series of phenylnaphthalenes 
in a recombinant 17β-HSD1 assay118,120 
This indicated that the nitrogen of the quinolone is either not forming any favourable 
interactions with Tyr218 and/or Ser222 or that the basicity of the nitrogen is not well 
tolerated by the active site. The effect of monohydroxylation on the phenylquinolone 
series is the same as that which was observed for the phenylnaphthalene series, in 
that there is either low or no activity observed. It was also highlighted that the 
position of the nitrogen within the compound has little effect on activity.  
1.7.2.3  Bis(hydroxyphenyl) substituted Azoles, Thiophenes, Benzenes and Aza-
benzenes 
As part of Hartmann’s non-steroidal inhibitor research programme, where the 
rationale for inhibitor design has been described previously, led to the discovery of a 
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new pharmacophore for the inhibition of 17β-HSD1. Where 1,2- and 1,3-
bis(hydroxyphenyl) and tris(hydroxyphenyl) azoles were described as novel ER 
ligands, of these ligands those bearing two hydroxphenyl moieties did not show any 
binding affinity to the ERs. As a result of this the bis(hydroxyphenyl) moieties were 
attached to a heterocyclic core and were used as a starting point for the investigation 
of these compounds as novel non-steroidal inhibitors of 17β-HSD1.45, 116  
The nature of the heterocyclic core was investigated with a range of hydrogen bond 
acceptors and donors used. The substitution pattern on the heterocyclic core was also 
assessed as well as the position of the hydroxyl groups on the phenyl rings. As well 
as whether one of the hydroxyls could be substituted with a bioisosteric moiety, with 
the aim of trying to introduce a variety of different moieties, and still maintain 
activity against 17β-HSD1. (Table 13) 
Compound R / R1 / R2 Structure IC50 (µM) 
98 
 
 
0.84 
99 
 
1.61 
100 
 
0.31 
101 
R = CH3  
R1 =  3-OH  
R2 = 3-OH 
 
ni 
102 
R = Ph  
R1 = 3-OH 
R2 = 4-OH 
 
ni 
46 
 
103 
R1 = 3-OH 
R2 = 4-OH 
 
0.05 
104 
R1 = 3-OH 
R2 = 4-OH  
 0.069 
105 
R1 = 4-OH 
R2 = 4-OH 
 
ni 
106 
R1 = 3-OH 
R2 = 3-OH 
 
0.243 
107 Me 
 
0.629 
108 F 
 
0.042 
109 F 
 
0.008 
110  
 
0.046 
111  
 
0.038 
47 
 
112 
 
 
0.130 
113 
 
 
0.427 
ni – No Inhibition 
Table 13: A table to show the biological activities of a series of bis(hydroxyphenyl) 
inhibitors as determined in a recombinant 17β-HSD1 assay121,122 
When looking at the biological results of a recombinant 17β-HSD1 assay it can be 
seen that compounds from the 5-membered ring series, bearing a heterocycle that 
acts as a hydrogen bond acceptor (1,2,3-triazoles 98 IC50 840 nM, oxazoles 101 IC50 
1.61 µM and isoxazole 106 IC50 310 nM)
45
 are active against 17β-HSD1. It was 
observed however that the 1,2,4-methyl/phenyl substituted triazoles 101 and 102 
however were inactive indicating that either the distribution of the nitrogens or the 
methyl/phenyl substitution are not tolerated by the enzyme.
117
 Replacement of the 
one of the nitrogens present in the heterocyclic core with sulphur gave a compounds 
with reasonable potency. This led to the investigation of the role of nitrogen in the 
ring with the synthesis of thiazoles and thiophenes 103-109. In fact the thiazole 103 
and thiophene 104 show almost identical potencies, indicating that the nitrogen does 
not contribute to binding through any obvious hydrogen bond interactions.
116 
The substitution pattern of the two hydroxyl groups of the hydroxyphenyl moieties 
play an important role in the activity of these compounds with a para-para 
substitution pattern showing low to no activity 105, whilst compounds bearing a 
meta-para 103, and meta-meta 106 substitution pattern are much more active. It was 
reasoned that the inactivity of the para-para compounds was due to the O-O distance 
being greater than the 10-13 Å, that was earlier stated as being the optimum distance 
required for activity.
44, 116 
As stated earlier substitution at position 3 on the heterocycle with either a methyl or 
phenyl moiety showed a reduction in activity compared to the parent compound.
123
 
This was also observed for substitution at position 5 on the meta-hydroxylphenyl 
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ring with a methyl 107 IC50 = 629 nM, but substitution with a flourine 108 led to an 
increase in activity IC50 = 42 nM. Substitution at position 4 with the same moieties 
gave a lower activity when compared to substitution at position 5 and the parent 
compound.
118
 Ortho substitution was not investigated because substitution at the 
ortho position would force the compounds to become non-planar, and planarity of 
these compounds was determined to be important for biological activity against 17β-
HSD1.
45
 Substitution at position 3 on the para-hydroxyphenyl ring with a polar or 
bulky moiety like a hydroxyl or phenyl gave a reduction in activity compared to the 
parent compound. The introduction of a F at the same position gave the highly potent 
compound 109 IC50 = 8 nM. Substitution with a methyl 110 and CF3 111 at the same 
position also demonstrated an improved activity compared to the parent compound 
with IC50 values of 46 and 38 nM respectively. Functional groups exhibiting a higher 
degree of flexibility like ethyl acrylate 112 and phenyl acrylamide 113 demonstrated 
lower activity than the parent compound with IC50 values of 130 nM and 427 nM 
respectively. These results indicate that there is space available for substitution in the 
active site around the para-hydroxy phenyl ring but the nature of the optimum 
substituent is still to be determined.
118 
All compounds show a low affinity to ER-α and ER-β. In T-47D cells IC50 values of 
426 nM and 282 nM were observed for compounds 110 and 109 respectively. These 
results indicate that that the compounds are able to permeate the cell membrane and 
successfully inhibit the transformation of E1 to E2. Compounds 110 and 109 do 
demonstrate some biological activity for CYP3A4 with IC50 values of 0.50 µM and 
0.82 µM respectively. This activity against the hepatic CYP has to be taken into 
further optimisation of these inhibitors.
118 
To try and introduce variation (Table 14) into these compounds one of the hydroxyl 
groups was substituted with a bioisostere. The reasoning behind this was that the 
hydroxyphenyl moiety is susceptible to phase II metabolism.
119
 It was previously 
shown that the meta-hydroxyl is important for the activity of these compounds
116
 and 
so was kept in the core structure. Replacement of the para-hydroxyl by either a F, 
NH2 or SH resulted in a decrease in activity (717 nM vs > 5000 nM). By moving the 
F to the meta position an improvement in activity was observed (IC50 535 nM 115a 
vs IC50 717 nM 114a) Replacement of the meta-Flourine 115a with a 
methylsulfonamide 114b did not result in a change of activity, whilst substitution at 
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the meta position with a bulky substituent like tosylsulfonamide 115c showed 
comparable activity to the monohydroxylated thiophene 116 with an IC50 value of 
350 nM compared to an IC50 value of 342 nM indicating that there is room for 
substitution on one of the phenyl rings but any interactions with amino acids in the 
active site is not occurring.
118
 Some inhibitors bearing one hydroxyl group did 
display some activity against 17β-HSD1. 
  
Compound R IC50 (nM)
a 
114a F 717 
114b NH2 >5000 
114c SH >5000 
115a F 535 
115b NHSO2CH3 523 
115c Tosylamide 350 
116  342 
a – IC50 determined in a recombinant 17β-HSD1 assay 
Table 14: A table displaying the IC50 values as determined in a recombinant 17β-
HSD1 assay for a series of thiophene modified compounds
118 
As an extension of this work a series of compounds were designed (Table 15) to 
determine the importance of an aromatic system for these inhibitors. When 
comparing compounds 117a and 117b it can be seen that for compound 117a the 
pyridone has a less pronounced aromatic character than the methoxy pyridine 117b 
and is inactive compared to an IC50 of 690 nM. The reasoning as to why 117b is 
more biologically activity when compared to 117a was that the nitrogen and oxygen 
of the methoxy pyridine moiety can potentially form hydrogen bonds with the amino 
acids that form the catalytic centre of the 17β-HSD1 active site. This high activity 
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was obtained with a meta-para substitution on the two hydroxyphenyl groups where 
the distance between the two electronegative atoms is greater than the 11 Å required 
determined previously as the ideal distance for activity,
44, 116
 and so a series of meta-
meta substituted compounds were synthesised where the distance between these two 
electronegative atoms is approximately 11 Å. The most potent of these was 
compound 118a with an IC50 value of 560 nM. When the chlorine moiety was 
removed from the compound the activity was reduced, highlighting the importance 
of the chlorine for the compounds activity. The addition of a nitrogen into the central 
benzene 118c-e did not improve the activity and so it can be concluded that the 
nitrogen is unable to interact with any of the amino acids in the active site. These 
compounds all show good selectivity for 17β-HSD1 over 17β-HSD2 as well as a low 
affinity for ER-α and ER-β.120 
   
Compound R X / Y / Z IC50 (nM)
a 
117a 
 
 
ni 
117b 
 
690 
118a Cl C 560 
118b Ph C 137 
118c Cl X = N 139 
118d Cl Y = N 850 
118e Cl Z = N 238 
ni – No Inhibition a – Measured in a recombinant 17β-HSD1 assay 
Table 15: A table to show the biological activities of a series of benzene and 
azabenzene compounds as determined in a recombinant 17β-HSD1 assay120 
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Even though mid nanomolar activity was observed with compounds bearing only a 
single hydroxyl group molecular modelling of heterocyclic substituted 
bihydroxyphenyls showed that linear and non-linear molecules could generate their 
activity via interactions with the amino acids in the catalytic centre of 17β-HSD1 and 
a lipohilic sub pocket below the active site. Compounds 119-121 (Table 16) with a 
ketone moiety and containing two hydroxyphenyls were designed to interact with 
three distinct areas of the active site shown in Figure 15. 
Amongst these the meta-meta 119a and meta-para 119d, but not para-meta, 
substituted hydroxyphenyls showed best activity with an IC50 of 22 nM and 33 nM 
respectively in a human placenta cell free assay,
121
 again demonstrating that the 
meta-substituted hydroxyphenyl A ring mimics and meta/para substituted D ring 
mimcs are the best substitution pattern for 17β-HSD1 activity.  
   
Compound R1 R2 IC50 (nM)
a 
119a 3-OH 3-OH 22 
119b 4-OH 3-OH 368 
119c 2-OH 3-OH 945 
119d 3-OH 4-OH 33 
119e 3-OH 2-OH 95 
120a F  18 
120b  2-F 6 
120c  4-CH3 207 
121a F  21 
121b  CF3 16 
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121c  Cl 5 
121d  CH3 8 
121e  F 19 
a – Determined in a recombinant 17β-HSD1 assay 
Table 16: A table demonstrating the biological activities of a series of thiophene 
based compounds as determined in a recombinant 17β-HSD1 assay121 
To try an increase the potential interactions with the active site a series of 
compounds containing methyl and fluoro substituted compounds were synthesised as 
it had been previously demonstrated by Bey et al.
116
 that fluoro substitution can 
improve the biological activity of the parent compounds. Substitution on either 
terminal ring with a F can be well tolerated because the biological activity is either 
similar or improved when compared to the parent compound 121a, IC50 values of 18 
nM, 22 nM and 6 nM were obtained for 120a, 121a, and 120b respectively. Methyl 
substitution though does reduce the activity when substituted on the hydroxyphenyl 
that is designed to mimic the A ring of E1. Compounds bearing a substitution with a 
methyl moiety on the D ring mimic of E1 display high activity for 17β-HSD1, but 
the relative positions of substitution for the methyl and hydroxyl is very important. 
This can be seen when comparing compounds 120c and 121d which have IC50 values 
of 207 nM and 8 nM respectively. To try and combine the inhibitory effects of both 
the methyl and fluoro substitutions a trifluoromethyl group and its bioisostere 
chlorine were introduced and these compounds have an IC50 value of 16 nM and 5 
nM respectively. 
When investigating the influence of the centre ring it was observed that the position 
of the sulphur is very important for activity (Table 17). When comparing compound 
122a and its isomer 122b there is a marked drop in activity, IC50 values of 8 nM and 
199 nM respectively. This trend can also be seen when looking at the thiazole 
isomers where compound 122c which has the sulphur in the same position as 122a 
has the highest IC50 value of 35 nM from the thiazole series, 122d 32% inhibition 
and 122e 19% inhibition.  
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Compound X IC50 (nM)
a 
a 
 
8 
b 
 
199 
c 
 
35 
d 
 
32%
b 
e 
 
19%
b 
a – Measured in a recombinant 17β-HSD1 assay b – percentage inhibition at 10 µM measured in a 
recombinant 17β-HSD1 assay 
Table 17: A table to show the biological activities for a series of thiophene and 
azathiophene based compounds as determined in a recombinant 17β-HSD1 assay127 
When looking at compounds 122a-c in a T-47D cell assay their activity was similar 
to that determined in the recombinant 17β-HSD1 assay. It was also shown in human 
liver microsomes that the most potent compounds 122a-c are classed in the medium 
clearance category and none of these compounds have an affinity for ER-α and ER-β. 
1.7.2.4  Benzothienopyrimidones 
As part of Solvay pharmaceuticals search for therapeutic agents for hormone 
dependent breast cancer, they investigated non-steroidal small molecules as 
inhibitors of E2 biosynthesis. Based upon molecular modelling experiments on the 
active site of 17β-HSD1122 a small commercial library of compounds were chosen, 
which were likely to fit into and be complementary to the hydrophobic nature of the 
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active site of 17β-HSD1 were screened for their inhibitory activity to try and identify 
potential non-steroidal inhibitors of 17β-HSD1.123 Compound 123 was identified as a 
lead compound (Figure 16).
124
 Compound 123 has a percentage inhibition of 41 and 
99% at 1 µM and 10 µM respectively in a cell based assay. 
 
Figure 16: The structure of the lead compound of the benzothienopyrimidone series 
To try and improve the biological activity of compound 123 it was decided that 
modifications were to be made at various positions of the benzothienopyrimidone 
core. These modifications included the synthesis of derivatives including an aliphatic 
thioether side chain and an aromatic thioether side chain. These derivatives were 
evaluated for their biological activity against 17β-HSD1 and 17β-HSD2 (Table 18). 
 
Compound R m 
% Inhibition of 
17β-HSD1 in a 
cell free assay 
% Inhibition of 
17β-HSD1 in a 
cell based assay 
 0.1 µM 1 µM 1 µM 10 µM 
124a  3 72 95 66 100 
124b  3 73 92 74 100 
124c  3 68 93 54 100 
124d 
 
3 65 93 72 100 
55 
 
124e 
 
3 0.3 3   
124f 
 
3 63 85 41 99 
124g 
 
3 87 92 37 77 
124h 
 
3 4 22   
124i 
 
3 89 90 25 72 
124j 
 
3 59 92 37 77 
124k 
 
3 94 97 53 84 
124l 
 
3 86 91 18 90 
124m Pr 1 17 67   
124n Pr 4 63 75   
125a Pr  69 86 36 79 
125b Ph  81 88 31 47 
Table 18: A table showing the biological activities of a series of 
benzothienopyrimidones
124
  
Most of these compounds showed good to excellent activity against 17β-HSD1. 
Charged substituents such as carboxylic acids were not well tolerated and their 
inhibitory activity was lost. The most potent inhibitors were compounds 124g, 124i, 
124k-l with inhibitory activities of 94-86% at 0.1 µM concentration. By reducing the 
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size of the D ring, 124m, the biological activity was reduced to 17% inhibition at 1 
µM compared to the activity of the lead compound 123 with a percentage inhibition 
of 41% at 1 µM. Similar inhibitory activities were found when the benzylic alcohol 
125 substitution was used to replace the aldehyde 124 on the A ring. This indicates 
that the aldehyde moiety is not essential for the activity of the compounds. It is also 
stated that the reduction of the aldehyde into the corresponding allylic alcohols 
maintained the biological activity further supporting this observation. In general all 
of the compounds based on the benzothienopyrimidine core were selective for 17β-
HSD1 over 17β-HSD2 and did not show any undesired estrogenicity in an ER-α or 
ER-β binding assay.124 
1.8 Aims of this Work 
The aims of this project are to design, synthesise and evaluate novel 17β-HSD1 
inhibitors. It is anticipated that inhibition of 17β-HSD1 would block the biosynthesis 
of the stimulatory sex hormone estradiol and that this could therefore be an effective 
clinical treatment for breast cancer and other estrogen-dependent diseases. Previous 
work in the group has already shown that a 17β-HSD1 inhibitor can exhibit positive 
effects in vivo.
43
 It is hoped that this project will produce compounds which are 
potent inhibitors and are selective over other isozymes of the 17β-HSD enzyme 
family particularly type 2 and that show attractive overall pharmaceutical properties. 
This project will utilise many modern medicinal chemistry techniques to introduce 
functionality at different positions of the steroid core in a step wise manner. In order 
to do this effectively, a survey of early-stage competitor compounds will be 
undertaken and from this structure activity relationships can be established. It is 
hoped that this will provide an effective starting point for synthesis. However, it is 
also an aim of this project that a multidiscinplinary approach be pursued personally, 
involving not only synthetic chemistry, but also biological assay development, 
computational chemistry, enzyme kinetic analysis and potentially protein 
crystallography. Thus, a very important aim was also the development of a wide skill 
set within the umbrella of a new area of drug discovery. 
The project will use modern computational chemistry techniques to assess the 
potential of compounds and to establish potential areas of space within the protein 
target that require further investigation. Several X-ray crystal structures of 17β-
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HSD1 are already available with the protein co-crystallised with a variety of ligands. 
The X-ray crystal structure pdb code 1FDT
76
 will be used as both estradiol and 
NADP
+
 are present occupying their respective binding sites at a resolution of 2.20 Å. 
This will enable potentially significant interactions between the enzyme and new 
inhibitors to be identified. 
During this project the compounds synthesised will be assessed for their biological 
activity against using a whole cell assay developed by colleagues at both Ipsen Paris 
and Imperial College London. At the start of the third year of this project, Ipsen 
decided to stop their involvement with this area of research, and so IC50 values 
determined in a cell based assay were not able to be obtained for a number of 
compounds. To investigate how selected established and new compounds interact 
with the active site of 17β-HSD1 and the type of inhibition that they display e.g. 
competitive, uncompetitive and mixed inhibition, production of the recombinant 
17β-HSD1 protein in-house will be necessary to provide large enough quantities for 
both X-ray crystallography, recombinant protein assay and kinetic work. It is 
envisaged that this will involve the transformation of the 17β-HSD1 gene into an 
appropriate expression vector followed by subsequent protein expression, 
purification and characterisation. 
Overall, the aim of this multidisciplinary project is to design and synthesise and 
evaluate novel inhibitors of 17β-HSD1 that ideally exhibit an IC50 of below 100 nM, 
are selective for 17β-HSD1 against other hydroxysteroid dehydrogenases and with 
good pharmaceutical properties which could ultimately be applied to an unmet 
clinical need. 
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Chapter 2 
Synthesis, Biological Evaluation and Computation Docking Study of the 2-
Substituted Mannich and Friedel-Crafts Series 
2.1 Introduction 
The following section describes the organic synthesis of novel steroidal 17β-HSD1 
inhibitors, where modifications to the steroid core are described in a step wise 
manner. The IC50 determination in a T-47D cell based assay of selected novel 
steroidal inhibitors was undertaken by collaborators at Ipsen in Paris, and the impact 
of these findings is evaluated. A computational docking study of the steroidal 
inhibitors with an X-ray crystal structure of 17β-HSD1 (pdb code 1FDT76) was 
undertaken in collaboration with Dr. M. Thomas who, under instruction by Mr. J 
Springall (JS) collected the raw data with, interpretation and refinement then being 
undertaken by JS. 
2.2 Design and Synthesis of 2-Substituted Mannich E1 and E2 Derivatives 
As stated previously, Hillisch et al.
72
 and Gege et al
73
. introduced substituents at the 
2-position of the E1 or E2 steroid core to try and increase selectivity for 17β-HSD1 
over 17β-HSD2 as well as to reduce any potential estrogenic effect that might be 
displayed by these inhibitors. It has been demonstrated that 2-substituted E1 
derivatives are potent inhibitors of 17β-HSD1, e.g. 3, IC50 = 47 nM determined in a 
recombinant protein assay.
7
 The compounds described by Hillisch et al.
72 
and Gege 
et al.
 73
 have relatively simple modifications and show that 17β-HSD1 inhibition can 
in principle be obtained with only subtle changes in the steroid core, although no 
estrogenicity or selectivity data have been reported. These 2-substituted compounds 
are likely to inhibit any CYP activity, in particular against CYP3A4 as the 2-position 
lies on a well-known major oxidative metabolic pathway.
74
 CYP inhibition might 
result in the undesired consequence of an increase in pharmalogical effects or 
toxicity caused by a decrease in drug metabolism. Due to the simplicity of the 
moieties introduced onto the E1 and D-homo-E1 core there is potential for improving 
both the activity of the 2-substituted compounds as well as their physico-chemical 
properties.
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Figure 17: Structure of 17β-HSD1 inhibitor STX2908 126 
2.2.1 Synthesis and Biological Results 
It is believed that the selective 17β-HSD1 inhibitor, STX2908 126 (Figure 17) is not 
particularly soluble in water and therefore it was thought that the introduction of a 
heteroatom into the 2-substituted moiety might maintain activity whilst also 
providing the option of forming salts to improve the solubility of these compounds. 
 
Scheme 1: Reaction scheme to show how the 2-substituted Mannich compounds are 
synthesised from E1 
The synthesis of compounds (Scheme 1) containing a nitrogen in the 2-substituted 
modification came by utilising the Mannich reaction procedure described by Patton 
et al.
125
 where a secondary amine is converted into an iminium ion which then 
readily reacts at the ortho position of a phenol. This mechanism is shown below in 
Scheme 2. 
60 
 
 
Scheme 2: The mechanism for the Mannich reaction between a secondary amine and 
phenol 
This mechanism can be applied to a wide range of commercially available secondary 
amines to rapidly access a series of 2-substituted E1 derivatives with the aim of 
maintaining biological activity against 17β-HSD1, whilst improving the 
physicochemical properties of the compounds. Figure 18 shows an illustrative 
example of a HPLC trace for two compounds synthesised in this series, 128 and 129. 
 
 
Figure 18: Illustrative examples of HPLC traces for compounds 128 and 129, 
(solvent system: 90% acetonitrile in water at 1.0 ml/min), Sunfire C18 reverse phase 
column 4.6 x 150 mm, 3.5 μm pore size 
Compound 129 
Compound 128 
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The 2-substituted E1 and E2 Mannich series will also investigate the potential role of 
aromaticity, ring size, which additional heteroatoms in the 2-substituted moiety can 
be tolerated and whether having a planar 2-substituent is necessary for activity 
against 17βSHD1 when compared to compound 126. The E1 and E2 compounds will 
be synthesised for each substitution as it is as yet uncertain as to what five membered 
D ring pattern provides the best inhibitory activity against 17β-HSD1. 
 
Compound R X % inhibition at 10 µM
a 
IC50 (nM)
a 
127 
 
O 28 ± 2 1854 ± 257 
128 
 
O 96 ± 4 723 ± 138 
129 
 
O 93 ± 6 1719 ± 331 
130 
 
OH 9 ± 0 nt 
131 
 
OH 55 ± 1 nt 
132 
 
OH 35 ± 7 nt 
nt: not tested; a – Measured in a T-47D cell based assay 
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Table 19: Synthesised 2-substituted Mannich series with biological results against 
17β-HSD1 as measured by Ipsen 
The data shown in Table 19 shows some interesting results. One of which is that of 
compound 128 where the substitution at position 2 is that of a morpholine moiety, 
which displays the best biological activity of this series with an IC50 value of 723 
nM. This is unexpected because compound 127 has the same ring size as compound 
128 but has a significantly lower inhibitory activity against 17β-HSD1 with an IC50 
value of 1854 nM. This increase in activity could be due to the oxygen of the 
morpholine moiety forming a beneficial interaction with an amino acid residue 
within the active site, potentially as an H-bond acceptor. It can be observed that all of 
the 2-substituted E2 derivatives display lower inhibitory activity against 17β-HSD1 
when compared to their 2-substituted E1 counterparts, for example compounds 128 
and 131 have percentage inhibition values of 96% and 55% respectively at 10 µM. 
This demonstrates that for this series, compounds bearing the E1 D ring are best for 
biological activity. When compared to compound 126 only compound 128 shows an 
improved activity in a cell based assay with an IC50 value of 723 nM compared to 1.0 
µM for 126 (unpublished results). This result implies that aromaticity and planarity 
of the 2-substituent are not key factors for determining the biological potency of the 
compounds. 
Compounds 128 and 129 were sent to the National Cancer Institute USA (NCI) for 
testing of their inhibitory potential against a variety of different cancer cell lines 
ranging from leukaemia, K-562; MOLT-4, to renal cancer, RXF393; TK-10 and UO-
31. Both compounds 128 and 129 show only minor to no effect against any of the 
cancer cell lines tested. 
2.2.2 Computational Docking Study 
Computational bonding interactions 
There are several types of non-covalent interaction that are partially responsible for 
stabilising the position of the compounds in the active site of the protein. These non-
covalent interactions are: 
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Hydrogen bonds 
A hydrogen bond is when a dipole is formed between a hydrogen atom, that is 
covalently bonded to an electronegative atom, and a second electronegative atom e.g. 
oxygen. Typical hydrogen bond lengths range between 2.6 and 3.5 Å. 
Van der Waals 
A Van der Waals interaction is where an inductive effect occurs between 
complimentary partial charges or dipoles in the electron density of adjacent atoms. 
Typical Van der Waals interactions occur over distances of 2.5 to 4.6 Å. 
π-π stacking interaction 
A π-π stacking interaction occurs when the p orbitals of two aromatic systems 
overlap. The π-π stacking interaction occurs at a distance of approximately 3.8 Å. 
Hydrophobic interaction 
Hydrophobic interactions occur when two non-polar residues are in close proximity, 
this results in the surface area being exposed to the solvent being reduced. This 
reduces the entropy of the residues and increases the entropy of all the water present 
therefore, the formation of hydrophobic interactions is a spontaneous process.  
For the docking studies of inhibitors in 1FDT
76
 the starting conformations used for 
receptor docking were generated from an energy minimization performed using the 
MMFF94s force field, with MMFF94 charges applied, as implemented in Sybyl 7.0. 
The resulting lowest energy conformer was then used for docking studies using Gold 
version 2.2 with default parameters. The active site was defined as a 12 Å radius and 
30 attempts were computed and scored using Gold score. 
The computational docking study provides an insight into how the compounds might 
bind in the active site of the protein, therefore it is important to bear in mind that any 
distances reported are only an approximation and not representative of what might be 
the case in ‘real’ structures. 
After analysis of the compounds through computational docking studies it can be 
seen that compound 128 has an increased number of interactions with the active site 
compared to compound 127. (Figures 19 and 20) 
64 
 
 
 
Figure 19: Compound 128 (cyan) docked into 1FDT
76
 with NADP (orange) and 
potential interactions with the morpholine substituent shown 
The oxygen of the morpholine substituent in the 2-position displays potential 
interactions (Figure 19) with the nitrogen and oxygen of the amide from the co-factor 
at distances of 2.7 Å and 3.0 Å respectively. Additional interactions occur between 
the nitrogen of the pyridyl ring of the co-factor at 4.1 Å. It was also observed that the 
nitrogen of the morpholine substituent and the oxygen of the amide present in NADP 
can potentially interact at a distance of 4.0 Å. The morpholine substituent also 
exhibits potential hydrogen bonding interactions with the active site of 17β-HSD1 
through the hydroxyl of Tyr155 at 4.2 Å. When comparing compound 128 to 
compound 127, which has a piperidine substituent at the 2-position, it can be seen 
from Figure 20, that there are potential hydrogen bond interactions between the 2-
substituted piperidine and the active site are with the nitrogen and oxygen of the 
amide from the co-factor at 3.5 Å and 4.0 Å respectively. This decreased number of 
potential hydrogen bonding interactions for 127 compared to 128 could explain why 
128 is approximately 3 times as potent as 127. When investigating the ring moiety of 
the 2-substituent for compound 127 it can be seen in Figure 19 that the morpholine 
ring of 127 is docked in a boat geometry which is an unstable geometry for a six 
membered ring to adopt due to steric reasons and bond angles between the carbon 
atoms within the ring. This indicates that the oxygen of the morpholine moiety is 
interacting favourably with either the co-factor or a residue within the active site, 
overcoming the instability of the boat geometry. In comparison compound 128 
bearing a piperidine moiety adopts the more stable chair geometry (Figure 20). This 
Tyr155 
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further indicates that the oxygen of the morpholine moiety of compound 127 is 
forming a favourable interaction with either the co-factor or a residue within the 
active site of 17β-HSD1. 
 
Figure 20: Compound 127 (yellow) docked into 1FDT
76
 with NADP (orange) and 
potential interactions with the piperidine substituent shown 
It was observed that, depending on the substituent in the 2-position, the orientation of 
the compound in the active site changes (Figure 21). This indicates that the active 
site of 17β-HSD1 is very large and that there is potentially more than one binding 
orientation for the 2-substituted E1 compounds. 
 
Figure 21: E1 (blue), STX2008 (yellow) a previously synthesised compound bearing 
a N(Me)2 2-substituted moiety, 127 (pink), 128 (orange), 129 (white) overlaid in the 
active site of 17β-HSD1 with the enzyme structure removed 
This ambiguity of binding orientation can also be observed from the low resolution 
X-ray crystal structure obtained of 126 within the active site of 17β-HSD1 (Figure 
22), where there is a possible dual confirmation for amino acid residue Phe259. The 
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electron density of 126 is not entirely resolved, however, there is some electron 
density which suggests that compound 126 might bind in a mixed orientation and 
Phe259 shifts accordingly to accommodate the compound. The first orientation 
consists of the D ring of the steroid core directed towards the NADP
+
 cofactor 
binding site, whilst in the second it is observed that the A ring of the steroid points 
towards the NADP
+
 cofactor binding site. From studying the available X-ray crystal 
strucures in the RSCB pdb database it has been observed from the structures for pbd 
codes 3KLP (Δ4-diol), 3KMO (3β-diol), 1QYW (androstanedione), 1JTV (T), 
3KLM and 3DEY (DHT) that the steroidal ligand binds in the steroidal active site 
with the D ring pointing away from the NADP
+
 co-factor binding site (Figure 22). 
This therefore indicates this observation is not entirely unexpected, although this 
structure is the first to suggest two competing binding modes. 
 
Figure 22: Crystal structure of STX2908 126 in the active site of 17β-HSD1 at 2.8Å 
in both binding orientations. 
When 129 was docked into the active site of 17β-HSD1 it was observed that it 
exhibited a different binding orientation to that seen for compounds 127 and 128 
(Figure 23) where the D ring points towards the co-factor. This is further evidence 
that amino acid residues within the active site of 17β-HSD1 can potentially shift to 
accommodate a variety of compounds. 
Phe259 
Phe259 
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Figure 23: Compound 129 (grey) docked into 1FDT
76
 with NADP (orange) and 
potential interactions with the inhibitors A ring and 2-substituent and the active site 
shown.  
The nitrogen of the pyrollidine substituent from 129 shows potential hydrogen 
bonding interactions with the oxygen atoms of Glu282 at 4.4 Å and 5.5 Å. The 
reduced number of interactions with the active site when compared to 128 as well as 
the change in binding orientation could potentially explain why 129 is not as 
biologically active as 128.  
These same trends for biological activity against 17β-HSD1 are also observed for the 
17β-OH, E2 mimic, compounds. The increased potency of the E1 mimics against 
17β-HSD1 compared to the E2 mimics can potentially be explained from the 
computational docking study as when 128 and 131 are overlaid within the active site 
of 17β-HSD1 (Figure 24) a change in binding position is observed. The position of 
131 moves the morpholine substituent away from the co-factor and therefore moving 
the morpholine moiety away from the co-factor preventing the formation of any 
potential intercations that were described previously. 
Glu282 
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Figure 24: Compound 128 (blue) and 131 (brown) overlaid in the active site of 17β-
HSD1 with the co-factor, NADP
+
 (orange) 
The reason for the near comparable activity of compounds 127 and 130 can be 
theorised as being due to the binding positions of the two compounds being 
essentially overlaid when determined via computational docking studies (Figure 25). 
 
Figure 25: Compound 127 (yellow) and 130 (green) overlaid in the active site of 
17β-HSD1 with the co-factor NADP+ (orange). 
2.3 Synthesis of Second 2-Substituted Mannich Series 
It was hypothesised that, because the morpholine substitution at the 2-position of the 
steroid core gave the best inhibitory activity against 17β-HSD1, that different 2-
substituents containing other heteroatoms might also improve the inhibitory activity 
against 17β-HSD1 and potentially reduce the estrogenicity of these compounds. 
However when attempts were made to synthesise other 2-substituted Mannich 
compounds, the presence of both the 2 and 4-regioisomers was observed in CDCl3 
from the 
1
H NMR (Figure 26, 27 and Table 20). 
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Figure 26: 
1
H NMR spectrum of compound 128 showing the aromatic hydrogen 
signals corresponding to the aromatic hydrogens on carbons 1 and 4 
 
Figure 27: 
1
H NMR showing the aromatic hydrogen signals indicating that the 
Mannich reaction occurs at both the 2 and 4-position 
 
 
1 4 CDCl3 
CDCl3 
1 
1 
2 
4 
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Amine % 2-Substituted E1 % 4-Substituted E1 
 
85 15 
 
Eschenmoser’s salt 
80 20 
 
127 
100 a 
 
128 
100 a 
 
129 
100 a 
 
75 25 
 
80 20 
a – No product detected 
Table 20: A table to show which amines were used in the Mannich reaction with 
estrone and the proportions of the 2 and 4 substituted products of each amine 
71 
 
Following synthesis of the compounds shown in Table 20, attempts were made to try 
and separate the regioisomers. These regioisomers could unfortunately not be 
separated by chromatography (HPLC and TLC) or re-crystallisation indicating that 
the energy required for bond formation at both the 2 and 4-position for the Mannich 
reaction in this series are very similar and therefore, regioselectivity is specific to the 
amine being reacted. 
When trying to synthesis the N-dimethyl-2-substituted E1, the reagent N,N,Nʹ,Nʹ-
tetramethylmethanediamine was initially used, and when studying the mechanism 
(Scheme 2) for the Mannich reaction between E1 and a secondary amine, it can be 
seen that an imine is formed in situ. To test whether the mechanism of the Mannich 
reaction between a secondary amine and E1 proceeded in the manner stated in 
Scheme 1 Eschenmoser’s salt was used without the presence of paraformaldehyde. 
The reaction between Eschenmoser’s salt and E1 provided both the 2 and 4-
substituted regiosiomers in the same ratios as was observed for the Mannich reaction 
using N,N,Nʹ,Nʹ-tetramethylmethanediamine, therefore showing that the Mannich 
reaction between E1 and a secondary amine must proceed with the formation of an 
imine intermediate in the manner of the mechanism shown in Scheme 2. 
2.4 Results of additional biological testing 
The most potent inhibitor from the 2-substituted Mannich series compound 128 was 
selected for further in vitro biological evaluation to be carried out by collaborators at 
Imperial College London. They were able to determine that 128 shows no 
cytotoxicity in either MCF-7 (ER
+
) or MDA-MB-231 (ER
-
) cell lines over 96 h for 
concentrations up to 50μM. MCF-7 and MDA-MB-231 are breast cancer cell lines 
which account for a large proportion of breast cancer cell studies. They were also 
able to demonstrate that 128 is selective for 17β-HSD1 against 17β-HSD2. 
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Figure 28: A graph to show the percentage inhibition of 17β-HSD2 activity in MDA-
MB-231 cells. STX3606 is compound 128 and STX511 was another compound 
under investigation as determined by collaborators at Imperial College London in 
MDA-MB-231 cells 
Compound 128 shows 37% inhibition of 17β-HSD2 at 10 μM (Figure 28), but is 
selective for 17β-HSD1 as it displays a percentage inhibition of 96% at 10 µM, 
giving 128 a selectivity ratio of approximately 2.6 for 17β-HSD1 over 17β-HSD2. 
Due to compound 128 displaying favourable biological results, it was taken forward 
for testing against certain cytochrome P450s (CYPs), namely CYP3A4 which is 
primarily associated with metabolism of the 2-position of the steroid core, to assess 
the metabolic stability of compound 128. This testing was performed by 
collaborators at Imperial College London using the commercially available 
CYP3A4BFC and CYP3A4BQ inhibition kits produced by Becton Dickinson 
Biosciences, designed to test the metabolic stability of the compounds under 
investigation. 
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 IC50 (µM) 
Compound Compound structure 3A4BFC 3A4BQ 
E1 
 
1.5 >100 
E2 
 
4.4 >100 
2-Ethyl E1 
 
<0.045 1.1 
2-Ethyl-3-
methoxy E1 
 
3.8 >100 
128 
 
84% @ 10 μM and 
70% @ 1 μM 
67% @ 10 μM and 
65% @ 1 μM 
Table 21: Table shows IC50 (μM) and percentage inhibition values for steroid-based 
compounds against specific CYP3A4 using both the CYP3A4BFC and CYP3A4BQ 
inhibition kits 
The compounds used selected in Table 21 were chosen because of their varying 
activities for CYP3A4 and of these compounds only 129 was synthesised by JS the 
other compounds had previously been provided to the collaborators at Imperial 
College London. From the data in Table 21 it can be seen that by having an ethyl 
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substituent in the 2-position the inhibitory activity against the CYPs is dramatically 
increased when compared to the natural substrate and product, E1 and E2 
respectively. It is also observed that by protecting the oxygen at the 3-position the 
CYP activity is significantly reduced, IC50 3.8 µM and > 100 µM when compared to 
IC50 values of < 0.045 µM and 1.1 µM for 2-ethyl-3-methoxy E1 compared to 2-
ethyl E1 using the CYP3A4BFC and CYP3A4BQ inhibition kits respectively. This 
substitution pattern is not very useful, however, because as stated earlier substitution 
at the 3-position can potentially reduce the activity of the compound significantly. 
When looking at 128 we can see that the percentage inhibition of CYP3A4 is high 
although this percentage reduces when the concentration is reduced from 10 μM to 1 
μM. It is important to bear in mind that these concentrations are much higher than 
would be seen in a target organ and so can only be used as an approximation of the 
inhibitory activity of 128 against CYP3A4. 
2.5 Design and Synthesis of the 2-Substituted Friedel-Crafts Series 
2.5.1 Synthesis and Biological Results 
A series of 2-substituted E1 compounds (Table 22) were synthesised utilising the 
Friedel-Crafts chemistry between commercially available acid chlorides and 3-
OMeE1 to provide a series of compounds substituted at the 2-position.  
A phenylchloro moiety was chosen for substitution, as in the literature Hartmann et 
al.
116, 121
 have shown that compounds substituted with halogens 120b, 121c and 121e 
can be more potent 17β-HSD1 inhibitors, (IC50 values of 6 nM, 5 nM and 19 nM 
respectively), than the corresponding parent compounds without any halogen 
substitution being present 119a and 119d (corresponding IC50 values of 22 nM and 
33 nM). This Friedel-Crafts series was designed to investigate whether aromaticity, 
the presence of a chlorophenyl moiety and length of the 2-substituted moiety are 
important for the biological activity of these compounds against 17β-HSD1. The 2-
substituted Friedel-Crafts series were synthesised (Scheme 3) by methylating the 3-
OH of E1, followed by the Friedel-Crafts reaction using the lewis acid aluminium 
chloride to generate the acylium ion that attacks ortho to the 3-OMe. The final step 
was to de-protect the 3-OMe compounds 134-138 by adding a mixture of ammonium 
hydrochloride and aluminium chloride to a cooled solution before allowing the 
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reaction mixture to warm to room temperature and then refluxed for two hours before 
being quenched by pouring slowly onto crushed ice to yield compounds 139-143. 
 
Scheme 3: The synthetic route followed to access the 2-Friedel-Crafts compounds 
139-143 
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Compound R X % Inhibition at 10 µM 
134
a 
 
OMe 73 (IC50 1.2 µM) 
135 
 
OMe 35 ± 5 
136 
 
OMe 36 ± 8 
137 
 
OMe 32 ± 9 
138 
 
OMe 44 ±3 
139
a 
 
OH 87  (IC50 1.1 µM)
 
140 
 
OH 46 ± 1 
141 
 
OH 74 ± 2 
142 
 
OH 55 ± 4 
143 
 
OH 22 ± 10 
 a previously synthesised 
Table 22: The biological activities of synthesised compounds 134–143 in a T-47D 
cell based assay as measured by Ipsen 
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When comparing the 3-OMe and the 3-OH compounds, the 3-OH compounds 
generally show a higher percentage inhibition, with compound 139 showing the 
highest percentage inhibition of 74% for the compounds tested. When comparing 
compound 135 with compound 134 and compound 140, with compound 139 it is 
observed that aromatic compounds are moe biologically active than the non-aromatic 
compounds of the 2-substituted Friedel-Crafts series against 17β-HSD1. It can also 
be concluded that a chloro moiety is tolerated by the active site but multiple chloro 
moieties as seen with compounds 137 and 142, lead to percentage inhibitions of 32% 
and 55% respectively and are not as well tolerated by 17β-HSD1 as the mono chloro 
substitution as observed with compounds 138 and 141 which have percentage 
inhibition values of 36% and 74% respectively. It can also be seen that the distance 
of the substituent away from the A ring is important for activity. For the 3-OMe 
compounds the methylene chlorophenyl compound 138 displays a percentage 
inhibition of 44%, whilst in the 3-OH series its analogue compound 143 has the 
lowest percentage inhibition of 22%. This is an unexpected result as usually 
compounds with a free hydroxyl at the 3-position on the A ring are more potent than 
their protected 3-position derivatives. None of the compounds from the Friedel-
Crafts series was assessed for estrogenicity but it is hypothesised that none of these 
2-substituted compounds will display estrogenic activity as described previously 
Vicker et al. stated that in silico studies using the crystal structure (pdb code 
3ERD
114
) of the ligand binding domain of the human ERα have shown that 
compounds bearing a C2 substitution of the steroid nucleus do not fit well, as the 2-
substituent disrupts key hydrophobic interactions in the ERα binding site. 
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2.5.2 Computational docking study 
Through computational docking studies it can be hypothesised that compound 139 
can be tolerated by the active site of 17β-HSD1 (Figure 29). 
 
Figure 29: Compound 139 (purple) and E2 (blue) overlaid in the active site of 17β-
HSD1. 
Only one binding orientation was observed for compound 139 unlike STX2908 123 
(Figure 22) which displays the potential for different binding orientations in the 
active site. The only difference between compound 123 and compound 139 is that 
there is a carbonyl between the steroid A ring and the phenyl of the 2-substituent. 
The carbonyl displays potential interactions with the amide of the NADP
+
 co-factor 
at 3.1 Å and 3.8 Å for the oxygen and nitrogen respectively. 
 
Figure 30: Compound 139 (purple) and NADP (orange) with potential hydrogen 
bonding interactions shown between the carbonyl of 139 and NADP 
The potential interactions between the carbonyl from the 2-substituent of compound 
139 and the co-factor doesn’t significantly alter the biological activity of compound 
139 with comparison to STX2908 123, IC50 values of 1.1 µM and 1.0 µM 
respectively. This would imply that the biological activity of these compounds is 
determined by the moieties present on the ring of the 2-substituent and that the linker 
79 
 
between the A ring and the ring of the 2-substituent does not play a significant role in 
the binding of these 2-substituted compounds. 
When compounds 138–143 were docked into the active site of 17β-HSD1 and 
overlaid (Figure 31) it can be seen that all of these compounds occupy the steroid 
binding site in the active site of 17β-HSD1. It was observed that compounds 140 and 
141 display two binding modes, the first binding mode is where the A ring of the 
steroid core is orientated towards the co-factor and the second binding mode is where 
the D ring of the steroid points towards the co-factor this is not surprising due to the 
similarity of these compounds to STX2908 123 which has been demonstrated to do 
the same. Compound 142 displays only the binding mode in which the D ring points 
towards the co-factor binding site whilst computational docking shows compound 
143 binding in an orientation where the A ring is in close proximity to the co-factor. 
 
Figure 31: An overlay of compounds 138 (white), 141 (yellow), 142 (pale pink) and 
143 (pink) docked into the active site with NADP
+
 (orange) present. 
When looking at compound 141 which displays the highest percentage inhibition, 
74.03% it can be seen that the chloro moiety displays a number of potential 
interactions with the NADP
+
 co-factor at 3.3, 4.4 and 4.9 Å (Figure 32). 
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Figure 32: Compound 141 (yellow) with potential interactions shown between the 
chloro moiety and the co-factor (orange), the hydroxyl on the A ring and the 
carbonyl linker and the co-factor (orange) and active site amino acid residues Tyr155 
and Glu194. 
Potential hydrogen bonding interactions were also observed for the hydroxyl present 
on the A ring and Tyr155 at 2.5 Å as well as the co-factor at 3.9 and 4.4 Å. (Figure 
32) Other potential hydrogen bonding interactions were also observed between the 
carbonyl linker and the amino acid residue Glu194 at 2.2 and 4.3 Å as well as the co-
factor at 4.0 and 4.9 Å (Figure 32). 
Docking of compound 142 showed that it adopts a binding orientation where the D 
ring of the steroid core pointing towards the co-factor. Therefore, this compound can 
form potential interactions with amino acid residues present in the opening of the 
active site for it to adopt this binding orientation. When looking at the A ring and the 
2-substitution of this compound it can be seen that there are several potential 
interactions between the chloro moieties, the carbonyl linker and the hydroxyl 
present at the 3-position of the steroid core (Figure 33). 
Tyr155 
Glu194 
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Figure 33: Compound 142 (pale pink) with potential hydrogen bond interactions 
shown with amino acid residues (green). 
The para chloro moiety displays potential interactions with the amino acid residues 
Glu228 at 3.6 Å and Glu282 at 4.1 and 4.8 Å, whilst the ortho-chloro moiety shows a 
potential interaction with Arg258 at 3.7 Å. The carbonyl linker has a potential long 
distance interaction with Met279 at 4.9 Å. The hydroxyl at the 3-position of the 
steroid A ring exhibits possible interactions with His221 at 2.8 Å and Arg282 at 3.8 
and 5.2 Å. These interactions can explain why compound 142 displays moderate 
biological activity against 17β-HSD1. 
It has been shown that minor modifications in the substituent at the 2-position of the 
steroid core can play an important role in the biological activity of these compounds 
against 17β-HSD1. Compound 127 has been identified as the most potent of the 
compounds described in this series with an IC50 value of 723 nM. Compound 127 has 
also been shown to be selective for 17β-HSD1 over 17β-HSD2 as well as displaying 
no cytotoxicity for 96 h at 50 µM. 
Chapter 3 
Synthesis, Biological Evaluation and Computation Docking Study of the 2,4-
Substituted Mannich Series 
3.1 Synthesis and biological results 
To further explore substitution of the A ring it was decided to investigate substitution 
at the 4-position. The reason for this is that compounds 91-96,
114
 which display a 
wide variety of substitutions at the 4-position of the A ring mimic, ranging from a 
bromine in compound 95, to a phenyl group in compound 96, have been shown to be 
Glu228 
Glu282 
Arg258 
Met279 
His221 Arg282 
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potent inhibitors of 17β-HSD1 with IC50 values of 40 nM and 20 nM respectively in 
a recombinant protein assay. Although compounds 91-96 are of a different class to 
those being investigated here it does highlight that minor changes in substituent at 
differing positions of the steroidal A ring can exhibit large effects in inhibitory 
activity against 17β-HSD1. 
To synthesise compounds 147-152 (Scheme 4), E1 was initially methylated at the 3-
OH moiety using methyl iodide, followed by regiospecific acetylation at the 2-
position using the Friedel-Crafts chemistry that has been previously described to give 
compound 144. Compound 144 was deprotected using trimethylamine hydrochloride 
and aluminium chloride to yield 2-acetyl E1 145 which was subsequently reduced 
using H2 and Pd on carbon for 5 days to give the key intermediate 2-ethyl E1 146. 
Compounds 147-152 were accessed by manipulation of the Mannich reaction 
described earlier, the reaction was regiospecific because the 2-ethyl moiety prevents 
attack of the iminium ion at the 2-position, therefore the only position which is 
accessible for attack is the 4-position. Successively compounds 153-155 were 
synthesised by reduction using NaBH4 of the C17 carbonyl to the β hydroxyl. This 
reduction forms only the β orientation and the C18 methyl group prevents attack 
from the α face.  
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Scheme 4: The synthetic route used for accessing the 2,4-substituted Mannich series 
 The added benefit of using the 2-ethyl E1 is that any of the compounds (Table 23) 
synthesised should not display any estrogenic activity. 
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Compound R X % Inhibition at 10 µM 
147 
 
=O 43 ± 3 (IC50 4.9 µM)
 
148 
 
=O 66 ± 6 
149 
 
=O 39 ± 5 
150 
 
=O 54 ± 4 
151 
 
=O 26 ± 4 
152 
 
=O 53 ± 6 
153 
 
βOH 63 ± 2 
154 
 
βOH 17 ± 17 
155 
 
βOH 13 ±13 
 
Table 23: Biological activities of the synthesised 2,4- substituted compounds against 
17β-HSD1 in a T-47D cell based assay as measured by Ipsen 
From the data in Table 23 is can be seen that the E1 derivatives are more active 
against 17β-HSD1 than their corresponding E2 derivatives. This was also 
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demonstrated for the 2-substituted Mannich series described earlier. It can also be 
observed that it is not the size of the substituent in the 4-position that determines the 
activity of the inhibitor against 17β-HSD1, as compound 152 with an azepane ring 
moiety is nearly as active as the compound 148 bearing a pyrolidine ring with 
percentage inhibition values of 66% and 53% respectively. It can be seen from the 
biological data for the E1 derivatives bearing a substiuent with a 6-membered ring 
that the morpholine compound 150 is the most potent with a percentage inhibition of 
54%, whilst the piperidine compound 149 which does not contain any additional 
heteroatoms has a lower percentage activity of 39%, which was also seen for the 2-
substiuted E1 Mannich derivatives. From this it could be hypothesised that the 
thiomorpholine compound 151 would be more biologically active against 17β-HSD1 
than the piperidine compound 149, which is not the case. This could be due to the 
sulphur atom forcing the six membered ring adopting an unfavourable conformation 
that is not well tolerated by the active site and therefore, forcing  compound 151 to 
bind in a manner that is not well tolerated by the active site of 17β-HSD1. 
Interestingly, when comparing compounds 149 and 127 the percentage inhibition of 
the 2,4-substituted piperidine compound 149 is higher than that observed for the 2-
substituted piperidine compound, which is not the case for any of the other 2,4-
substituted E1  compounds and their 2-substituted E1 analogues. 
When looking at the E2 derivatives, 153 displays the best biological activity, 63% 
inhibition, with a marked decrease in activity observed for compounds 154 and 155 
when compared to their E1 counterparts compounds 150 and 152, which show very 
similar percentage inhibitions of 17% and 13% respectively. It is difficult to draw 
many conclusions for how compounds 154 and 155 interact with the active site of 
17β-HSD1 due to the large limits on the percentage inhibition that was measured by 
collaborators IPSEN. This indicates that when these compounds bear a β-hydroxyl 
on the D ring they bind in a manner that the size of the 4-substituent plays an 
increasingly important role in the inhibitory effect of the compounds. In a 
recombinant protein assay where percentage inhibition is being oberserved in the E2 
to E1 direction compound 153 is shown to be acting as a substrate, this has been 
described in further detail in Section 6.3.5. Overall it appears that the 2,4-substituted 
E1 and E2 derivatives are moderate to poor inhibitors of 17β-HSD1 and that the 
nature of the 4-substituent can play an important role in the inhibitory effect of the 
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compounds against 17β-HSD1. It can also be noted that the substitution of the D ring 
plays an equally important role in the binding of these inhibitors with the E1 
derivatives having a higher affinity for 17β-HSD1 than the E2 derivatives. 
3.2 Computational Docking Study 
From computational analysis of the 2,4-substituted Mannich compounds docked into 
the active site of the protein crystal structure of 17β-HSD1 (pdb code 1FDT76) it is 
observed that all of these compounds 147 – 152 fit into the active site (Figure 35). 
 
Figure 35: Overlay of compounds 147 (yellow), 148 (pink), 149 (white), 150 (dark 
blue), 151 (orange), 152 (purple) docked into the active site of 1FDT
76
 with the co-
factor (orange) shown. 
Interestingly, the docking results of compounds 147 – 152 all appear to bind with the 
D ring of the steroid core in close proximity to the NADP
+
 co-factor. Only 
compound 147 the 4-substituted N-dimethyl compound positions itself so that the 
carbonyl present on the D ring at position 17 of the steroid core is in the vicinity of 
the catalytic triad of Tyr155, Lys159 and Ser142 (Figure 36). It can be observed 
from Figure 35 that when the 4-substituent is a large ring moiey, the compounds 
dock into the active site of 17β-HSD1 with the the steroid core rotated through 
approximately 180º on an axis running through all the rings. 
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Figure 36: Overlay of compound 147 (yellow) and E2 (blue) with the co-factor 
(orange) and amino acid residues of the catalytic triad, Tyr155, Ser142, Lys159 
shown (green) and an overlay of compounds 148 (pink), 149 (white), 150 (dark 
blue), 151 (orange) and 152 (purple) with E2 (blue) and co-factor (orange) and 
amino acid residues (green) 
Attempts were made to synthesise a series of 2,4-substituted compounds utilising the 
Friedel-Crafts approach however, all attempts were unsuccessful. This could be due 
to steric hindrance around the 4-position of the steroid A ring, preventing attack of 
the acylium ion intermediate and therefore preventing formation of the desired 2,4-
substituted Friedel-Crafts compounds. 
It can be seen from the data in Table 23 that the 2,4-substituted Mannich series of 
inhibitors display poor to moderate inhibition of 17β-HSD1, and are less active than 
the 2-substituted Mannich series. This implies that to achieve optimum activity 
against 17β-HSD1 the best position for substitution on the steroid A ring is the 2-
position. It can also be concluded that the nature of the substituent plays a very 
important role in determining the inhibitory potential of the compounds against 17β-
HSD1. 
 
 
 
 
Tyr155 
Tyr155 
Ser142 
Ser142 
Lys159 
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Chapter 4 
Synthesis, Biological Evaluation and Computation Docking Study of the C17 
Amide Series 
4.1 Synthesis and Biological Results 
It has been shown in the literature
47, 78 
that modifications and substitution at the C17 
position of E1 can be tolerated by the active site of 17β-HSD1 and that these 
compounds have the potential to act as inhibitors. The hypothesis behind why these 
C17 modified compounds act as inhibitors for 17β-HSD1 is because the modification 
acts as a bioisostere for the hydroxyl at C17 of E2 (Figure 14). 
 
Scheme 5: The synthetic route for accessing compounds 163-167 
The C17 amine 157 was accessed via a reductive amination between 3-O-benzyl E1 
156, ammonium acetate and sodium cyanoborohydride in THF and methanol at room 
temperature for four days. Sodium cyanoborohydride was chosen as the reducing 
agent as it is especially suitable for reductive aminations, since the rate for the 
reduction of iminium ions is much faster than the rate observed for ketones. The C17 
amine adopts a β stereochemistry because the sodium cyanoborohydride attacks from 
the α face of the steroid core due to the steric hindrance from the β C18 methyl 
group. The mechanism for this reduction is shown in scheme 6. 
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Scheme 6: Reductive amination mechanism for the formation of compound 157 
The C17 amine 157 was then reacted with a series of commercially available benzoic 
acids using EDCI.HCl, DMAP and triethylamine as an amide coupling reagents to 
yield the desired C17 amides 158-162, before the final deprotection of the 3-
hydroxyl via a palladium catalysed de-benzylation 163-167. This amide coupling 
reaction was initially attempted with a series of benzoic acid chlorides as it was 
thought that the increased reactivity of the acid chloride would provide higher yields 
when compared to the EDCI.HCl coupling route. However, these reactions provided 
the compound in relatively low yields and were troublesome to purify by flash 
chromatography. 
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Figure 37: FT-IR of compound 157, showing that the signal corresponding to the 
carbonyl stretch is no longer present confirming the synthesis of compound 157 
It was hypothesised that these compounds would bind in the active site with the D 
ring pointing towards the NADP
+
 co-factor and the A ring towards the opening of the 
active site. A methoxy substitution on the benzoic acid moiety was decided upon as 
this group is an electron donating group and so would provide information about the 
electronic effects of this region of the active site as well as if there is any size 
limitation in this region. 
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Compound Substitution % Inhibition at 10 µM 
 2 3 4 5 6  
163 H H OMe H H 19 ± 11 
164 OMe H OMe H H 27 ± 3 
165 OMe OMe H H H 5 ± 2 
166 OMe H H OMe H 16 ± 3 
167 OMe H OMe OMe H 65 ± 3 
168
a 
H H H H H 15
 
a – Previously synthesised 
Table 24: Biological activities of the synthesised C17 amide compounds 163-168 in 
a T-47D cell assay measured by IPSEN 
It can be seen from Table 24 that 166 is the most active compound of the methoxy 
substituted compounds with a percentage inhibition of 65%. When looking at how 
the percentage inhibition of these compounds varies with the position of the methoxy 
substituent it can be seen that having a methoxy moiety in the 4-position the 
compounds 163 and 164 provide moderate activity against 17β-HSD1 with 
percentage inhibitions of 19% and 27% respectively. Other compounds 166 and 167 
bearing a methoxy moiety at the 2-position are tolerated by the active site and 
demonstrate moderate to good activity against 17β-HSD1. However, 165 with a 
methoxy substituent present in the 2 and 3-position shows the lowest activity of all 
this series of compounds with a percentage inhibition of 5%. The percentage 
inhibition of 165 is lower than that of 168 which does not bear any substitution of the 
phenyl ring, indicating that compounds bearing electron donating groups in both the 
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ortho and meta positions are not well tolerated by the active site. Interestingly 166 
shows approximately three times the percentage inhibition of that displayed by 165, 
16% and 5% respectively, showing that meta substitution of the phenyl ring can be 
accepted by the active site, so long as the ortho-meta substitution pattern is present 
on opposing sides of the phenyl ring. Compound 166 shows a similar percentage 
inhibition to 168 signifying that the 2,5-methoxy substitution is as biologically active 
as the non-substituted phenyl ring. When combining the inhibitory effects of 2,4,5-
methoxy substitution in a single compound an increase in percentage inhibition of 
approximately 3 fold is observed for compound 167 compared to 163, 164 and 166. 
4.2 Computational Docking Study 
Results from a computational docking study of compounds 163-167 docked into the 
protein crystal structure 1FDT
76
 shows that all of these compounds are tolerated by 
the active site (Figure 38). 
 
Figure 38: Overlay of compounds 163 (grey), 164 (pink), 165 (green), 166 (yellow), 
167 (blue) docked into the mesh protein crystal structure 1FDT with co-factor 
(orange) shown. 
The majority of compounds that belong to the C17 amide series display low 
inhibitory activity against 17β-HSD1 in a T-47D cell based assay. Due to this it can 
be concluded that this series of compounds can be tolerated by the active site, 
however the interactions that are formed are not entirely favourable and so an in 
depth compoutational docking study was not undertaken for the C17 amide series. 
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Chapter 5 
Synthesis, Biological Evaluation and Computation Docking Study of the 16-
Substituted Extended Linker and Reverse Amide Series 
5.1 Introduction 
It has been shown by Pelletier et al.
91, 92
 that large substituents at C16 of E2 are well 
tolerated by the active site of 17β-HSD1. Allan et al.43 have also demonstrated that 
the Bath drug candidate STX1040 1 (Figure 5) inhibited E1 stimulated proliferation 
of T-47D cells in vitro and significantly decrease tumour volumes and plasma E2 
levels in vivo
43
. Further research into the SAR of compounds bearing a C16 
substituent is an attractive proposition. To develop the SAR two strategies were 
devised, the first being the moving of the pyridine substituted amide side chain of the 
C16 substituent, of STX1040 1, one carbon away from the steroid core to investigate 
what the optimum linker length for these C16 substituted compounds is; the second 
approach being the reversal of the amide orientation of STX2109 169 (Figure 39), 
103% inhibition at 1 µM and an IC50 value of 75 nM,  which is designed to 
investigate whether the same biological activity can be obtained as that seen for 
STX2109 169 despite a minor change in structure and therefore providing an insight 
into how these compounds bind in the active site of 17β-HSD1. 
 
Figure 39: Structure of University of Bath compound STX2109 160 
We thus decided to synthesise compounds of the following structures: 
94 
 
Figure 40: The C16 substituted target compounds 
5.2 Design, Synthesis and Biological Evaluation of C16 Extended Linker 
Series 
5.2.1 Synthesis and Biological Results 
It has been shown in the literature that by extending the length of the C16 linker that 
biological activity towards 17β-HSD1 can be increased. This can be seen by 
comparing compounds 57k which contains a linker length of 3 atoms and 58k 
containing a linker length of 4 atoms, which have IC50 values of 0.51 µM and 0.037 
µM respectively.
75
 By extending the linker length to five atoms we can easily 
determine what the optimum linker length is for this series of 17β-HSD1 inhibitors. 
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Scheme 7: Reaction scheme for how to access compounds 174-176. 
Compounds 174-176 were accessed by a condensation reaction between ethyl 
formate and 3-O-benzyl E1 156, followed by a Wittig reaction with a stabilised 
phosphoylide to give 171. The driving force behind the Wittig reaction is the 
formation of the very stable triphenylphosphine oxide; it is believed that the 
zwitterionic betaine intermediate rapidly closes to form a cyclic four membered 
oxaphosphetane which then, depending on the whether the ylide used is a stabilised, 
or destabilised ylide reacts to give the E or Z alkene respectively (Scheme 8). 
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Scheme 8: Wittig mechanism for the formation of compound 171 
Formation of the C16 alkene present in compound 171 can be confirmed by looking 
at the 
1
H NMR spectrum in Figure 41 where a doublet is observed at approximately 
3.3 ppm which corresponds to a CH2 bonded to the C16 alkene and the carbonyl. If 
the double bond formed a single bond further away from the C16 then two doublets 
would be observed at a higher ppm of approximately 6 ppm to 6.5 ppm. A quartet 
would also be observed for the C16 CH at approximately 2.5 ppm to 3 ppm which is 
not the case. 
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Figure 41: 
1
H NMR demonstrating the formation of compound 171, with a CH2 
signal highlighted to show that the oxaphosphetane reacts in the manner shown in 
Scheme 3 
The ensuing reduction of the alkene and deprotection of the 3-O-benzyl group 
yielded compound 172. Subsequent saponification of compound 172 gave the key 
intermediate, the ethyl carboxylic acid compound 173. An amide coupling reaction 
between a variety of pyridyl amines using EDCI.HCl, DMAP and triethylamine as 
amide coupling re-agents yielding the desired compounds 174-176 (Scheme 4). The 
biological results for these compounds can be seen in Table 25. 
 
Compound R % inhibition at 10 µM 
174 
 
63 ± 3 
175 
 
68 ± 1 
98 
 
176 
 
49 ±13 
Table 25: Biological results of the synthesised compounds 174-176 in a T-47D cell 
assay as measured by Ipsen 
These inhibitors were tested as mixtures of diastereoisomers, for which the ratio of R 
and S was undetermined as only one set of peaks was observed in the 
1
H NMR 
spectrum. It can be seen that these compounds display moderate to good inhibition of 
17β-HSD1 at 10 µM. As stated earlier, the position of the nitrogen in the pyridyl 
moiety plays an important role in the biological activity of these compounds. This 
series of compounds again highlights this observation with the N-para pyridyl 
compound 176 displaying the lowest percentage inhibition of 49%, which is 
approximately 14% lower than the N-ortho pyridyl compound 174 and 
approximately 19% less than that observed for the most active N-meta pyridyl 
compound 175.  The most active compound having the nitrogen in the meta position 
is not unexpected, as compounds bearing this substitution pattern have been 
previously shown to be the most active compounds of their series.
75, 104
  
5.2.2 Computational Docking Study 
From computational docking studies it can be seen that compounds 174-176 are all 
well tolerated by the active site of 17β-HSD1 and adopt the same binding orientation 
where the C16 substituent is pointing towards the co-factor binding site which is the 
proposed binding orientation for STX1040 1 when it is docked into 17β-HSD1. It 
was also observed that the steroid cores of compounds 174-176 all occupy the same 
space as the E2 steroid core of 1FDT
76
 (Figure 42). 
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Figure 42: Compounds 174-176 docked into 1FDT
76
 with the co-factor (orange), 
highlighting that they all appear to bind in the same orientation and occupy the same 
site 
Several potential interactions between 174 and both the active site of 17β-HSD1 and 
the co-factor were identified (Figure 43). These include interactions between the 
nitrogen of the amide present in the C16 extended linker and a hydroxyl of the ribose 
linker at a distance of 4.1 Å, and the nitrogen of the pyridyl moiety at a distance of 
4.7 Å, as well as the oxygen of the amide present in the C16 extended linker and the 
nitrogen of the amide present on the pyridyl moiety at a distance of 4.5 Å.  
 
 
Figure 43: Compound 174 (green) docked into 1FDT
76
 with all potential interactions 
with the co-factor (orange) and amino acid residues (green) shown 
Compound 174 displays potential interactions with certain amino acid residues 
present in the active site of 17β-HSD1, consisting of Tyr155 interacting with both the 
nitrogen and oxygen of the amide present in the extended C16 linker at distances of 
2.7 Å and 4.5 Å respectively. The nitrogen of the pyridyl moiety of compound 174 
Tyr155 
Leu93 Gly94 
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looks to have some potential interactions with the oxygen and nitrogen of Leu93 and 
the nitrogen of Gly94 at distances of 4.2 Å, 4.3 Å and 2.9 Å respectively. 
When compound 175 was docked into the active site of 17β-HSD1 (1FDT76) 
potential interactions were observed with both the co-factor and amino acid residues 
present in the active site. The interactions with the co-factor consist of the nitrogen in 
the pyridyl ring of compound 175 interacting with oxygen atoms present in the co-
factor backbone at distances of 2.7 Å and 2.9 Å, as well as the nitrogen of amide 
present in the C16 extended linker displaying potential interactions with a hydroxyl 
present on the ribose at a distance of 4.4 Å and the nitrogen of the pyridyl of the co-
factor at a distance of 4.5 Å and with the nitrogen of the amide of the co-factor at a 
distance of 4.3 Å (Figure 44). 
 
 
Figure 44: Compound 175 (grey) docked into 1FDT
76
 with all potential interactions 
with the co-factor (orange) and amino acid residues (green) shown 
Interactions with amino acid residues Gly94 and Tyr155 were observed (Figure 44). 
The oxygen of the C16 extended amide linker of 175 displays a potential interaction 
with the nitrogen of Gly94 at a distance of 4.6 Å, as well as an interaction with the 
oxygen present in Tyr155 at a distance of 4.8 Å.  The nitrogen of the C16 extended 
amide also interacts with the oxygen of Tyr155 at a distance of 3.1 Å. All of these 
interactions with both the co-factor and amino acid residues are very similar for both 
compounds 174 and 175, which was expected considering their very similar 
percentage inhibitions of 17β-HSD1 at 10 µM which are 63% and 68% respectively. 
A computational docking investigation of compound 176 the least biologically active 
compound from the extended C16 linker with a percentage inhibition value of 49% 
Glu94 
Tyr155 
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identified similar interactions to those observed for compounds 174 and 175 between 
the compounds and both the co-factor and amino acid residues Gly94 and Tyr155 
(Figure 45). The interactions with the co-factor are between the nitrogen of the amide 
present in the C16 extended linker and a hydroxyl of the ribose linker at a distance of 
4.0 Å, in addition to the nitrogen of the pyridyl of the co-factor at a distance of 4.1 Å, 
as well as the nitrogen of the amide present in the co-factor at a distance of 4.3 Å. An 
interaction between the C17 carbonyl of compound 176 and the oxygen of the amide 
present on the pyridyl ring of the co-factor exists at a distance of 4.8 Å. It appears 
that unlike compounds 174 and 175, the oxygen of the amide from the C16 extended 
linker for compound 176 does not form any potential interactions with the co-factor. 
This could be one reason why compound 176 displays a lower percentage inhibition 
when compared to compounds 174 and 175. 
 
 
Figure 45: Compound 176 (brown) docked into 1FDT
76
 with all potential interactions 
with the co-factor (orange) and amino acid residues (green) shown 
Similarly to compounds 174 and 175 potential interactions between compound 176 
and amino acid residues Gly94 and Tyr155 were observed. The nitrogen of the 
pyridyl E ring of compound 176 can interact with the nitrogen of Gly94 at a distance 
of 4.2 Å. The oxygen of the amide present in the C16 extended linker can interact 
with the same nitrogen of Gly94 at a distance of 4.5 Å as well as the oxygen of 
Tyr155 at a distance of 3.2 Å. The nitrogen of the amide present in the C16 extended 
linker appears to be able to interact with the same oxygen of Tyr155 at a distance of 
3.4 Å. It was noted that no potential interactions with Leu93 were observed for 
compound 176 when compared to 174 and 175 which again could explain why 
Glu94 
Tyr155 
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compound 176 is the least biologically active compound from the C16 extended 
linker series. 
When comparing the biological activities of this series of compounds 174-176 to 
those observed for compounds 1, 57j-k and 58k-m,
109,110
 it can be seen that all of the 
compounds containing a linker length of five atoms 58m and 174-176 display similar 
percentage inhibition values in the range of 50 – 70%, whilst compounds 57j-k, 58k-
l bearing a linker length of three or four atoms show percentage inhibition values of 
approximately 90% and compounds 58k-l depending on the position of the nitrogen 
in the pyridyl ring. This implies that a linker length of 3-4 atoms is the optimum 
number of atoms for biological activity against 17β-HSD1. A reason as to why 
compounds 58m and 174-176 bearing a linker containing five atoms displaying 
lower percentage inhibitions than compounds with a linker of 3-4 atoms is that the 
extension of the linker forces the pyridyl ring further into the co-factor binding site, 
therefore displacing the pyridyl ring away from the optimum binding position. 
5.3 Design and Synthesis of the C16 Reverse Amide Series 
5.3.1 Synthesis and Biological Results 
To access compounds designed from the second SAR strategy 2-ethyl-3-OMe-16-
CHOH E1 177 was reacted with 179 a source of electrophilic nitrogen which was 
synthesised by reacting hydroxylamine and trifluoroacetic acid anhydride at reflux 
under anhydrous comditions by a preparation described by Pomeroy et al.
126
 to give 
the 2-ethyl-3-OMe-16-CN E1 compound 180. The proposed mechanism for this 
reaction is shown in Scheme 9. 
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Scheme 9: Proposed mechanism for the formation of compound 179 
It is proposed that the alkene of compound 178 attacks the electrophilic nitrogen of 
179 to form the electrophilic amide intermediate that would readily react with the 
trifluoroactate anion to form an imine intermediate and trifluoroacetic anhydride. The 
lone pair of the hydroxyl is then thought to attack the proton of the imine and 
therefore use the formation of the cyano moiety as he driving force for the reaction 
and giving water as a by product. 
A single X-ray crystal structure of this diastereoisomer, compound 180, shows that it 
is triclinic and adopts the P1 unit cell. The X-ray crystal structure (Figure 46) 
confirms the stereochemistry of the 16 and 17 positions of the diastereoisomer 180 as 
β at both centres. Compound 180 was then reduced with LiAlH4 to give the 16β-
methyl amine-17β-hydroxyl diastereoisomer 181. The amine 181 was then reacted 
with an aromatic acid chloride to yield the 3-OMe protected desired compound. 
Reacting the diastereoisomer 181 with the acid chloride was not regiospecific and 
provided both the 16-N-substituted and 17-O-substituted compounds. It was thought 
that this lack of regiospecificity could be avoided because the pKa of the amine is 
higher than that of the hydroxyl therefore making it a better nucleophile and more 
likely to attack the electrophilic centre present in the acid chloride. To make the 
substitution regiospecific for the amine an amide coupling approach was adopted 
where EDCI.HCl was used in conjunction with DMAP and triethylamine to give 
compounds 182-184. Demethylation of the resulting compounds with BBr3 yielded 
the desired final compounds 185-187 (Scheme 10). 
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Scheme 10: Reaction scheme for the synthesis of compounds 185-187 
 
Figure 46: X-ray crystal structure for compound 180 demonstrating the 
stereochemisty at C16 
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Figure 47: X-ray packing diagram of the diastereoisomer 180 
The LiAlH4 reduction
 132
 of both the cyano and carbonyl to the corresponding amine 
and alcohol of compound 181 can be easily monitored by observing the stretches of 
the corresponding functional groups by FT-IR to ensure that the reaction has 
proceeded to completion. See Figure 48 and 49 for the FT-IR spectra of compounds 
180 and 181.  
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Figure 48: FT-IR spectrum of compound 180 showing the formation of the cyano 
moiety by the cyano signal at a frequency of 2244.6 cm
-1
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Figure 49: FT-IR spectra of compound 181 with iillustrating that the LiAlH4 
reduction has occurred by the loss of signals corresponding to the cyano and 
carbonyl moities. 
 
Compound R % Inhibition at 10 µM 
185 
 
45 ± 3 
186 
 
81 ± 1 
187 
 
41 ± 1 
Table 26: Percentage inhibition data for synthesised compounds 185-187 against 
17β-HSD1 at 10 µM concentrations in a T-47D cell assay measured by IPSEN 
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It can be seen that these compounds display moderate to good inhibition of 17β-
HSD1 at 10 µM (Table 26). As previously stated, the substitution pattern of the 
nitrogen in the pyridyl ring plays an important role in the biological activity of these 
compounds. This series of compounds again highlights this observation with the N-
para pyridyl compound 187 displaying the lowest percentage inhibition of 41%, 
which is very similar to the 45% inhibition observed for the N-ortho pyridyl 
compound 185. The percentage inhibition of both these compounds 185 and 187 is 
approximately two fold lower than that observed for the most active N-meta pyridyl 
186 compound, displaying a percentage inhibition of 81%. The most active 
compound being that having the nitrogen in the meta position is not unexpected as 
compounds bearing this substitution pattern have been previously shown to be the 
most active compounds of their series.
75, 104 
5.3.2 Computational Docking Study 
From computational docking studies it can observed that compounds 185-187 all fit 
into the active site and adopt the same binding orientation with the C16 moiety 
pointing towards the co-factor binding site (Figure 50), which is the hypothesised 
binding mode for STX1040 1. It can also be seen that the steroid core of compound 
185-187 all overlay the steroid core of E2 very closely. 
 
Figure 50: Compounds 185-187 docked into 1FDT
76
 with the co-factor (orange), 
showing that they all appear to bind in the same orientation and occupy the same 
binding site 
The similar biological activities of compounds 174-176 and 185-187 against 17β-
HSD1, an be explained as the compounds 186-187 are shown to adopt a very similar 
binding mode (Figure 51) in the active site of 17β-HSD1 and display similar 
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potential interactions with the co-factor and amino acids residues present in the 
active site of 17β-HSD1 as that observed for compounds 174-176. 
 
Figure 51: Compounds 174-176 and 185-187 overlaid in their determined docking 
orientation with the protein structure removed 
When compound 185 was docked into the active site (Figure 52) of the protein 
crystal structure of 17β-HSD1 (pdb code 1FDT76) potential interactions were 
observed with the co-factor; these include the nitrogen of the pyridyl E ring 
interacting with a hydroxyl from the ribose linker at a distance of 4.4 Å. The 
carbonyl of the amide present in the C16 linker interacts with a hydroxyl of the 
ribose linker, the nitrogen of the pyridyl ring of the co-factor and the nitrogen of the 
amide moiety attached to the co-factor pyridyl ring at a distances of 3.6 Å, 3.1 Å and 
3.9 Å respectively. The nitrogen of the amide present in the C16 linker shows a 
potential interaction with the oxygen present in the amide moiety attached to the 
pyridyl ring of the co-factor at a distance of 4.0 Å. 
 
 
Figure 52: Compound 185 (yellow) docked into 1FDT
76
 with all potential 
interactions with the co-factor (orange) and amino acid residues (green) shown 
Gly94 Tyr155 
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Compound 185 also displays potential interactions with amino acid residues Leu93, 
Gly94 and Tyr155. The nitrogen present in the pyridyl E ring of compound 185 
interacts with the oxygen present in Leu93 at a distance of 4.3 Å, the nitrogen present 
in Gly94 at a distance of 4.1 Å and the oxygen of Tyr155 at a distance of 3.7 Å.  The 
carbonyl oxygen of the amide present in the C16 linker can interact with the 
hydroxyl present in Tyr155 at a distance of 2.7 Å. The hydroxyl of Tyr155 can also 
interact with the nitrogen of the amide present in the C16 linker over a distance of 
3.4 Å. 
Compound 186 displays potential interactions with the co-factor as well as amino 
acid residues Leu93, Gly94 and Tyr155 (Figure 53). When looking specifically at the 
interactions between the co-factor and compound 186 it can be seen that the nitrogen 
in the pyridyl E ring can form long distance interactions with the two hydroxyls 
present on the ribose linker at distances of 5.4 Å and 5.5 Å. The oxygen present in 
the amide of the C16 linker can form potential interactions with the nitrogen of the 
co-factor pyridyl ring, the nitrogen and oxygen of the amide present on the co-factor 
pyridyl at distances of 3.2 Å, 3.5 Å and 3.8 Å respectively. The nitrogen of the amide 
present in the C16 linker can interact with the oxygen of the amide moiety present on 
the co-factor pyridyl ring at a distance of 4.0 Å. 
 
 
Figure 53: Compound 186 (dark green) docked into 1FDT
76
 with all potential 
interactions with the co-factor (orange) and amino acid residues (green) shown 
As stated earlier, compound 186 also interacts with amino acid residues present in 
the active site of 17β-HSD1.  These interactions include the nitrogen of the pyridyl E 
ring of compound 186 forming potential interactions with both the nitrogen and 
Leu93 
Gly94 
Tyr155 
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oxygen of Leu93 at a distance of 3.6 Å, as well as interacting with the nitrogen of 
Gly94 at a distance of 3.1 Å. The same nitrogen also can form a long range 
interaction with the hydroxyl of Tyr155 at a distance of 5.0 Å. The amino acid 
residue Tyr155 can also form potential interactions with the oxygen and nitrogen of 
the amide moiety of the C16 linker at distances of 3.1 Å and 3.6 Å respectively. This 
large number of potential interactions can be used to explain why compound 186 is 
the most biologically active compound from the reverse amide series. 
Computational docking studies of compound 187 shows that similar interactions to 
those observed for compounds 185 and 186 between the co-factor and amino acid 
residues are present in the active site. The interactions between compound 187 
(Figure 54) and the co-factor include those between the nitrogen of the pyridyl E ring 
of compound 187 and a hydroxyl of the ribose linker at a distance of 4.9 Å as well as 
an oxygen atom present in the co-factor backbone at a distance of 3.7 Å. The oxygen 
of the amide present in the C16 linker can form potential interactions with the 
nitrogen of the pyridyl ring of the co-factor and both the nitrogen and oxygen of the 
amide moiety of the pyridyl ring of the co-factor at distances of 3.1 Å, 3.7 Å and 4.2 
Å respectively. The nitrogen of the amide present in the C16 linker of compound 187 
interacts with the oxygen of the amide present on the pyridyl ring of the co-factor at 
a distance of 4.0 Å. 
 
 
Figure 54: Compound 187 (grey) docked into 1FDT
76
 with all potential interactions 
with the co-factor (orange) and amino acid residues (green) shown 
The nitrogen of the pyridyl E ring of compound 187 also forms interactions with the 
nitrogen of the amino acid residue Leu93 and the nitrogen of Gly94 at distances of 
3.8 Å and 4.5 Å respectively. The hydroxyl of Tyr155 can form interactions with 
Leu93 Gly94 Tyr155 
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both the oxygen and nitrogen of the amide of the C16 linker at distances of 2.9 Å and 
3.4 Å respectively. 
The combination of the biological data and the computational docking study 
indicates that compounds 174-176 and 185-187 adopt a similar binding orientation to 
that hypothesised for STX1040 1, where the steroid core binds in the steroid binding 
site. From the computational docking study it can be concluded that the co-factor 
binding region is large enough to accommodate both the C16 side chain and the co-
factor, which allows interactions between the C16 side chain and the co-factor. It can 
be seen from the percentage inhibition values in Tables 24 and 25 that these C16 
substituted inhibitors are moderate to good inhibitors of 17β-HSD1, with compound 
187 being the most potent from this series with a percentage inhibition of 81%. 
When comparing compounds 174-176 and 185-187 against STX1040 1 and 
STX2109 169 it can be observed that they display a lower inhibitory activity and this 
therefore indicates that STX1040 1 and STX2109 169 has the optimum linker length 
of four atoms between the steroid core and the pyridyl ring, and the preferred 
orientation of the amide for 17β-HSD1 activity. From studying the biological data 
and computational docking study it can be concluded that compounds 174-176 and 
185-187 can potentially act as “dual site” inhibitors, however the nature of the 
inhibition can not be determined from the computational docking study alone. 
Enzyme kinetics analysis has been further described in Section 6.3.4. 
Chapter 6 
Biological Evaluation 
6.1 Aims 
The objective of this part of the overall project was to synthesise and obtain large 
enough quantities of both the His tagged (H6) and un-tagged forms of 17β-HSD1 for 
use in protein crystallography trials and developing an in house recombinant protein 
assay to study the inhibitory effect of novel steroidal ligands whose synthesis has 
been previously described. The recombinant protein assay will also be used to 
investigate how selected synthesised compounds are inhibiting 17β-HSD1. 
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6.2 Expression and Purification of 17β-HSD1 
To do this it is necessary to express the human form of the 17β-HSD1, then isolate 
and purify the protein. 17β-HSD1 has been previously expressed by our group in a 
mammalian cell line, but unfortunately the low level of expression makes it difficult 
to undertake crystallographic studies. The mammalian system used is the gene for 
17β-HSD1 cloned into the pCEP4 vector (Figure 55) and protein is then expressed in 
293-EBNA cells. Collaborators from Imperial College London have managed to 
gain access to constructs of both the untagged and His-tagged versions of 17β-
HSD1. 
 
Figure 55: pCEP4 vector map displaying the restriction enzyme site and gene for 
antibiotic resistance 
Therefore, a bacterial expression system was developed to try and attain larger 
quantities of the protein. The first step in expressing the protein was to clone both 
the His-tagged and untagged forms of the 17β-HSD1 gene from the mammalian 
expression vector pCEP4 into a bacterial expression vector pET-24a (Figure 56).  
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Figure 56: A map of the pET24a bacterial expression vector displaying the 
restriction enzyme site and gene for kanamycin resistance  
To do this the restriction enzymes Nhe1 and Xho1 were used to remove the required 
gene from pCEP4 mammalian expression vector and to digest the pET-24a bacterial 
vector. An agarose gel was run to identify the restriction enzyme products for 17β-
HSD1 and pCEP4, the band corresponding to 17β-HSD1 gene was removed from 
the agarose gel and then purified using a QIAquick gel extraction kit.  The pET-24a 
restriction enzyme digest product was purified using the Qiagen PCR purification 
kit, followed by use of CIP alkalinephosphatase to prevent re-ligation of the bacterial 
expression vector with itself by removing the terminal phosphates, followed by a 
final purification step, a Qiagen purification kit was used to remove any unwanted 
enzymes and buffers that are present to ensure that only the desired fragment of 
pET-24a isolated. The next stage was to ligate the extracted gene for 17β-HSD1 into 
the pET-24a bacterial expression vector using a New England Biolabs Quick 
Ligation Kit to form the desired vector that codes for 17β-HSD1 (Figure 57). 
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Figure 57: Schematic representation of the insertion of the 17β-HSD1 gene into the 
pET-24a bacterial expression vector from the mammalian pCEP4 expression vector 
This process was repeated for the H6-17β-HSD1 gene. To be able to amplify the 
ligated vector the ligation products were transformed into competent cells. The 
XL10 Gold cells were chosen as they are highly competent, therefore increasing the 
chances that the ligated vector will enter the cells. The XL10 Gold cells are able to 
do this as they have what is termed to be a ‘leaky’ membrane, meaning they can 
easily incorporate new vectors within themselves. As only the fully ligated vector 
and the pET-24a bacterial expression vector contains antibiotic resistance to 
kanamycin, the XL10 Gold cells that incorporate the fully ligated vector will survive 
in the LB agar plates that contain the antibiotic kanamycin. Therefore only the 
colonies growing in the LB agar plates are the XL10 gold cells containing the fully 
ligated vector. For the untagged 17β-HSD1/pET-24a plate one colony was observed, 
whilst for the H6-17β-HSD1/pET-24a plate four colonies were seen. The next step 
was to pick these colonies onto a fresh LB agar plate and grow up a 10 ml culture of 
each and purify the DNA using a QIAquick mini-preparation kit. Additional NheI 
and XhoI double digests were then undertaken to help successfully identify two 
bands of the correct size corresponding to the pET-24a (5.3 Kbp) and the 17β-HSD1 
gene (1.2 Kbp) by agarose gel electrophoresis, staining with ethidium bromide and 
analysing by UV visualisation of the gel. Once successful clones were identified, by 
agarose gel electrophoresis, they needed to be transformed into an E.coli bacterial 
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expression strain, in this case BL21(DE3) pLysS, and then expression of the protein 
induced. 
 
Figure 58: The protein cloning expression region of pET-24a with the lac operon 
region and NheI and XheI region identified 
Protein expression is induced by using a compound called isopropyl β-D-1-
thiogalactopyranoside (IPTG) which brings about a chemical response within the 
cell which starts the process of protein expression. The lac operon is an operon 
responsible for the transport and metabolism of lactose in E. coli. The lac operon 
utilises a two part control mechanism to ensure that the cell only expends energy in 
producing the gene that is encoded for after the lac operon only when necessary. It 
achieves this with the lac repressor, which halts protein production in the absence of 
lactose. When lactose is present, a lactose metabolite called allolactose, binds to the 
lac repressor causing a change in its shape and therefore preventing the repressor 
from binding to the operator and allowing the RNA polymerase (RNAP) to 
transcribe the genes located after the operon and so leading to encoded proteins. 
IPTG acts as an allolactose mimic (Figure 59) and so triggers transcription of the lac 
operon.  
In the pET-24a bacterial expression vector being used for this section of the project, 
the cloning/ expression region is shown in Figure 59, there is a T7 promoter 
sequence code before the lac operator sequence and a T7 terminator sequence after 
the pET-24a cloning/ expression region. The T7 RNAP is an RNAP from the T7 
bacteriophage that catalyses the formation of the RNA in the 5’ → 3’ direction. The 
117 
 
T7 RNAP is extremely promotor and terminator specific and only transcribes DNA 
after a T7 promoter sequence and transcription is halted DNA at the T7 terminator 
sequence. These T7 RNA polymerase regions define the region for protein 
expression within the pET-24a bacterial expression vector being used. By using the 
restriction enzymes NheI and XhoI the 17β-HSD1 gene is inserted between the T7 
promotor, lac operator sequence and the T7 terminator sequence, therefore if the 
17β-HSD1 gene is ligated successfully into the pET24a bacterial expression vector, 
17β-HSD1 will be expressed. 
 
Figure 59: Structures of Allolactose and its mimic IPTG, which is used to induce 
protein expression 
BL21(DE3)pLysS was the first bacterial expression strain to be tried because it 
multiplies very quickly and is a standard bacterial expression strain.  
Disappointingly, the protein was not overly expressed using this particular strain as 
can be seen in the SDS PAGE protein gels below (Figure 60).  
Figure 60: Protein gels showing that the (H6-) 17β-HSD1 enzyme has not been 
overly expressed. The arrows indicate the position at which the band for over 
expression of 17β-HSD1 is expected to be seen 
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One possible reason as to why the E. coli bacterial expression strain BL21(DE3) 
pLysS did not overly express the protein is that the codons used for amino acids are 
not preferred for the bacteria E. coli but are for humans. For this reason a new E. coli 
bacterial expression strain, Rosetta 2 was used. Rosetta 2 are BL21 derivatives 
designed to enhance the expression of eukaryotic proteins that contain codons rarely 
used in E.coli. This particular strain codes for specific human t-RNAs for the rare 
codons; AGA, AGG, AUA, CUA, GGA, CCC and CGG coding for the amino acids 
arginine, leucine, isoleucine and proline. Once the transformation into Rosetta 2 has 
taken place and enough of the strain has been grown, the next step was to induce 
protein expression. 
After leaving the culture to express the protein overnight, the culture is centrifuged 
and the supernatant and pellet are separated. The supernatant consists of mainly the 
LB broth that the cells were grown in, and the pellet is the desired fraction as this 
contains the Rosetta 2 cells with the desired protein. After re-suspending the pellet 
we have to break open the Rosetta 2 cells and further centrifuge the solution to 
separate the desired soluble protein from the insoluble fraction which contains the 
cell debris and other insoluble proteins. To see if the protein had been overly 
expressed using the Rosetta 2 strain a SDS PAGE protein gel was run (Figure 61) 
and, as can be clearly seen the protein has been overly expressed both in the soluble 
and insoluble fractions. Although the majority of the protein is insoluble, enough of 
the protein is present in the soluble fraction for further use. To increase the amount 
of soluble protein that can be harvested a series of investigations into how the 
amount of IPTG, the temperature at which the culture is left, and the time period for 
which the culture is left to express affects the expression were undertaken. IPTG 
concentrations of 250 µM, 50 µM, 25 µM and 12.5 µM were used to investigate 
what is the optimum concentration of IPTG to be used for the expression of 17β-
HSD1 in the soluble fraction. From the SDS PAGE gels that can be seen from 
Figures 61 and 62 it can be seen that the lower concentration of 12.5 µM provides 
the best expression of H6-17β-HSD1 in the soluble fraction when compared to the 
250 µM IPTG concentration. It was also found from these experiments that to obtain 
the largest quantity of soluble protein the culture has to be left overnight and at a 
temperature of 16 ºC. Figure 62 shows the H6-17β-HSD1 form of the protein was 
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expressed at higher levels than the untagged protein and so it was decided to try and 
puify the H6-17β-HSD1 first. 
 
Figure 61: SDS PAGE gel displaying the increased expression of (H6-) 17β-HSD1 in 
the non-soluble fraction using 250 µM IPTG. 
Once the protein was overly expressed in the soluble fraction the next stage was to 
isolate and purify the protein (Figure 62). The reason for using the H6-17β-HSD1 
form of the protein is that the His tag enables affinity purification to occur and 
therefore making the purification process much more efficient as any proteins that do 
not specifically interact with the nickel can be eluted from the His-bind column 
using low concentrations of imidazole before the His tag protein is eluted with a 
higher concentration of imidazole. Initially, batch elution of the protein was 
undertaken with 500 mM imidazole. This, however, did not provide the protein in a 
high enough purity and therefore stepwise elutions using 50 mM, 100 mM, 200 mM 
and 500 mM imidazole were utilised. This step wise approach did improve the purity 
of the eluted protein. 
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Figure 62: SDS PAGE gel showing the results for the batch elution at 500 mM 
imidazole after expression at 12.5 µM IPTG 
However, to make the purification process more controllable and reproducible it was 
decided to use an AKTA FPLC. The FPLC purification was undertaken using a 
single His-Bind column with an elution gradient of 20-500 mM imidazole (Figure 
63). The eluted protein was of an acceptable purity, but for protein crystallography 
the protein used must be of a very high purity. Therefore, to further improve the 
purity of the protein a Q-sepharose column purification step with a NaCl elution was 
used (Figure 64). 
 
Figure 63: SDS PAGE gel showing the purification of H6-17β-HSD1 using a His 
bind column with imidazole elution 
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After purification the protein underwent dialysis to reduce the concentration of 
imidazole that was present. This dialysis step was followed by concentration of the 
protein to the desired concentration for use in either biological assays or 
crystallisation trials. The addition of a His-tag should not affect the structure or 
activity of the protein due to its small size and low immunogenicity as well as the 
fact that the tag is located on the exterior of the protein and so should not hinder the 
entry of compounds into the active site. If, however, the presence of the His-tag does 
impact upon the co-crystallisation with the inhibitor or activity of the enzyme in a 
recombinant protein assay, it is possible to cleave the tag from the protein before use 
by using an enterokinase kit supplied by Novagen, as an enterokinase cleavage site is 
coded for between the his tag and the start codon at the start of the protein coding 
sequence present in the 17β-HSD1 gene being used. 
 
Figure 64: SDS PAGE gel showing the purification of (H6-)17β-HSD1 using a  Q-
sepharose NaCl elution 
6.3 Enzyme Kinetic Analysis 
Having successfully synthesised and purified the protein, it was important to prove 
that it was active and therefore could be used for enzyme kinetic analysis and X-ray 
protein crystallography. To do this an enzyme kinetics assay was developed based 
on an absorbance assay from Mazza et al.
128
 This assay measures the change in 
absorbance of NADPH at 340 nm (Figure 65). 
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Figure 65: The reversible reaction of the conversion of E1 to E2 and what change in 
absorbance is being monitored at 340 nm 
The assay conditions can be found in the Experimental section of this report. 
6.3.1 UV Cuvette Assay 
 The activity of 17β-HSD1 can be measured in either direction depending on the 
conditions used. This shows that the activity of the enzyme is reversible. It was 
decided to use the E2 to E1 direction as this means going in the NADP to NADPH 
direction. If trying to measure the rate of the reaction in the opposite direction (E1 to 
E2) NADPH is being converted to NADP. As NADPH can be reduced to NADP in 
solution without having the enzyme present, a background rate is observed, which 
makes it more difficult to get accurate results from running the assay. 
When undertaking enzyme kinetic studies the first results determined are the VMAX 
and Michaelis-Menten constant, the KM for the assay conditions used. 
Experimental studies of enzyme kinetics are typically conducted by monitoring the 
initial rate of product formation in a solution in which the substrate is present at an 
excess to the enzyme. The principle features of many enzyme-catalysed reactions 
are: 
1. For a given initial concentration of the substrate, [S]0, the initial rate of 
product formation is proportional to the total concentration of the enzyme, 
[E]0. 
2. For a given [E]0 and low values of [S]0, the rate of product formation is 
proportional to [S]0. 
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3. For a given [E]0 and high values of [S]0, the rate of product formation 
becomes independent of [S]0, reaching a maximum value known as the 
maximum velocity, VMAX, which in this case is where the enzyme active site 
is saturated with substrate. 
The Michaelis-Menten mechanism accounts for these principle features. According 
to this mechanism, an enzyme-substrate complex is formed and either the substrate 
is released unchanged or after modification to form products. 
 
Eqn1 
          
Eqn2 
The rate of product formation according to this mechanism is: 
 
Eqn3 
The concentration of the enzyme-substrate complex can be obtained by applying the 
steady state approximation, and therefore writing: 
 
Eqn4 
It therefore follows that: 
 
Eqn5 
Where [E] and [S] are the concentration of the free enzyme and substrate, 
respectively.  
To express the rate law in terms of the concentration of the free enzyme and 
substrate added it is noted that [E]0 = [E] + [ES]. As the substrate is typically in a 
large excess relative to the enzyme, the free substrate concentration is approximately 
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equal to the initial substrate concentration and so it can be written that [S] = [S]0. It 
then follows that: 
 
Eqn6 
By substituting this result into Equation 3, we obtain the Michaelis-Menten equation 
for the rate of an enzyme-catalysed reaction: 
 
Eqn7 
The constant (kʹa + kb) / ka)) is characteristic of a given enzyme acting on a given 
substrate; it is called the Michaelis-Menten constant (KM). It is also possible to 
express the Michaelis-Menten constant as KM = [E][S] / [ES]. It therefore follows 
that the KM has the units of concentration. For practical purposes the KM is the 
concentration of substrate that achieves half VMAX. 
The KM is a way of quantifying the affinity of an enzyme for its substrate. If the 
enzyme has a low affinity for its substrate we obtain a large KM value and if the 
enzyme has a high affinity we obtain a low KM value. As we are dealing with a two 
substrate / two product reaction, KM is actually KMapp and VMAX is actually VMAXapp. 
Using our assay conditions we showed that the bacterially expressed H6-17β-HSD1 
was active (Figure 66) and we were able to plot a Michaelis-Menten graph (Figure 
67) from the data that was obtained. 
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Figure 66: A plot showing the activity of H6-17β-HSD1 from the UV cuvette assay 
 
Figure 67: Michaelis-Menten plot for 17β-HSD1, VMAXapp = 0.046 ΔAbs/min and 
KMapp = 87 μM at 100 µM NADP and 96 µM H6-17β-HSD1 
There are other methods for determining the KM value of 17β-HSD1 from 
experimental data, the most common of which is the Lineweaver-Burk and Eadie 
Hofstee plots (Figure 68). 
In accordance with experimental observations: 
1. When [S]0 << KM the rate is proportional to [S]0: 
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Eqn8 
2. When [S]0 >> KM the rate reaches its maximum value and is independent of 
[S]0: 
 
Eqn9 
Substitution of KM and VMAX into equation 8 gives: 
 
Eqn10 
Equation 10 can be re-arranged into a form that allows data analysis via linear 
regression to be able to take place in the form of the Lineweaver-Burk equation 
(Equation 11): 
 
Eqn11 
A Lineweaver-Burk plot is a double recipricol plot of 1/v versus 1/[S]0 which gives a 
straight line with a slope of KM/VMAX, a y-intercept at 1/VMAX and an x-intercept at -
1/KM.  
Equation 10 can also be re-arranged to allow data analysis via a different linear 
regression called the Eadie-Hofstee equation: 
 
Eqn12 
The Eadie-Hofstee plot is a plot of v versus v/[S]0 which yields a straight line with a 
slope of –KM, a y-intercept of VMAX and an x-intercept of VMAX / KM. 
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Both the Lineweaver-Burk and Eadie-Hofstee plots have their positives and 
negatives. The Lineweaver-Burk plot provides good precision of the VMAX and KM, 
however as it is a double recipricol plot it places undue weighting on the data points 
at lower concentrations of [S]0. The Eadie-Hofstee plot does not place undue 
weighting on the lower concentrations of [S]0; however, it has the disadvantage that 
the dependent variable, v, is used on both axis and so results in the lower precision 
of the VMAX and KM values. 
Analysis by using the Lineweaver-Burk and Eadie Hofstee equations give values of 
KMapp = 62.5 and 94.7 μM and VMAXapp = 0.035 and 0.047 ΔAbs/min respectively. 
These data show similar values to the non-linear regression from the Michaelis-
Menten plot, and all the values are easily within an order of magnitude of each other. 
The KMapp value also shows that the enzyme has a high affinity for the substrate as is 
expected. The plot that is preferred is the non-linear Michaelis-Menten graph; as can 
be seen from the plot, the points fit the curve much better than is observed in the 
linear regression plots shown in Figure 68. This means that the most accurate KMapp 
value for 17β-HSD1 from this assay is 87 μM. However, it can be observed from 
both the Lineweaver-Burk and Eadie Hofstee plots that the data does not fit the 
Lineweaver-Burk and Eadie Hofstee derivations of the Michaelis-Menten equation. 
 
Figure 68: Eadie Hofstee and Lineweaver Burk plots. An alternative way of 
analysing enzyme kinetic data 
It is also very important to prove that our inhibitors are not acting as a substrate for 
the enzyme. This can sometimes be the case when inhibitors are designed to be very 
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similar in structure to the natural substrate (Figure 69) and can lead to the inhibitor 
being metabolised in a very similar manner to the natural substrate, potentially 
leading to off target effects. 
 
Figure 69: A schematic representation of why STX2109 169 is being used to see if 
this series of steroidal ligands act as substrates for 17β-HSD1 in the UV absorbance 
assay 
This was tested by running an assay with an inhibitor, in this case STX2109 169, 
present in place of the natural substrate. A control assay comprising of the enzyme 
with the substrate, E2, and co-factor, NADP, with no inhibitor present was also run 
to provide a maximum expected rate. An assay containing just the enzyme in the 
presence of the co-factor without either the natural substrate, E2, or an inhibitor 
being present was also run to provide a controlled minimum rate (Figure 70). The 
reason for using STX2109 169 instead of STX1040 1 in this experiment was because 
STX2109 169 is designed to be an E2 mimic (Figure 69) and so would give the best 
representation as to whether this class of inhibitors would act as substrates towards 
17β-HSD1 in an assay measuring the conversion of E2 to E1. 
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Figure 70: A plot to show that STX2109 169 does not act as a substrate for 17β-
HSD1 
Assay Rate dA/dt P value 
Significantly 
Different 
17β-HSD1 -0.0002128 0.5043 No 
17β-HSD1 and 
STX2109 169 
0.001008 0.5315 No 
17β-HSD1 and E2 0.01528 <0.0001 Yes 
Table 27: Results showing that STX2109 169 does not act as a substrate for 17β-
HSD1 
The data obtained from the substrate investigation study (Table 27) assay show that 
the rate for 17β-HSD1 without the natural substrate, E2, compared to the rate 
observed for 17β-HSD1 with the inhibitor, STX2109 169 are not statistically 
significantly different. The statistical analysis was performed using the graph fittig 
software Prism. A P value of less than 0.05 shows that the null hypothesis, in this 
case that there is no difference between two selected sets of data, is not correct. This 
shows that the inhibitor STX2109 169 is not acting as a substrate for 17β-HSD1. The 
rate for when the E2 is present with the enzyme is notably different (approximately 
15 fold greater) than that of 17β-HSD1 with the inhibitor STX2109 169 and 17β-
HSD1 without the natural substrate E2.  
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6.3.2 Microplate Reader Assay 
The decision was made to change the method of analysis for the assay from using a 
UV cuvette based method which was very time consuming and laborious to one 
which used a Molecular Devices Versamax tunable microplate reader and 96 well 
plates. The decision for this change was to reduce the amount of time it was taking 
to perform the enzyme kinetic analysis. As the microplate reader is able to analyse 
multiple wells simultaneously, this therefore saves time on preparation of the assay 
conditions and overall time taken to perform the analysis. 
To assess the capabilities of the absorbance assay as a tool for studying how 
inhibitors act with the active site of 17β-HSD1, an inhibitor was selected to test the 
assay. It has been stated earlier that STX1040 1 is a highly potent inhibitor of 17β-
HSD1 with an IC50 value of 47 nM in a cell based assay and this therefore makes 
STX1040 1 a good candidate to use for the testing of the assay. For the reaction 
direction of 17β-HSD1 that is being used for this assay STX1040 1 cannot act as a 
substrate due to the carbonyl present on C17. Therefore, any rate observed when 
using STX1040 1 will be entirely due to the conversion of E2 to E1.  
The modifications made to the assay described by Mazza et al.
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 involved changing 
the solvent that was used to dissolve the inhibitor compounds. This was done as THF 
was dissolving the 96 well plates that were being used, and so affecting the ability to 
record the rates that were being obtained from the assay. The new solvent that was 
selected had to have the ability to dissolve compounds that were highly hydrophobic, 
because if the compounds are insoluble an accurate measurement of the rate cannot 
be obtained. This inaccuracy can lead to a misinterpretation of how the inhibitor is 
interacting with the enzyme. To decide upon which solvent is the best for the assay, 
a solubility study of the inhibitor being used, STX1040 1, was undertaken. A series 
of solvents was selected that were known to be good at dissolving compounds that 
were relatively insoluble. The solvents used were MeOH, a mixture of 
DMSO/isopropanol (50/50 v/v) and DMSO. The solvent that was best for dissolving 
STX1040 1 was DMSO and so was used here in for the enzyme kinetics 
experiments. 
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 To characterise the interaction of H6-17β-HSD1 with the inhibitor, STX1040 1, the 
assay can be used to work out IC50 values of STX1040 1 at varying concentrations of 
our substrate E2. STX1040 is used for this experiment as it has been shown to be our 
most potent inhibitor of 17β-HSD1. The IC50 value is the concentration of inhibitor 
that provides 50% inhibition of a maximum possible biological function. In this case 
the biological function is the rate at which the enzyme uses the substrate.  The reason 
for doing this is so that we can show that the inhibitor STX1040 1 does in fact act as 
an inhibitor of the enzyme 17β-HSD1 using this assay. An IC50 curve (Figure 71) is 
effectively a dose-response curve where we are examining the effect of different 
inhibitor concentrations on the rate of the enzyme being tested, where in this case the 
rate observed is for the conversion of E2 to E1 by the enzyme. 
 
Figure 71: IC50 plot at 200μM E2 for STX1040 1 
Using plots as shown in Figure 72 it is possible to obtain IC50 values; in the example 
shown this is 14.5 μM for STX1040 1. This value is much higher than that stated 
earlier for the IC50 of STX1040 1 in the cell-based assay; this is because a different 
assay is being used to gain the IC50 values and so they are non-comparable. As can 
also be clearly seen the inhibitor STX1040 1 is actively inhibiting the enzyme 17β-
HSD1. 
The next stage is to determine what type of inhibitor STX1040 1 is: competitive, 
non-competitive, or un-competitive. A competitive inhibitor binds to the enzyme and 
forms an enzyme-inhibitor complex in the active site, preventing any natural 
substrate from binding in the active site. A non-competitive inhibitor binds to the 
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enzyme but not at the active site, potentially changing the tertiary structure of the 
enzyme and preventing the natural substrate from binding to the active site of the 
enzyme. An un-competitive inhibitor binds the complex formed when the substrate 
is bound in the active site of the enzyme and prevents the release of the product. One 
method for determining the type of inhibitor STX1040 1 is by using a graphical 
representation called a Dixon Plot (Figure 73). A Dixon Plot is a graph of the 
reciprocal of the rate of conversion of E2 to E1 by the enzyme, versus the inhibitor 
concentration at varying concentrations of substrate. The type of inhibitor is 
determined by where the linear regressions intersect. For a competitive inhibitor or 
mixed site inhibitor the linear regressions would intersect above the x-axis, for a 
non-competitive inhibitor they would intersect on the x-axis and for un-competitive 
inhibitors they would run parallel with each other. Other information that can be 
determined from a Dixon Plot is Ki, the inhibition constant. From the Dixon Plot one 
obtains the Ki value by dropping a vertical line from where the lines intersect down 
to the x-axis. 
 
Figure 72: A Dixon Plot of the reciprocal of the rate versus the concentration of 
STX1040 1 
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Figure 73: The expanded region of the Dixon plot identifying where the linear 
regressions intersect 
From Figures 72 and 73 we can see that all the linear regressions intersect above the 
x-axis; however, they do not all intersect at the same point with each other. 
Therefore this data can not be used to conclusively prove that STX1040 1 is acting 
as a competitive inhibitor.  
6.3.3 MTS/PES Microplate Reader Assay 
6.3.3.1 Introduction 
The results obtained for the Dixon plot (Figure 72) using the microplate reader assay 
occured over a small absorbance range. To obtain more accurate and reproducible 
results an assay with a larger absorbance range is required. It was hypothesised that 
the low absorbance response, due to the extinction co-efficient of NADPH, from the 
assay was the reason as to why the data did not fit the Dixon plot model.  To 
increase the detected absorbance of the assay a literature search revealed that 
electron carrier agents can be used to provide an increased absorbance.
129 
NADPH 
has a high molar extinction co-efficient (ε) at the λMAX of 259 nm, 16900 M
-1
cm
-1
. 
However, at this wavelength it is difficult to accurately monitor this compound in 
physiological and biochemical systems, because cell-free extracts contain several 
components (NADP, and most proteins) with absorption maxima at λ = 260 nm. 
Consequently NADPH is usually monitored at its secondary absorption maximum of 
339 nm where the ε value is much lower, 6220 M-1cm-1. This is very important to 
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note as when considering the Beer-Lambert law (Equation 13), the lower the ε value 
the lower the value generated for the absorbance. 
 
Eqn13 
Where T = transmittance, I = intensity, ε = molar absorptivity, l = path length and c 
= concentration.  
When considering the transmittance expressed in terms of absorbance Equation 13 
can be written as: 
 
Eqn14 
Where A = absorbance, I = intensity, ε = molar absorptivity, l = path length and c = 
concentration. Equation 14 implies a linear relationship between absorbance and 
concentration. 
Therefore, it can be difficult to quantify the amount of NADPH as reaction products 
generated in cell-free extracts. This difficulty can be greatly reduced by coupling the 
formation of NADPH to the formation of a dye or other coloured substance which 
has an absorbance in the visible region of the spectrum, 450-700 nm. Formazan / 
tetrazolium couples represent an approach used for some cell proliferation assays. 
Formazans of these compounds e.g. MTT are insoluble in aqueous solutions and 
therefore are not useful in cell-free activity assays coupled to the generation of 
NADPH. Fortunately, the formazan MTS (Figure 74) is aqueous soluble and also 
exhibits a broad absorption band, 450-580 nm) giving a considerable λ range in 
which it may be usefully measured, therefore making MTS a useful indicator of the 
NADPH produced in physiological buffers.
129
 To enable conversion between the 
tetrazolium salt and formazan an electron coupling reagent is required.  
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Figure 74: The structures of the tetrazolium salt MTS and the corresponding 
formazan 
Traditionally, phenazine methosulfate, PMS is used as the electron coupling reagent. 
However more recently phenazine ethosulfate has been used as it is more chemically 
stable and so does not expire as quickly. Figure 75 shows the redox pathway for the 
conversion of NADP
+
 to NADPH and the roles in which MTS/PES plays. 
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Figure 75: Redox pathway for the formation of formazan from the tetrazolium salt
129 
6.3.3.2 Assay Development 
6.3.3.2.1 Michaelis-Menten Analysis 
By using MTS/PES it is proposed that an increase in absorbance will be observed 
compared to the absorbance assay previously described. 
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Figure 76: A plot showing the change in absorbance due to the conversion of E2 to 
E1 using the MTS-PES assay 
By applying the Michaelis-Menten equation to the data obtained for the conversion 
of E2 to E1 a KMapp value for E2 was determined as 30.99 µM and a VMaxapp of 1.94 
ΔAbs/min.  
 
Figure 77: Michaelis-Menten plot for the rate of conversion for E2 to E1 assessed 
over 60 s 
From the plot (Figure 77) it was calculated that the data fits the Michaelis-Menten 
model for ligand binding with reasonable accuracy, an R
2
 value of 0.9793 was 
determined.  
To aid in assessing how well the data fit the Michaelis-Menten model, residual plots 
can be used. A residual plot is a way of showing if the regression being used for 
analysis is suitable. The residuals plot shows the variance of the data points from the 
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curve in the y-axis. For the regression to be suitable for the data being analysed a 
random scattering of the points should be observed above and below the x-axis. 
When this random scattering is not observed it implies that another type of regression 
would better fit the data. The residuals plot for the Michaelis-Menten model does not 
show a random scattering through the plot as all but one point above the x-axis. 
(Figure 78) 
 
Figure 78: The residuals plot for the Michaelis-Menten analysis shown in Figure 83 
Non-linear Michaelis-Menten analysis (Figure 79) of the observed rate for the 
conversion of E2 to E1 at varying concentrations of NADP
+
 provides us with 
information about the KMapp of NADP
+
, which in this assay is 23.71 µM and has a 
VMaxapp of 2.525 ΔAbs/min.  
 
Figure 79: Michaelis-Menten analysis for the NADP
+
 binding site 
The residuals plot (Figure 80) for the Michaelis-Menten model displays a random 
scattering pattern, indicating that this ligand binding model can be used for the 
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binding of NADP
+
 with 17β-HSD1. An R2 value 0.9489 was determined for the 
Michaelis-Menten model, indicating the data fits the non-linear regression with 
reasonable accuracy. 
 
Figure 80: The residuals plot for the Michaelis-Menten analysis shown in Figure 85 
In order to be able to use the MTS/PES assay for inhibitor experiments certain 
parameters have to be determined to ensure that the data obtained is representative of 
how the enzyme operates at optimum conditions. 
The first of these is the effect of temperature upon the enzyme. It is expected that the 
best temperature to use would be 37 ºC as this is human body temperature. An assay 
was run at both 37 ºC and room temperature, 22 ºC and as expected a temperature of 
37 ºC was found to be the optimum temperature for the assay to be run at. This is 
because an increased rate was observed for all concentrations of E2 (Figure 81). 
Therefore when undertaking inhibitor studies any small changes in rate at low 
concentrations of E2 will be observed and not over looked. The temperature of 37 ºC 
was then used for all future assays. 
140 
 
 
Figure 81: A plot to show the effect of temperature upon the rate of conversion of E2 
to E1 
When analysing the assay data using the Michaelis-Menten model the residuals plot 
(Figure 82) shows a very interesting result. 
 
Figure 82: The residuals plot for the Michaelis-Menten analysis for the effect of 
temperature on the assay 
For the Michaelis-Menten analysis a clear trend can be seen from the residuals plot 
where the points adopt an upside down ‘U’ shape. This upside down ‘U’ is a clear 
indication that this particular curve fitting model is not the most suitable for this set 
of data, therefore implying that 17β-HSD1 does not obey Michaelis-Menten kinetics.  
The choice of buffer for running of these assays is very important. To assess which 
buffer out of those that have been reported in the literature both 0.1 M Tris pH 7.5 
and 0.05 M Potassium pyrophosphate pH 9.2 were analysed (Figure 83). 
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Figure 83: A plot to show how changing buffer alters the rate of conversion of E2 to 
E1 
From the plot it can be seen that both buffers have very similar curves at all 
concentration of E2. The KMapp values determined are 42.73 µM and 36.93 µM and 
VMAXapp values of 1.760 and 1.590 ΔAbs/min for 0.1 M Tris pH 7.5 and 0.05 M 
potassium pyrophosphate pH 9.2 respectively. 
 
Figure 84: The residuals plot for the effect of Buffer on the MTS/PES assay 
The residuals plot (Figure 84) for both the Michaelis-Menten model is shown above. 
It can be clearly seen that there is a trend within the data and that some other non-
linear regression would be better suited to the data. It was decided that the 0.1 M Tris 
pH 7.5 would be used for future assays as this was the buffer used in the UV 
absorbance assay previously described. 
The concentration of 17βSHD1 used in the assays is an important factor to consider 
because the aim is for the assay to provide a large enough maximum rate so that any 
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inhibition of this rate can be observed against a large response, but the rate should 
not be too large so that large quantities of inhibitor are required to bring about a 
reduction in the response, and therefore any potential low affinity inhibitors can not 
be identified. 
 
Figure 85: A plot to show the change in absorbance against time for varying 
concentrations of 17β-HSD1 
From Figure 89 it can be seen that the relationship between the absorbance observed 
for the conversion of E2 to E1 against time is a linear one at all concentrations of 
17β-HSD1 tested. The R2 values are all in the range of 0.9198 to 0.9825 for all 
concentrations of 17β-HSD1 (Table 28), suggesting that the data strongly fits a linear 
regression analysis model. 
[17β-HSD1] (µM) R2 value 
0.002 0.9198 
0.034 0.9686 
0.069 0.9671 
0.137 0.9705 
0.275 0.9825 
0.550 0.9639 
1.099 0.9652 
Mean 0.9625 
SD 0.02 
% RSD 2.06% 
Table 28: R
2
 results for various concentraions of 17β-HSD1 being investigated 
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The % RSD shown in Table 28 is less than 5% indicating that the experiment is 
linear for all of the concentrations of 17β-HSD1 used enabling the choice of 17β-
HSD1 concentration that best suits the experiment. 
To further assess what concentration of 17β-HSD1 should be used for the MTS/PES 
assay it was decided to select three concentrations of 17β-HSD1 and undertake an 
enzyme kinetics analysis (Figure 86), in this case 0.002, 0.034 and 0.069 µM were 
selected, as these concentrations provide a good change in absorbance due to the 
conversion of E2 to E1. 
 
Figure 86: Michaelis-Menten analysis to show the effect of 17β-HSD1 concentration 
on the rate of conversion of E2 to E1 
The results above show that as expected as the concentration of 17β-HSD1 increases 
so does the VMAXapp. To decide what concentration of the enzyme to use the KMapp 
values were compared alongside the R
2
 values. KMapp values of 16.57 µM, 24.54 µM 
and 28.91 µM and R
2
 values of 0.9347, 0.9895 and 0.9901 were determined 
respectively for 0.002, 0.034 and 0.069 µM. Due to the closeness in results for 0.034 
µM and 0.069 µM for KMapp and R
2
 the VMAXapp is what the choice is based upon. In 
this case it was decided that a larger VMAXapp value was desirable and so 0.069 µM of 
17β-HSD1 was used for all future assays. The concentration of 0.002 µM was not 
chosen because of the low VMAXapp and low KMapp value in comparison to the other 
17β-HSD1 concentrations. 
As some of the inhibitors under investigation have poor solubility in water, DMSO 
was added to the assay to help make them soluble and therefore aid in getting a true 
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understanding of their effects on 17β-HSD1. Therefore it was decided that the 
optimum amount of DMSO to add to the assay was an important factor to determine 
as potentially DMSO could have a negative effect upon 17β-HSD1. Figure 87 shows 
the effect that DMSO has upon the conversion of E2 to E1. 
 
Figure 87: A linear plot to show that concentrations of up to 20% DMSO have no 
negative impact upon the rate of conversion of E2 to E1 compared to 0% DMSO 
From the data that generated Figure 87 and the slopes calculated for this data in 
Table 29 it can be concluded that the amount of DMSO added up to and including 
20% does not deviate from the 0% control data. 
% DMSO Slope of linear regression 
0 
1.298×10
-5
 ± 7.615×10
-4 
5 7.262×10
-6
 ± 7.615×10
-6 
10 
4.881×10
-6
 ± 1.131×10
-5 
20 
1.048×10
-5
 ± 6.135×10
-6 
Table 29: Results showing the slopes of the linear regressions at varying DMSO 
concentrations 
Due to all DMSO concentrations investigated providing similar results, any of the 
concentrations investigated could be used. It was decided that 20% of DMSO was to 
be used for the MTS/PES inhibitor assay investigations as 20% DMSO would ensure 
that both E2 and the inhibitors would stay in solution for the duration of the assay. 
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The final parameter that was assessed was the concentration of MTS/PES that would 
be used for the assay. As this is the electron carrier agent and is therefore responsible 
for the absorbance generated from the conversion of E2 to E1 it is a very important 
parameter to assess. 
 
Figure 88: Michaelis-Menten analysis of the effect in changing the MTS/PES 
concentration in the assay 
From Figure 88 it can be seen that the VMAXapp increases, 2.003 to 2.758 ΔAbs/min 
for 5 µL and 20 µL respectively, as the concentration of MTS/PES increases this was 
as expected and it is assumed that at higher concentrations of MTS/PES the VMAXapp 
will eventually remain constant. However, it was not viable to undergo experiments 
at these concentrations as this would have had a significant effect on the 
concentration of E2, 17β-HSD1 and the inhibitors under investigation. The large 
VMAXapp is desirable for the assessment of inhibitors, however a small volume of 
MTS/PES is required so as to enable suitable amounts of E2, NADP and the inhibitor 
to be used and so therefore 10 µL of MTS/PES was used for all future assays. 
Residual plot analysis (Figure 89) of the Michaelis-Menten model for the MTS/PES 
data indicates that a trend was observed, where the points adopt an upside down ‘U’ 
shape. This upside down ‘U’ is a clear indication that this particular curve fitting 
model is not the most suitable for this set of data.  
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Figure 89: The residuals plot for the Michaelis-Menten analysis for the effect in 
changing the MTS/PES concentration 
6.3.3.2.2 Hill analysis 
It was observed from the residual plots that some of the data does not fit the 
Michaelis-Menten model, because of this it was decided to analyse the data using the 
Hill co-efficient (H) as well. The Hill co-efficient (H) provides a quantitative method 
for determining binding co-operativity, where if H > 1 then positive cooperativity is 
observed, which means that binding of a ligand at one site increases the binding 
affinity of a ligand at another site within the macromolecule. If H < 1 then negative 
cooperativity is observed, meaning that the binding of a ligand at one site decreases 
the binding affinity of a ligand at another site within the macromolecule. Puranen et 
al.
130
 published results stating that 17β-HSD1 exists as a homodimer131 consisting of 
two non-covalently bound subunits. It was also stated that substitution directed at the 
hydrophobic dimer interface resulted in inactive aggregates of the protein, indicating 
an exceptionally strong association between the monomers. As 17β-HSD1 exists as a 
homodimer analysis using the Hill model is acceptable. For all of the experiments 
described previously the data was also analysed using the Hill model to ascertain 
which model is best for the analysis of the data. 
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Figure 90: A Hill plot for the analysis of E2 conversion to E1 in the MTS/PES assay 
It can be seen that the data fits the Hill model (Figure 90) for ligand binding 
reasonably well, an R
2
 value of 0.9803 was determined. From the Hill model a KD 
value of 37.47 µM, VMAXapp of 2.081 ΔAbs/min, which are very similar to those 
calculated from the Michaelis-Menten model, and an H value of 0.8948 were 
calculated. This means that analysis using the Hill model, 17β-HSD1 acts in a 
negatively cooperative manner towards other binding subunits within the 
macromolecule after E2 has bound. 
The residuals plot for the Hill model shows a random scattering, this confirms that 
the Hill model fits the data better than the Michaelis-Menten model. (Figure 91) 
 
Figure 91: The residuals plot for the Hill analysis of the conversion of E2 to E1 
Hill analysis for the binding of NADP
+
 (Figure 92) provides very similar data to that 
observed for the Michaelis-Menten model, a KD of 19.46 µM and a VMAXapp of 2.752 
ΔAbs/min were determined. A H value of 1.174 is calculated this suggests that 
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binding of NADP
+
 to 17β-HSD1 results in positively cooperative manner towards the 
other subunits within the macromolecule. 
 
Figure 92: A Hill plot for the analysis of the conversion of NADP
+
 NADPH 
The residuals plot (Figure 93) for the Hill model displays a random scattering 
pattern, indicating the Hill model is suitable to use for the analysis of NADP
+
 to 17β-
HSD1. An R
2
 value of 0.9509 is observed for the Hill model.  
 
Figure 93: Residuals plot for the determination of the KD for NADP
+
 by Hill analysis 
For analysis of the effect of temperature by the Hill model (Figure 94) very similar 
curves are obtained to those observed by the Michaelis-Menten analysis, however 
there are key differences in the residual plots (Figure 95). 
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Figure 94: A Hill plot to show the effect of temperature upon the rate of conversion 
of E2 to E1 
 
Figure 95: Residuals plot for the Hill analysis for the effect of temperature upon the 
rate of conversion of E2 to E1 
For the Michaelis-Menten analysis a clear trend was observed in the residuals plot 
where the points adopt an upside down ‘U’ shape, whilst the Hill analysis is a 
random scattered plot, suggesting that analysis of the conversion of E2 to E1 by 17β-
HSD1 should be determined using the Hill model. 
The analysis for determining which buffer was used for running the assay using the 
Hill analysis (Figure 96) provided similar results to those obtained from the 
Michaelis-Menten analysis. 
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Figure 96: A plot to show how changing buffer alters the rate of conversion of E2 to 
E1 
The KD values determined are 42.73 µM and 36.93 µM and VMAXapp values of 1.760 
and 1.590 ΔAbs/min for 0.1 M Tris pH 7.5 and 0.05 M potassium pyrophosphate pH 
9.2 respectively. 
 
Figure 97: Residuals plot for the Hill analysis for the effect of buffer upon the rate of 
conversion of E2 to E1 
It was observed from the Michaelis-Menten residuals plot that there is a trend within 
the data and that some other non-linear regression would be better suited to the data. 
The residuals plot (Figure 97) for the Hill model shows a random scattering and 
therefore this non-linear regression fits the data. 
Hill analysis of the concentration of MTS/PES (Figure 98) to be used displays 
similar curves to those seen when analysis by the Michaelis-Menten model was 
undertaken. 
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Figure 98: A plot to show how changing the MTS/PES concentration alters the rate 
of conversion of E2 to E1 
Residual plot analysis (Figure 99) of the Hill model for the MTS/PES data shows a 
random scattering of the data points, again suggesting that the data should be 
analysed using the Hill model. 
 
Figure 99: Residuals plot for the Hill analysis for the effect of MTS/PES 
concentration upon the rate of conversion of E2 to E1 
Further work is however, required to further clarify which non-linear regression 
should be used for the analysis of the data obtained. The final conditions for the 
MTS/PES inhibitor assay have been determined to be: 
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Condition Final conditions Volume per well 
Temperature 37 ºC  
Buffer 0.1 M Tris pH 7.5 10 µL 
17β-HSD1 concentration 0.069 µM 5 µL 
E2 concentration 30 µM (~ KM) 10 µL 
MTS/PES volume 10 µL 10 µL 
NADP concentration 25 µM (~ KM) 10 µL 
Inhibitor concentration Varying concentrations 10 µL 
Water  45 µL 
Total well volume 100 µL 
Table 30: The final conditions that were determined for the MTS/PES assay 
E2 and the inhibitors under investigation were dissolved in DMSO to improve the 
solubility of the compounds within the assay, therefore giving a final volume of 
DMSO being added of 20 µL (20%). 
6.3.4 Enzyme-Inhibitor Study 
6.3.4.1 Assay Comparison 
It was decided to test the MTS/PES assay as a predictive tool for inhibitory activity 
of the compounds against 17β-HSD1 by comparing the percentage inhibitions 
determined using the rec17β-HSD1 MTS/PES assay to that determined from a cell 
based assay for a variety of compounds featuring a number of different substitution 
patterns (Table 31). 
 MTS/PES recombinant protein 
assay 
T-47D cell assay
a 
Compound % inhibition @ 10 µM % inhibition @ 10 µM 
STX670 65 ± 3 100  
STX1040 1 80 ± 2 99 
STX2818 26 ± 1 119 
127 11 ± 3 
28 ± 2 
128 10 ± 1 
96 ± 4 
132 -6 ± 9 
35 ± 7 
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135 10 ± 2 
35 ± 5 
137 1 ± 10 
32 ± 9 
141 20 ± 6 74 ± 2 
143 17 ± 1 22 ± 10 
154 6 ± 2 17 ±18 
155 38 ± 6 13 ± 13 
164 -7 ± 15 
27 ± 3 
165 6 ± 0 
5 ± 2 
166 4 ± 8 
16 ± 3 
167 1 ± 3 
65 ± 3 
174 31 ± 3 
63 ± 3 
175 27 ± 1 
68 ± 1 
176 17 ± 1 
49 ± 13 
185 5 ± 2 45 ± 3 
186 7 ± 4 81 ± 1 
187 10 ± 8 41 ± 1 
a – Cell based assay results were measured by Ipsen 
Table 31: Comparison of the percentage inhibition values from the MTS/PES assay 
and a cell-based assay 
It can be clearly observed that the MTS/PES assay does not provide the same 
sensitivity as the cell based assay. There are, however agreements between the two 
assays. When comparing the two sets of data it can be seen that the compounds that 
have low percentage inhibition values (< 60%) in the cell based assay also display a 
low percentage inhibition in the MTS/PES assay. Examples include compounds 128, 
135, 168 and 175 with percentage inhibitions of 28%, 35%, 49% and 41% 
respectively in the cell based assay and percentage inhibitions of 11%, 10%, 17% 
and 10% respectively in the MTS/PES assay. For compounds displaying greater than 
60% inhibition in the cell based assay, these also display higher than average 
percentage inhibition in the MTS/PES assay at 10 µM. However, these compounds 
will need to be tested at 200 µM to further prove this.  Examples of these compounds 
include STX1040 1, 166, 167 which display percentage inhibition values of 99%, 
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63% and 68% respectively in the cell based assay and percentage inhibition values of 
91%, 65% and 65% respectively in the MTS/PES assay. There are a couple of 
exceptions to this, compounds 152 and 174 which display either high percentage 
inhibition in the cell based assay and then low percentage inhibition in the MTS/PES 
assay or low percentage inhibition in the cell based assay and high percentage 
inhibition in the MTS/PES assay. 
Therefore, it can be concluded that the MTS/PES assay can be used to assess the 
potency of 17β-HSD1 inhibitors.  The limitations of the MTS/PES assay when 
compared to the cell based assay include: lower sensitivity, no information is 
gathered with regards to membrane permeability and the MTS/PES assay is using 
17β-HSD1 in the reverse direction and therefore the inhibition data obtained is only a 
rough approximation of the biological activity of the compounds. Advantages of the 
MTS/PES assay when compared to the cell based assay are; the inhibitory effect is 
solely due to the effect of the compounds upon the enzyme, the assay is quick to run 
and the assay can be used to determine whether compounds can act as substrates. 
6.3.5 Inhibitor Substrate Study 
It is important for further drug design to understand how the compounds interact with 
the active site of the target protein. One important thing to know is whether or not the 
compound acts as a substrate. Figure 100 shows that when varying concentrations of 
compound 129 are present with NADP and 17β-HSD1 in the absence of E2 no rate is 
observed for the conversion of NADP to NADPH, therefore indicating that 
compound 129 does not act as a substrate for 17β-HSD1. 
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Figure 100: A linear plot demonstrating that compound 129 does not act as a 
substrate for 17β-HSD1 
As compound 150 gave an enhanced rate at both 10 µM and 200µM in the 
recombinant 17β-HSD1 MTS/PES assay, in collaboration with Dr. G. Cozier a 
variety of compounds that were potent in the cellular assay were tested to see if they 
could potentially act as substrates for 17β-HSD1 (Table 32). 
Compound Rate (ΔAbs/min) % Activity 
No Inhibitor 0.0006 ± 0.00002 0.0 ± 0.06 
E2 0.0369 ± 0.00003 100.0 ± 0.08 
STX1040 1 0.0022 ± 0.00001 4.3 ± 0.03 
141 0.0037 ± 0.00007 8.5 ± 0.20 
153 0.1062 ± 0.00009 291.4 ± 0.24 
167 0.0066 ± 0.00003 16.4 ± 0.07 
174 0.0020 ± 0.00001 3.8 ± 0.02 
175 0.0013 ± 0.00001 1.9 ± 0.04 
186 0.0020 ± 0.00001 3.9 ± 0.03 
Table 32: Inhibitor substrate investigation results 
It can be concluded that 153 can potentially act as a very good substrate, the fact that 
153 can act as a substrate and, therefore binds well to 17β-HSD1, means it will 
appear as an inhibitor in the cell based assay, which measures the amount of radio-
active E1 that is converted rather than the amount of NADP. However, by using the 
MTS/PES assay which measures the conversion of NADP to NADPH it can be 
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determined that compound 153 acts as a substrate. It can also be stated that 167 can 
also potentially act as a substrate, but not a very good one. However, further work 
would be required to confirm this. From the data obtained for the other compounds 
assessed in Table 31 it can be stated that they do not to act as substrates for 17β-
HSD1. 
6.3.6 Type of Inhibitor Investigation 
Compound 128 was selected for further biological evaluation with the use of the 
MTS/PES assay; the reason for this is that compound 128 is known to be a moderate 
inhibitor of 17β-HSD1 in a cell based assay as well as not acting as a substrate as 
previously described, therefore making it a good candidate to investigate whether the 
MTS/PES assay can be used to determine IC50 values. Figure 101 displays the IC50 
curve that was determined. An IC50 value of 70 ± 1.2 µM was calculated for 
compound 128 using the MTS/PES assay. This is different to the IC50 value of 723 ± 
138 nM that was determined using a cell based assay one reason for this is that the 
MTS/PES assay is being conducted at concentrations that are much higher than those 
observed at the cellular level. In a cell based assay the compounds can potentially be 
metabolised inside the cell and these metabolism products can potentially be 
responsible for the inhibitory effect. Taking these factors into account makes it very 
difficult to compare results between cell based and recombinant protein based assays.  
 
Figure 101: IC50 curve for compound 128 
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A better way of interpreting IC50 values between assays, is to look at relative IC50 
values (Table 33) giving a better representation of the inhibitory activity of the 
compounds. The IC50 plots of STX1040 1 and 127 can be found later in this report. 
Compound 
T-47D Cell based 
assay IC50 (nM) 
Cell based 
assay relative 
IC50 
MTS/PES 
assay IC50 
(µM) 
MTS/PES 
assay relative 
IC50 
STX1040 1 47  3 ± 0.4  
127 1854 ± 257 39 59 ± 11 21 
128 723 ± 138 15 70 ± 20 25 
Table 33: A table showing the relative IC50 values for both the MTS/PES and cell-
based assays 
The relative IC50 values do not follow the same trend between the two assays. An 
explaination for this is that the IC50 curves for compounds 127 and 128 lack the 
section of the curve that corresponds to the maximum inhibition therefore, the IC50 
values for compounds 127 and 128 are estimates and could change if IC50 curves 
were produced with high enough inhibitor concentrations to reach the maximum 
inhibition. For the highly active compound STX1040 1 this is not particularly an 
issue because the IC50, had already started to tail off at the higher STX1040 1 
concentrations and so would not make much difference to the IC50 value determined. 
6.3.6.1 Compound 127 
It is hypothesised that the most potent inhibitor STX1040 1 against 17β-HSD1, in a 
cell based assay with an IC50 value of 47 nM binds in both the substrate and co-factor 
binding sites and therefore acts as a “dual site” inhibitor. By using carefully designed 
enzyme kinetic experiments the mode of binding of STX1040 1 can potentially be 
determined. To do this a compound that is not hypothesised to interact with the co-
factor binding site compound 127 was used as a control for STX1040 1.  
To determine whether the compounds are competitive inhibitors for the E2 and 
NADP binding site IC50 values were determined at varying concentrations of E2 and 
NADP. The E2 concentrations used were approximately half of the KMapp (15 µM), 
the KMapp (30 µM) and four times the KMapp (120 µM). If the compounds act as 
competitive inhibitors for the E2 binding site then an increased IC50 value should be 
observed for each increasing E2 concentration used. This is because as the 
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concentration of E2 is being increased, it makes it more difficult for the compound to 
outcompete the natural substrate for the binding site within the enzyme. If no change 
in IC50 value is observed then it can be concluded that the compound does not 
interact with the specified binding site. 
 
Figure 102: IC50 curves for 127 at varying concentrations of E2 
For compound 127 IC50 values of 18.19 ± 8.1 µM, 59.21 ± 11.0 µM and 90.46 ± 15.3 
µM were determined for 15 µM, 30 µM and 120 µM of E2 respectively (Figure 102), 
therefore indicating that compound 127 does as hypothesised interact with the E2 
binding site of 17β-HSD1. 
The same principle can be applied to the NADP co-factor binding site where 
approximately half the KMapp (12.5 µM), KMapp (25 µM) and five times the KMapp 
(125 µM) of NADP were used to determine whether or not the compounds interact 
with the co-factor binding site. 
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Figure 103: IC50 curves for 127 at varying concentrations of NADP 
For compound 127 IC50 values of 47.94 ± 1.2 µM, 59.21 ± 1.3 µM and 97.95 ± 1.4 
µM were determined for 12.5 µM, 25 µM and 125 µM of NADP respectively (Figure 
103), therefore indicating that compound 127 interacts with the NADP binding site 
of 17β-HSD1. However, as the IC50 curves lack the section corresponding to 
maximum inhibition, the IC50 curves obtained are ony estimates and could change if 
IC50 curves were produed with high enough inhibitor concentrations. One way of 
determining what type of interaction the compound has with the active site of the 
protein is to use a Dixon and Cornish-Bowden plots. The Dixon plot has been 
described earlier in section 6.3.2. The Cornish-Bowden plot is a graphical 
representation where substrate concentration over the rate is plotted on the y-axis and 
the inhibitor concentration is plotted on the x-axis and the linear regressions 
correspond to the different substrate concentrations used. Like the Dixon plot the 
type of inhibitor is determined by the position at which the linear regressions 
intersect. For a competitive inhibitor the linear regressions run parallel to each other 
and do not intersect, for a mixed action inhibitor the linear regressions intersect 
below the x-axis and the x value of this intersection corresponds to the Ki value. 
Unlike the Dixon plot the Cornish-Bowden plot can be used to determine the Ki of an 
un-competitive inhibitor, un-competitive inhibition is characterised by the point of 
intersection taking place above the x-axis, and the Ki value is obtained by dropping a 
vertical line from the point of intersection to the x-axis. 
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Figure 104: Dixon plot for 127, where each linear regression corresponds to a 
different E2 concentration 
 
Figure 105: Expanded region from the Dixon plot of 127, demonstrating that 127 is a 
competitive inhibitor against E2 
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Figure 106: Cornish-Bowden plot for 127, demonstrating that 127 is acting as a 
competitive inhibitor for the E2 binding site 
From the Dixon plots in Figure 104 and 105 and the Cornish-Bowden plot in Figure 
106 it can be determined that 127 acts as a competitive inhibitor of the E2 binding 
site as in the Dixon plot the linear regressions intersect above the x-axis and from the 
Cornish-Bowden plot the lines run parallel to each other. This result agrees with the 
hypothesis determined from computational docking studies that compound 127 binds 
in the steroid binding site. From the Dixon plot a Ki value of approximately 60 µM is 
determined. 
When looking at the NADP binding site it can be tentatively be concluded that 127 
acts as an un-competitive inhibitor as the Dixon plot in Figure 107 shows the linear 
regressions run parallel to each other, however they do intersect indicating that this 
form of modelling does not give the best representation of the mode of action of 
compound 127. From the Cornish-Bowden plot in Figure 108 it can be seen that the 
linear regressions intersect on or at a point just above the x-axis, corresponding to a 
Ki value of approximately 110 µM, therefore agreeing with the results determined 
from the Dixon plot in saying that compound 127 is acting as a non-competitive 
inhibitor of the NADP binding site of 17β-HSD1. 
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Figure 107: Dixon plot for 127 at varying concentrations of NADP 
 
Figure 108: Cornish-Bowden plot for 127 at varying concentrations of NADP 
demonstrating the un-competitive inhibition for the NADP binding site 
 
Figure 109: An expanded view of the Cornish-Bowden plot for 127, highlighting the 
position at which the linear regressions intersect 
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However, the linear regressions for the Dixon plot and Cornish-Bowden plots do not 
fit the data very well for both the variable E2 and variable NADP concentrations. 
Therefore, these results indicate that 17β-HSD1 does not obey the Michaelis-Menten 
model. However, as 17β-HSD1 is a two substrate two product reaction mechanism, 
analysis using the ternary complex and substituted enzyme mechanisms might 
provide a better insight into how 17β-HSD1 behaves. This has been discussed in 
more detail in Section 6.4. 
6.3.6.2 STX1040 (1) 
It is hypothesised from the use of compoutational docking studies that STX1040 1 
acts as a “dual site” inhibitor where the C16 moiety interacts with the active site of 
the co-factor. It is hypothesised that STX1040 1 acts as a competitive inhibitor for 
both the steroid and co-factor binding site of 17β-HSD1. The reason for this 
hypothesis is that the X-ray crystal structure (pdb code 1I5R) of compound EM-1745 
40 with 17β-HSD1 shows the inhibitor occupying both the steroid and co-factor 
binding sites. Therefore STX1040 1 which also displays a C16 substituted moiety 
that is designed to be a NADPH mimic, coupled with the highly potent IC50 value of 
47 nM should theoretically bind in the same manner. When the principle to 
determine whether the compounds are competitive inhibitors for the E2 and NADP 
binding site, by determining IC50 values at varying concentrations of E2 and NADP, 
is applied to investigate how STX1040 1 binds in the active site of 17β-HSD1 IC50 
values of 1.78 ± 0.2 µM, 2.82 ± 0.4 µM and 4.90 ± 1.0 µM for 15 µM, 30 µM and 
120 µM of E2 respectively (Figure 110). This therefore indicates that as 
hypothesised, STX1040 1 acts as a competitive inhibitor in the E2 binding site of 
17β-HSD1. 
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Figure 110: IC50 plots for STX1040 1, at varying concentrations of E2 
 
Figure 111: IC50 plots for STX1040 1, at varying concentrations of NADP 
However, IC50 values of 2.27 ± 1.2 µM, 2.82 ± 0.8 µM and 2.00 ± 0.5 µM are 
determined for 12.5 µM, 25 µM and 125 µM of NADP respectively (Figure 111). 
These IC50 values are very similar and so suggest that STX1040 1 does not act as a 
competitive inhibitor of NADP, therefore disproving the hypothesis that STX1040 1 
acts as a competitive “dual site” inhibitor. However, it cannot be said that the C16 
moiety of STX1040 1 does not interact with the co-factor binding site in a different 
capacity, so Dixon and Cornish-Bowden plots were produced to investigate the type 
of inhibition that STX1040 1 displays against 17β-HSD1. 
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Figure 112: Dixon plot for STX1040 1, the linear regressions correspond to varying 
E2 concentrations 
 
Figure 113: An expanded view of the Dixon plot for STX1040 1, highlighting the 
points at which the linear regressions intersect 
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Figure 114: Cornish-Bowden plot for STX1040 1, demonstrating that STX1040 1 is 
potentially a mixed action inhibitor 
From Figures 112 and 114 it can be determined that STX1040 1 is acting as a mixed 
action inhibitor. This can be observed from the Cornish-Bowden plot as the point of 
intersection for the linear regressions lies below the x-axis, however it is observed 
there is more than one point of intersection indicating that STX1040 1 is behaving in 
a manner that cannot be fully explained by these plots alone and further investigation 
is required. 
 
Figure 115: Dixon plot for STX1040 1, the linear regressions correspond to different 
concentrations of NADP 
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Figure 116: An expanded view of the Dixon plot for STX1040 1 highlighting the 
position at which the linear regressions intersect, suggesting STX1040 1 acts as a 
mixed action inhibitor. 
 
Figure 117: Cornish-Bowden plot for STX1040 1, with the linear regressions 
corresponding to different NADP concentrations 
From Figures 115 and 117 the data suggests that STX1040 1 in the variable NADP 
concentration experiments acts as a mixed inhibition compound. Using the Cornish-
Bowden plot shown in Figure 117 it can be seen that the linear regression intersect 
on the x-axis, giving a Ki value of approximately 20 µM, this result is confirmed by 
the Dixon plot (Figure 115). Further experimentation is required to conclusively 
prove these preliminary results. 
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The Dixon and Cornish-Bowden plots are simple linear regression plots based upon 
there being a single substrate and single product, however 17β-HSD1 is a two 
substrate two product enzyme and this is further confirmed as the linear regressions 
do not accurately fit the data obtained for both 128 and STX1040 1. Therefore 
further work is required before any non-preliminary conclusions can be made about 
the mode of inhibition utilised by these inhibitors against both the steroid and co-
factor binding sites of 17β-HSD1. 
6.4 Two Substrate Two Product Enzyme Mechanisms
132 
There are two main classifications of the two substrate two product models; the 
ternary complex mechanism, so called because it contains the enzyme and both 
substrates in a single complex, and the substituted enzyme mechanism, where the 
enzyme is modified by conversion of the substrate to the product, therefore enabling 
the second substrate to bind and be converted to the second product (Figure 118). 
 
Figure 118: Schematic representations of the three principle two substrate two 
product enzyme mechanisms 
A and B represent the substrates, P and Q represent the products. Written below the 
line is the role of the enzyme and the complexes formed during the enzyme reaction 
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mechanism. The arrows represent the addition and release of the substrates and 
products respectively.  
6.4.1 Ternary Complex Mechanism 
6.4.1.1 Ordered-Ternary Complex Mechanism 
The ternary complex mechanism can proceed in one of two ways, ordered and 
random. For the ordered ternary complex mechanism, it is generally accepted that the 
structures of both the enzyme and substrate can be altered on binding. This gives the 
enzyme the ability to preferentially bind one substrate over another during the initial 
stages of the enzyme reaction, or that no binding site exists on the enzyme for one of 
the two substrates until the other has bound. Once the required substrate has bound 
this then changes the affinity of the enzyme for the second substrate, or a structural 
change takes place in the enzyme upon binding of substrate, A, resulting in the 
formation of the binding site for substrate, B, resulting in the formation of the ternary 
complex, followed by a stepwise release of the products.
132 
6.4.1.2 Random Ternary-Complex Mechanism 
The random ordered ternary complex mechanism occurs where either of the 
substrates, A and B, can form an enzyme-substrate intermediate complex leading to 
the formation of the ternary complex and the subsequent formation and release of the 
two products. 
6.4.2 Substituted Enzyme Mechanism 
For the substituted enzyme mechanism there is only one mechanistically reasonable 
order for the enzyme reaction to proceed and so no random order alternative is 
possible. The substituted enzyme mechanism involves the binding and conversion of 
substrate A to product P and during this process the enzyme is modified in a manner 
that allows the binding and conversion of substrate B to product Q, which prior to the 
release of product P was not possible. It is not anticipated that 17β-HSD1 follows the 
substituted enzyme mechanism because the conversion of E1 to E2 involves the 
transfer of the ProS hydride from the NADPH co-factor, and not the enzyme 
converting the co-factor to its oxidised form followed by the binding of the steroid 
E1 and the subsequent reduction to E2. This is further supported by the X-ray crystal 
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structure displaying both the steroid and co-factor occupying their respective binding 
sites (pdb code 1FDT
80
).
132 
It can be hypothesised that 17β-HSD1 follows a random order ternary complex based 
upon the X-ray structures of the protein in complex with steroidal ligands and co-
factor ligands. Work by Negri et al.
37
 further supports this hypothesis, however 
further enzyme kinetic experiments are required to conclusively prove this. 
6.4.3 Dead End Complexes 
The formation of dead end complexes can occur for any of the mechanisms described 
above. The formation of a dead end complex is when the incorrect substrate or one of 
the products, occupies the binding site for substrate, A, preventing the change in 
affinity or structural change of the enzyme taking place and therefore, the catalytic 
action of the enzyme proceeding (Figure 119).This makes determining the 
mechanism by which the enzyme operates a very complex and time consuming 
process, which was beyond the scope of this project. 
 
Figure 119: An example of the formation of a dead end complex, and how this can 
affect the enzyme mechanism, in this example an ordered ternary-complex 
mechanism 
6.5 Design of Experiments to Determine the Two Substrate Two Product 
Reaction Mechanism 
6.5.1 Determination Between a Ternary-Complex and Substituted Enzyme 
Mechanism
132 
Initially KMapp values for the two substrates should be determined. At each 
concentration of constant substrate, B, the variable substrate, A, concentration should 
range from approximately 0.2 to about 10 times its KMapp. This is then repeated with 
the substrate A concentration remaining constant and varying the concentration of 
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substrate B. Plots of these data will provide information as to which mechanism the 
protein adopts. For example a plot of substrate A concentration/rate on the y-axis 
versus substrate A concentration on the x-axis for a ternary complex will show the 
linear regressions intersecting below the x-axis, where the x-axis value corresponds 
to –KiA and the y-axis value corresponds to (KMA – KiA)/rate. The same plot for a 
substituted enzyme mechanism would show the linear regressions intersecting on the 
y-axis, corresponding to a value of KMA/rate. 
6.5.2 Determination Between an Ordered Ternary-Complex and Random 
Order Ternary-Complex Mechanism
132 
Product inhibition studies are a very useful tool for determining the order of binding 
of substrates and release of products, providing that only one product is added to the 
reaction mixture. The question of whether a particular product acts as a competitive, 
un-competitive or mixed inhibitor is dependent upon which substrate concentration is 
considered to be variable.  
Table 34 shows the type of inhibition expected for each combination of the product 
and variable substrate. The arrows indicate the tendency to modify the type of 
inhibition at saturating concentrations of the constant substrate. For example if mixed 
inhibition is observed for substrate A and product P with a tendency towards a un-
competitive inhibition being observed at saturating concentrations of the constant 
substrate, B, this would indicate that an ordered ternary-complex order mechanism is 
adopted by the enzyme under investigation. However, if competitive inhibition is 
observed then a random ordered ternary complex mechanism is adopted by the 
enzyme. 
Product 
Variable 
Substrate 
Type of inhibition observed 
Ordered ternary-complex 
mechanism 
Random ordered ternary-complex 
mechanism 
P A Mixed → un-competitive Competitive 
P B Mixed Competitive 
Q A Competitive Competitive 
Q B Mixed → no inhibition Competitive 
Table 34: Product inhibition in the three principal two substrate two product 
mechanisms
132 
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In order to prove conclusively that STX1040 1 and 128 behave in the manner 
described previously, full enzyme kinetic analysis will need to be undertaken so that 
a better understanding of the mode of action for the conversion of the substrates to 
products can be gained. This will enable the design of inhibitor experiments that can 
fully investigate how these compounds behave with both substrate binding sites 
present in 17β-HSD1. 
Chapter 7 
Protein Crystallography 
7.1 Literature Structures 
When searching the RSCB pdb database 21 X-ray crystal structures of 17β-HSD1 
were found. All of these crystal structures occupy a C2 space group, but vary in 
resolution and structure of ligand(s) that has been co-crystallised in the active site.  
The earliest reported X-ray crystal structure is of the apoenzyme at a resolution of 
2.20 Å. (pdb code 1BHS
33
). This first structure was closely followed by one from 
Housset et al.
76
 who provided the first X-ray crystal structures of 17β-HSD1 
complexed with a steroidal ligand, E2 and E2 co-crystallised NADP
+
 (pdb codes 
1FDS
80
 and 1FDT
76
) at resolutions of 1.70 Å and 2.20 Å (Figure 120) respectively. 
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Figure 120: A schematic representation of how the cofactor NADP
+
 binds in the 
active site of 17β-HSD1 (pdb code 1FDT76) 
 Other steroidal ligands have been co-crystallised with 17β-HSD1, these include 
DHT,
133
 dehydroepiandrosterone,
134
 equilin
131
, T,
135
  Δ4-dione,136 and E2B.137 From 
all of these X-ray crystal structures it can be seen that the steroidal ligands all occupy 
the same binding site within the active site of 17β-HSD1 (Figure 121). 
 
Figure 121: Schematics of the key interactions between different steroidal ligands, 
E2 (pdb code 1FDS) and DHT (pdb code 1DHT), and amino acid residues within the 
active site of 17β-HSD1 
It has been observed from the structures for pbd codes 3KLP (Δ4-diol), 3KMO (3β-
diol), 1QYW (Δ4-dione), 1JTV (T), 3KLM and 3DEY (DHT) that the steroidal 
ligand binds in the steroidal active site orientated with the D ring pointing away from 
the NADP
+
 co-factor binding site (Figure 122). This implies that the active site of 
17β-HSD1 is large and that the moieties present on the A ring play an important role 
in determining the binding orientation of the steroidal ligand within the active site. 
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Figure 122: A schematic representation of how the steroidal ligand DHT binds in the 
active site of 17β-HSD1 (pdb code 3KLM) 
There have also been X-ray crystal structures (pdb codes 1I5R and 3HB4) which 
depict how C16 substituted steroidal inhibitors bind in the active site of 17β-HSD1 
(Figure 123). Both of these ligands bind with their C16 substituents positioned 
towards the NADP
+
 co-factor binding pocket with EM1745 40 (pdb code 1I5R) 
displaying how the C16 substituent occupies the NADP
+
 cofactor binding site. 
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Figure 123: A schematic representation of how the steroidal inhibitors E2B (pdb 
code 3HB4) and EM1745 (pdb code 1I5R) binds in the active site of 17β-HSD1 
7.2 X-Ray Protein Crystallography 
As stated previously, it has been hypothesised that inhibitors bearing a C16 
substituent of which STX1040 1 is the most potent, IC50 value of 47 nM from a cell 
based assay, interact with both the substrate and co-factor binding sites in the active 
site of 17β-HSD1. To prove this hypothesis attempts were made to obtain an X-ray 
crystal structure of the protein co-crystallised with the inhibitor STX1040 1 in the 
presence of and without NADP. 
Once a large enough quantity of protein had been obtained, crystallization studies 
were started in collaboration with Dr. G. Cozier. The initial conditions used to start 
the crystallography trials were a series of conditions which have been previously 
used in the literature to crystallise the protein.
133
 In the case described in the 
literature the vapour diffusion technique was used for crystallisation. The reservoir 
contained 0.15 M MgCl2, 0.1 M Hepes, (N-(2-hydroxyethyl) piperzine-N’-2-
ethanesulfonic acid) pH 7.5 and 28% polyethyleneglycol (PEG) 4000 as the 
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precipitant. Hanging drops of concentrated protein and glycerol were used. Initially, 
it was decided to try and crystallise the apoenzyme without the co-factor or the 
inhibitors being present as well as co-crystallisation with inhibitors STX1040 1 and 
STX2109 169 with and without the presence of the co-factor NADP
+
. The rationale 
behind this was that if a set of crystallization conditions could be established then it 
would be easier to start co-crystallising the protein with some steroidal inhibitors as 
many of the reported structures were obtained when the compounds had been soaked 
into the forming crystals of the apoenzyme. Initial trials at crystallising the 
bacterially expressed protein utilised a range of PEG4000 concentrations at varying 
MgCl2 concentrations. Using these crystallization conditions as well as others that 
were similar in counter-ion concentration and polymer concentration, a starting point 
was established for trying to crystallise the protein. Some very small needle and 
urchin like crystals were found to have grown under these conditions initially. 
Although these crystals could not be used for X-ray crystallography, they did 
provide some information about the concentration of PEG4000 that should be used 
in the trials.  Needle / urchin like crystals formed when lower concentrations of 
PEG4000 were used. 
As crystallization of the protein proving difficult, based on the conditions reported in 
the literature,
128
 it was decided that the best course of action would be to set up 
screens to look for other suitable conditions. A Phoenix nano-litre drop dispensing 
crystallography robot was used to set up a series of 96 well plates using the 
Molecular Dimensions Ltd structure screen 1 and 2 and the PACT structure screen. 
There were several hits from the screens, most notable of which were: 0.2 M 
Magnesium Acetate and 0.1 M Sodium Cacodylate pH 6.5 against 20% PEG8000 
(1:2 ratio of protein to well buffer) and 1.6 M Sodium Citrate pH 6.5 (2:1 ratio of 
protein to well buffer). From these initial hits a series of optimised conditions were 
set up. These were 0.05 M - 0.4 M Magnesium acetate with 0.1 M sodium 
cacodylate against 15–37.5% PEG8000, as well as 1.3 M–1.8 M Sodium citrate pH 
6.5. The best crystals were obtained with 0.2 M Magnesium Acetate, 0.1M sodium 
cacodylate pH 6.5 with 20% PEG8000 (Figure 124). However, these crystals were 
not large enough to use on the home source X-ray diffractor, the X-ray diffraction 
data was collected by Prof. R. Acharya at the synchrotron radiation source (Diamond 
U.K.). Data were indexed and reduced with DENZO and SCALEPACK modules of 
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the HKL suite
138
 in the C2 space group. The structure was determined by Dr. G. 
Cozier using the molecular replacement method using pdb code 1FDT
76
 as the 
search model with the programme Phaser
139 
from the CCP4i programme suite. 
Refinement was performed using Refmac
140
 from the programme package CCP4i in 
addition to the manual model building using the programme COOT.
141
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1      2 
1) 0.2M Mg Acetate + 0.1M Na Cacodylate pH 6.5 + 20% PEG 8000  
2) 1.6M Na Citrate pH 6.5 
Figure 124: Single crystals of H6-17β-HSD1 and the conditions under which they 
were grown 
The Data collection results can be seen below in Table 35 and are very similar to 
results which have been previously published for 17β-HSD1.  
Data Collection  
Space Group C2 
Unit cell 
A = 122.386  b = 43.755  c = 60.705Å 
α = 90.00 β = 99.35 γ = 90.00o 
Resolution (Å) 30.19 – 2.46 
Completeness for range (%) 97.70 
Measured Reflections 51953 
Number of Unique Reflections 11478 
I / σI
a
 
15.7 
(outermost shell 2.55-2.46Å I/σ = 11.4) 
Rsym 
0.040 
(outermost shell 2.55- 2.46Å Rsym 0.091) 
Table 35: Data collection results for diffraction of H6-17β-HSD1 
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Figure 125: 17β-HSD1 protein structure derived from X-ray crystallography. α-
Helices are shown in blue and β-sheets are shown in green 
 
Figure 126: Active site of 17β-HSD1 with some secondary structure removed for 
clarity and catalytic residues highlighted with hydrogen bonds represented by dashed 
lines 
Figure 125 shows the solved structure of the apo-enzyme crystal that was diffracted 
at Diamond in Oxford. Figure 126 shows the overlaid structures of E1 and NADP in 
the active site of the solved structure of 17β-HSD1. The key catalytic residues 
Ser142, Gly144, Tyr155 and Lys159 that are used in the reduction mechanism of E1 
to E2 are shown.  
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An X-ray crystal structure of STX2908 127 co-crystallised with 17β-HSD1 at a 
resolution of 2.8 Å was obtained (Figure 22). It was observed that the inhibitor 127 
can potentially bind in two different orientations within the steroid binding site of 
17β-HSD1. The first orientation consists of the D ring of the steroid core directed 
towards the NADP
+
 cofactor binding site, whilst in the second it is observed that the 
A ring of the steroid points towards the NADP
+
 cofactor binding site. As stated 
previously from studying the available X-ray crystal strucures in the RSCB pdb 
database it has been observed from the structures for pbd codes 3KLP (Δ4-diol), 
3KMO (3β-diol), 1QYW (Δ4-dione), 1JTV (T), 3KLM and 3DEY (DHT) that the 
steroidal ligand binds in the steroidal active site with the D ring pointing away from 
the NADP
+
 co-factor binding site. This therefore shows that this observation is not 
entirely unexpected, although it is believed that this structure is the first to suggest 
two competing binding modes. 
Chapter 8 
Conclusions 
This project set out to explore the design and inhibitory potential of compounds 
against 17β-HSD1, with the long-term and overarching aim of developing a new 
molecule that could be clinically significant for treatment for hormone dependent 
breast cancer. Although the latter aim is likely to be many years away, this project 
has identified some potentially significant compounds, that will likely require further 
optimisation and development. 
Initial targets were planned, based around modifications of the steroidal estrone / 
estradiol core, utilising the Mannich and Friedel-Crafts reaction. Over 20 compounds 
substituted at C2 and C4 of the steroid core were synthesised and display biological 
activites ranging from 9-96% inhibition at 10 µM for the Mannich series and 22-74% 
inhibition at 10 µM for the Friedel-Crafts series in a 17β-HSD1 cell-based assay. 
From the data described earlier it is observed that compounds displaying 
modifications of the E1 core are more biologically active than their E2 counterparts. 
The most potent compound in this series is (13S)-3-hydroxy-13-methyl-2-
(morpholinomethyl)-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-
thren-17(14H)-one 128 with an IC50 of 723 nM; 128 is also shown to be selective for 
17βSHD1 over 17β-HSD2 and does not display any cytotoxicity at 50 µM over a 
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period of 96 hours in estrogen receptor positive and estrogen receptor negative cells. 
Similar biological activities are observed for compounds substituted at the C2 and 
C4. The wide range of biological activity observed indicates that the optimum 
substitution at these positions has still not yet been identified and so there is scope 
for further improvement of these compounds. 
Modifications of the steroid core at the C17 position gave a series of compounds 
where a bioisostere was introduced in place of the C17 carbonyl group, enabling 
expansion from this position. Six compounds were synthesised and display poor to 
moderate biological activity against 17β-HSD1, with percentage inhibition values of 
5-65% at 10 µM. The most potent compound in this series is N-((13S,17S)-3-
hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-
thren-17-yl)-2,4,5-trimethoxybenzamide 167, with a percentage inhibition of 65% at 
10µM. Further modification of this series of compounds is required to provide a fully 
coherent SAR for the effect of substitution at this position. Results have been 
observed for compounds bearing a C17 E ring moiety
113
 that can be used in 
conjunction with the results obtain within the project to build an early stage SAR. 
Further research into the SAR of compounds bearing a C16 substituent is an 
attractive proposition, because the most biologically active compound observed in 
the literature STX1040 1 with an IC50 of 47 nM from a cell-based assay, has been 
shown to inhibit E1 stimulated proliferation of T-47D cell in vitro and significantly 
decreases tumour volumes and plasma E2 levels in vivo.
49
 Two strategies were 
therefore devised to develop the SAR for this position of the steroid core, the first 
being extending the C16 linker length to investigate what is the optimum linker 
length for biological activity; the second being the reversal of the amide orientation 
present in the C16 linker to investigate what effect minor changes of STX1040 1 
might have on the biological activity of the compounds. Six compounds were 
synthesised and display moderate to good inhibition of 17β-HSD1. Percentage 
inhibition values range from 41-81% inhibition at 10 µM. The most potent 
compound being N-(((13S,16R,17S)-2-ethyl-3,17-dihydroxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-3-yl)acetamide 186 with a percentage inhibition value of 81% 
at 10µM. Both series of compounds designed to investigate the SAR of the C16 
position display lower biological activity to that observed for STX1040 1, indicating 
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that STX1040 1 exhibits the optimum linker length and preferred amide orientation 
present in the C16 linker. Further optimisation can be performed by changing the 2-
substitution from an ethyl moiety to one that has been shown to be active from the 2-
substituted Mannich series described in this project. This will result in an increase in 
relative molecular mass, however the introduction of an amine can be utilised to 
form a quaternary ammonium salt and so potentially increase the solubility of these 
compounds in aqueous media. All of the synthetic and SAR studies were 
underpinned by molecular modelling studies, using the established X-ray crystal 
structure 1FDT of 17β-HSD1. Results showed that E1 derivatives are more 
biologically active than their corresponding E2 derivatives, and that compounds 
bearing a 3-OH moiety are more biologically active than their corresponding 3-OMe 
derivatives. It can also be concluded that for 2-substituted compounds aromaticity is 
important for biological activity, however, this can be overcome by the addition of an 
electronegative atom e.g. oxygen. Compounds with large 2-substituted moieties are 
well tolerated by the active site of 17β-HSD1 but further investigation is required to 
determine the optimum substitution at this position. Substitution at the 4-position is 
tolerated by the active site however, does no provide good biological activity. 
Results show that by substituting the carbonyl at C17 with an amide these 
compounds are not as well tolerated by 17β-HSD1. It has been determined that a C16 
linker length of 3 / 4 atoms is the optimum linker length for inhibitory activity 
against 17β-HSD1 and that reversing the amide orientation is also detrimental to 
biological activity for this series of C16 substituted compounds.   
Another aim was to explore in-house the interaction of synthetic compounds with the 
enzyme by both structural and kinetic evaluations. Sufficient quantities of the His-
tagged H6-17β-HSD1 protein, were successfully synthesised and purified. The H6-
17β-HSD1 was shown to be active, therefore permitting an in house MTS/PES 
recombinant protein assay to be developed so as to enable the study of the inhibitory 
effect of novel steroidal ligands against 17β-HSD1. The MTS/PES assay was shown 
to give similar trends for biological activity against 17βSHD1 when compared to the 
cell-based assay that was used for obtaining the percentage inhibition values. The 
MTS/PES assay was used to investigate how two compounds 127 and STX1040 1, 
for which it is hypothesised interact in different manners with the binding sites of 
17β-HSD1. It can tentatively be concluded that compound 127 acts as a competitive 
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inhibitor for the E2 binding site with a Ki value of approximately 60 µM and as a 
non-competitive inhibitor for the NADP
+
 binding site with a Ki value of 
approximately 110 µM. In addition it can also be tentatively be concluded that 
STX1040 1 acts as a mixed action inhibitor for both the E2 and NADP
+
 binding 
sites. Further experimentation is required to conclusively prove or disprove these 
preliminary results. 
As ample quantities of H6-17β-HSD1 were obtained protein X-ray crystallography 
trials were also able to be undertaken and resulted in an X-ray crystal structure of the 
apo-enzyme being obtained at a resolution of 2.46 Å using the hanging drop 
diffusion technique. The data collection results are very similar to results which have 
been previously published for 17β-HSD1.36 A X-ray crystal structure of STX2908 
126 co-crystallised with 17β-HSD1 at a resolution of 2.8 Å was obtained. It was 
observed that the inhibitor 126 can potentially bind in two different orientations 
within the steroid binding site of 17β-HSD1. The first orientation consists of the D 
ring of the steroid core directed towards the NADP
+
 cofactor binding site, whilst in 
the second it is observed that the A ring of the steroid points towards the NADP
+
 
cofactor binding site. From studying the available X-ray crystal strucures in the 
RSCB pdb database it has been observed for pbd codes 3KLP (Δ4diol), 3KMO (3β-
diol), 1QYW (androstanedione), 1JTV (T), 3KLM and 3DEY (DHT) that the 
steroidal ligand binds in the steroidal active site with the D ring pointing away from 
the NADP
+
 co-factor binding site. This therefore shows that this observation is not 
entirely unexpected, although it is believed that this structure is the first to suggest 
two competing binding modes. 
It is fair to note that to gain a better understanding of how these inhibitors interact 
with the steroid and co-factor binding sites of 17β-HSD1 an in depth study into the 
mechanism of action for the enzyme is required. However, the use of biological 
assays can provide useful preliminary data as to how these compounds may achieve 
their biological activity. This will all help bring the project closer to the development 
of a potential safe, effective clinical treatment for hormone dependent breast cancer 
and other estrogen-dependent diseases and disorders to augment the range of 
endocrine therapy currently available. Progress on this project overall was 
unfortunately curtailed at the start of the third year of work, when the industrial 
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funder Ipsen decided to stop all work in this and related areas and therefore became 
unable to assay further compounds synthesised in this work. 
To date, there are no named development compounds from any group for 17β-HSD1 
as a new cancer target. These are therefore very early days for the concept explored 
here. However, the in vivo activity for STX1040 1 published by our group in a cancer 
model augurs well for this approach. 
Chapter 9 
Experimental Details: Chemistry 
All chemicals were purchased from Aldrich Chemical Co. (Gillingham, UK) or 
Lancaster Synthesis (Morecambe, U.K.). All organic solvents of A. R. grade were 
supplied by Fisher Scientific (Loughborough, U.K.). Reactions using anhydrous 
solvents were carried out under nitrogen. Thin-layer chromatography (TLC) was 
performed on precoated plates (Merck TLC aluminum sheets silica gel 60 F254). 
Product(s) and starting material(s) were detected by either viewing under UV light 
and/or treating with a suitable staining system, for example vanillin followed by 
heating. Flash column chromatography was performed on silica gel (Sorbsil/Matrex 
C60) or using Argonaut prepacked columns with a Flashmaster II. IR spectra were 
recorded on a Perkin Elmer Spectrum RXI FT-IR in KBr discs and peak positions are 
expressed in cm
-1
. 
1
H NMR (400 MHz) and DEPT edited 
13
C NMR (101 MHz) 
spectra were recorded with a Varian Mercury VX 400 NMR spectrometer, and 
chemical shifts are reported in parts per million (ppm). HPLC analyses were 
performed on a Waters Millenium 32 instrument equipped with a Waters 996 PDA 
detector using either a Waters Radialpack C18 reversed phase column (8 × 100 mm), 
or a Symmetry C18 reverse phase column (4.6 × 150 mm) eluting with the solvent 
system specified at 1.0 mL/min. FAB low and high-resolution mass spectra were 
recorded at the Mass Spectrometry Service Centre, University of Bath, using m 
nitrobenzyl alcohol (NBA) as the matrix. ESI and APCI low resolution mass spectra 
were obtained on a Waters Micromass ZQ. Elemental analyses were performed by 
the Microanalysis Service, University of Bath. Melting points were determined using 
an Optimelt block and are uncorrected. 
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Experimental Details: Chapters 2-5 
(13S)-3-Hydroxy-13-methyl-2-(piperidin-1-ylmethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 127), 
C24H33NO2, MW 367.25,
 
 
127 
To a solution of estrone (2.00 g, 74 mmol) in EtOH/toluene (1/1, 60 mL) was added 
piperidine (1.26 g, 150 mmol) and paraformaldehyde (227 mg). The reaction mixture 
was heated to reflux for 18 h and then cooled to room temperature. The reaction 
mixture was concentrated in-vacuo to approximately 10 mL. The reaction mixture 
was diluted with water (50 mL) and extracted with diethyl ether (2  50 mL), the 
organic phase was separated and washed with brine (20 mL), dried (MgSO4), filtered 
and evaporated in-vacuo. The crude product was re-crystallized from EtOH to give 
the title compound 127 (717 mg, 26%) as white crystalline needles. m.p. 195-198 C, 
HPLC: tr 1.12 min (90% Acetonitrile in Water) 95%, 
1
H NMR ( 400 MHz, CDCl3): δ 
0.90 (3H, s, 18-CH3), 1.46–1.53 (11H, m), 1.91-2.23 (6H, m), 2.31-2.53 (6H, m), 
2.83-2.86 (2H, m, 6-CH2), 3.56-3.67 (2H, m, 2-CCH2), 6.56 (1H, s, ArH) and 6.86 
(1H, s, ArH), 
13
C NMR ( 101 MHz, CDCl3): δ 13.87 (18-CH3), 21.57, 24.02, 25.86 
(2 × CH2), 26.02, 26.61, 29.25, 31.60, 35.88 (CH2), 38.42, 43.94 (CH), 48.02 (C), 
50.43 (CH), 53.90 (2 × CH2), 62.21 (2-CCH2), 115.81 (ArCH), 119.23 (ArC), 125.30 
(ArCH), 130.09, 136.72, 155.84 (ArC) and 221.10 (CO), LRMS (ESI) calcd for 
C24H34NO2 [M+H
+
]: m/z = 368.3, found m/z = 368.3, HRMS (ESI) calcd for 
C24H34NO2 [M+H
+
]: m/z = 368.2511, found m/z = 368.2584, Anal. calcd. for 
C24H33NO2: C 78.43, H 9.05, N 3.81%, found C 78.40 H 9.09, N 3.67%. Data 
obtained for melting point identical to that in the literature.
 125 
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(13S)-3-Hydroxy-13-methyl-2-(morpholinomethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 128), 
C23H31NO3, MW 369.50, 
 
128 
To a solution of estrone (1.00 g, 37 mmol) in EtOH/toluene (1/1, 60 mL) was added 
morpholine (0.65 g, 74 mmol) and paraformaldehyde (227 mg). The mixture was 
heated to reflux for 18 h and then cooled to room temperature. The reaction mixture 
was concentrated in-vacuo to approximately 10 mL. The reaction mixture was 
diluted with water (50 mL) and extracted with diethyl ether (2  50 mL), the organic 
phase was separated and acidified with saturated aqueous citric acid (30 mL), the 
neutralised with 1 M NaHCO3. The crude products were extracted with EtOAc (2  
50 mL), washed with brine (20 mL), dried (MgSO4), filtered and evaporated in-
vacuo. The crude product was re-crystallized from EtOH to give the title compound 
128 (91 mg, 35%) as white crystalline needles. m.p. 205-209 C, HPLC: tr 1.15 min 
(90% Acetonitrile in water) 93%, 
1
H NMR (CDCl3, 400 MHz): δ 0.90 (3H, s, 18-
CH3), 1.38-1.65 (7H, m), 1.92-2.20 (5H, m), 2.34-2.38 (1H, m), 2.46-2.56 (4H, m), 
2.83-2.86 (2H, m, 6-CH2), 3.61-3.74 (6H, m), 6.58 (1H, s, ArH) and 6.89 (1H, s, 
ArH). 
13
C NMR (101 MHz, CDCl3): δ 13.83 (18-CH3), 21.55, 25.98, 26.54, 29.22, 
31.56, 35.84 (CH2), 38.35, 43.89 (CH), 47.97 (C), 50.38 (CH), 52.91 (2 × CH2), 
61.90 (2-CCH2), 66.78 (2 × CH2), 115.93 (ArCH), 118.19 (ArC), 125.67 (ArCH), 
130.59, 137.28, 155.20 (ArC) and 220.96 (CO), LRMS (ESI) calcd for C23H32NO3 
(M+H)
+
: m/z = 370.2, found m/z = 370.1, HRMS (ESI) calcd for C23H32NO3 
(M+H)
+
: m/z = 370.2304, found m/z = 370.2372. Anal. calcd. for C23H31NO3: C 
74.76, H 8.46, N 3.79%, found C 74.40, H 8.48, N 3.76%. Data obtained for melting 
point identical to that in the literature.
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(13S)-3-Hydroxy-13-methyl-2-(pyrrolidin-1-ylmethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 129), 
C23H31NO2, MW 353.50, 
 
129 
To a solution of estrone (2.00 g, 74 mmol) in EtOH/toluene (1/1, 60 mL) was added 
pyrrolidine (1.07 g, 150 mmol) and paraformaldehyde (227 mg). The mixture was 
heated to reflux for 18 h and then cooled to room temperature. The reaction mixture 
was concentrated in-vacuo to approximately 10 mL. The reaction mixture was 
diluted with water (50 mL) and extracted with diethyl ether (2  50 mL), the organic 
phase was separated and washed with brine (20 mL), dried (MgSO4), filtered and 
evaporated in-vacuo. The crude product was re-crystallized from EtOH to give the 
title compound 129 (204 mg, 8%) as white crystalline needles. m.p. 160-163 C, 
HPLC: tr 1.12 min (90% Acetonitrile in water) 99%, 
1
H NMR ( 400 MHz, CDCl3): δ 
0.91 (3H, s, 18-CH3), 1.38-1.67 (4H, m), 1.82 (4H, quin, J = 3 Hz) 1.92-2.21 (7H, 
m), 2.35-2.39 (1H, m), 2.46-2.53 (1H, m), 2.62 (4H, br. s), 2.83-2.86 (2H, m, 6-
CH2), 3.69-3.84 (2H, m, 2-CCH2), 6.56 (1H, s, ArH), 6.88(1H, s, ArH). 
13
C NMR 
(101 MHz, CDCl3): δ 13.85 (18-CH3), 21.54, 23.62 (2 × CH2), 25.97, 26.59, 29.22, 
31.58, 35.85 (CH2), 38.38, 43.92 (CH), 47.99 (C), 50.40 (CH), 53.50 (2 × CH2), 
58.87 (2-CCH2), 115.72 (ArH), 120.01 (ArC), 124.63 (ArCH), 129.96, 136.66, 
155.75 (ArC) and 221.08 (CO), LRMS (ESI) calcd for C23H32NO2 (M+H)
+
: m/z = 
354.2, found m/z = 354.2. HRMS (ESI) calcd for C23H32NO2 (M+H)
+
: m/z = 
354.2355, found m/z = 354.2419. Anal. calcd. for C23H31NO2: C 78.15, H 8.84, N 
3.96%, found C 77.90, H 8.92, N 3.78%. Data obtained for melting point identical to 
that in the literature.
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(13S,17S)-13-Methyl-2-(piperidin-1-ylmethyl)-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol (Compound 130), 
C24H35NO2, MW 369.54,
 
 
130 
Prepared by modification to the literature procedure.
 142
 
Sodium borohydride (40 mg, 1.06 mmol) was added portion-wise to a solution of 
(13S)-3-hydroxy-13-methyl-2-(piperidin-1-ylmethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (300.0 mg, 0.82 mmol) 127 
dissolved in MeOH/THF (1/1, 6 mL) at 0 C. The resulting solution was stirred for 2 
h and then treated with water (5 mL). The crude products were extracted with ethyl 
acetate (2  5 mL), washed with brine (5 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the title compound 130 (244 mg, 81%) as a white foam. 
m.p. 98-101 ºC, HPLC: tr 1.29 min (90% Acetonitrile in water) 93%, 
1
H NMR 
(CDCl3, 400 MHz): δ 0.77 (3H, s, 18-CH3), 1.14-1.52 (6H, m), 1.61-1.73 (6H, m), 
1.82-1.88 (3H, m), 2.07-2.17 (3H, m), 2.21-2.32 (1H, m), 2.47-2.78 (4H, br. s), 2.79-
2.83 (2H, m, 6-CH2), 3.56-3.66 (2H, quin, J = 14 Hz, 2-CCH2), 3.70-3.74 (1H, t, J = 
9 Hz, 17-CH), 6.54 (1H, s, ArH) and 6.86 (1H, s, ArH). 
13
C NMR (CDCl3, 101 
MHz): δ 11.06 (18-CH3), 23.12, 24.04, 25.86 (2 × CH2), 26.40, 27.31, 29.38, 30.63, 
36.73 (CH2), 38.89, 43.24 (CH), 43.90 (C), 50.04 (CH), 53.91 (2 × CH2), 62.24 (2-
CCH2), 81.95 (17-CH), 115.77 (ArCH), 119.05 (ArC), 125.31 (ArCH), 130.70, 
136.97 (ArC) and 155.63 (ArC). LRMS (ES) calcd for C24H36NO2 (M+H)
+
: m/z = 
370.3, found m/z = 370.2. Anal. calcd. for C24H35NO2: C 74.76, H 8.46, N 3.79%, 
found C 74.40, H 8.48, N 3.76%. Data obtained for melting point is identical to that 
in the literature.
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(13S,17S)-13-Methyl-2-(morpholinomethyl)-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol (Compound 131), 
C23H33NO3, MW 371.51, 
 
131 
Prepared by modification to the literature procedure.
142 
Sodium borohydride (40.0 mg, 1.06 mmol) was added portion-wise to a solution of 
(13S)-3-hydroxy-13-methyl-2-(morpholinomethyl)-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one (300.0 mg, 0.81 mmol) 128 dissolved 
in MeOH/THF (1/1, 6 mL) at 0 C. The resulting solution was stirred for 2 h and 
then treated with water (5 mL). The crude products were extracted with ethyl acetate 
(2  5 mL), washed with brine (5 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure to give the title compound 131 (247 mg, 82%) as a white foam. 
m.p. 164-168 C, HPLC: tr 1.01 min (90% Acetonitrile in water) 99%, 
1
H NMR 
(CDCl3, 400MHz): δ 0.77 (3H, s, 18-CH3), 1.12-1.73 (8H, m), 1.83-1.96 (2H, m), 
2.04-2.18 (2H, m), 2.22-2.31 (1H, m), 2.43-2.64 (4H, br. s), 2.76-2.82 (2H, m, 6-
CH2), 3.58-3.76 (7H, m), 6.56 (1H, s, ArH) and 6.91 (1H, s, ArH). 
13
C NMR (CDCl3, 
100MHz): δ 11.06 (18-CH3), 23.11, 26.39, 27.26, 29.38, 30.62, 36.70 (CH2), 38.85, 
43.23 (CH), 43.87 (C), 50.03 (CH), 52.94 (2 × CH2), 61.96 (2-CCH2), 66.83 (2 × 
CH2), 81.91 (17-CH), 115.90 (ArCH), 118.03 (ArC), 125.69 (ArCH), 131.22, 137.55 
(ArC), 155.04 (ArC), LRMS (ESI) calcd for C23H34NO3 (M+H)
+
: m/z = 372.3, found 
m/z = 372.1. HRMS (ESI) calcd for (M+H)
+
: m/z = 372.2460,  found m/z = 372.2528. 
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(13S,17S)-13-Methyl-2-(pyrrolidin-1-ylmethyl)-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol (Compound 132), 
C23H33NO2, MW 355.51, 
 
132 
Prepared by modification to the literature procedure.
142 
Sodium borohydride (28.0 mg, 0.74 mmol) was added portion-wise to a solution of 
(13S)-3-hydroxy-13-methyl-2-(pyrrolidin-1-ylmethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (200.0 mg, 0.57 mmol) 129 
dissolved in MeOH/THF (1/1, 6 mL) at 0 C. The resulting solution was stirred for 2 
h and then treated with water (5 mL). The crude products were extracted with ethyl 
acetate (2  5 mL), washed with brine (5 mL), dried (MgSO4), filtered and 
evaporated under reduced pressure to give the title compound 132 (153 mg, 76%) as 
a white foam. m.p. 77-80 ºC, HPLC: tr 0.97 min (90% Acetonitrile in water) 99%, 
1
H 
NMR (CDCl3, 400 MHz): δ 0.78 (3H, s, 18-CH3), 1.14-1.52 (6H, m), 1.65-1.73 (2H, 
m), 1.82-1.87 (6H, m), 2.08-2.17 (2H, m), 2.25-2.30 (1H, m), 2.63-2.79 (4H, br. s, 2 
× CH2), 2.81-2.83 (2H, m, 6-CH2), 3.70-3.74 (2H, m, 2-CCH2), 3.81-3.84 (1H, d, J = 
13.7 Hz, 17-CH), 6.55 (1H, s, ArH) and 6.88 (1H, s, ArH). 
13
C NMR (CDCl3, 101 
MHz): δ 11.06 (18-CH3), 23.11, 26.39, 27.26, 29.38, 30.62, 36.70 (CH2), 38.85, 
43.23 (CH), 43.87 (C), 50.03 (CH), 52.94 (2 × CH2), 61.96 (2-CCH2),  66.83 (2 × 
CH2), 81.91 (17-CH), 115.90 (ArCH), 118.03 (ArC), 125.69 (ArCH), 131.22 , 
137.55 (ArC) and 155.04 (ArC). LRMS (ESI) calcd for C23H34NO2 (M+H)
+
: m/z = 
356.3, found m/z = 356.2. HRMS (ESI) calcd for C23H34NO2 (M+H)
+
: m/z = 
356.2511,  found m/z = 356.2578. 
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(8R,9S,13S,14S)-3-Methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 133), C19H24O2, MW 
284.18,  
 
133 
Potassium carbonate (41.46 g, 300 mmol) was added portion-wise to a magnetically 
stirred solution of estrone (20.00 g, 74 mmol) in anhydrous DMF (200 mL), the 
resulting mixture was stirred for 10 mins under an atmosphere of nitrogen. To the 
reaction mixture was added methyl iodide (9.96 mL, 160 mmol) drop-wise and the 
reaction mixture was stirred at room temperature for 2 d. Water was slowly added to 
the stirred solution and the product precipitated. The product was filtered from the 
solution and dried in an oven at 105 °C for 2 h to give the title compound 133 (21.03 
g, 100%) as a white solid. m.p. 171-173 °C, 
1
H NMR (400 MHz, CDCl3): δ 0.91 
(3H, s, 18-CH3), 1.38-1.68 (6H, m), 1.92-2.20 (4H, m), 2.22-2.30 (1H, m), 2.36-2.44 
(1H, m), 2.46-2.56 (1H, m), 2.86-2.94 (2H, m 6-CH2), 3.78 (3H, s, 3-OCH3), 6.65 
(1H, d, J = 3 Hz, ArH), 6.72 (1H, dd, J = 9 and 3 Hz, ArH) and 7.20 (1H, d, J = 9 
Hz, ArH). 
13
C NMR (101 MHz, CDCl3): δ 13.84 (18-CH3), 21.57, 25.92, 26.54, 
29.65, 31.57, 35.86 (CH2), 38.37, 43.97 (CH), 48.00 (C), 50.40 (CH), 55.20 (3-
OCH3), 111.55 (ArCH), 113.87 (ArC), 126.33 (ArCH), 132.01, 137.74, 157.58 
(ArC) and 220.97 (CO), LRMS (ESI) calcd for C19H25O2 (M+H)
+
: m/z = 285.2, 
found m/z = 285.2. Anal. Calcd. for C19H24O2: C 80.24, H 8.51, N 0.00%, found C 
80.50, H 8.33, N 0.10%. Data obtained for melting point identical to that in the 
literature.
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192 
 
(13S)-2-Benzoyl-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 134), C26H28O3, MW 
388.50, 
 
134 
Benzoyl chloride (2.04 mL, 17.6 mmol) was added drop-wise to a cooled, 0 °C (ice 
bath), suspension of aluminium chloride (2.47 g, 18.5 mmol) in DCM (30 mL). A 
solution of (8R,9S,13S,14S)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one (2.5 g, 87.9 mmol) in DCM (10 mL) 
was added slowly and stirring continued for 15 min at this temperature. The reaction 
was quenched by pouring onto crushed ice. DCM (30 mL) and water (30 mL) were 
added and the resulting mixture was stirred vigorously for 10 min. The organic layer 
was separated and the organics extracted with DCM (2 × 10 mL), dried (MgSO4), 
filtered and evaporated in-vacuo to give the title compound 134 (2.90 g, 82%) as a 
white amorphous solid. m.p. 221-226 ºC, HPLC: tr 2.65 min (90% Acetonitrile in 
water) 98%, 
 1
H NMR (400 MHz, CDCl3): δ 0.91 (3H, s, 18-CH3), 1.43-1.69 (4H, 
m), 2.03-2.19 (5H, m), 2.24-2.37 (3H, m), 2.47-2.54 (1H, m), 2.96-2.99 (2H, m, 6-
CH2), 3.68 (3H, s, 3-OCH3), 6.70 (1H, s, ArH), 7.30 (1H, s, ArH), 7.43 (2H, t, J = 8 
Hz, ArH), 7.53 (1H, t, J = 8 Hz, ArH) and 7.80 (2H, d, J = 8 Hz, ArH). 
13
C NMR 
(CDCl3, 101 MHz): δ 13.81 (18-CH3), 21.54, 25.75, 26.37, 29.92, 31.42, 35.81 
(CH2), 38.22, 43.77 (CH), 47.93 (CH2), 50.60 (CH), 55.60 (3-OCH3), 111.74, 127.06 
(ArCH), 128.07 (2 × ArCH), 129.76 (2 × ArCH), 131.94 (ArC), 132.65 (ArCH), 
138.16 , 140.98, 155.50 (ArC), 196.49 and 220.68 (CO), LRMS (ESI) calcd for 
C26H29O3 (M+H)
+
: m/z = 389.2, found m/z = 389.4. HRMS (ESI) calcd for C26H29O3 
(M+H)
+
: m/z = 389.2038, found m/z = 389.2105. 
 
193 
 
(13S)-2-(Cyclohexanecarbonyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 135), 
C26H34O3, MW 394.55, 
 
135 
Cyclohexanecarbonyl chloride (4.17 mL, 35.2 mmol) was added drop-wise to a 
cooled, 0 °C (ice bath), suspension of aluminium chloride (4.93 g, 36.9 mmol) in 
DCM (60 mL). A solution of (8R,9S,13S,14S)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (5.00 
g, 17.6 mmol) in DCM (20 mL) was added slowly and stirring continued for 15 min 
at this temperature. The reaction mixture was quenched by pouring onto crushed ice. 
DCM (30 mL) and water (30 mL) were added and the resulting mixture was stirred 
vigorously for 10 min. The organic layer was separated and the organics extracted 
with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated in-vacuo to give the 
title compound 135 (5.90 g, 85%) as a white amorphous solid. m.p. 158-160 ºC, 
HPLC: tr 4.69 min (90% Acetonitrile in water) 97%, 
 1
H NMR (400 MHz, CDCl3): δ 
0.90 (3H, s, 18-CH3), 1.24-1.67 (9H, m), 1.76-1.79 (4H, m), 1.87-1.97 (4H, m), 2.00-
2.25 (4H, m), 2.43-2.53 (2H, m), 2.91-2.94 (2H, m, 6-CH2), 3.17-3.22 (1H, m, 2-
CCOCH), 3.84 (3H, s, 3-OCH3), 6.65 (1H, s, ArH) and 7.47 (1H, s, ArH). 
13
C NMR 
(101 MHz, CDCl3): δ 13.78 (18-CH3), 21.52, 25.75 (2 × CH2), 25.93, 26.41, 30.02 (2 
× CH2), 31.52, 35.93 (CH2), 37.97, 42.89 (CH), 47.98 (CH2), 51.12 (CH), 55.48 (3-
OCH3), 111.65, 127.54 (ArCH), 131.87, 138.16, 156.31 (ArC), 196.75 and 221.24 
(CO), LRMS (ESI) calcd for C26H35O3 (M+H)
+
: m/z = 395.3, found m/z = 395.5. 
HRMS (ESI) calcd for C26H35O3 (M+H)
+
: m/z = 395.2508, found m/z = 395.2587. 
 
194 
 
(13S)-2-(4-Chlorobenzoyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 136), C26H27ClO3, MW 
422.94, 
 
136 
4-Chlorophenyl acid chloride (0.89 mL, 7.03 mmol) was added drop-wise to a 
cooled, 0 °C (ice bath), suspension of aluminium chloride (984 mg, 7.38 mmol) in 
DCM (60 mL). A solution of (8R,9S,13S,14S)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (1.00 
g, 3.52 mmol) in DCM (20 mL) was added slowly and stirring continued for 15 min 
at this temperature. The reaction mixture was quenched by pouring onto crushed ice. 
DCM (30 mL) and water (30 mL) were added and the resulting mixture was stirred 
vigorously for 10 min. The organic layer was separated and the crude products 
extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated in-vacuo 
to give the title compound 136 (1.27 g, 85%) as a white amorphous solid. m.p. 191-
193 ºC, 
1
H NMR (400 MHz, CDCl3): δ 0.81 (3H, s, 18-CH3), 1.32-1.57 (6H, m), 
1.79-1.85 (1H, m), 1.93-2.06 (3H, m), 2.12-2.17 (1H, m), 2.22-2.27 (1H, m), 2.37-
2.43 (1H, m), 2.88 (2H, m, 6-CH2), 3.57 (3H, s, 3-OCH3), 6.60 (1H, s, ArH), 7.20 
(1H, s, ArH), 7.28 (2H, d, J = 9 Hz, 2 × ArH) and 7.62 (2H, d, J = 9 Hz, 2 × ArH). 
13
C NMR (101 MHz, CDCl3): δ 13.78 (18-CH3), 21.50, 25.74, 26.31, 29.89, 31.42, 
35.74 (CH2), 38.19, 43.73 (CH), 47.85 (C), 50.32 (CH), 55.53 (3-OCH3), 111.77 
(ArCH), 125.91 (ArC), 127.06 (ArCH), 128.32 (2 × ArCH), 131.02 (2 × ArCH), 
132.19, 136.69, 138.84, 141.44, 155.45, 195.12 (ArC) and 220.21 (CO). HRMS 
(ESI) calcd for C26H27Cl
35
O3Na (M+Na)
+
: m/z = 445.1541, found m/z = 445.1534, 
calcd for C26H27Cl
37
O3Na (M+Na)
+
: m/z = 447.1511, found m/z = 445.1534, Anal. 
Calcd. for C26H27ClO3: C 73.83, H 6.43, N 0.00%, found C 73.40, H 6.42, N 0.00%. 
 
195 
 
(13S)-2-(2,4-Dichlorobenzoyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 137), 
C26H26Cl2O3, MW 457.39, 
 
137 
2,4-Dichlorobenzoyl chloride (0.98 mL, 7.03 mmol) was added drop-wise to a 
cooled, 0 °C (ice bath), suspension of aluminium chloride (984 mg, 7.38 mmol) in 
DCM (60 mL). A solution of (8R,9S,13S,14S)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (1.00 
g, 3.52 mmol) in DCM (20 mL) was added slowly and stirring continued for 15 min 
at this temperature. The reaction mixture was quenched by pouring onto crushed ice. 
DCM (30 mL) and water (30 mL) were added and the resulting mixture was stirred 
vigorously for 10 min. The organic layer was separated and the crude products 
extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated in-vacuo 
to give the title compound 137 (1.05 g, 65%) as a white amorphous solid. m.p. 217-
220 ºC, 
 1
H NMR (400 MHz, CDCl3): δ 0.92 (3H, s, 18-CH3), 1.44-1.65 (7H, m), 
1.95-2.10 (4H, m), 2.19-2.23 (1H, m), 2.40-2.54 (2H, m), 2.94 (2H, m, 6-CH2), 3.59 
(3H, s, 3-OCH3), 7.25 (1H, s, ArH), 7.28 (1H, d, J = 2Hz, ArH), 7.31 (1H, s, ArH), 
7.39 (1H, d, J = 2 Hz, ArH) and 7.64 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3): δ 
13.78 (18-CH3), 21.50, 25.72, 26.20, 30.00, 31.40, 35.74 (CH2), 38.14, 43.70 (CH), 
47.87 (C), 50.36 (CH), 55.67 (3-OCH3), 112.04 (ArCH), 124.87 (ArC), 126.77, 
128.43, 129.40, 129.99, 132.04 (ArCH), 132.53, 135.83, 139.76, 144.34, 157.32 
(ArC), 193.05 (CO) and 220.31 (CO),  HRMS (ESI) calcd for C26H27Cl2O3 (M+H)
+
: 
m/z = 459.1302, found m/z = 459.1313, Anal. Calcd. for C26H27Cl2O3: C 68.27, H 
5.73, N 0.00%, found C 67.70, H 5.71, N 0.00%. 
 
196 
 
(13S)-2-(2-(4-Chlorophenyl)acetyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 138), 
C27H29ClO3, MW 436.97, 
 
138 
4-Chlorophenylacetyl chloride (1.03 mL, 7.03 mmol) was added drop-wise to a 
cooled, 0 °C (ice bath) suspension of aluminium chloride (984 mg, 7.38 mmol) in 
DCM (60 mL). A solution of (8R,9S,13S,14S)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (1.00 
g, 3.52 mmol) in DCM (20 mL) was added slowly and stirring continued for 15 min 
at this temperature. The reaction mixture was quenched by pouring onto crushed ice. 
DCM (30 mL) and water (30 mL) were added and the resulting mixture was stirred 
vigorously for 10 min. The organic layer was separated and the crude products 
extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure to give the title compound 138 (1.11 g, 73%) as a white amorphous 
solid. m.p. 177-180 ºC, 
1
H NMR (400 MHz, CDCl3): δ 0.89 (3H, s, 18-CH3), 1.41-
1.66 (8H, m), 1.93-2.24 (5 H, m), 2.40-2.53 (2H, m), 2.93 (2H, m, 6-CH2), 3.87 (3H, 
s, 3-OCH3), 4.23 (2H, d, J = 4 Hz, 2-CCOCH2), 6.66 (1H, s, ArH), 7.13 (2H, d, J = 8 
Hz, 2 × ArH), 7.24 (2H, d, J = 8 Hz, 2 × ArH) and 7.64 (1H, s, ArH). 
13
C NMR (101 
MHz, CDCl3): δ 13.75 (18-CH3), 21.49, 25.69, 26.23, 29.84, 31.40, 35.73 (CH2), 
38.17, 43.69 (CH), 47.85 (2-CCOCH2), 49.29 (C), 50.33 (CH), 55.39 (3-OCH3), 
111.73 (ArCH), 125.28 (ArC), 128.01 (ArCH), 128.33 (2 × ArCH), 130.92 (2 × 
ArCH), 132.31, 132.38, 133.95, 143.30, 156.62 (ArC), 198.76 (CO) and 220.24 
(CO), HRMS (ESI) calcd for C27H30ClO3 (M+H)
+
: m/z = 437.1818, found m/z = 
437.1866, Anal. Calcd. for C27H29ClO3: C 74.21, H 6.69, N 0.00%, found C 73.40, H 
6.67, N 0.00% 
 
197 
 
(13S)-2-Benzoyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 139), C25H26O3, MW 
374.47, 
 
139 
Trimethylamine hydrochloride (3.44 g, 36 mmol) was added to a suspension of 
aluminium chloride (13.51 g, 72 mmol) in DCM (20 mL) at 0 °C (ice bath). The 
resulting mixture was stirred for 30 min at room temperature before a solution of 
(13S)-2-benzoyl-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one 134 (2.80 g, 7.2 mmol)  in DCM (20 mL) 
was added drop-wise before the reaction mixture was brought to reflux for 2 h. After 
cooling to room temperature the reaction mixture was poured onto crushed ice and 
vigorously stirred for 10 min. The organics were extracted with DCM (2 × 20 mL), 
dried (MgSO4), filtered and evaporated in-vacuo to give the title compound 139 
(1.94 g, 74%) as a pale yellow solid. m.p. 199-203 ºC, HPLC: tr 3.62 (90% 
Acetonitrile in water) 99%, 
1
H NMR (400 MHz, CDCl3): δ 0.90 (3H, s, 18-CH3), 
1.37-1.67 (6H, m), 1.87-1.90 (1H, m), 2.00-2.21 (5H, m), 2.46-2.54 (1H, quart, J = 9 
Hz), 2.92-2.96 (2H, m, 6-CH2), 6.81 (1H, s, ArH), 7.49 (1H, s, ArH), 7.52 (2H, t, J = 
7 Hz, ArH), 7.60 (1H, t, J = 7 Hz, ArH), 7.66 (2H, d, J = 7 Hz, ArH) and 11.87 (1H, 
broad s, OH). 
13
C NMR (101 MHz, CDCl3): δ 13.79 (18-CH3), 21.51, 25.65, 26.10, 
29.85, 31.32, 35.79 (CH2), 38.09, 43.55 (CH), 47.84 (C), 50.32 (CH), 117.20 (ArC), 
117.71, 128.35 (2 × ArCH), 129.04 (2 × ArCH), 130.41 (ArCH), 130.64 (ArC), 
131.82, 138.13 (ArCH), 146.84, 160.99 (ArC), 201.17 (CO) and 220.56 (CO). 
LRMS (ESI) calcd for C25H27O3 (M+H)
+
: m/z = 375.2, found m/z = 375.2. 
 
198 
 
(13S)-2-(Cyclohexanecarbonyl)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 140), 
C25H32O3, MW 380.52, 
 
140 
Trimethylamine hydrochloride (604 mg, 6.34 mmol) was added to a suspension of 
aluminium chloride (1.69 g, 12.7 mmol) in DCM (15 mL) at 0 °C (ice bath). The 
resulting mixture was stirred for 30 min at room temperature before a solution of 
(13S)-2-(cyclohexanecarbonyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 135 (500 mg, 1.27 mmol)  in 
DCM (10 mL) was added drop-wise before the reaction mixture was brought to 
reflux for 2 h. After cooling to room temperature the reaction mixture was poured 
onto crushed ice and vigorously stirred for 10 min. The organics were extracted with 
DCM (2 × 20 mL), dried (MgSO4), filtered and evaporated in-vacuo to give the title 
compound 139 (1.94 g, 74%) as a pale yellow solid. HPLC: tr 5.44 (90% Acetonitrile 
in water) 92%, 
1
H NMR (400 MHz, CDCl3): δ 0.92 (3H, s, 18-CH3), 1.25-1.71 (9H, 
m), 1.76-1.82 (4H, m), 1.85-1.97 (4H, m), 2.00-2.31 (4H, m), 2.41-2.54 (2H, m), 
2.90-2.93 (2H, m, 6-CH2), 3.15-3.20 (1H, m, 2-CCOCH), 6.67 (1H, s, ArH) and 7.43 
(1H, s, ArH). 
13
C NMR (101 MHz, CDCl3): δ 14.01 (18-CH3), 21.61, 25.78 (2 × 
CH2), 25.89, 26.44, 30.11 (2 × CH2), 31.49, 35.97 (CH2), 38.01, 42.92 (CH), 48.03 
(CH2), 51.23 (CH), 111.68, 127.57 (ArCH), 131.87, 138.16, 157.43 (ArC), 201.62 
and 220.13 (CO) LRMS (ESI) calcd for C25H33O3 (M+H)
+
: m/z = 381.2, found m/z = 
381.1. 
 
 
 
 
199 
 
(13S)-2-(4-Chlorobenzoyl)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 141), C25H25ClO3, MW 
408.92, 
 
141 
Trimethylamine hydrochloride (186 mg, 1.95 mmol) was added to a suspension of 
aluminium chloride (520 mg, 3.90 mmol) in DCM (10 mL) at 0 °C (ice bath). The 
resulting mixture was stirred for 30 min at room temperature before a solution of 
(13S)-2-(4-chlorobenzoyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 136 (165 mg, 0.39 mmol)  in DCM (10 
mL) was added drop-wise. The reaction mixture was brought to reflux for 2 h. After 
cooling to room temperature the reaction mixture was quenched by pouring onto 
crushed ice and vigorously stirred for 10 min. The crude products were then 
extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated in-vacuo 
to give the title compound 141 (69 mg, 43%) as a pale yellow solid. HPLC: tr 1.63 
min (90% Acetonitrile in water) 93%, 
1
H NMR (400 MHz, CDCl3): δ 0.89 (3H, s, 
18-CH3), 1.39-1.66 (6H, m), 1.88-1.91 (1H, m), 1.99-2.17 (5H, m), 2.46-2.53 (1H, 
m), 2.93 (2H, m, 6-CH2), 6.79 (1H, s, ArH), 7.42 (1H, s, ArH), 7.47 (2H, d, J = 9 Hz, 
2 × ArH), 7.60 (2H, d, J = 9 Hz, 2 × ArH) and 11.71 (1H, s, OH). 
13
C NMR (101 
MHz, CDCl3): δ 13.76 (18-CH3), 21.49, 25.64, 26.04, 29.85, 31.25, 35.77 (CH2), 
38.00, 43.48 (CH), 47.81 (C), 50.26 (CH), 116.94 (ArC), 117.82 (ArCH), 128.70 (2 
× ArCH), 129.40 (ArCH), 130.50 (2 × ArCH), 130.83, 136.37, 138.20, 147.18, 
160.91 (ArC), 199.70 (CO) and 221.12 (C17). LRMS (ESI) calcd for C25H26ClO3 
(M+H)
+
: m/z = 409.2, found m/z = 409.1. 
 
200 
 
(13S)-2-(2,4-Dichlorobenzoyl)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 142), 
C25H24Cl2O3, MW 443.36, 
 
142 
Trimethylamine hydrochloride (74 mg, 0.78 mmol) was added to a suspension of 
aluminium chloride (207 mg, 1.55 mmol) in DCM (10 mL) at 0 °C (ice bath). The 
resulting mixture was stirred for 30 min at room temperature before a solution of 
(13S)-2-(2,4-dichlorobenzoyl)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 137 (71 mg, 0.16 mmol)  in 
DCM (5 mL) was added drop-wise. The reaction mixture was brought to reflux for 2 
h. After cooling to room temperature the reaction mixture was quenched by pouring 
onto crushed ice and vigorously stirred for 10 min. The crude products were then 
extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure to give the title compound 142 (35 mg, 51%) as an amorphous pale 
yellow solid. HPLC: tr 1.59 min (90% Acetonitrile in water) 95%, 
1
H NMR (400 
MHz, CDCl3): δ 0.87 (3H, s, 18-CH3), 1.24-1.63 (7H, m), 1.83-1.88 (1H, m), 1.96-
2.14 (5H, m), 2.45-2.52 (1H, m), 2.93 (2H, m, 6-CH2), 6.79 (1H, s, ArH), 7.09 (1H, 
s, ArH), 7.27 (1H, d, J = 8 Hz, ArH), 7.39 (1H, dd, J = 8 and 2 Hz, ArH), 7.52 (1H, 
d, J = 2 Hz, ArH) and 11.67 (1H, s, OH). 
13
C NMR (101 MHz, CDCl3): δ 13.74 (18-
CH3), 21.47, 25.51, 25.94, 29.98, 31.19, 35.76 (CH2), 37.91, 43.34 (CH), 47.79 (C), 
50.23 (CH), 117.26 (ArC), 117.80, 127.23, 129.55, 129.88, 130.06 (ArCH), 131.36, 
131.83, 135.89, 136.63, 148.35, 160.97 (ArC), 198.82 (CO) and 220.84 (CO), LRMS 
(ESI) calcd for C25H25Cl2O3 (M+H)
+
: m/z = 443.1, found m/z = 443.1. 
 
201 
 
(13S)-2-(2-(4-Chlorophenyl)acetyl)-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 143), 
C26H27ClO3, MW 422.94, 
 
143 
Trimethylamine hydrochloride (88 mg, 0.92 mmol) was added to a suspension of 
aluminium chloride (244 mg, 1.83 mmol) in DCM (10 mL) at 0 °C (ice bath). The 
resulting mixture was magnetically stirred for 30 min at room temperature before a 
solution of (13S)-2-(2-(4-chlorophenyl)acetyl)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 138 
(80 mg, 0.18 mmol)  in DCM (5 mL) was added slowly. The reaction mixture was 
brought to reflux for 2 h. After cooling to room temperature the reaction mixture was 
poured onto crushed ice and vigorously stirred for 10 min. The crude products were 
then extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure to give the title compound 143 (36 mg, 47%) as an amorphous 
white solid. HPLC: tr 1.55 min (90% Acetonitrile in water) 95%, 
1
H NMR (400 
MHz, CDCl3): δ 0.91 (3H, s, 18-CH3), 1.39-1.67 (6H, m), 1.94-2.24 (5H, m), 2.35-
2.38 (1H, m), 2.47-2.54 (1H, m), 2.90 (2H, m, 6-CH2), 4.24 (2H, d, J = 3 Hz, 2-
CCOCH2), 6.70 (1H, s, ArH), 7.17 (2H, d, J = 9 Hz, 2 × ArH), 7.29 (2H, d, J = 9 Hz, 
2 × ArH), 7.69 (1H, s, ArH) and 11.91 (1H, s, OH). 
13
C NMR (101 MHz, CDCl3): δ 
13.75 (18-CH3), 21.51, 25.85, 26.02, 29.72, 31.36, 35.78 (CH2), 37.95, 43.44 (CH), 
44.31 (2-CCOCH2), 47.82 (C), 50.29 (CH), 116.95 (ArC), 117.89, 126.79 (ArCH), 
128.84 (2 × ArCH), 130.77 (2 × ArCH), 131.09, 132.59, 133.05, 147.32, 160.57 
(ArC), 202.73 (CO) and 220.03 (CO), LRMS (ESI) calcd for C26H28ClO3 (M+H)
+
: 
423.2, found m/z = 423.1. 
 
202 
 
(13S)-2-Acetyl-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 144), C21H26O3, MW 
326.43, 
 
Acetyl chloride (14.5 mL, 204 mmol) was added to a suspension of aluminium 
trichloride (28.8g, 216 mmol) in DCM (200mL) at 0 ºC (ice bath). A solution of 
(8R,9S,13S,14S)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one  133 (24.6g, 86.5 mmol) in DCM (150 mL) 
and was added slowly over a period of 20 min. After addition, the reaction mixture 
was stirred for another 30 min at 0 ºC (ice bath). The reaction was quenched by 
pouring over ice and was left standing over-night. The organics were extracted with 
chloroform (200 mL), dried (MgSO4), filtered and concentrated in-vacuo to give the 
title compound 144 as a white solid. (25.77g, 91%). m.p. 182-184 ºC, 
1
H NMR (400 
MHz, CDCl3) δ: 0.89 (3H, s, 18-CH3), 1.32-1.76 (6H, m), 1.88-2.27 (5H, m), 2.42-
2.51 (2H, m), 2.55 (3H, s, 2-CCOCH3), 2.87-2.92 (2H, m, 6-CH2), 3.86 (3H, s, 3-
OCH3), 6.67 (1H, s, ArH) and 7.66 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3): δ 
13.79 (18-CH3), 21.54, 25.79, 26.28, 29.88, 31.42 (CH2), 31.87 (2-CCOCH3), 35.81, 
35.81 (CH2), 38.22, 43.74 (CH), 47.93 (C), 50.32 (CH), 55.47 (3-OCH3), 111.79 
(ArCH), 125.71 (ArC), 127.62 (ArCH), 132.07, 143.14, 157.11 (ArC), 199.36 (CO) 
and 220.60 (CO). Data obtained for melting point is identical to that in the 
literature.
144 
 
 
 
203 
 
(13S)-2-Acetyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 145), C20H24O3, MW 
312.40, 
 
145 
Trimethylamine HCl (41.5 g, 433 mmol) was added portion-wise over 30 min to a 
suspension of AlCl3 (115.6 g, 867 mmol) in DCM (200 mL) at 0 °C (ice bath). The 
reaction is quite exothermic. After 10 min a solution of (13S)-2-acetyl-3-methoxy-
13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-
one 144 (25.74 g, 78.85 mmol) in DCM (70 mL) was added over 30 min. The 
reaction mixture was refluxed for 3 h until no more gas was evolved. The reaction 
mixture was cooled to room temperature and was quenched by slowly pouring onto 
crushed ice. After melting the phases were separated and the organics extracted with 
DCM (2 × 75 mL). The combined organics were washed with 2 M HCl (2 × 75 mL), 
water (2 × 75 mL) and brine (150 mL), dried (MgSO4) and concentrated in-vacuo to 
~ 100 mL and the product precipitated by the addition of hexane, collected by 
filtration and dried under high vacuum to give the title compound 145 as a beige 
solid (23.89 g, 97%). m.p. 136-138 ºC, 
1
H NMR (400 MHz, CDCl3): δ 0.89 (3H, s, 
18-CH3), 1.38-1.67 (6H, m), 1.92-2.08 (3H, m), 2.13-2.27 (2H, m), 2.33-2.51 (2H, 
m), 2.57 (3H, s, 2-CCOCH3), 2.83-2.94 (2H, m, 6-CH2), 6.63 (1H, s, ArH), 7.57 (1H, 
s, ArH) and 12.01 (1H, br. s, OH). 
13
C NMR (101 MHz, CDCl3): δ 13.74 (18-CH3), 
21.48, 25.83, 26.04 (CH2), 26.42 (2-CCOCH3), 29.69, 31.34, 35.75 (CH2), 38.01, 
43.46 (CH), 47.81 (C), 50.32 (CH), 117.56 (ArCH), 117.84 (ArC), 127.22 (ArCH), 
130.85, 146.82, 160.05 (ArC), 203.96 (CO) and 220.47 (CO). LRMS (ESI) calcd for 
C20H25O3 (M+H)
+
: m/z = 313.2, found m/z = 312.9.  
 
204 
 
(13S)-2-Ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compund 146), C20H26O2, MW 
298.42, 
 
146 
A solution of (13S)-2-acetyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 145 (39.812 g, 0.128 mol) in MeOH / 
THF (3/2, 450 mL) was stirred with 10% palladium on charcoal (5 g, 0.037 eq. in 
Pd) under an atmosphere of hydrogen for 5 d. The reaction mixture was filtered 
through a pad of celite to remove the catalyst and the resulting yellow solution was 
evaporated in-vacuo. The resulting yellow solid was recrystallised from EtOAc / 
hexane (1/1) to give the title compound 146 (35.234 g, 93%) as colourless crystals. 
m.p. 201-205 ºC, 
1
H NMR (400 MHz, CDCl3): δ 0.91 (3H, s, 18-CH3), 1.23 (3H, t, J 
= 8 Hz, 2-CCH2CH3), 1.32- 2.53 (13H, m), 2.62 (2H, quart, J = 8 Hz, 2-CCH2), 2.82 
(2H, m, 6-CH2), 6.53 (ArH), 7.04 (ArH), LRMS (ESI) calcd for C20H27O2 (M+H)
+
: 
m/z = 298.2, found m/z = 298.2. Data obtained for melting point is identical to that in 
the literature.
107 
(13S)-4-((Dimethylamino)methyl)-2-ethyl-3-hydroxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 
(Compound 147), C23H33NO2, MW 355.51, 
 
147 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (2.98 g, 10.0 mmol) in EtOH / 
205 
 
toluene (1/1, 40 mL) was added N,N,N',N'-tetramethyldiaminomethane (2.0 g, 20 
mmol) and paraformaldehyde (300 mg). The mixture was heated to reflux for 5 h, 
cooled to room temperature and concentrated in-vacuo. Water (50 mL) was added to 
the residue and the organics were extracted with Et2O (3 x 50 mL). The combined 
organic extracts were washed with brine (30 mL), dried (MgSO4) and concentrated 
in-vacuo to give the title compound 147 (3.39 g, 95%) as a white foam. HPLC: tr 
1.12 min (90% Acetonitrile in water) 97%, 
1
H NMR
 
(400 MHz, CDCl3) δ: 0.89 (3H, 
s, 18-CH3), 1.20 (3H, t,  J = 8 Hz, 2-CCH2CH3), 1.30-1.64 (6H, m), 1.90-1.96 (1H, 
m), 1.99-2.18 (3H, m), 2.20-2.28 (1H, m), 2.32 (6H, s, N(CH3)2), 2.39-2.68 (5H, m), 
2.76-2.84 (1H, m), 3.60 (1H, d, J = 14 Hz, 4-CCH2A), 3.68 (1H, d, J = 14 Hz, 4-
CCH2B), 7.00 (1H, s, ArH); 
13
C NMR (101 MHz, CDCl3) δ: 13.81 (18-CH3), 14.43 
(2-CCH2CH3), 21.33, 22.93, 26.04, 26.66, 26.74, 31.45, 35.62 (CH2), 37.42, 44.12 
(CH), 44.20 (N(CH3)2), 47.65 (C), 50.18 (CH), 58.00 (4-CCH2), 118.32, 124.79 
(ArCH), 128.19, 129.48, 131.48, 154.30 (ArC) and 221.1 (CO), LRMS (ESI) calcd 
for C23H34NO2 (M+H)
+
: m/z = 356.2, found m/z = 356.1,  HRMS (FAB+) calcd for 
C23H34NO2 (M+H)
+
:
 
m/z = 356.2584, found m/z = 356.2572. 
 
(13S)-2-Ethyl-3-hydroxy-13-methyl-4-(pyrrolidin-1-ylmethyl)-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 
(Compound 148), C25H35NO2, MW 381.55, 
 
148 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (300 mg, 1.0 mmol) in EtOH / 
toluene (1/1, 9 mL) was added pyrrolidine (0.166 mL, 2.0 mmol) and 
paraformaldehyde (60 mg). The mixture was heated to reflux for 5 h, cooled to room 
temperature and concentrated in-vacuo. Water (10 mL) was added to the residue and 
the organics were extracted with Et2O (3 x 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried (MgSO4) and concentrated in-vacuo to give 
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the title compound 148 (199 mg, 52%) as white foam. HPLC: tr 1.27 min (90% 
Acetonitrile in water) 95%, 
1
H NMR (400 MHz, CDCl3) δ: 0.90 (3H, s, 18-CH3), 
1.21 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.33-1.66 (7H, m), 1.85 (4H, s, CH2), 1.93-2.17 
(4H, m), 2.24 (1H, m), 2.42-2.58 (2H, m), 2.60-2.70 (7H, m), 2.80 (1H, m), 3.78 
(1H, d, J = 14 Hz, 4-CCH2A), 3.88 (1H, d, J = 14 Hz, 4-CCH2B) and 7.03 (1H, s, 
ArH). 
13
C NMR (101 MHz, CDCl3) δ: 13.69 (18-CH3), 14.30 (2-CCH2CH3), 21.42, 
23.07 (CH2), 23.57 (2 × CH2), 26.10, 26.75, 26.83, 31.52, 35.77 (CH2), 37.51, 44.21 
(CH), 47.76 (C), 50.28 (CH), 53.53 (4-CCH2), 54.29 (2 × CH2), 118.80 (ArC), 
124.74 (ArCH), 128.29, 129.48, 131.21, 154.35 (ArC) and 220.84 (CO). LRMS 
(ESI) calcd for C25H36NO2 (M+H)
+
: m/z = 382.2, found m/z = 382.0. HRMS (ESI) 
calcd for C25H36NO2 (M+H)
+
: m/z = 382.2741, found m/z = 382.2749. 
 
(13S)-2-Ethyl-3-hydroxy-13-methyl-4-(piperidin-1-ylmethyl)-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 
(Compound 149), C26H37NO2, MW 395.58, 
 
149 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (300 mg, 1.0 mmol) in EtOH / 
toluene (1/1, 9 mL) was added piperidine (0.198 mL, 2.0 mmol) and 
paraformaldehyde (60 mg). The mixture was heated to reflux for 5 h, cooled to room 
temperature and concentrated in-vacuo. Water (10 mL) was added to the residue and 
the organics were extracted with Et2O (3 x 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried (MgSO4) and concentrated in-vacuo to give 
the title compound 149 (190 mg, 48%) as white foam. HPLC: tr 0.91 min (90% 
Acetonitrile in water) 97%, 
1
H NMR (400 MHz, CDCl3) δ: 0.90 (3H, s, 18-CH3), 
1.21 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.32-1.53 (6H, m), 1.55-1.63 ( 6H, br. s), 1.91-
2.17 (4H, m), 2.36 (1H, s, CH), 2.42-2.54 (2H, m), 2.61 (2H, quart, J = 8 Hz, 2-
CCH2), 2.68 (1H, m), 2.77 (1H, m), 3.60 (1H, d, J = 14 Hz, 4-CCH2A), 3.68 (1H, d, J 
207 
 
= 14 Hz, 4-CCH2B) and 7.03 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 13.83 
(18-CH3), 14.43 (2-CCH2CH3), 21.56, 23.24, 23.98 (CH2), 25.77 (2 × CH2), 26.25, 
26.89, 26.99, 31.65, 35.91 (CH2), 37.66, 44.35 (CH), 47.90 (C), 50.41 (CH), 53.85 (2 
×CH2), 57.54 (4-CCH2), 118.27 (ArC), 124.90 (ArCH), 128.43, 129.69, 131.93, 
154.53 (ArC), 221.00 (CO). LRMS (ESI) calcd for C26H38NO2 (M+H)
+
: m/z = 396.2, 
found m/z = 396.0. HRMS (ESI) calcd for C26H38NO2 (M+H)
+
: m/z = 396.2824, 
found m/z = 396.2888, Anal. Calcd. for C26H38NO2: C 78.94, H 9.43, N 3.54%, 
found C 78.40, H 9.49, N 3.43%. 
 
(13S)-2-Ethyl-3-hydroxy-13-methyl-4-(morpholinomethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 150), 
C25H35NO3, MW 397.55, 
 
150 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (300 mg, 1.0 mmol) in EtOH / 
toluene (1/1, 9 mL) was added morpholine (0.175 mL, 2.0 mmol) and 
paraformaldehyde (60 mg). The mixture was heated to reflux for 5 h, cooled to room 
temperature and concentrated in-vacuo. Water (10 mL) was added to the residue and 
the organics were extracted with Et2O (3 x 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried (MgSO4) and concentrated in-vacuo to give 
the title compound 150 (164 mg, 41%) as a white foam. HPLC: tr 2.74 min (90% 
Acetonitrile in water) 99%, 
1
H NMR (400 MHz, CDCl3) δ: 0.89 (3H, s, 18-CH3), 
1.20 (3H, t, J = 7 Hz, 2-CH2CH3), 1.33-1.63 (6H, m), 1.90-1.95 (1H, m), 2.02-2.17 
(3H, m), 2.23-2.37 (1H, m), 2.41-2.71 (9H, m), 2.79-2.85 (1H, m), 3.46 (6H, m), 
7.05 (1H, s, ArH) and 11.36 (1H, br. s, OH). 
13
C NMR (101 MHz, CDCl3) δ: 13.59 
(18-CH3), 14.20 (2-CCH2CH3), 21.32, 22.99, 26.04, 26.62, 26.87, 31.42, 35.65 
(CH2), 37.39, 44.10 (CH), 47.62 (C), 50.13 (CH), 52.62 (4-CCH2), 56.85 (2 × CH2), 
66.50 (2 × CH2), 117.23 (ArC), 125.51 (ArCH), 128.29, 130.00, 131.92, 153.70 
208 
 
(ArC) and 220.56 (CO). LRMS (ESI) calcd for C25H36NO3 (M+H)
+
: m/z = 398.2, 
found m/z = 398.2, HRMS (ESI) calcd for C25H36NO3 (M+H)
+
: m/z = 398.2690, 
found m/z = 398.2698. 
 
(13S)-2-Ethyl-3-hydroxy-13-methyl-4-(thiomorpholinomethyl)-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 
(Compound 151), C25H35NO2S, MW 413.62, 
 
151 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (300 mg, 1.0 mmol) in EtOH / 
toluene (1/1, 9 mL) was added thiomorpholine (0.190 mL, 2.0 mmol) and 
paraformaldehyde (60 mg). The mixture was heated to reflux for 5 h, cooled to room 
temperature and concentrated in-vacuo. Water (10 mL) was added to the residue and 
the organics were extracted with Et2O (3 x 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried (MgSO4) and concentrated in-vacuo to give 
the title compound 151 (95 mg, 23%) as white foam. HPLC tr 1.83 min (90% 
Acetonitrile in water) 100%, 
1
H NMR (400 MHz, CDCl3) δ: 0.89 (3H, s, 18-CH3), 
1.20 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.34-1.66 (6H, m), 1.91-2.23 (6H, m), 2.41-2.81 
(14H, m), 3.65 (1H, d, J = 14 Hz, 4-CCH2A), 3.73 (1H, d, J = 14 Hz, 4-CH2B) and 
7.05 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 13.78 (18-CH3), 14.33 (2-
CCH2CH3), 21.51, 23.15, 26.21, 26.80, 27.04 (CH2), 27.87 (2 × CH2), 31.59, 35.86 
(CH2), 37.58, 44.28 (CH), 47.85 (C), 50.34 (CH), 54.28 (4-CCH2), 57.46 (2 × CH2), 
117.58 (ArC), 125.32 (ArCH), 128.62, 130.22, 132.16, 154.02 (ArC) and 220.93 
(CO). LRMS (ESI) calcd for C25H36NO2S (M+H)
+
: m/z = 414.2, found m/z = 414.0. 
HRMS (ESI) calcd for C25H36NO2S (M+H)
+
: m/z = 414.2389, found m/z = 414.2449. 
 
209 
 
(13S)-4-(Azepan-1-ylmethyl)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 152), 
C27H39NO2, MW 409.60, 
 
152 
To a solution of (13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-
6H-cyclopenta[a]-phenan-thren-17(14H)-one 146 (300 mg, 1.0 mmol) in EtOH / 
toluene (1/1, 9 mL) was added azepane (0.226 mL, 2.0 mmol) and paraformaldehyde 
(60 mg). The mixture was heated to reflux for 5 h, cooled to room temperature and 
concentrated in-vacuo. Water (10 mL) was added to the residue and the organics 
were extracted with Et2O (3 x 10 mL). The combined organic extracts were washed 
with brine (10 mL), dried (MgSO4) and concentrated in-vacuo to give the title 
compound 152 (221 mg, 54%) as white foam. HPLC: tr 1.16 min (90% Acetonitrile 
in water) 99%, 
1
H NMR (400 MHz, CDCl3) δ: 0.91 (3H, s, 18-CH3), 1.22 (3H, t, J = 
7 Hz, 2-CCH2CH3), 1.32-1.62 (6H, m), 1.65-1.70 (9H, m), 1.95-2.27 (5H, m), 2.43-
2.58 (2H, m), 2.60-2.84 (8H, m), 3.73 (1H, d, J = 15 Hz, 4-CCH2A), 3.81 (1H, d, J = 
15 Hz, 4-CCH2B) and 7.04 (1H, s, ArH), 
13
C NMR (101 MHz, CDCl3) δ: 13.71 (18-
CH3), 14.37 (2-CCH2CH3), 21.44, 23.13, 26.11 (CH2), 26.53 (2 × CH2), 26.79, 26.87 
(CH2), 27.56 (2 × CH2), 31.55, 35.78 (CH2), 37.53, 44.23 (CH), 47.78 (C), 50.29 
(CH), 55.08 (2 × CH2), 57.17 (4-CCH2), 118.85 (ArC), 124.83 (ArCH), 128.40, 
129.45, 131.63, 154.74 (ArC) and 220.85 (CO). LRMS (ESI) calcd for C27H40NO2 
(M+H)
+
:  m/z = 410.3, found m/z = 410.1. 
 
210 
 
(13S,17S)-4-((Dimethylamino)methyl)-2-ethyl-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol 
(Compound 153), C23H35NO2, MW 357.53, 
 
153 
Prepared by modification to the literature procedure.
142 
Sodium borohydride (12 mg, 0.31 mmol) was added portion-wise to a solution of 
(13S)-4-((dimethylamino)methyl)-2-ethyl-3-hydroxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 147 
(100 mg, 0.28 mmol) dissolved in MeOH / THF (1/1, 4 mL) at 0 C (ice bath). The 
resulting solution was stirred for 2 h and treated with water (5 mL). The crude 
products were extracted with ethyl acetate (2  5 mL), washed with brine (5 mL), 
dried (MgSO4), filtered and evaporated in-vacuo to give the title compound 153 (82 
mg, 82%) as a white foam. HPLC tr = 2.73 min (90% Acetonitrile in water) 97%, 
1
H 
NMR
 
(400 MHz, CDCl3) δ: 0.91 (3H, s, 18-CH3), 1.23 (3H, t,  J = 8 Hz, 2-
CCH2CH3), 1.29-1.61 (6H, m), 1.87-1.92 (1H, m), 2.00-2.18 (3H, m), 2.21-2.32 (1H, 
m), 2.36 (6H, s, N(CH3)2), 2.39-2.70 (5H, m), 2.77-2.82 (2H, m), 3.59 (1H, d, J = 14 
Hz, 4-CCH2A), 3.72 (1H, d, J = 14 Hz, 4-CCH2B), 7.02 (1H, s, ArH); 
13
C NMR (101 
MHz, CDCl3) δ: 13.96 (18-CH3), 14.53 (2-CCH2CH3), 21.30, 22.97, 26.12, 26.70, 
26.77, 31.54, 35.64 (CH2), 37.45, 44.14 (CH), 44.43 (N(CH3)2), 47.68 (C), 50.21 
(CH), 58.06 (4-CCH2), 81.73 (17-CH) 118.35, 124.83 (ArCH), 128.22, 129.53, 
131.54 (ArC) and 154.35 (ArC), HRMS (ESI) calcd for C23H36NO2 (M+H)
+
: m/z = 
358.2668, found m/z = 358.2754. 
 
 
 
 
211 
 
(13S,17S)-2-Ethyl-13-methyl-4-(morpholinomethyl)-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol (Compound 154), 
C25H37NO3, MW 399.57, 
 
154 
Prepared in accordance with the literature procedure.
 142
 
Sodium borohydride (8.0 mg, 0.29 mmol) was added portion-wise to a solution of 
(13S)-2-ethyl-3-hydroxy-13-methyl-4-(morpholinomethyl)-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 150 (72.0 mg, 0.18 mmol) 
dissolved in MeOH / THF (1/1, 3 mL) at 0 C (ice bath). The resulting solution was 
stirred for 2 h and treated with water (5 mL). The crude products were extracted with 
ethyl acetate (2  5 mL), washed with brine (5 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the title compound 154 (53 mg, 73%) as a white foam. 
HPLC: tr 1.05 min (90% Acetonitrile in water) 97%, 
1
H NMR (400 MHz, CDCl3) δ: 
0.76 (3H, s, 18-CH3), 1.20 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.24-1.51 (10H, m), 1.65-
1.68 (1H, m), 1.92-1.96 (2H, m), 2.04-2.39 (2H, m), 2.62-2.73 (4H, m), 2.59 (2H, 
quart, J = 8 Hz, 2-CCH2), 2.73-2.79 (3H, m), 3.69-3.74 (6H, m) and 7.05 (1H, s, 
ArH). 
13
C NMR (101 MHz, CDCl3) δ: 11.02 (18-CH3), 14.46 (2-CCH2CH3), 24.51, 
26.42, 27.03, 27.47, 29.24, 30.37, 36.64 (CH2), 38.11, 43.17 (CH), 44.33 (C), 49.78 
(CH), 50.42 (CH2), 56.61 (2 × CH2), 66.80 (2 × CH2), 81.40 (17-CH), 117.48, 125.43 
(ArC), 128.43 (ArCH), 130.93, 132.45 (ArC) and 153.77 (ArC). LRMS (ESI) calcd 
for C25H38NO3 (M+H)
+
:  m/z = 400.3, found m/z = 400.1, HRMS (ESI) calcd for 
C25H38NO3 (M+H)
+
: m/z = 400.2773, found m/z = 400.2861. 
 
 
 
212 
 
(13S,17S)-4-(Azepan-1-ylmethyl)-2-ethyl-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-3,17-diol (Compound 155), 
C27H41NO2, MW 411.62, 
 
155 
Prepared by modification to the literature procedure.
142 
Sodium borohydride (188 mg, 0.49 mmol) was added portion-wise to a solution of 
(13S)-4-(azepan-1-ylmethyl)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 152 (185 mg, 0.45 mmol) 
dissolved in MeOH / THF (1/1, 10 mL) at 0 C (ice bath). The resulting solution was 
stirred for 2 h and treated with water (5 mL). The crude products were extracted with 
ethyl acetate (2  5 mL), washed with brine (5 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the title compound 155 (146 mg, 79%) as a white foam. 
HPLC: tr 3.21 min (90% Acetonitrile in water) 98%, 
1
H NMR (400 MHz, CDCl3) δ: 
0.89 (3H, s, 18-CH3), 1.27 (3H, t, J = 7 Hz, 2-CCH2CH3), 1.30-1.64 (6H, m), 1.67-
1.73 (9H, m), 1.95-2.27 (5H, m), 2.38-2.42 (2H, m), 2.57-2.74 (8H, m), 3.74 (1H, d, 
J = 15 Hz, 4-CCH2A), 3.77 (1H, t, J = 5 Hz, CH), 3.83 (1H, d, J = 15 Hz, 4-CCH2B) 
and 7.09 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 11.12 (18-CH3), 14.52 (2-
CCH2CH3), 23.27 (CH2), 26.72 (2 × CH2), 27.31 (CH2), 27.73 (2 × CH2), 29.81, 
30.59, 36.91 (CH2), 38.21, 43.20 (CH), 44.40 (C), 50.16 (CH), 55.24 (2 × CH2), 
57.33 (4-CCH2), 81.87 (17-CH) 118.97, 125.02 (ArC), 128.39 (ArCH), 130.30, 
131.99 (ArC) and 154.67 (ArC). LRMS (ESI) calcd for C27H42NO2 (M+H)
+
: m/z = 
412.3, found m/z = 412.2, HRMS (ESI) calcd for C27H42NO2 (M+H)
+
: m/z = 
412.3137, found m/z = 412.3218. 
 
 
213 
 
(13S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 156), C25H28O2, MW 
360.49, 
 
156 
To a stirred solution of estrone (10.0 g, 37 mmol) and potassium carbonate (6.14 g, 44 
mmol) in anhydrous DMF (300 mL) under an atmosphere of nitrogen, benzyl bromide (5.27 
mL, 44 mmol) was added drop-wise. The resulting reaction mixture was stirred at room 
temperature for 30 h. To quench the reaction water (200 mL) was added and the resulting 
precipitate was filtered, re-dissolved in DCM (200 mL) and washed with brine (200 mL), 
dried (MgSO4), filtered and the solvent evaporated  in-vacuo to yield the title compound 156 
(13.07 g, 98%) as a white solid. m.p. 128-130 ºC, 
1
H NMR (400 MHz, CDCl3) δ: 0.95 (3H, 
s, 18-CH3), 1.43-1.69 (7H, m), 1.96-2.23 (5H, m), 2.26-2.34 (1H, m), 2.39-2.43 (1H, m), 
2.48-2.57 (1H, m), 6.77(1H, d, J = 4 Hz, ArH), 6.84 (1H, dd, J = 8 and 4 Hz, ArH), 7.23 
(1H, d,  J = 8 Hz, 2 × ArH), 7.36 (1H, t, J = 8 Hz, ArH), 7.41 (2H, t, J = 8 Hz, 2 × ArH) and 
7.46 (2H, d, J = 8 Hz, ArH), 
13
C NMR (101 MHz, CDCl3) δ: 13.90 (18-CH3), 21.62, 25.96, 
26.59, 29.69, 31.65, 35.90 (CH2), 38.41, 44.04 (CH), 48.04 (C), 50.48 (CH), 70.01 (3-
OCH2), 112.45, 114.98, 126.37 (ArCH), 127.45 (2 × ArCH), 127.88 (ArCH), 128.57 (2 × 
ArCH), 132.38, 137.34, 137.82, 156.94 (ArC) and 220.14 (CO). LRMS (ESI) calcd for 
C25H29O2 (M+H)
+
: m/z = 361.2, found m/z = 361.2, HRMS (ESI) calcd for C25H29O2 
(M+H)
+
: m/z = 361.2089, found m/z = 361.2154. Data obtained for melting point is 
identical to that in the literature.
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214 
 
(13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-amine (Compound 157), C25H31NO, MW 361.52, 
 
157 
Sodium cyanoborohydride (2.85 g, 45.3 mmol) was added to a solution of (13S)-3-
(benzyloxy)-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-
thren-17(14H)-one 156 (13.62 g, 37.8 mmol) and ammonium acetate (29.14 g, 0.38 
mol) in THF / MeOH (200/67) (267 mL) with stirring for 4 d. The reaction mixture 
was poured into chilled 5% sodium hydrogen carbonate (250 mL), at which point a 
precipitate formed. The precipitate was collected by filtration, re-dissolved in DCM 
(200 mL), dried (MgSO4), filtered and the solvent evaporated in-vacuo to yield the 
title compound 157 (5.19 g, 38%) as a white solid. m.p. 88-91 ºC, IR (KBr): 561-
1448, 1506, 1578, 1613, 2843, 2934, 3035 cm
-1
, 
1
H (400 MHz, CDCl3) δ: 0.71 (3H, 
s, 18-CH3), 1.21-1.57 (5H, m), 1.72-1.77 (1H, m), 1.87-1.91 (2H, m), 2.09 (3H, s), 
2.18-2.24 (1H, m), 2.27-2.36 (1H, m), 2.80 (1H, t, J = 8 Hz, 17-CH), 2.85 (2H, quart, 
J = 4 Hz, CH2), 5.03 (2H, s, 3-OCH2), 6.72 (1H, d, J = 2 Hz, ArH), 6.78 (1H, dd, J = 
8 and 2 Hz, ArH), 7.20 (1H, d, J = 8 Hz, ArH), 7.31 (1H, t, J = 8 Hz, ArH), 7.38 (2H, 
t, J = 8 Hz, 2 × ArH) and 7.44 (2H, d, J = 8 Hz, 2 × ArH), 
13
C NMR (101 MHz, 
CDCl3) δ: 11.22 (18-CH3), 23.42, 26.38, 27.47, 29.84, 30.99, 36.78 (CH2), 39.10 
(CH), 42.86 (C), 44.03, 52.06 (CH), 62.84 (17-CH), 70.01 (3-OCH2), 112.31, 
114.91, 126.32 (ArCH), 127.45 (2 × ArCH), 127.84 (ArCH), 128.55 (2 ×ArCH), 
133.03, 137.41, 138.08 (ArC) and 156.79 (ArC). LRMS (ESI) calcd for C25H32NO 
(M+H)
+
: m/z = 362.2, found m/z = 362.4, HRMS (ESI) calcd for C25H32NO (M+H)
+
: 
m/z = 362.2406, found m/z = 362.2481. 
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N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-2,4,5-trimethoxybenzamide (Compound 
158), C35H41NO5, MW 555.70, 
 
158 
To a solution of 2,4,5-trimethoxybenzoic acid (236 mg, 1.11 mmol) in DCM (30 mL) 
EDCI.HCl (264 mg, 1.38 mmol) was added followed by addition of DMAP (169 mg, 
1.38 mmol) and triethylamine (0.64 mL, 4.56 mmol) in a portionwise manner. The 
resulting reaction mixture was stirred for 15 min at room temperature. A solution 
(13S,17S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-amine 157 (500 mg, 1.38 mmol) in DCM (10 mL 
was added  drop-wise to the reaction mixture and the mixture was stirred for 18 h at 
room temperature. The reaction was quenched with saturated ammonium chloride 
(30 mL). The crude products were extracted with DCM (2 × 15 mL), dried (MgSO4), 
filtered and evaporated in-vacuo to give the crude product. The crude product was 
then purified by flash chromatography DCM / MeOH (0 – 20%) to yield the title 
compound 158 (560 mg, 73%) as a white solid. m.p. 197 – 200 °C, 1H NMR (400 
MHz, CDCl3): δ 0.82 (3H, s, 18-CH3), 1.38–1.44 (8H, m), 1.79-1.91 (4H, m), 2.25-
2.31 (3H, m), 2.85-2.87 (2H, m, 6-CH2), 3.89 (3H, s, OCH3), 3.92 (3H, s, OCH3), 
3.95 (3H, s, OCH3), 5.02 (2H, s, 3-OCH2), 6.53 (1H, s, ArH), 6.72 (1H, d, J = 2 Hz, 
ArH), 6.76 (1H, dd, J = 8 and 2 Hz, ArH), 7.20 (1H, d, J = 8 Hz, ArH), 7.31 (1H, t, J 
= 8 Hz, ArH), 7.36 (2H, t, J = 8 Hz, 2 × ArH), 7.43 (2H, d, J = 8 Hz, 2 × ArH) and 
7.78 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 12.36 (18-CH3), 23.60, 26.35, 
27.44, 29.18, 29.84, 37.24 (CH2), 39.11, 43.53 (CH), 43.94 (C), 51.71 (CH), 56.20, 
56.30, 56.97 (OCH3), 59.36 (17-CH), 70.00 (3-OCH2), 97.12 (CH), 112.32 (ArCH), 
113.81 (ArC), 114.24, 114.89, 126.38 (ArCH), 127.45 (2 × ArCH), 127.83 (ArCH), 
128.53 (2 × ArCH), 133.04, 137.42, 138.00, 143.54, 152.16, 152.53, 156.79 (ArC) 
and 164.95 (CO), HRMS (ESI) (M+H)
+
: calcd for C35H42NO5 m/z = 556.2985, found 
m/z = 556.3057. 
216 
 
 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-4-methoxybenzamide (Compound 159), 
C33H37NO3, MW 495.65, 
 
159 
To a solution of 4-methoxybenzoic acid (169 mg, 1.11 mmol) in DCM (30 mL) 
EDCI.HCl (264 mg, 1.38 mmol) was added followed by addition of DMAP (169 mg, 
1.38 mmol) and triethylamine (0.64 mL, 4.56 mmol) in a portionwise manner. The 
resulting reaction mixture was stirred for 15 min at room temperature. A solution of 
(13S,17S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-amine 157 (500 mg, 1.38 mmol) in DCM (10 mL) 
was added  drop-wise to the reaction mixture and the mixture was stirred for 18 h at 
room temperature. The reaction was quenched with saturated ammonium chloride 
(30 mL). The crude products were then extracted with DCM (2 × 15 mL), dried 
(MgSO4), filtered and evaporated in-vacuo to give the crude product. The crude 
product was then purified by flash chromatography DCM / MeOH (0 – 20%) to yield 
the title compound 159 (465 mg, 68%) as a white solid. m.p. 195 – 197 °C, 1H NMR 
(400 MHz, CDCl3) δ: 0.82 (3H, s, 18-CH3), 1.41-1.54 (8H, m), 1.81-1.92 (3H, m), 
2.24-2.37 (3H, m), 2.86 (2H, s, 6-CH2), 3.85 (3H, s, OCH3), 5.04 (2H, s, 3-OCH2), 
6.72 (1H, d, J = 2 Hz, ArH), 6.79 (1H, dd, J = 8 and 2 Hz, ArH), 6.93 (2H, d, J = 8 
Hz, 2 × ArH), 7.21 (1H, d, J = 8 Hz, ArH), 7.31 (1H, t, J = 8 Hz, ArH), 7.38 (2H, t, J 
= 8 Hz, 2 × ArH), 7.43 (2H, d, J = 8 Hz, 2 × ArH) and 7.75 (2H, d, J = 8 Hz, 2 × 
ArH). 
13
C NMR (101 MHz, CDCl3) δ: 12.28 (18-CH3), 23.47, 26.32, 27.41, 28.95, 
29.83, 37.16 (CH2), 39.08, 43.75 (CH), 43.91 (C), 51.73 (CH), 55.43 (OCH3), 59.26 
(17-CH), 70.02 (3-OCH2), 112.33 (ArCH), 113.78 (2 × ArCH), 126.40 (ArCH), 
127.39 (2 × ArCH), 127.84 (ArCH), 128.55 (2 × ArCH), 128.61 (2 × ArCH), 132.99, 
137.42, 137.96, 156.81, 162.11 (ArC) and 166.94 (CO), HRMS (ESI) (M+H)
+
: calcd 
for C33H38NO3 m/z = 496.2773, found m/z = 496.2830. 
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N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-2,3-dimethoxybenzamide (Compound 160), 
C34H39NO4, MW 525.68, 
 
160 
To a solution of 2,3-dimethoxybenzoic acid (169 mg, 1.11 mmol) in DCM (30 mL) 
EDCI.HCl (264 mg, 1.38 mmol) was added followed by addition of DMAP (169 mg, 
1.38 mmol) and triethylamine (0.64 mL, 4.56 mmol) in a portionwise manner. The 
resulting reaction mixture was stirred for 15 min at room temperature. A solution of 
(13S,17S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-amine 157 (500 mg, 1.38 mmol) in DCM (10 mL) 
was added  drop-wise to the reaction mixture and the mixture was stirred for 18 h at 
room temperature. The reaction was quenched with saturated ammonium chloride 
(30 mL). The crude products were extracted with DCM (2 × 15 mL), dried (MgSO4), 
filtered and evaporated in-vacuo to give the crude product. The crude product was 
then purified by flash chromatography DCM / MeOH (0 – 20%) to yield the title 
compound 160 (551 mg, 76%) as a white solid. m.p. 135 – 139 °C, 1H NMR (400 
MHz, CDCl3) δ: 0.85 (3H, s, 18-CH3), 1.42-1.51 (8H, m), 1.93 (3H, m), 2.31 (3H, 
m), 2.87 (2H, s, 6-CH2), 3.90 (3H, s, OCH3), 3.94 (3H, s, OCH3), 5.04 (2H, s, 3-
OCH2), 6.74 (1H, d, J = 4 Hz, ArH), 6.79 (1H, dd, J = 8 and 4 Hz, ArH), 7.05 (1H, 
dd, J = 8 and 4 Hz, ArH), 7.17 (1H, t, J = 8 Hz, ArH), 7.22 (1H, d, J = 8 Hz, ArH), 
7.33 (1H, t, J = 8 Hz ArH), 7.38 (2H, t, J = 8 Hz, 2 × ArH), 7.45 (2H, d, J = 8 Hz, 2 
× ArH), 7.75 (1H, dd, J = 8Hz, ArH) and 8.10 (1H, d, J = 8 Hz, NH). 
13
C NMR (101 
MHz, CDCl3) δ: 12.45 (18-CH3), 23.59, 26.36, 27.46, 29.06, 29.85, 37.28 (CH2), 
39.09, 43.95, 51.79 (CH), 56.14 (OCH3), 59.37 (17-CH), 61.38 (OCH3), 70.01 (3-
OCH2), 112.35, 114.93, 115.27, 122.98, 124.51, 126.39 (ArCH), 127.14 (ArC), 
127.46 (2 × ArCH), 127.84 (ArCH), 128.55 (2 × ArCH), 133.02, 137.46, 137.99, 
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147.46, 152.64, 156.83 (ArC) and 164.99 (CO), HRMS (ESI) (M+H)
+
: calcd for 
C34H40NO4 m/z = 526.2879, found m/z = 526.2935. 
N-((13S,17S)-3-Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-2,4-dimethoxybenzamide (Compound 161), 
C34H39NO4, MW 525.68, 
 
161 
To a solution of 2,4-dimethoxybenzoic acid (169 mg, 1.11 mmol) in DCM (30 mL) 
EDCI.HCl (264 mg, 1.38 mmol) was added followed by addition of  DMAP (169 
mg, 1.38 mmol) and triethylamine (0.64 mL, 4.56 mmol) in a portionwise manner. 
The resulting reaction mixture was stirred for 15 min at room temperature. A 
solution of (13S,17S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-17-amine 157 (500 mg, 1.38 mmol) in 
DCM (10 mL) was added  drop-wise to the reaction mixture and the mixture was 
stirred for 18 h at room temperature. The reaction was quenched with saturated 
ammonium chloride (30 mL). The crude products were extracted with DCM (2 × 15 
mL), dried (MgSO4), filtered and evaporated in-vacuo to give the crude product. The 
crude product was then purified by flash chromatography DCM / MeOH (0 – 20%) 
to yield the title compound 161 (515 mg, 71%) as a white solid. m.p. 159 – 162 °C, 
1
H NMR (400 MHz, CDCl3) δ: 0.85 (3H, s, 18-CH3), 1.42-1.46 (8H, m), 1.91-1.94 
(3H, m), 2.30-2.34 (3H, m), 2.88 (2H, s, 6-CH2), 3.84 (3H, s, OCH3), 3.94 (3H, s, 
OCH3), 5.04 (3-OCH2), 6.50 (1H, d, J = 4 Hz, ArH), 6.62 (1H, dd, J = 8 and 4 Hz, 
ArH), 6.75 (1H, d, J = 4 Hz, ArH), 6.80 (1H, dd, J = 8 and 4 Hz, ArH), 7.21 (1H, d, J 
= 8 Hz, ArH), 7.33 (1H, t, J = 8 Hz, ArH), 7.38 (2H, t, J = 8 Hz, 2 × ArH), 7.44 (2H, 
d, J = 8 Hz, 2 × ArH) and 7.88 (1H, d, J = 8 Hz, ArH). 
13
C NMR (101 MHz, CDCl3) 
δ: 12.39 (18-CH3), 23.64, 26.40, 27.49, 29.24, 29.88, 37.23 (CH2), 39.15, 43.51 
(CH), 43.98 (C), 51.76 (CH), 55.54, 56.07 (OCH3), 59.26 (17-CH), 70.01 (3-OCH2), 
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98.76, 105.47, 112.35, 114.94, (ArCH) 115.01 (ArC), 126.42, 127.48 (2 × ArCH), 
127.85 (ArCH), 128.56 (2 × ArCH), 133.10 (ArCH), 133.91, 137.48, 138.02, 156.83, 
158.82, 163.27 (ArC), and 164.97 (CO), HRMS (ESI) (M+H)
+
: calcd for C34H40NO4 
m/z = 526.2879, found m/z = 526.2945. 
 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-2,5-dimethoxybenzamide (Compound 162), 
C34H39NO4, MW 525.68, 
 
162 
To a solution of 2,5-dimethoxybenzoic acid (169 mg, 1.11 mmol) in DCM (30 mL) 
EDCI.HCl (264 mg, 1.38 mmol) was added followed by addition of  DMAP (169 
mg, 1.38 mmol) and triethylamine (0.64 mL, 4.56 mmol) in a portionwise manner. 
The resulting reaction mixture was stirred for 15 min at room temperature. A 
solution of (13S,17S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-17-amine 157 (500 mg, 1.38 mmol) in 
DCM (10 mL) was added  portion-wise to the reaction mixture and the mixture was 
stirred for 18 h at room temperature. The reaction was quenched with saturated 
ammonium chloride (30 mL). The crude products were extracted with DCM (2 × 15 
mL), dried (MgSO4), filtered and evaporated in-vacuo to give the crude product. The 
crude product was then purified by flash chromatography DCM / MeOH (0 – 20%) 
to yield the title compound 162 (464 mg, 64%) as a white solid. m.p. 152 – 156 °C, 
1
H NMR (400 MHz, CDCl3) δ: 0.85 (3H, s, 18-CH3), 1.42-1.57 (8H, m), 1.83-1.94 
(3H, m), 2.23-2.34 (3H, m), 2.88 (2H, s, 6-CH2), 3.84 (3H, s, OCH3), 3.94 (3H, s, 
OCH3), 5.04 (2H, s, 3-OCH2), 6.50 (1H, d, J = 4 Hz, ArH), 6.62 (1H, dd, J = 8 and 2 
Hz, ArH), 6.75 (1H, d, J = 2 Hz, ArH), 6.80 (1H, dd, J = 8 and 2 Hz, ArH), 7.21 (1H, 
d, J = 8 Hz, ArH), 7.33 (1H, t, J = 8 Hz, ArH), 7.38 (2H, t, J = 8 Hz, 2 × ArH), 7.45 
(2H, d, J = 8 Hz, 2 × ArH) and 7.88 (1H, d, J = 8 Hz, ArH), 
13
C NMR (101 MHz, 
CDCl3) δ: 12.39 (18-CH3), 23.64, 26.40, 27.49, 29.24, 29.88, 37.23 (CH2), 39.15, 
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43.51 (CH), 43.98 (C), 51.76 (CH), 55.54, 56.07 (OCH3), 59.26 (17-CH), 70.01 (3-
OCH2), 98.76, 105.47 (CH), 112.35, 114.94 (ArCH), 115.02 (ArC), 126.42 (ArCH), 
127.48 (2 × ArCH), 127.85 (ArCH), 128.56 (2 × ArCH), 133.10 (ArCH), 133.91, 
137.48, 138.02, 156.83, 158.82, 163.27 (ArC) and 164.97 (CO), HRMS (ESI) 
(M+H)
+
: calcd for C34H40NO4 m/z = 526.2879, found m/z = 526.2955. 
 
N-((13S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-4-methoxybenzamide (Compound 163), 
C26H31NO3, MW 405.53, 
 
163 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-17-yl)-4-methoxybenzamide 159 (100 mg, 0.20 mmol) 
was dissolved in a mixture of THF / EtOH (3/2, 50 mL) and pumped through an H 
Cube at 0.8 mL/min, 40 °C, full hydrogen 10% Pd/C. The reaction mixture was 
collected, dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product as a white amorphous solid. Re-crystallisation from methanol gave the title 
compound 163 (70 mg, 86%) as white crystalline needles. 
1
H NMR (400 MHz, 
CDCl3) δ: 0.79 (3H, s, 18-CH3), 1.25-1.43 (7H, m), 1.65-1.86 (3H, m), 2.12-2.26 
(3H, m), 2.78 (2H, s, 6-CH2), 3.84 (3H, s, OMe), 6.61 (1H, d, J = 2 Hz, ArH), 6.67 
(1H, dd, J = 8 and 2 Hz, ArH), 6.74 (1H, s, NH), 6.69 (2H, d, J = 8 Hz, 2 × ArH), 
7.09 (2H, d, J = 8 Hz, ArH) and 7.73 (2H, d, J = 8 Hz, 2 × ArH). 
13
C NMR (101 
MHz, CDCl3) δ: 12.26 (18-CH3), 23.44, 26.30, 27.39, 28.88, 29.66, 37.09 (CH2), 
39.06 (CH), 43.75 (C), 43.81, 51.65 (CH), 55.44 (OMe), 59.39 (17-CH), 112.98 
(ArCH), 113.869 (2 × ArCH), 115.48 (ArCH), 126.37 (2 ×ArCH), 127.08 (ArC), 
128.68 (ArCH), 132.00, 137.91, 154.15, 162.23 (ArC) and 167.40 (CO). HRMS 
(ESI) calcd for C26H32NO3 (M+H)
+
: m/z = 406.2377, found m/z = 406.2363. 
 
221 
 
N-((13S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,4-dimethoxybenzamide (Compound 164), 
C27H33NO4, MW 435.56, 
 
164 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,4-dimethoxybenzamide 161 (110 mg, 0.21 
mmol) was dissolved in a mixture of THF / EtOH (3/2, 50 mL) and pumped through 
an H Cube at 0.8 mL/min, 40 °C, full hydrogen 10% Pd/C. The reaction mixture was 
collected, dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product. Re-crystallisation from MeOH gave the title compound 164 (72 mg, 79%) 
as white crystalline cubes. m.p. 230-233 ºC, 
1
H NMR (400 MHz, CDCl3) δ: 0.81 
(3H, s, 18-CH3), 1.36-1.44 (8 H, m), 1.82-1.88 (4H, m), 2.17-2.25 (4H, m), 2.84 (2H, 
m, 6-CH2), 3.89 (3H, s, OCH3), 3.94 (3H, s, OCH3), 6.57 (1H, s, ArH), 6.62 (1H, d, J 
= 2 Hz, ArH), 6.65 (1H, dd, J = 8 and 2 Hz, ArH), 7.13 (1H, d, J = 8 Hz, ArH) and 
7.75 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 12.36 (18-CH3), 23.61, 26.35, 
27.44, 29.18, 29.70, 37.16 (CH2), 39.14 (CH), 43.51 (C), 43.88, 51.65 (CH), 56.19, 
5583., 56.94 (OCH3), 59.45 (17-CH), 97.08, 112.92 (ArCH), 113.57 (ArC), 114.22, 
115.48, 126.36 (ArCH), 132.15, 137.91, 143.56, 152.24, 152.55, 154.16 (ArC) and 
165.23 (CO). HRMS (ESI) calcd for C27H34NO4 (M+H)
+
: m/z = 436.2482, found m/z 
= 436.2480. 
 
222 
 
N-((13S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,3-dimethoxybenzamide (Compound 165), 
C27H33NO4, MW 435.56, 
 
165 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,3-dimethoxybenzamide 160 (92 mg, 0.17 mmol) 
was dissolved in anhydrous methanol (10 mL) at room temperature and 10% Pd/C (8 
mg, 5% mol eq.), was added and the reaction vessel was then charged with hydrogen 
with the use of a hydrogen balloon and the mixture was stirred overnight. The 
reaction mixture was filtered through celite and, the filtrate washed with methanol (3 
× 15 mL). The organic filtrate was dried (MgSO4) and concentrated in-vacuo to give 
the title compound 165 as a white solid (65 mg, 88%). m.p. 267-269 ºC 
1
H NMR 
(400 MHz, CDCl3) δ: 0.82 (3H, s, 18CH3), 1.36-1.58 (7H, m), 1.73-1.86 (3H, m), 
2.14-2.28 (3H, m), 2.81 (2H, s, 6-CH2), 3.90 (3H, s, OCH3), 3.92 (3H, s, OCH3), 
6.04 (1H, broad s, OH), 6.60 (1H, d, J = 4 Hz, ArH), 6.66 (1H, dd, J = 8 and 4 Hz, 
ArH), 7.03 (1H, dd, J = 8 and 4 Hz, ArH), 7.13 (1H, t, J = 8 Hz, ArH), 7.16 (1H, d, J 
= 8 Hz, ArH), 7.71 (1H, dd, J = 8 and 4 Hz, ArH) and 8.12 (1H, d, J = 8 Hz, NH). 
13
C NMR (101 MHz, CDCl3) δ: 12.41 (18-CH3), 23.54, 26.33, 27.40, 29.00, 29.65, 
37.18 (CH2), 39.07, 43.54 (CH), 43.87 (C), 51.70 (CH), 56.13 (OCH3), 59.41 (17-
CH), 61.40 (OCH3), 112.88, 115.31, 115.41, 122.97, 124.56, 126.98 (ArCH), 128.53, 
132.24, 138.03, 147.43, 152.59, 153.94 (ArC) and 165.19 (CO), HRMS (ESI) calcd 
for C27H33NO4Na (M+Na)
+
: m/z = 458.2307, found m/z = 458.2270. 
 
223 
 
N-((13S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,5-dimethoxybenzamide (Compound 166), 
C27H33NO4, MW 435.56, 
 
166 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,5-dimethoxybenzamide 161 (125 mg, 0.24 
mmol) was dissolved in a mixture of THF / EtOH (3/2, 50 mL) and pumped through 
an H Cube at 0.8 mL/min, 40 °C, full hydrogen 10% Pd/C. The reaction mixture was 
collected, dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product. Re-crystallisation from methanol gave the title compound 166 (71 mg, 68%) 
as white crystalline needles. 
1
H NMR (400 MHz, CDCl3) δ: 0.82 (3H, s, 18-CH3), 
1.43 (8H, m), 1.88-1.91 (3H, m), 2.17-2.30 (3H, m), 2.83 (2H, m, 6-CH2), 3.82 (3H, 
s, OCH3), 3.93 (3H, s, OCH3), 4.74 (1H, s, OH), 6.57 (1H, d, J = 2 Hz, ArH), 6.63 
(1H, dd, J = 8 and 2 Hz, ArH), 6.97 (1H, d, J = 2 Hz, ArH), 7.15 (1H, d, J = 8 Hz, 
ArH), 7.78 (1H, d, J = 2 Hz, ArH) and 8.08 (1H, d, J = 4 Hz, NH). 
13
C NMR (101 
MHz, CDCl3) δ: 12.31 (18-CH3), 23.58, 26.54, 27.42, 29.08, 29.64, 37.16 (CH2), 
39.09, 43.56 (CH), 43.63 (C), 51.69 (CH), 55.45, 55.84 (OCH3), 59.41 (17-CH), 
112.70, 113.24, 115.27, 115.54, 126.55 (ArCH), 132.56, 137.73, 143.35, 152.14, 
153.42, 153.89 (ArC) and 164.86 (CO), HRMS (ESI) calcd for C27H34NO4 (M+H)
+
: 
m/z = 436.2482, found m/z = 436.2465. 
 
224 
 
N-((13S,17S)-3-Hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,4,5-trimethoxybenzamide (Compound 167), 
C28H35NO5, MW 465.58, 
 
167 
N-((13S,17S)-3-(Benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-17-yl)-2,4,5-trimethoxybenzamide 158 (85 mg, 0.15 
mmol) was dissolved in a mixture of THF / EtOH (3/2, 50 mL) and pumped through 
an H Cube at 0.8 mL/min, 40 °C, full hydrogen 10% Pd/C. The reaction mixture was 
collected, dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product. Re-crystallisation from MeOH gave the title compound 167 (61 mg, 87%) 
as white crystalline needles. 
1
H NMR (400 MHz, CDCl3) δ: 0.80 (3H, s, 18-CH3), 
1.38-1.46 (8 H, m), 1.82-1.88 (4H, m), 2.19-2.27 (4H, m), 2.80 (2H, m, 6-CH2), 3.87 
(3H, s, OCH3), 3.92 (3H, s, OCH3), 3.95 (3H, s, OCH3), 6.53 (1H, s, ArH), 6.60 (1H, 
d, J = 2 Hz, ArH), 6.67 (1H, dd, J = 8 and 2 Hz, ArH), 7.10 (1H, d, J = 8 Hz, ArH), 
7.77 (1H, s, ArH) and 8.03 (1H, d, J = 8 Hz, NH). 
13
C NMR (101 MHz, CDCl3) δ: 
12.34 (18-CH3), 23.58, 26.34, 27.42, 29.15, 29.67, 37.13 (CH2), 39.11 (CH), 43.49 
(C), 43.86, 51.62 (CH), 56.19, 56.26, 56.96 (OCH3), 59.42 (17-CH), 97.05, 112.94 
(ArCH), 113.59 (ArC), 114.20, 115.46, 126.38 (ArCH), 132.13, 137.99, 143.55, 
152.22, 152.57, 154.12 (ArC) and 165.20 (CO). HRMS (ESI) calcd for C28H36NO5 
(M+H)
+
: m/z = 466.2588, found m/z = 466.2578. 
 
 
 
 
 
 
 
 
 
225 
 
(13S,Z)-3-(Benzyloxy)-16-(hydroxymethylene)-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one (Compound 170), 
C26H28O3, MW 388.50, 
 
170 
Potassium tert-butoxide (4.7g, 41 mmol) was added portion-wise to a stirred solution 
of (13S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one 156 (5.0 g, 14 mmol) in toluene (125 mL) 
at room temperature under an atmosphere of nitrogen. After 20 min ethyl formate 
(7.4 mL, 97 mmol) was added over 5 min and the resulting suspension was stirred for 
2.5 h. The reaction mixture was poured onto water (150 mL) and acidified with 5 M 
HCl. The organics were extracted with ethyl acetate (3 × 75 mL), washed with brine 
(100 mL), dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product. The crude product was purified on silica by flash chromatography DCM / 
MeOH (0 – 5%) to give the title compound 170 (2.99 g, 55%) as white solid. m.p. 
147-149 ºC, IR (KBr): 542-1499, 1606, 1699, 2925, 3230 cm
-1
, 
1
H NMR (400 MHz, 
CDCl3) δ: 0.98 (3H, s, 18-CH3), 1.41-1.52 (2H, m), 1.53-1.61 (6H, m), 1.93-2.07 
(2H, m), 2.16-2.21 (1H, m), 2.27-2.32 (1H, m), 2.38-2.42 (1H, m), 2.46-2.49 (1H, 
m), 2.88-2.90 (2H, m, 6-CH2), 5.04 (2H, s, 3-OCH2), 6.74 (1H, s, ArH), 6.79 (1H, d, 
J = 8 Hz, ArH), 7.09 (1H, s, 16-CCHOH), 7.20 (1H, d, J = 8 Hz, ArH), 7.32 (1H, t, J 
= 8 Hz, ArH), 7.36 (2H, t, J = 8 Hz, 2 × ArH) and 7.43 (2H, d, J = 8 Hz, 2 × ArH), 
13
C NMR (101 MHz, CDCl3) δ: 14.62 (18-CH3), 24.78, 25.87, 26.82, 29.60, 31.57 
(CH2), 38.02, 44.03 (CH), 48.93 (C), 51.04 (CH), 70.03 (3-OCH2), 112.56, 115.00, 
126.23 (ArCH), 127.43 (2 × ArCH), 127.87 (ArCH), 128.55 (2 × ArCH), 132.35 (16-
C), 137.32, 137.75, 156.96 (ArC), 197.76 (16-CCHOH) and 214.88 (CO), LRMS 
(ESI) calcd for C26H29O3 (M+H)
+
: m/z = 388.2, found m/z = 388.1. Data obtained for 
melting point is identical to that in the literature.
78 
 
226 
 
(Z)-Methyl 3-((13S)-3-(benzyloxy)-13-methyl-17-oxo-7,8,11,12,13,14,15,17-
octahydro-6H-cyclopenta[a]-phenan-thren-16(9H)-ylidene)propanoate 
(Compound 171), C29H32O4, MW 444.56, 
 
171 
To a solution of (13S,Z)-3-(benzyloxy)-16-(hydroxymethylene)-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 170 
(2.82 g, 7.26 mmol) in chloroform (50 mL) was added 
(triphenylphosphoranylidene)acetate (2.42 g, 7.26 mmol). The mixture was stirred at 
room temperature overnight. The reaction mixture was concentrated in-vacuo and the 
residue was purified by flash chromatography CHCl3 / acetone (100/1) followed by 
re-crystallization from MeOH to give the title compound 171 (2.78 g, 86%) as 
colorless needles. m.p. 179-181 °C, 
1
H NMR (400 MHz, CDCl3) δ: 0.93 (3H, s, 18-
CH3), 1.42-1.69 (5H, m), 1.94-2.06 (2H, m), 2.13 (1H, t, J = 8 Hz), 2.20-2.28 (1H, 
m), 2.36-2.42 (1H, m), 2.66 (1H, dd, J = 8 and 4 Hz), 2.87-2.94 (2H, m, 6-CH2), 3.23 
(2H, d, J = 8 Hz, 16-CCHCH2), 3.73 (3H, s, OCH3), 5.02 (2H, s, 3-OCH2), 6.75 (1H, 
d, J = 4 Hz, ArH), 6.77 (1H, t, J = 8 Hz, 16-CCH), 6.81 (1H, dd, J = 8 and 4 Hz, 
ArH), 7.21 (1H, d, J = 8 Hz, ArH), 7.31 (1H, t, J = 8 Hz, ArH), 7.38 (2H, t, J = 8 Hz, 
2 × ArH) and 7.43 (2H, d, J = 8 Hz, 2 × ArH). 
13
C NMR (101 MHz, CDCl3) δ: 14.44 
(18-CH3), 25.97, 26.40, 26.80, 29.66, 31.62, 35.01 (CH2), 37.93, 44.03 (CH), 47.72 
(C), 48.46 (CH), 52.15 (OCH3), 69.98 (3-OCH2), 112.49, 115.03, 126.32 (ArCH), 
127.45 (2 × ArCH), 127.88 (ArCH), 128.58 (2 × ArCH), 132.35 (16-C), 137.39, 
137.72 (ArC), 139.90 (16-CCH), 156.99 (ArC), 170.53 (COOCH3) and 207.70 (CO), 
LRMS (ESI) calcd for C29H33O4 (M+H)
+
: m/z = 445.2, found m/z = 445.3, HRMS 
(FAB
+
) calcd for C29H33O4 (M+H)
+
:
 
 445.2373, found 445.2368. 
 
227 
 
Methyl 3-((13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-16-yl)propanoate (Compound 172), 
C22H22O4, MW 356.46, 
 
172 
(Z)-Methyl-3-((13S)-3-(benzyloxy)-13-methyl-17-oxo-7,8,11,12,13,14,15,17-
octahydro-6H-cyclopenta[a]-phenan-thren-16(9H)-ylidene)propanoate 171 (2.66 g, 
5.98 mmol) was dissolved in anhydrous MeOH / THF (1/1, 120 mL). 10% Pd/C (160 
mg, 0.60 mmol) was added to the reaction mixture and placed under an atmosphere 
of hydrogen. The reaction mixture was stirred for 18 h, and filtered over celite. The 
reaction filtrate was concentrated in-vacuo to give the crude product (1.77 g, 83%). 
The residue was purified by flash chromatography CHCl3 / acetone (10:1) followed 
by crystallization from MeOH to give the title compound 172 as colourless 
crystalline needles (2.08 g, 98%). m.p. 178-180 ºC, 
1
H NMR (400 MHz, CDCl3) δ: 
0.84 (3H, s, 18-CH3), 1.12-1.55 (6H, m), 1.67-1.79 (1H, m), 1.94-2.03 (2H, m), 2.14-
2.27 (4H, m), 2.31-2.38 (1H, m), 2.47 (2H, t, J = 8 Hz, 16-CHCH2CH2), 2.84 (2H, 
m, 6-CH2), 3.69 (3H, s, OCH3), 5.89 (1H, broad s, OH), 6.58 (1H, d, J = 4 Hz, ArH), 
6.65 (1H, dd, J = 8 and 4 Hz, ArH) and 7.11 (1H, d, J = 8 Hz, ArH). 
13
C NMR (101 
MHz, CDCl3) δ: 14.05 (18-CH3), 25.84, 26.71, 27.64, 28.48, 29.46, 31.89, 32.59 
(CH2), 37.95, 44.07 (CH), 48.41 (C), 48.60, 48.87 (CH), 51.75 (OCH3), 112.97, 
115.38, 126.38 (ArCH), 131.75, 137.87, 153.93 (ArC) and 173.90 (CO), LRMS 
(ESI) calcd for C22H23O4 (M+H)
+
: m/z = 357.2, found m/z = 357.2. 
 
 
228 
 
3-((13S)-3-Hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-16-yl)propanoic acid (Compound 173), C21H26O4, 
MW 342.43, 
 
173 
Methyl-3-((13S)-3-hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-16-yl)propanoate 172 (2.00 g, 5.61 
mmol) was dissolved in 3 M NaOH (150 mL) and heated to reflux for 2 h. The 
reaction mixture was neutralised with 6 M HCl and the organics extracted with DCM 
(3 × 50 mL), dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product (1.40 g, 73%). The residue was purified by flash chromatography DCM / 
MeOH (0–10%) followed by crystallization from MeOH to give the title compound 
173 as colourless  crystalline needles (1.84 g, 96%). 
1
H NMR (400 MHz, CDCl3) δ: 
0.88 (1.5H, s, 18-CH3A), 0.95 (1.5H, s, 18-CH3B), 1.37-1.52 (6H, m), 1.98-2.36 (9H, 
m), 2.86 (2H, m, 6-CH2), 6.57 (1H, d, J = 4 Hz, ArH), 6.65 (1H, dd, J = 8 and 4 Hz, 
ArH) and 7.14 (1H, d, J = 8 Hz, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 14.02 (18-
CH3), 25.81, 26.46, 26.71, 27.45, 27.60, 28.38, 29.44, 31.91, 32.53 (CH2), 37.96 
(CH), 38.33 (C), 43.97, 48.37, 48.84 (CH), 113.05, 115.39, 126.07 (ArCH), 130.61, 
137.53, 154.99 (ArC),  175.10 (CO) and 220.13 (CO), LRMS (ESI) calcd for 
C21H27O4 (M+H)
+
: m/z = 343.2, found m/z = 343.2. 
 
229 
 
3-((13S)-3-Hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-16-yl)-N-(pyridin-2-ylmethyl)propanamide 
(Compound 174), C27H32N2O2, MW 432.55, 
 
174 
To a solution of 2-picoylamine (0.07 ml, 0.70 mmol) in DCM (15 mL) EDCI.HCl 
(112 mg, 0.58 mmol) was added portion-wise followed by addition of DMAP (71 
mg, 0.58 mmol) and triethylamine (0.27 mL, 1.93 mmol). The resulting reaction 
mixture was stirred for 15 min at room temperature. A solution of 3-((13S)-3-
hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-
phenan-thren-16-yl)propanoic acid 173 (200 mg, 0.58 mmol) in DCM (5 mL) was 
added  portion-wise to the reaction mixture and the mixture stirred for 18 h at room 
temperature. The reaction was quenched with saturated ammonium chloride (15 mL). 
The crude products were extracted with DCM (2 × 15 mL), dried (MgSO4), filtered 
and evaporated in-vacuo to give the crude product. The crude product was then 
purified by flash chromatography DCM / MeOH (0 – 5%) to yield the title 
compound 174 (115 mg, 46%) as an amorphous pale yellow solid. m.p. 179-183 ºC, 
1
H NMR (400 MHz, CDCl3) δ: 0.72 (18-CH3), 1.36-1.47 (7H, m), 2.10-2.31 (4H, m), 
2.39-2.44 (3H, m), 2.83 (2H, m, 6-CH2), 4.57 (2H, d, J = 4 Hz, NHCH2), 6.59 (1H, s, 
ArH), 6.61 (1H, dd, J = 9 Hz, ArH), 7.00 (1H, d, J = 9 Hz, ArH), 7.21 (1H, t, J = 5 
Hz, ArH), 7.30 (1H, d, J = 5 Hz, ArH), 7.68 (1H, t, J = 5 Hz, ArH) and 8.54 (1H, d, J 
= 5 Hz, ArH). 
13
C NMR (101 MHz, CDCl3) δ: 13.87 (18-CH3A), 13.98 (18-CH3B), 
25.75, 26.68, 27.49, 27.71, 28.44, 28.62, 31.67, 31.78, 34.85, 35.03, 37.93, 38.19 
(CH2), 43.90, 44.39, 48.25 (CH), 48.46 (C), 48.82 (CH), 113.05, 115.46, 122.40, 
122.52, 126.30 (ArCH), 131.30 (ArC), 137.05 (ArCH), 137.66 (ArC), 148.81 
(ArCH), 154.41, 156.32 (ArC), 172.99 (CONH) and 222.18 (CO), HRMS (ESI) 
calcd for C27H33N2O2 (M+H)
+
: m/z = 433.2486, found m/z = 433.2470. 
 
230 
 
3-((13S)-3-Hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]phenan-thren-16-yl)-N-(pyridin-3-ylmethyl)propanamide 
(Compound 175), C27H32N2O2, MW 432.55, 
 
175 
To a solution of 3-picoylamine (0.07 ml, 0.70 mmol) in DCM (15 mL) EDCI.HCl 
(112 mg, 0.58 mmol) was added portion-wise followed by addition of DMAP (71 
mg, 0.58 mmol) and triethylamine (0.27 mL, 1.93 mmol). The resulting reaction 
mixture was then stirred for 15 min at room temperature. A solution of 3-((13S)-3-
hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-
phenan-thren-16-yl)propanoic acid 173 (200 mg, 0.58 mmol) in DCM (5 mL) was 
added  portion-wise to the reaction mixture and the mixture stirred for 18 h at room 
temperature. The reaction was quenched with saturated ammonium chloride (15 mL). 
The crude products were extracted with DCM (2 × 15 mL), dried (MgSO4), filtered 
and evaporated in-vacuo to give the crude product. The crude product was purified 
by flash chromatography DCM / MeOH (0 – 5%) to yield the title compound 175 
(130 mg, 52%) as an amorphous pale yellow solid. m.p. 178-182 ºC, 
1
H NMR (400 
MHz, CDCl3) δ: 0.85 (3H, s, 18-CH3), 1.15-1.53 (7H, m), 1.76-2.01 (4H, m), 2.09-
2.43 (3H, m), 2.78 (2H, m, 6-CH2), 4.45 (2H, s, NHCH2), 6.53 (1H, s, ArH), 6.64 
(1H, t, J = 6 Hz, ArH), 6.83 (1H, d, J = 5 Hz, ArH), 7.01 (1H, d, J = 5 Hz, ArH), 
7.29 (1H, d, J = 6 Hz, ArH), 7.67 (1H, d, J = 6 Hz, ArH) and 8.50 (1H, s, ArH), 
13
C 
NMR (101 MHz, CDCl3) δ: 13.94 (18-CH3A), 14.06 (18-CH3B), 25.70, 26.62, 28.50, 
29.44, 31.76, 34.64 (CH2), 37.90 (CH), 40.97 (NHCH2), 43.85, 47.66 (CH), 48.53 
(C), 48.67 (CH), 113.04, 115.44, 123.75, 126.24 (ArCH), 131.04 (ArC), 134.33 
(ArCH), 136.04, 137.71 (ArC), 148.32, 148.65 (ArCH), 154.53 (ArC), 172.99 
(CONH) and 222.88 (CO), HRMS (ESI) calcd for C27H33N2O2 (M+H)
+
: m/z = 
433.2486, found m/z = 433.2473. 
 
 
231 
 
 
3-((13S)-3-Hydroxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[a]-phenan-thren-16-yl)-N-(pyridin-4-ylmethyl)propanamide 
(Compound 176), C27H32N2O2, MW 432.55, 
 
176 
To a solution of 4-picoylamine (0.07 ml, 0.70 mmol) in DCM (15 mL) EDCI.HCl 
(112 mg, 0.58 mmol) was added portion-wise followed by addition of DMAP (71 
mg, 0.58 mmol) and triethylamine (0.27 mL, 1.93 mmol). The resulting reaction 
mixture was stirred for 15 min at room temperature. 3-((13S)-3-hydroxy-13-methyl-
17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)propanoic acid 173 (200 mg, 0.58 mmol) in DCM (5 mL) was added drop-wise to 
the reaction mixture and stirred the mixture for 18 h at room temperature. The 
reaction was quenched with saturated ammonium chloride (15 mL). The crude 
products were extracted with DCM (2 × 15 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the crude product. The crude product was then purified 
by flash chromatography DCM / MeOH (0 – 5%) to yield the title compound 176 
(128 mg, 51%) as an amorphous yellow solid. m.p. 163-165 ºC, 
1
H NMR (400 MHz, 
CDCl3) δ: 0.87 (3H, s, 18-CH3), 1.39-1.54 (7H, m), 1.92-2.24 (4H, m), 2.27-2.51 
(3H, m), 2.90 (2H, m, 6-CH2), 4.46 (2H, d, J = 3 Hz, NHCH2), 6.59 (1H, s, ArH), 
6.64 (1H, dd, J = 7 and 2 Hz, ArH), 6.84 (1H, d, J = 7 Hz, ArH), 7.22 (2H, d, J = 6 
Hz, 2 × ArH) and 8.54 (2H, d, J = 6 Hz, 2 × ArH). 
13
C NMR (101 MHz, CDCl3) δ: 
14.00 (18-CH3A), 14.08 (18CH3B), 25.80, 26.50, 28.79, 28.87, 31.70, 32.90, 34.57 
(CH2), 37.94 (CH), 42.16 (NHCH2), 44.01, 47.67 (CH), 48.36 (C), 48.87 (CH), 
112.99, 115.40 (ArCH), 122.46 (2 × ArCH), 131.35, 137.77, 147.83 (ArC), 149.64 
(2 × ArCH), 154.23 (ArC), 172.99 (CONH) and 222.88 (CO), HRMS (ESI) calcd for 
C27H33N2O2 (M+H)
+
: m/z = 433.2486, found m/z = 433.2470. 
 
 
232 
 
(13S)-2-Ethyl-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (Compound 177), C21H28O2, MW 
312.45, 
 
177 
Potassium carbonate (9.26 g, 67 mmol) was added portion-wise to a solution of 
(13S)-2-ethyl-3-hydroxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one (4.968 g, 17 mmol) in anhydrous DMF (50 
mL). The resulting mixture was stirred for 10 mins under an atmosphere of nitrogen. 
To the reaction mixture was added methyl iodide (2.30 mL, 37 mmol) drop-wise and 
the reaction mixture was stirred at room temperature for 2 d. Water was slowly added 
to the stirred solution and the product precipitated. The product was filtered from the 
solution and dried in an oven at 105 °C for 2 h to give the title compound 177 (5.31 
g, 100%) as a white solid. m.p. 105-108 °C, 
1
H NMR (400 MHz, CDCl3): δ 0.84 
(3H, s, 18-CH3), 1.10 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.34-1.59 (7H, m), 1.91-2.09 
(5H, m), 2.12-2.23 (1H, m), 2.35-2.46 (2H, m), 2.54 (2H, quart, J = 8 Hz, 2-CCH2), 
2.82 (2H, m, 6-CH2), 3.73 (3H, s, OCH3), 6.51 (1H, s, ArH) and 7.01 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3): δ 13.83 (18-CH3), 14.49 (2-CCH2CH3), 21.55 (CH2), 
23.20 (2-CCH2), 25.99, 26.65, 29.53, 31.64, 35.82 (CH2), 38.49, 44.03 (CH), 47.98 
(C), 50.41 (CH), 55.29 (OCH3), 110.67, 126.04 (ArCH), 130.07, 131.33, 134.65, 
155.43 (ArC) and 220.31 (CO). 
 
 
233 
 
(13S,Z)-2-Ethyl-16-(hydroxymethylene)-3-methoxy-13-methyl-
7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 
(Compound 178), C22H28O3, MW 340.46,
 
 
178 
Potassium tert-butoxide (8.08g, 72 mmol) was added portion-wise to a stirred 
solution of (13S)-2-ethyl-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-octahydro-6H-
cyclopenta[a]-phenan-thren-17(14H)-one 177 (7.5 g, 24 mmol) in toluene (175 mL) 
at room temperature under an atmosphere of nitrogen. After 20 min ethyl formate 
(12.97 mL, 170 mmol) was added over 5 min and the resulting suspension was 
stirred for 2.5 h. The reaction mixture was poured onto water (200 mL) and acidified 
with 5 M HCl. The organics were extracted with ethyl acetate (3 × 100 mL), washed 
with brine (200 mL), dried (MgSO4), filtered and concentrated in-vacuo to give the 
crude product. The crude product was purified on silica by flash chromatography 
DCM / MeOH (0 – 5%) to give the title compound 178 as an amorphous white solid 
(3.51 g, 43%). IR (KBr): 542-1409, 1464, 1505, 1612, 1718, 2866, 2933, 3421 cm
-1
, 
1
H NMR (400 MHz, CDCl3): δ 1.02 (3H, s, 18-CH3), 1.25 (3H, t, J = 8 Hz, 2-
CCH2CH3), 1.39-1.67 (5H, m), 2.03-2.34 (4H, m), 2.46-2.49 (2H, m), 2.64 (2H, 
quart, J = 8 Hz, 2-CCH2),  2.94 (2H, m, 6-CH2), 3.84 (3H, s, OCH3), 6.62 (1H, s, 
ArH) and 7.12 (1H, s, ArH). 
13
C NMR (101 MHz, CDCl3): δ 14.64 (18-CH3), 15.34 
(2-CCH2CH3), 23.35, 24.82, 25.71, 26.73, 29.56, 31.24 (CH2), 37.95, 44.06 (CH), 
47.69 (C), 48.98 (CH), 55.36 (OCH3), 110.78 (ArCH), 112.58 (ArC), 126.00 
(ArCH), 130.20 (16-C), 131.40, 134.70, 155.56 (ArC), 196.78 (16-CCHOH) and 
211.98 (CO), LRMS (ESI) calcd for C22H29O3 (M+H)
+
: m/z = 341.2, found m/z = 
341.1. 
 
234 
 
(13S,16R)-2-Ethyl-3-methoxy-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-threne-16-carbonitrile (Compound 180), 
C22H27NO2, MW 337.46, 
 
180 
(13S,Z)-2-Ethyl-16-(hydroxymethylene)-3-methoxy-13-methyl-7,8,9,11,12,13,15,16-
octahydro-6H-cyclopenta[a]-phenan-thren-17(14H)-one 178 (1.93 g, 5.68 mmol) was 
added portionwise to a solution of pyridine in anhydrous toluene (75 mL) and 2,2,2-
trifluoro-N-(2,2,2-trifluoroacetoxy)acetamide which was prepared in accordance with 
the literature procedure
126
 179 (3.83 g, 17.04 mmol) by reacting hydroxylamine 
hydrochloride (5.63 g, 81 mmol) and trifluoroacetic anhydride (28.15 mL, 0.20 mol) 
at reflux for 1.5 h under atmosphere of nitrogen. The resulting mixture was heated to 
reflux for 3 h. The reaction mixture was cooled and the reaction was quenched with 
water (40 mL). The organics were extracted with DCM (2 × 75 mL), washed with 
brine (40 mL), dried (MgSO4), filtered and concentrated in-vacuo to give the crude 
product. The crude product was re-crystallised from DCM to give the title compound 
180 as pale yellow cubic crystals (2.35 g, 41%). IR (KBr): 532-1456, 1499, 1574, 
1611, 1745, 2245, 2858, 2904 cm
-1
, 
1
H NMR (400 MHz, CDCl3): δ 1.00 (3H, s, 18-
CH3), 1.13 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.38-1.47 (4H, m), 1.54-1.62 (1H, m), 
1.87-2.02 (3H, m), 2.17-2.26 (1H, m), 2.36-2.43 (1H, m), 2.45-2.53 (1H, m), 2.56 
(2H, quart, J = 8 Hz, 2-CCH2), 2.85 (2H, m, 6-CH2), 3.03 (1H, t, J = 5 Hz, 16-CH), 
3.72 (3H, s, OCH3), 6.65 (1H, s, ArH) and 7.01 (1H, s, ArH), 
13
C NMR (101 MHz, 
CDCl3): δ 14.15 (18-CH3), 14.52 (2-CCH2CH3), 23.34, 25.66, 26.34, 28.04, 29.29, 
32.70 (CH2), 36.64, 37.93 (CH), 43.87 (16-CH), 48.36 (C), 48.26 (CH), 55.34 
(OCH3), 110.72 (ArCH), 117.40 (16-CHC), 125.99 (ArCH), 130.25, 130.52, 134.42 
(C), 155.63 (ArC) and 207.84 (CO), LRMS (ESI) calcd for C22H28NO2 (M+H)
+
: m/z 
= 337.2, found m/z = 337.2. 
 
235 
 
(13S,16R,17S)-16-(Aminomethyl)-2-ethyl-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-17-ol 
(Compound 181), C22H33NO2, MW 343.50,
 
 
181 
Prepared by modification to the literature procedure.
127 
A solution of (13S,16R)-2-ethyl-3-methoxy-13-methyl-17-oxo-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-threne-16-
carbonitrile 180 (1.26 g, 3.73 mmol) in anhydrous THF (75 mL) was added drop-
wise to a suspension of LiAlH4 (424 mg, 11.20 mmol) in THF (50 mL) at 4 ºC under 
at atmosphere of nitrogen, and stirred overnight at 22 ºC. The excess of LiAlH4 was 
destroyed by the successive drop-wise additions of water (25 mL), 15% aqueous 
NaOH (15 mL) and water (25 mL). The reaction mixture was filtered and the solid 
fraction was washed with THF (4 × 50 mL) after evaporation of the solvent the crude 
residue was purified by flash chromatography DCM / MeOH (0-10%) to give the 
title compound 181 as an amorphous white solid (973 mg, 76%). m.p. 160-163 ºC, 
IR (KBr): 556-1464, 1506, 1543, 1613, 2924, 3146, 3677 cm
-1
, 
1
H NMR (400 MHz, 
MeOD): δ 0.78 (3H, s, 18-CH3), 1.11 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.27-1.44 (5H, 
m), 1.84-1.98 (3H, m), 2.13-2.17 (1H, m), 2.21-2.31 (2H, m), 2.54 (2H, quart, J =8 
Hz, 2-CCH2), 2.80 (2H, m, 6-CH2), 3.76 (3H, s, OCH3), 6.55 (1H, s, ArH) and 6.99 
(1H, s, ArH). 
13
C NMR (101 MHz, MeOD): δ 13.12 (18-CH3), 15.17 (2-CCH2CH3), 
24.32, 27.65, 28.87, 30.69, 30.94, 31.38 (CH2), 38.96 (16-CH), 39.95, 43.55 (CH), 
45.41 (C), 50.15 (CH), 55.69 (OCH3), 83.21 (17-CH), 111.70, 126.96 (ArCH), 
130.79, 133.18, 136.00 (ArC) and 156.65 (ArC), LRMS (ESI) calcd for C22H34NO2 
(M+H)
+
: m/z = 344.2, found m/z = 344.2, HRMS (ESI) calcd for C22H34NO2 
(M+H)
+
: m/z = 344.2584, found m/z = 344.2575. 
 
236 
 
N-(((13S,16R,17S)-2-Ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-2-yl)acetamide (Compound 182), C29H38N2O3, MW 462.62, 
Fischer J med chem 2005 48 18 5749 
 
182 
To a solution of 4-pyridylacetic acid hydrochloride (189 mg, 1.09 mmol) in DCM 
(12 mL), EDCI.HCl (238 mg, 1.24 mmol) was added portion-wise, followed by 
addition of DMAP (catalytic) and triethylamine (0.36 mL, 2.55 mmol). The resulting 
reaction mixture was stirred for 15 min at room temperature. A solution of 
(13S,16R,17S)-16-(aminomethyl)-2-ethyl-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-17-ol 181 
(250 mg, 0.73 mmol) in DCM (5 mL) was added  drop-wise to the reaction mixture, 
which was stirred for 18 h at room temperature. The reaction was quenched with 
saturated ammonium chloride (20 mL). The crude products were extracted with 
DCM (2 × 20 mL), dried (MgSO4), filtered and evaporated in-vacuo to give the 
crude product. The crude product was then purified by flash chromatography DCM / 
MeOH (0 – 5%) to yield the title compound 182 (159 mg, 47%) as an amorphous 
yellow solid. 
1
H NMR (400 MHz, CDCl3): δ 0.73 (3H, s, 18-CH3), 1.03-1.13 (2H, 
m), 1.16 (3H, t, J = 7 Hz, 2-CCH2CH3), 1.25-1.44 (3H, m), 1.81-1.94 (3H, m), 2.13-
2.18 (1H, m), 2.26-2.32 (2H, m, CH2), 2.56 (2H, quart, J = 7 Hz, 2-CH2), 2.81(2H, 
m, 6-CH2), 3.15 (1H, td, J = 7 and 3 Hz, CH), 3.56 (OCH3), 3.77 (2H, s, CH2), 6.54 
(1H, s, ArH), 7.01 (1H, s, ArH), 7.16 (1H, d, J = 6 Hz, ArH), 7.29 (1H, t, J = 6 Hz, 
ArH), 7.64 (2H, t, J = 6 Hz, ArH) and 8.54 (2H, d, J = 6 Hz, ArH). 
13
C NMR (101 
MHz, CDCl3): δ 12.74 (18-CH3), 14.50 (2-CCH2CH3), 23.18, 26.34, 27.43, 29.53, 
29.83, 37,64 (CH2), 38.25, 40.59 (CH), 41.17 (C), 43.66 (CH2), 44.03 (CH), 44.19 
(CH2), 48.71 (CH), 55.26 (OCH3), 81.70 (CH), 110.65, 121.88, 123.94, 125.97 
(ArCH), 129.82, 134.85 (ArC) 136.85, 149.04 (ArCH), 154.48, 155.88 (ArC) and 
168.54 (CO), HRMS (ESI) calcd for C29H39N2O3 (M+H)
+
: m/z = 463.2955, found 
m/z = 463.2943. 
237 
 
 
N-(((13S,17S)-2-Ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-3-yl)acetamide (Compound 183), C29H38N2O3, MW 462.62, 
 
183 
To a solution of 3-pyridylacetic acid hydrochloride (198 mg, 1.14 mmol) in DCM 
(15 mL) EDCI.HCl (252 mg, 1.32 mmol) was added portion-wise followed by 
addition of DMAP (catalytic) and triethylamine (0.39 mL, 2.88 mmol). The resulting 
reaction mixture was stirred for 15 min at room temperature. A solution of 
(13S,16R,17S)-16-(aminomethyl)-2-ethyl-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-17-ol 181 
(300 mg, 0.87 mmol) in DCM (15 mL) was added  drop-wise to the reaction mixture, 
which was stirred for 18 h at room temperature. The reaction was quenched with 
saturated ammonium chloride (20 mL). The crude products were extracted with 
DCM (2 × 20 mL), dried (MgSO4), filtered and evaporated in-vacuo to give the 
crude product. The crude product was then purified by flash chromatography DCM / 
MeOH (0 – 5%) to yield the title compound 183 (213 mg, 53%) as an amorphous 
pale yellow solid. 
1
H NMR (400 MHz, CDCl3): δ 0.74 (3H, s, 18-CH3), 1.03-1.13 
(6H, m), 1.15 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.41-1.48 (2H, m), 1.85-1.90 (3H, m), 
2.13-2.19 (1H, m), 2.27-2.31 (2H, m), 2.57 (2H, quart, J = 8 Hz, 2-CCH2), 2.81 (2H, 
m, 6-CH2), 3.18 (1H, td, J = 10 and 4 Hz, 17-CH), 3.56-3.64 (2H, m 16-CHCH2), 
3.77 (3H, s, OCH3), 6.54 (1H, s, ArH), 7.03 (1H, s, ArH), 7.27 (1H, t, J = 7 Hz, 
ArH), 7.70 (1H, dt, J = 7 Hz and 2 Hz, ArH), 8.43 (1H, dd, J = 8 and 2 Hz, ArH) and 
8.47 (1H, d, J = 2 Hz, ArH). 
13
C NMR (101 MHz, CDCl3): δ 12.43 (18-CH3), 14.55 
(2-CCH2CH3), 23.24, 26.28, 27.51, 29.56, 29.61, 37.58 (CH2), 38.21 (16-CH), 40.32, 
40.85 (CH), 41.55 (CH2), 43.85 (CH), 44.33 (CH2), 46.19 (C), 48.81 (CH), 55.27 
(OCH3), 81.89 (17-CH), 110.60, 123.72, 125.99 (ArCH), 129.80, 131.33, 131.69, 
134.84 (ArC), 137.25, 148.08, 149.95 (ArCH), 155.23 (ArC) and 169.50 (CO), 
HRMS (ESI) calcd for C29H39N2O3 (M+H)
+
: m/z = 463.2955, found m/z = 463.2942. 
238 
 
 
N-(((13S,17S)-2-Ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-4-yl)acetamide (Compound 184), C29H38N2O3, MW 462.62, 
 
184 
To a solution of 4-pyridylacetic acid hydrochloride (189 mg, 1.09 mmol) in DCM 
(10 mL) EDCI.HCl (238 mg, 1.24 mmol) was added portion-wise followed by 
addition of DMAP (catalytic) and triethylamine (0.36 mL, 2.55 mmol). The resulting 
reaction mixture was stirred for 15 min at room temperature. A solution of 
(13S,16R,17S)-16-(aminomethyl)-2-ethyl-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-17-ol 181 
(250 mg, 0.73 mmol) in DCM (15 mL) was added  drop-wise to the reaction mixture, 
which was stirred for 18 h at room temperature. The reaction was quenched with 
saturated ammonium chloride (20 mL). The crude products were then extracted with 
DCM (2 × 20 mL), dried (MgSO4), filtered and evaporated in-vacuo to give the 
crude product. The crude product was then purified by flash chromatography DCM / 
MeOH (0 – 5%) to yield the title compound 184 (162 mg, 48%) as an amorphous 
pale yellow solid. 
1
H NMR (400 MHz, CDCl3): δ 0.75 (3H, s, 18-CH3), 1.03-1.08 
(2H, m), 1.16 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.27-1.33 (1H, m), 1.42-1.47 (2H, m), 
1.81-1.94 (3H, m), 2.13-2.18 (1H, m), 2.26-2.32 (2H, m, CH2), 2.56 (2H, quart, J = 8 
Hz, 2-CCH2), 2.81(2H, m, 6-CH2), 3.15 (1H, td, J = 7 and 3 Hz, CH), 3.56 (OCH3), 
3.77 (2H, s, CH2), 6.54 (1H, s, ArH), 7.03 (1H, s, ArH), 7.26 (2H, d, J = 6 Hz, 2 × 
ArH) and 8.44 (2H, d, J = 6 Hz, 2 × ArH). 
13
C NMR (101 MHz, CDCl3): δ 12.52, 
14.54 (CH3), 23.23, 26.28, 27.52, 29.46, 29.62, 37,62 (CH2), 38.23, 40.19 (CH), 
41.67 (C), 43.19 (CH2), 43.85 (CH), 44.42 (CH2), 48.87 (CH), 55.27 (OCH3), 81.89 
(CH), 110.60 (ArCH), 124.92 (2 × ArCH), 125.97 (ArCH), 129.78, 131.68, 134.85, 
144.67 (ArC), 149.54 (2 × ArCH), 155.23 (ArC) and 168.54 (CO). HRMS (ESI) 
calcd for C29H39N2O3 (M+H)
+
: m/z = 463.2955, found m/z = 463.2947. 
 
239 
 
N-(((13S,16R,17S)-2-Ethyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-16-yl)methyl)-2-(pyridin-2-
yl)acetamide (Compound 185), C28H36N2O3, MW 448.60, 
 
185 
To a solution of N-(((13S,17S)-2-ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-4-yl)acetamide 182 (150 mg, 0.32 mmol) in DCM (7 mL) at -
78 ºC (dry ice/acetone bath) under an atmosphere of nitrogen, boron tribromide (0.09 
mL, 0.97 mmol) was added drop-wise. The resulting solution was stirred for 20 h at 
room temperature. The reaction was quenched with H2O (10 mL). The crude 
products were extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the crude product. The crude product was then purified 
by flash chromatography DCM / MeOH (0 – 10%) to yield the title compound 185 
(59 mg, 41%) as an amorphous yellow solid. HPLC: tr 1.36 min (90% Acetonitrile in 
water) 95%, 
1H NMR (400 MHz, MeOD): δ 0.81 (3H, s, 18-CH3), 1.12-1.15 (2H, 
m), 1.20 (3H, t, J = 7 Hz, 2-CCH2CH3), 1.28-1.54 (5H, m), 1.80-2.02 (2H, m), 2.11-
2.17 (1H, m), 2.27-2.46 (2H, m), 2.59 (2H, quart, J = 7 Hz, 2-CCH2), 2.75 (2H, m, 6-
CH2), 3.26 (1H, m), 3.76 (2H, s, CH2), 3.80 (1H, d, J = 10 Hz, CH), 6.50 (1H, s, 
ArH), 7.00 (1H, s, ArH), 7.35 (1H, t, J = 6 Hz, ArH), 7.46 (1H, d, J = 6 Hz, ArH), 
7.83 (1H, t, J = 6 Hz, ArH) and 8.54 (1H, d, J = 6 Hz, ArH). 
13
C NMR (101 MHz, 
MeOD): δ 13.00 (18-CH3), 15.10 (2-CCH2CH3), 24.27, 27.40, 28.65, 30.31, 31.23, 
38.84 (CH2), 39.61, 41.43 (CH), 42.28, 45.00 (CH2), 45.21 (C), 45.31, 49.99, 82.47 
(CH), 115.85, 123.57, 125.92, 126.98 (ArCH), 128.97 (ArC), 132.31, 135.73 (ArC), 
138.76, 149.88 (ArCH), 153.62 156.86 (ArC) and 171.80 (CO), LRMS (ESI) calcd 
for C28H37N2O3 (M+H)
+
: m/z = 449.2, found 449.1, HRMS (ESI) calcd for 
C28H37N2O3 (M+H)
+
: m/z = 449.2799, found m/z = 449.2823. 
 
240 
 
N-(((13S,16R,17S)-2-Ethyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-16-yl)methyl)-2-(pyridin-3-
yl)acetamide (Compound 186), C28H36N2O3, MW 448.60,
 
 
186 
To a solution of N-(((13S,17S)-2-ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-3-yl)acetamide 183 (150 mg, 0.32 mmol) in anhydrous DCM 
(7 mL) at -78 ºC (dry ice/acetone bath), boron tribromide in DCM (0.09 mL, 1.0 M 
in DCM) was added drop-wise. The reaction mixture was stirred for 20 h at room 
temperature under an atmosphere of nitrogen. The reaction was quenched with H2O 
(10 mL). The crude products were extracted with DCM (2 × 10 mL), dried (MgSO4), 
filtered and evaporated in-vacuo to give the crude product. The crude product was 
then purified by flash chromatography DCM / MeOH (0 – 10%) to yield the title 
compound 186 (54 mg, 38%) as an amorphous yellow solid. HPLC: tr 1.30 min (90% 
Acetonitrile in water) 94%, 
1H NMR (400 MHz, MeOD): δ 0.84 (3H, s, 18-CH3), 
1.10-1.16 (2H, m), 1.21 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.32-1.52 (6H, m), 1.84-1.94 
(2H, m), 2.01-2.04 (1H, m), 2.17-2.23 (1H, m), 2.34-2.44 (2H, m), 2.60 (2H, quart, J 
= 8 Hz, 2-CCH2), 2.78 (2H, m, 6-CH2), 3.44 (1H, m), 3.63 (2H, s, CH2), 3.82 (1H, d, 
J = 10 Hz, CH), 6.50 (1H, s, ArH), 7.01 (1H, s, ArH), 7.46 (1H, t, J = 5 Hz, ArH), 
7.87 (1H, d, J = 5 Hz, ArH), 8.50 (1H, d, J = 5 Hz, ArH) and 8.55 (1H, s, ArH). 
13
C 
NMR (101 MHz, MeOD): δ 12.99 (18-CH3), 15.09 (2-CCH2CH3), 24.28, 27.66, 
30.34, 31.32, 38.85 (CH2), 40.02 (CH2), 40.87 (CH), 41.44 (CH2), 45.44, 49.19, 
85.55 (CH), 115.85, 125.27 (ArCH), 127.00 (ArC), 129.00, (ArCH), 132.32, 133.45, 
135.76 (ArC), 138.98, 148.47, 150.53 (ArCH), 153.65 (ArC) and 171.65 (CO), 
LRMS (ESI) calcd for C28H37N2O3 (M+H)
+
: m/z = 449.2, found 449.2. HRMS (ESI) 
calcd for C28H37N2O3 (M+H)
+
: m/z = 449.2799, found m/z = 449.2784. 
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N-(((13S,16R,17S)-2-Ethyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[a]-phenan-thren-16-yl)methyl)-2-(pyridin-4-
yl)acetamide (Compound 187), C28H36N2O3, MW 448.60, 
 
187 
To a solution of N-(((13S,17S)-2-ethyl-17-hydroxy-3-methoxy-13-methyl-
7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]-phenan-thren-16-
yl)methyl)-2-(pyridin-4-yl)acetamide 184 (131 mg, 0.28 mmol) in DCM (7 mL) at -
78 ºC (dry ice/acetone bath) under an atmosphere of nitrogen, boron tribromide (0.08 
mL, 0.85 mmol) was added drop-wise. The resulting solution was stirred for 20 h at 
room temperature. The reaction was quenched with H2O (10 mL). The crude 
products were extracted with DCM (2 × 10 mL), dried (MgSO4), filtered and 
evaporated in-vacuo to give the crude product. The crude product was then purified 
by flash chromatography DCM / MeOH (0 – 10%) to yield the title compound 187 
(54 mg, 43%) as an amorphous yellow solid. HPLC: tr 1.24 min (90% Acetonitrile in 
water) 93%, 
1H NMR (400 MHz, MeOD): δ 0.84 (3H, s, 18-CH3), 1.12-1.15 (2H, 
m), 1.21 (3H, t, J = 8 Hz, 2-CCH2CH3), 1.31-1.54 (5H, m), 1.82-1.93( 2H, m), 1.96-
2.04 (1H, m), 2.14-2.23 (1H, m), 2.33-2.46 (2H, m), 2.60 (2H, quart, J = 8 Hz, 2-
CCH2), 2.77 (2H, m, 6-CH2), 3.44 (1H, m), 3.65 (2H, s, CH2), 3.80 (1H, d, J = 10 
Hz, CH), 6.50 (1H, s, ArH), 7.01 (1H, s, ArH), 7.45 (2H, d, J = 5 Hz, 2 × ArH) and 
8.52 (2H, d, J = 5 Hz, 2 × ArH). 
13
C NMR (101 MHz, MeOD): δ 13.01 (18-CH3), 
15.10 (2-CCH2CH3), 24.27, 27.63, 28.83, 30.32, 31.32, 38.82 (CH2), 39.99, 41.42 
(CH), 42.87, 43.18 (CH2), 45.33 (C), 45.39, 49.99, 82.51 (CH), 115.84, 126.19 
(ArCH), 127.00 (2 ×ArCH), 128.98, 132.32, 135.75, 147.72 (ArC), 150.05 (2 × 
ArCH), 153.65 (ArC) and 171.77 (CO), LRMS (ESI) calcd for C28H37N2O3 (M+H)
+
: 
m/z = 449.2, found 449.1, HRMS (ESI) calcd for C28H37N2O3 (M+H)
+
: m/z = 
449.2799, found m/z = 449.2834. 
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Experimental Details: Computational Chemistry 
For the docking studies of inhibitors in 1FDT
76
 the starting conformations used for 
receptor docking were generated from an energy minimization performed using the 
MMFF94s force field, with MMFF94 charges applied, as implemented in Sybyl 7.0. 
The resulting lowest energy conformer was then used for docking studies using Gold 
version 2.2 with default parameters. The active site was defined as a 12 Å radius 
around the C alpha atom of Serine 142 and 30 attempts were computed and scored 
using Gold score. To develop a QSAR using CoMSIA, the ligands were initially 
minimized using the MMFF94s force field as implemented within the Sybyl 7.0 
package. The molecules were aigned using FlexS, with a common core elucidated by 
DISTILL which correspond to the steroid backbone. Gastegier-Huckel charges were 
used for the charge descriptors in FlexS and CoMSIA was performed using the 
aligned compounds and the standard Sybyl 7.0 CoMSIA fields. Alignment and shape 
similarity studies were carried out using The PyMOL Molecular Graphics System 
(2002), http://www.pymol.org. 
Experimental Details: Biochemistry 
All chemicals were purchased from Aldrich Chemical Co. (Gillingham, UK), or 
Fischer Scientific (Loughborough, UK).  pET-24a bacterial expression vector, 
Rosetta 2 competent cells and the BugBuster master mix were purchased from 
Novagen. The 17β-HSD1 gene was supplied in the pCEP4 vctor by colleagues at 
Imperial College London. The Quick ligation kit, restriction enzymes, NheI and 
XhoI and calf intestinal alkaline phosphatase, were purchased from New England 
Biolabs. XL10-Gold Ultracompetent cells were purchased from Stratagene. For 
purification of the H6-17β-HSD1 protein Wizard mini-prep kits were purchased from 
Promega (Southampton, UK) an AKTA FPLC from Amersham Biosciences (GE 
Healthcare), HiTrap chelating HP column from Pharmacia (GE Healthcare) loaded 
with Ni
2+
, and a Q-sepharose column Amersham Biosciences (GE Healthcare) were 
used. For enzyme and inhibitor assays Cell Titer 96
®
 AQueous One solution was 
purchased from Promega (Southampton, UK). 
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Experimental Details: Chapter 6 
Protein Expression 
Miniprep plasmid purification  
Splinters of ‘ice’ were scraped off from frozen cells using a sterile loop, and streaked 
onto a LB plate containing the appropriate antibiotic. The plate was incubated 
overnight at 37 °C. A single colony was inoculated into 5 mL of LB medium 
containing the antibiotic in a 50 mL Falcon tube, and the culture grown overnight at 
37 °C and 250 r.p.m. The pellet was collected from the overnight culture by 
centrifugation at 13,000 r.p.m. for one minute DNA was prepared by either of the 
following miniprep methods: 
Standard miniprep procedures  
The cell pellet was completely resuspended in solution I (250 μL, 50 mM Tris-HCl, 
pH 8.0, 10 mM EDTA, 50 mM glucose, 100 μg/mL RNase A). Solution II (250 μL, 
200 mM NaOH, 1% SDS) was added and the tube was inverted five times to give a 
clear solution and left at room temperature for 5 min. Solution III (250 μL, 2.55 M 
potassium acetate, pH 5.4) was added and the tube inverted again five times and the 
kept in ice for 15 min. The resulting solution was centrifuged at 13,000 r.p.m. for 15-
20 min. The supernatant was transferred into a fresh tube and 0.7 volumes, relative to 
the supernatant of isopropanol was added. After keeping the tubes at room 
temperature for 5 min the solution was centrifuged at 13,000 r.p.m. for 15-20 min. 
The DNA pellet was washed twice by centrifugation with 70% (v/v) cold ethanol in 
water and bench dried. The DNA was redissolved in 40 μL of sterile Milli-Q water or 
TE buffer and stored at –20 C. 
Wizard Minipreps DNA purification system 
The cell pellet was completely resuspended in cell resuspension solution (200 μL, 
containing 50 mM Tris-HCl, 10 mM EDTA, pH 7.5 and 100 μg/mL of RNase A). 
Cell lysis solution (200 μL, containing 0.2 M NaOH and 1% SDS) was added and the 
suspension mixed by inverting the tube five times until the suspension became clear. 
Neutralisation solution (200 μL, containing 1.32 M potassium acetate, pH 4.8) was 
added and mixed as before. After cooling on ice for 5 min, the solution was 
centrifuged at 13,000 r.p.m. for 12 min and the supernatant was carefully transferred 
to a new tube. After mixing with Wizard
TM
 Plus minipreps resin (1 mL), the solution 
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was poured to a Wizard
TM
 minicolumn. The solution was slowly expelled using the 
syringe plunger. DNA adhering to the resin was washed twice with 2 mL of the wash 
solution (80 mM potassium acetate, 8.3 mM Tris-HCl, pH 7.5, 40 μM EDTA and 
55% ethanol in water), and the minicolumn was dried by centrifugation for 2 min. 
Plasmid DNA was eluted by adding sterile water or TE buffer (20 μL), waiting for 1 
min followed by centrifugation at 13,000 r.p.m. for 1 min, and stored at –20 °C until 
required. 
Restriction enzyme digestion 
Plasmid DNA was digested with various restriction enzymes for cloning. Enzyme 
digestions were usually performed in a 0.5 mL Eppendorf tube containing the 
following: plasmid (3-30 μL, ca. 1-10 μg), BSA if needed (1 μL), recommended 
buffer (1-5 μL, 10X), sterile Milli-Q water (to final volume of 10-50 μL) and 
restriction enzymes (1-4 μL, ca. 10-400 U) were mixed and incubated at 37 C for 1-
4 h. A sample of 5 μL was used for the subsequent agarose electrophoresis analyses. 
When large scale restricted DNA was needed for cloning, the whole 50 μL sample 
was loaded on gel and the required DNA fragments were gel purified. 
Alkaline Phosphatase Treatment  
Suspend DNA in 1X NEBuffer (0.5 μg/10 μl). Add 0.5 units/μg vector DNA. 
Incubate for 60 minutes at 37 °C. Purify DNA by gel purification, spin-column 
purification or phenol extraction. 10 mM sodium orthovanadate inhibits CIP activity 
(10 units) by 90% and 50 mM EDTA inactivates CIP (10 units) by 100%. 
Agarose Gel Electrophoresis 
DNA samples were analysed by electrophoresis using a submarine gel 
electrophoresis system (Bio-Rad) with a horizontal agarose minigel. In general, 1X 
TBE or 1X TAE was used as running buffer. The concentration of agarose used was 
0.8-2.0%, (w/v) depending on the size of DNA to be analysed and the resolution 
required. Samples were mixed with 0.2 volumes of 6X loading solution before 
applying to individual wells in the minigel. A DNA ladder (1 kb marker) was run 
alongside as a standard marker. Gels were run at 80 V and stained in 1X TAE 
containing 3.0 g/mL ethidium bromide for 15 min. After destaining in 1X TAE for 
10 min, gels were viewed on a UV transluminator at 312 nm. 
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Preparation of agarose gels: Ultrapure agarose (0.8 g for 0.8% gel or 2 g for 2% gel) 
was added to TAE buffer (100 mL, 1X) and dissolved in microwave for 2 min. After 
cooling to ~50 ºC the mixture was poured into the gel tank to a depth of 3-7 mm 
thick. The comb was then inserted and the gel was left to solidify at room 
temperature.  
Sample loading buffer (6x): Bromophenol blue [0.2% (w/v)], xylene cyanol [0.25% 
(w/v)] and Ficoll 400 [15% (w/v)]. 
Purification of DNA from agarose gels 
The DNA fragment on the agarose gel was excised using a clean scalpel. The slice 
was weighed and transferred into a sterile 1.5 mL Eppendorf tube. Add 3 volumes 
Buffer QG to 1 volume gel (100 mg ~ 100 μl). After incubate at 50 °C for 10 min (or 
until the gel slice has completely dissolved), and mixing the solution every 2–3 min 
to help dissolve the gel slice. After the gel slice has dissolved completely, check that 
the colour of the mixture is yellow, if the colour of the mixture is orange or violet; 
add 10 μl of 3 M sodium acetate, pH 5.0, and mix. The colour of the mixture will 
turn yellow. Add 1 gel volume of isopropanol to the sample and mix. A QIAquick 
spin column was placed into a provided 2 ml collection tube. To bind the DNA, the 
sample was applied to the QIAquick column and centrifuged at 13,000 r.p.m. for 1 
min through the column. Discard the flow-through and place the QIAquick column 
back into the same collection tube. For sample volumes of >800 μl, the sample was 
loaded and spun again, 0.5 ml of Buffer QG was added to the QIAquick column and 
centrifuged at 13,000 r.p.m.for 1 min. The flow-through was discarded and the 
QIAquick column placed back into the same collection tube. To wash the DNA, add 
0.75 ml Buffer PE to QIAquick column and was centrifuged at 13,000 r.p.m. for 1 
min. The flow-through was discarded and the QIAquick column placed back into the 
same collection tube. The QIAquick column was centrifuged at 13,000 r.p.m. for 1 
min to remove residual wash buffer. The QIAquick column was placed into a clean 
1.5 ml microcentrifuge tube.The DNA was eluted by, adding 50 μl Buffer EB (10 
mM Tris·Cl, pH 8.5) to the center of the QIAquick membrane and the QIAquick 
column was centrifuged at 13,000 r.p.m. for 1 min. For increased DNA 
concentration, 30 μl Buffer EB was added to the center of the QIAquick membrane, 
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and the column was left to stand for 1 min, and then centrifuged at 13,000 r.p.m. for 
1 min.  
Ligation into expression vectors 
The plasmids were purified from an overnight culture and digested with appropriate 
restriction enzyme at 37 °C for 4 h. Upon completion of the reaction the samples and 
the 1 kb DNA ladder were loaded onto a 0.8%-2% (w/v) agarose gel. The vector and 
the insert bands were excised from the agarose gel and the DNA was purified from 
the gel. In the ligation solution, the vector DNA fragment (2.5 μL, 100 ng, pET-24a) 
and the insert DNA fragment (2.5 μL, 100 ng) were mixed and incubated at 48 °C for 
5 min followed by keeping on ice for 5 min. T4 DNA ligase buffer (1 μL, 10X), 
rATP (1 μL, 10 mM), autoclaved Milli-Q water (2 μL) and T4 DNA ligase (1.0 μL) 
were then added into the solution to make the final volume of 10 μL and incubated at 
16 °C overnight (> 20 h). The ligated DNA (10 μL) was transformed into E. coli 
XL10-Gold competent cells (100 μL) and plated onto a LB agar containing the 
appropriate antibiotics, and incubated at 37 C overnight. To identify the new 
recombinant plasmid, the DNA was purified and double digested with the 
appropriate restriction enzymes. Only those plasmids with the correct gene inserted 
gave a fragment of the appropriate length. 
Preparation of competent cells  
Splinters of ‘ice’ were scraped from frozen cells using a sterile loop and streaked 
onto an LB plate [15 μg/mL of tetracycline for E. coli XL cell; no antibiotic was 
required for BL21(DE3)pLysS cells]. One colony was inoculated into 10 mL of LB 
medium containing antibiotic, if required in a 50 mL Falcon tube, and grown 
overnight at 37 C and 250 r.p.m. The overnight culture (0.5 mL) was aseptically 
transferred to a 20 mL Erlenmeyer flask containing 10 mL of LB medium with 
antibiotic if required and incubated at 37 C and 250 r.p.m. until the OD600 was 
reached 0.25 ~ 0.5. The cells were then harvested re-suspended in 1 mL of sterile, ice 
cold 50 mM CaCl2. After centrifugation at 4,000 r.p.m. the supernatant was 
discarded, the pellet was resuspended gently in 0.5 mL of sterile, ice cold 50 mM 
CaCl2 and incubated on ice for 30 min ready for transformation 
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Transformation 
DNA (10 μL ligation mixture or 1 μL of miniprep plasmid DNA) solution was mixed 
with E. coli competent cells (200 μL) in a pre-chilled 50 mL Falcon tube, and the 
mixture was placed on ice for 30 mins. The sample was heat shocked in a 42 C 
water bath for exactly 45 s and chilled on ice for 2 min. SOC medium (1 mL) was 
added and the mixture was incubated at 37 C and 250 r.p.m. for 1 h. When the 
ligation mixture was transformed the cells were precipitated by centifugation at 
4,000 r.p.m. for 10 min. The pellet was redissolved in 100 μL of residual SOC 
medium and plated onto a LB agar plate supplemented with the appropriated 
antibiotics. When miniprep DNA was transformed then cultured cells (100 μL) were 
spread evenly onto a LB agar plate supplemented with the appropriate antibiotic and 
incubated overnight at 37 C. 
Quick 5 minTransformation 
Pre-warm the agar plates to 37–42 °C. 1–3 µL of miniprep DNA was added to 100 
µL of ice cold competent cells. Incubate the competent cells on ice for 5 mins. The 
competent cells were spread onto the pre-warmed agar plates and incubated at 37 °C 
overnight. 
  
Glycerol stock 
A single colony from an overnight plate was inoculated into 5 mL of LB broth with the 
appropriate antibiotic. The cells were grown to late log phase (OD600 ca. 0.8), and 1 
mL of cell culture was mixed with 0.2 mL of sterile glycerol, and stored at –80 C. 
Time-dependent expression  
A single colony was inoculated into 5 mL of LB medium with the appropriate 
antibiotic and incubated overnight at 37 C and 250 r.p.m. The overnight culture (1 
mL) was used to inoculate LB medium (100 mL) with antibiotic in a 500 mL flask 
and incubated at 30 C and 250 r.p.m. until the OD600 reached 0.7~0.8, IPTG was 
added to a final concentration of 0.5 mM. Growth media (5 mL) was transferred into 
a 50 mL Falcon tube and centrifuged at 4,000 r.p.m. for 10 min and the pellet was 
stored at –80 C until analyses. Further samples were taken after 1, 2, 3 and 4 h. 
Pellets were thawed and resuspended in 50 mM Tris-HCl, pH 7.5, 100 mM NaCl (4 
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mL/100 mL culture). The suspension was treated with the BugBuster
TM
 kit from 
Novagen. Cell lysate (200 μL) was aliquoted in a 1.5 mL Eppendorf tube and 
centrifuged at 13,000 r.p.m. for 10 min. Supernatant was separated in a separate tube 
and mixed with 50 μL of 5X SDS sample loading buffer. To check for insoluble 
expression of protein, the pellet was dissolved in 200 μL of 1X loading buffer. Both 
soluble and insoluble fraction tubes were incubated in heat block at 90 C for 10 min. 
Insoluble fractions (mostly cell wall lipids) were precipitated by centrifugation at 
13,000 r.p.m. for 5 min, and samples were analysed by loading 15 μL of each onto 
10-15% SDS-PAGE. 
Large Scale expression  
Large scale overnight expression required a single colony to be inoculated into 5mL 
of LB medium with the appropriate antibiotic and incubated for 6 h at 37 
o
C. 
Transfer the 5mL culture to 100mL of fresh LB medium with antibiotic and incubate 
overnight at 37 
o
C and 250 r.p.m. Transfer 25mL of the overnight culture to 1 L fresh 
LB medium and incubate at 37 
o
C and 250 r.p.m until an OD600 = 0.6 Abs is 
measured. Cool the culture to room temperature and add 12.5μM IPTG. Incubate 
overnight. Growth media (1 L) was transferred into a 50 mL Falcon tubes and 
centrifuged at 4,000 r.p.m. for 10 min and the pellet was stored at –80 C.  
Protein Purification 
Batch purification 
Pellets were re-suspended in approximately 30 mL of Buffer A containing 40 mM 
Tris HCl pH 7.5, 20% Glycerol, 100 mM NaCl, 20 mM imidazole, 0.2 mM DTT, 0.4 
mM PMSF and Benzonase. The re-suspended pellet was put through a One Shot 
Constant Cell Disruption System and then centrifuged at 10000 r.p.m. for 30 min at 4 
ºC. The supernatant was collected and steri-filtered prior to manually passing through 
a HiTrap chelating HP column pre-loaded with Nickel ions. The protein was eluted 
with 40 mL of Buffer A, followed by 40 mL of Buffer B containing 40 mM Tris HCl 
pH 7.5, 20% Glycerol, 500 mM imidazole, 0.2 mM DTT and 0.4 mM PMSF. The 
eluted protein was concentrated to approximately 1 mL using a size filter falcon tube 
centrifuging at 5,500 r.p.m. for 15 min. The protein was dialysed at 5 ºC using a 
dialysis buffer containing 40 mM Tris HCl, pH 7.5, 20% Glycerol, 0.2 mM DTT and 
1 mM EDTA and a Slide-a-lyzer
®
 Dialysis cassette 10000 MCUCO cartridge for 3-4 
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h before leaving the dialysis cell in fresh dialysis buffer overnight. For storage the 
protein was removed from the dialysis cell and stored at 5 ºC. 
HiTrap column purification 
Pellets were re-suspended in approximately 30 mL of Buffer A. The re-suspended 
pellet was put through a One Shot Constant Cell Disruption System and then 
centrifuged at 10000 r.p.m. for 30 min at 4 ºC. The supernatant was collected and 
steri-filtered prior to injection onto an AKTA FPLC using a HiTrap chelating HP 
column pre-loaded with Nickel ions. After the supernatant was injected the protein 
was eluted with 40 mL of Buffer A, followed by 20 mL of Buffer B, followed by a 
gradient of 10% Buffer B to 100% Buffer B at 3.0 mL/min for 30 min. The fractions 
containing the purified protein were identified by using SDS-PAGE gel 
electrophoresis. Prior to concentration of the eluted protein 0.06% of N-Octyl-β-D-
glucopyranoside was added. The eluted protein was concentrated to approximately 1 
mL using a size filter falcon tube centrifuging at 5,500 r.p.m. for 15 min. The protein 
was dialysed at 5 ºC using a dialysis buffer containing 40 mM Tris HCl, pH 7.5, 20% 
Glycerol, 0.2 mM DTT and 1 mM EDTA and a Slide-a-lyzer
®
 Dialysis cassette 
10000 MCUCO cartridge for 3-4 h before leaving the dialysis cell in fresh dialysis 
buffer overnight. For storage the protein was removed from the dialysis cell and 
stored at 5 ºC. 
Q-Sepharose column purification 
The concentrated protein was diluted to approximately 30 mL using Buffer C 
containing 40 mM Tris HCl pH 7.5, 20% Glycerol, 20 mM NaCl, 0.2 mM DTT and 
0.4 mM PMSF. The diluted protein was steri-filtered prior to injection onto an 
AKTA FPLC using a Q-sepharose column. After the diluted protein was injected the 
protein was eluted with 40 mL of Buffer C, followed by 20 mL of Buffer D 
containing 40 mM Tris HCl pH 7.5, 20% Glycerol, 500 mM NaCl, 0.2 mM DTT and 
0.4 mM PMSF, followed by a gradient of 10% Buffer D to 100% Buffer D at 3.0 
mL/min for 30 min. The fractions containing the purified protein were identified by 
using SDS-PAGE gel electrophoresis. Prior to concentration of the eluted protein 
0.06% of N-Octyl-β-D-glucopyranoside was added. The eluted protein was 
concentrated to approximately 1 mL using a size filter falcon tube centrifuging at 
5,500 r.p.m. for 15 min. The protein was dialysed at 5 ºC using a dialysis buffer 
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containing 40 mM Tris HCl, pH 7.5, 20% Glycerol, 0.2 mM DTT and 1 mM EDTA 
and a Slide-a-lyzer
®
 Dialysis cassette 10000 MCUCO cartridge for 3-4 h before 
leaving the dialysis cell in fresh dialysis buffer overnight.  For storage the protein 
was removed from the dialysis cell and stored at 5 ºC. 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using a Mini Protean II
TM
 apparatus (Bio-Rad). A 3% 
stacking gel and 10%, 12.5% or 15% running gel were used along with gel running 
buffer containing 25 mM Tris, 0.2 M glycine and 0.5% (w/v) SDS. 
Stacking gel: 30% (w/v) acrylamide and 0.8% (w/v) bisacrylamide solution (320 
μL), Tris-HCl (1 M, pH 6.8, 400 μL), 10% (w/v) SDS (32 μL), 1% (w/v) ammonium 
persulphate (160 μL), H2O (2.32 mL), TEMED (5 μL). 
Running gel: 30% (w/v) acrylamide and 0.8% (w/v) bisacrylamide solution (2 mL 
for 10%, 2.5 mL for 12.5%, 3 mL for 15%), Tris-HCl (0.75 M, pH 8.8, 3 mL), 10% 
Pr(w/v) SDS (60 μL), 1% (w/v) ammonium persulphate (300 μL), H2O (750 μL for 
10%, 200 μL for 12.5% and no water in 15%), TEMED (5 μL). 
Sample loading buffer (2x): Tris-HCl (0.625 M, pH 6.8, 2.5 mL), glycerol (2.0 mL), 
10% (w/v) SDS solution (5.0 mL), β-mercaptoethanol (1.0 mL), H2O (9.5 mL), 
0.01% (w/v) bromophenol blue. 
Gel staining solution: Coomassie Brilliant Blue R-250 [0.25% (w/v)] with water in 
methanol [30% (v/v)] in water and acetic acid [10% (v/v)] in water. 
Gel destaining solution: methanol [30% (v/v)] in water, acetic acid [10% (v/v)] in 
water. 
Gel storing solution: methanol [30% (v/v)] in water, glycerol [3% (v/v)] in water. 
The protein sample (10 μL, ~10 μg) and 5X SDS sample loading buffer (2 μL) were 
transferred into an Eppendorf tube. The tube was boiled for 5 min and the sample 
loaded onto a SDS-PAGE with a 3% stacking gel. The power supply was set at 40 
mA per gel, 250 V for gel electrophoresis. Gels were stained and destained after 
electrophoresis using the above solutions. Standard molecular weight markers were 
used to calibrate the SDS-PAGE containing: 250 kDa, 148 kDa, 98 kDa, 64 kDa, 50 
kDa, 36 kDa, 22 kDa, 16 kDa and 4 kDa marker proteins.  
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Protein concentration determination 
Protein concentrations were determined by the method of Bradford. The Bradford 
reagent was gently mixed and brough to room temperature. Protein standards in 
buffer ranging from 0.1-1.4 mg/ml were prepared using a BSA standard. 5 µL of the 
protein standard were added to separate wells in a 96 well plate. For the blank wells 
5 µL of buffer were added. The unknown protein sample was prepared with 
approximate concentrations between 0.1-1.4 mg/ml. To each well, 250 µL of the 
Bradford reagent was added and mixed on a shaker for approximately 30 s. The 
samples were left to incubate at room temperature for 5 to 45 min to construct a 
standard curve at 595 nm. The protein concentration was determined by comparing 
the absorbance vaues of the sample protein against the standard curve at 595 nm. 
Enzyme Assay 
Enzyme Kinetic Absorbance Assay 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 340 nm. Reactions were run in 1 mL solutions made up of 50 
nM Sodium Pyrophosphate buffer, pH 9.2, and 10% THF, containing 0-400 µM 
steroid (E2), 0.1 mM NADP solution and Milli-Q water. Reactions were initiated by 
the addition of 1.9 µM of H6-17β-HSD1, and the absorbance variations were 
measured against a blank containing all components except the steroid (E2). 
Reactions were followed from 30 s to 5 min after addition of NADP on a Perkin 
Elmer λ40 UV-vis spectrophotometer. 
Inhibitor Enzyme Kinetic Absorbance Assay 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 340 nm. Reactions were run in 1 mL solutions made up of 50 
nM Sodium Pyrophosphate buffer, pH 9.2, and 10% THF, containing 30 µM steroid 
(E2), 0.1 mM NADP solution and Milli-Q water. Reactions were initiated by the 
addition of 1.9 μM of H6-17β--HSD1 which was incubated with 20-400 μM of 
inhibitor dissolved in DMSO before addition. The absorbance variations were 
measured against a blank containing all components except the steroid. Reactions 
were followed from 30 s to 5 min after addition of NADP on a Perkin Elmer λ40 
UV-vis spectrophotometer. 
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Enzyme Kinetic Absorbance Assay – Plate Reader 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 340 nm. Reactions were run in 200 μL solutions made up of 
10 mM Sodium Pyrophosphate buffer, pH 9.2, and 10% DMSO, containing 0–400 
μM steroid (E2), 0.1 mM NADP solution and Milli-Q Water. Reactions were 
initiated by the addition of 1.9 μM of H6-17β-HSD1, and the absorbance variations 
were measured against a blank containing all components except the steroid (E2). 
Reactions were followed from 30 s to 5 min after addition of NADP on a Molecular 
Devices Versamax tunable microplate reader. 
Inhibitor Enzyme Kinetic Absorbance Assay – Plate Reader 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 340 nm. Reactions were run in 200 μL solutions made up of 
10 mM Sodium Pyrophosphate buffer, pH 9.2, and 10% DMSO, containing 10 μM 
steroid (E2), 0.1 mM NADP solution and Milli-Q Water. Reactions were initiated by 
the addition of 1.9 μM of H6-17β--HSD1 which was incubated with 75-300 μM of 
inhibitor dissolved in DMSO before addition. The absorbance variations were 
measured against a blank containing all components except the steroid (E2). 
Reactions were followed from 30 s to 5 min after addition of NADP on a Molecular 
Devices Versamax tunable microplate reader. 
Enzyme Kinetic Absorbance Assay – MTS Assay Plate Reader Temperature 
Investigation 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 459 nm at 22ºC or 37 ºC. Reactions were run in 100 μL 
solutions made up of 10 mM Tris HCl buffer, pH 7.5, and 10% DMSO, containing 
0–200 μM steroid (E2), 0.1 mM NADP solution, 10 µL MTS/PES and Milli-Q 
Water. Reactions were initiated by the addition of H6-17β-HSD1 giving a final 
concentration of 0.069 µM, and the absorbance variations were measured against a 
blank containing all components except the steroid (E2). Reactions were followed 
from 0 s to 60 s after addition of NADP on a Molecular Devices Versamax tunable 
microplate reader. 
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Enzyme Kinetic Absorbance Assay – MTS Assay Plate Reader Buffer 
Investigation 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 459 nm at 37 ºC. Reactions were run in 100 μL solutions 
made up of 10 mM Tris HCl buffer, pH 7.5 or 5 mM Potassium pyrophosphate 
buffer, pH 9.2, and 10% DMSO, containing 0–200 μM steroid (E2), 0.1 mM NADP 
solution, 10 µL MTS/PES and Milli-Q Water. Reactions were initiated by the 
addition of H6-17β-HSD1 giving a final concentration of 0.069 µM, and the 
absorbance variations were measured against a blank containing all components 
except the steroid (E2). Reactions were followed from 0 s to 60 s after addition of 
NADP on a Molecular Devices Versamax tunable microplate reader. 
Enzyme Kinetic Absorbance Assay – MTS Assay Plate Reader (E2) 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 459 nm at 37 ºC. Reactions were run in 100 μL solutions 
made up of 10 mM Tris HCl buffer, pH 7.5, and 10% DMSO, containing 0–200 μM 
steroid (E2), 0.1 mM NADP solution, 10 µL MTS/PES and Milli-Q Water. Reactions 
were initiated by the addition of H6-17β-HSD1 giving a final concentration of 0.069 
µM, and the absorbance variations were measured against a blank containing all 
components except the steroid (E2). Reactions were followed from 0 s to 60 s after 
addition of NADP on a Molecular Devices Versamax tunable microplate reader. 
Enzyme Kinetic Absorbance Assay – MTS Assay Plate Reader (NADP) 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 459 nm at 37 ºC. Reactions were run in 100 μL solutions 
made up of 10 mM Tris HCl buffer, pH 7.5, and 10% DMSO, containing 0–1000 μM 
NADP, 0.3 mM steroid (E2) solution, 10 µL MTS/PES and Milli-Q Water. Reactions 
were initiated by the addition of H6-17β-HSD1 giving a final concentration of 0.069 
µM, and the absorbance variations were measured against a blank containing all 
components except the steroid (E2). Reactions were followed from 0 s to 60 s after 
addition of NADP on a Molecular Devices Versamax tunable microplate reader. 
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Inhibitor Enzyme Kinetic Absorbance Assay – MTS Assay Plate Reader 
The enzyme was assayed by spectrophotometric measurement of the concentration 
changes of NADPH at 459 nm at 37 ºC. Reactions were run in 100 μL solutions 
made up of 10 mM Tris HCl buffer, pH 7.5, and 10% DMSO, containing 0–200 μM 
steroid (E2), 0.1 mM NADP solution, 10 µL MTS/PES and Milli-Q Water. Reactions 
were initiated by the addition of H6-17β--HSD1 giving a final concentration of 0.069 
µM which was incubated with 0-200 μM of inhibitor dissolved in DMSO before 
addition. The absorbance variations were measured against a blank containing all 
components except the steroid (E2). Reactions were followed from 0 s to 60 s after 
addition of NADP on a Molecular Devices Versamax tunable microplate reader. 
Experimental Details: Cell Based Assay 
Measurement of inhibition of 17β-HSD1 
T-47D human breast cancer cells were incubated with 
3
H-E1 at a concentration of 2 
nM per well, in a 24 well tissue culture plate, in the absence or presence of the 
inhibitor (0.1 nM – 10 µM). After incubation of the substrate ± inhibitor for 30 min 
at 37 ºC, the products were isolated from the mixture by extraction with diethyl ether 
(4 ml), using 
14
C-E2 (5000 dpm) to monitor procedural losses. Separation of 
3
H-E2 
from the mixture was achieved using TLC (DCM/EtOAc, 4:1 v/v) and the mass of 
3
H-E2 produced was calculated from the 
3
H counts detected and recovery of 
14
C-E2.  
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Appendix 1: X-ray Crystallography Data 
Table 1: Crystal data and structure refinement. 
                                                        
 Identification code k10farm3 
 Empirical formula C22 H27 N O2 
 Formula weight 337.45 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Triclinic 
 Space group P1 
 Unit cell dimensions 
o
 
       
o
 
       c = 14.2860
o
 
 Volume 928.30(3) Å
3
 
 Z 2 
 Density (calculated) 1.207 Mg/m
3
 
 Absorption coefficient 0.076 mm
-1
 
 F(000) 364 
 Crystal size 0.45 x 0.40 x 0.35 mm 
 Theta range for data collection 3.74 to 27.49
o
 
 Index ranges -10<=h<=10; -10<=k<=10; -18<=l<=18 
 Reflections collected 17910 
 Independent reflections 7997 [R(int) = 0.0267] 
  6933 
 Data Completeness 0.993 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.835 and 0.808 
 Refinement method Full-matrix least-squares on F
2
 
 Data / restraints / parameters 7997 / 33 / 498 
 Goodness-of-fit on F
2
 1.038 
 Final R indices [I>2 (I)] R1 = 0.0475   wR2 = 0.1185 
 R indices (all data) R1 = 0.0587  wR2 = 0.1270 
 Absolute structure parameter 0.3(10) 
 Largest diff. peak and hole 0.471 and -0.260 eÅ
-3
 
  
Notes: There are two molecules in the asymmetric unit of this structure. The ethyl 
and ethoxy groups attached to C2’ and C3’ (respectively) are disordered over two 
proximate positions in a 50:50 ratio. Distance and ADP restraints were applied to 
partial disordered atoms. 
 
Table 2: Atomic coordinates ( x 10
4
) and equivalent isotropic displacement 
parameters (Å
2
 x 10
3
). U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
O(1) 6012(2) 6256(2) 8722(1) 48(1) 
O(2) 12468(2) -5462(2) 5888(1) 38(1) 
O(1') 1313(3) -1559(3) 3836(2) 66(1) 
O(2') 12782(7) 3427(9) 585(5) 53(2) 
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O(2*) 12714(7) 3814(10) 860(5) 54(2) 
N(1) 8467(4) 7638(3) 10268(2) 66(1) 
N(1') -2110(3) 1719(3) 5181(2) 63(1) 
C(1) 9475(3) -1748(2) 6515(1) 31(1) 
C(2) 10195(3) -3256(2) 6140(1) 32(1) 
C(3) 11791(3) -3968(2) 6293(1) 33(1) 
C(4) 12597(3) -3205(2) 6806(2) 33(1) 
C(5) 11863(2) -1665(2) 7169(1) 31(1) 
C(6) 12858(3) -837(3) 7677(2) 39(1) 
C(7) 12251(3) 1006(3) 7693(2) 36(1) 
C(8) 10321(2) 1363(2) 8076(1) 29(1) 
C(9) 9462(2) 804(2) 7355(1) 30(1) 
C(10) 10270(2) -921(2) 7035(1) 29(1) 
C(11) 7521(3) 1054(3) 7738(2) 36(1) 
C(12) 6779(3) 2861(3) 7946(2) 36(1) 
C(13) 7655(2) 3467(2) 8624(1) 31(1) 
C(14) 9602(2) 3174(2) 8207(1) 28(1) 
C(15) 10258(3) 4190(2) 8817(2) 34(1) 
C(16) 8974(3) 5814(2) 8824(1) 34(1) 
C(17) 7302(3) 5309(3) 8724(1) 35(1) 
C(18) 7109(3) 2697(3) 9670(2) 40(1) 
C(19) 14219(3) -6047(3) 5833(2) 46(1) 
C(1') 9684(3) 887(3) 1498(2) 52(1) 
C(2') 11195(3) 1444(4) 1067(2) 70(1) 
C(3') 11255(3) 3084(4) 1186(2) 57(1) 
C(4') 9848(3) 4084(3) 1688(2) 41(1) 
C(5') 8340(3) 3488(3) 2105(2) 35(1) 
C(6') 6832(3) 4681(3) 2609(2) 46(1) 
C(7') 5158(3) 4139(2) 2664(2) 39(1) 
C(8') 5221(2) 2355(2) 3082(1) 29(1) 
C(9') 6574(3) 1204(2) 2395(1) 32(1) 
C(10') 8232(3) 1855(3) 2028(1) 33(1) 
C(11') 6726(3) -559(3) 2856(2) 47(1) 
C(12') 5040(3) -1204(3) 3110(2) 50(1) 
C(13') 3615(3) -16(2) 3723(2) 36(1) 
C(14') 3556(2) 1730(2) 3234(1) 31(1) 
C(15') 1871(3) 2685(3) 3784(2) 40(1) 
C(16') 669(3) 1438(3) 3816(2) 45(1) 
C(17') 1811(3) -291(3) 3811(2) 45(1) 
C(19') 12703(15) 5164(10) 530(8) 60(3) 
C(19*) 12793(16) 5522(11) 830(7) 53(2) 
C(2A) 9392(3) -4091(3) 5531(2) 40(1) 
C(16A) 8695(3) 6836(3) 9638(2) 43(1) 
C(17A) 3810(3) -135(3) 4774(2) 46(1) 
C(2A') 12963(5) 565(7) 660(5) 58(2) 
C(2A*) 12413(7) 290(6) 318(3) 49(1) 
C(2B) 7709(3) -3188(3) 5377(2) 54(1) 
C(2B') 13912(7) -601(7) 718(4) 53(1) 
C(2B*) 12878(8) -1066(9) 544(5) 71(2) 
C(16C) -877(3) 1581(3) 4592(2) 46(1) 
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 Table 3: Bond lengths [Å] and angles [
o
]. 
  
O(1)-C(17) 1.199(3) O(2)-C(3) 1.385(2) 
O(2)-C(19) 1.421(3) O(1')-C(17') 1.195(3) 
O(2')-C(3') 1.392(4) O(2')-C(19') 1.425(6) 
O(2*)-C(3') 1.402(4) O(2*)-C(19*) 1.427(6) 
N(1)-C(16A) 1.136(3) N(1')-C(16C) 1.139(3) 
C(1)-C(2) 1.384(3) C(1)-C(10) 1.411(3) 
C(1)-H(1) 0.9500 C(2)-C(3) 1.399(3) 
C(2)-C(2A) 1.511(3) C(3)-C(4) 1.377(3) 
C(4)-C(5) 1.403(3) C(4)-H(4) 0.9500 
C(5)-C(10) 1.394(3) C(5)-C(6) 1.519(3) 
C(6)-C(7) 1.519(3) C(6)-H(6A) 0.9900 
C(6)-H(6B) 0.9900 C(7)-C(8) 1.529(3) 
C(7)-H(7A) 0.9900 C(7)-H(7B) 0.9900 
C(8)-C(14) 1.523(3) C(8)-C(9) 1.544(3) 
C(8)-H(8) 1.0000 C(9)-C(10) 1.528(3) 
C(9)-C(11) 1.537(3) C(9)-H(9) 1.0000 
C(11)-C(12) 1.541(3) C(11)-H(11A) 0.9900 
C(11)-H(11B) 0.9900 C(12)-C(13) 1.524(3) 
C(12)-H(12A) 0.9900 C(12)-H(12B) 0.9900 
C(13)-C(17) 1.519(3) C(13)-C(14) 1.547(3) 
C(13)-C(18) 1.548(3) C(14)-C(15) 1.532(3) 
C(14)-H(14) 1.0000 C(15)-C(16) 1.549(3) 
C(15)-H(15A) 0.9900 C(15)-H(15B) 0.9900 
C(16)-C(16A) 1.461(3) C(16)-C(17) 1.561(3) 
C(16)-H(16) 1.0000 C(18)-H(18A) 0.9800 
C(18)-H(18B) 0.9800 C(18)-H(18C) 0.9800 
C(19)-H(19A) 0.9800 C(19)-H(19B) 0.9800 
C(19)-H(19C) 0.9800 C(1')-C(2') 1.383(4) 
C(1')-C(10') 1.402(3) C(1')-H(1') 0.9500 
C(2')-C(3') 1.403(5) C(2')-C(2A') 1.504(3) 
C(2')-C(2A*) 1.547(3) C(3')-C(4') 1.378(3) 
C(4')-C(5') 1.393(3) C(4')-H(4') 0.9500 
C(5')-C(10') 1.395(3) C(5')-C(6') 1.512(3) 
C(6')-C(7') 1.515(3) C(6')-H(6'1) 0.9900 
C(6')-H(6'2) 0.9900 C(7')-C(8') 1.530(3) 
C(7')-H(7'1) 0.9900 C(7')-H(7'2) 0.9900 
C(8')-C(14') 1.517(3) C(8')-C(9') 1.541(2) 
C(8')-H(8') 1.0000 C(9')-C(10') 1.514(3) 
C(9')-C(11') 1.533(3) C(9')-H(9') 1.0000 
C(11')-C(12') 1.529(4) C(11')-H(11C) 0.9900 
C(11')-H(11D) 0.9900 C(12')-C(13') 1.535(3) 
C(12')-H(12C) 0.9900 C(12')-H(12D) 0.9900 
C(13')-C(17') 1.522(3) C(13')-C(14') 1.535(3) 
C(13')-C(17A) 1.541(3) C(14')-C(15') 1.532(3) 
C(14')-H(14') 1.0000 C(15')-C(16') 1.554(3) 
C(15')-H(15C) 0.9900 C(15')-H(15D) 0.9900 
C(16')-C(16C) 1.458(3) C(16')-C(17') 1.561(4) 
C(16')-H(16') 1.0000 C(19')-H(19D) 0.9800 
C(19')-H(19E) 0.9800 C(19')-H(19F) 0.9800 
C(19*)-H(19G) 0.9800 C(19*)-H(19H) 0.9800 
C(19*)-H(19I) 0.9800 C(2A)-C(2B) 1.506(3) 
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C(2A)-H(2A1) 0.9900 C(2A)-H(2A2) 0.9900 
C(17A)-H(17A) 0.9800 C(17A)-H(17B) 0.9800 
C(17A)-H(17C) 0.9800 C(2A')-C(2B') 1.134(7) 
C(2A')-H(2A3) 0.9900 C(2A')-H(2A4) 0.9900 
C(2A*)-C(2B*) 1.156(8) C(2A*)-H(2A5) 0.9900 
C(2A*)-H(2A6) 0.9900 C(2B)-H(2B1) 0.9800 
C(2B)-H(2B2) 0.9800 C(2B)-H(2B3) 0.9800 
C(2B')-H(2B4) 0.9800 C(2B')-H(2B5) 0.9800 
C(2B')-H(2B6) 0.9800 C(2B*)-H(2B7) 0.9800 
C(2B*)-H(2B8) 0.9800 C(2B*)-H(2B9) 0.9800 
                                            
C(3)-O(2)-C(19) 116.65(16) C(3')-O(2')-C(19') 107.1(7) 
C(3')-O(2*)-C(19*) 126.5(7) C(2)-C(1)-C(10) 123.20(18) 
C(2)-C(1)-H(1) 118.4 C(10)-C(1)-H(1) 118.4 
C(1)-C(2)-C(3) 117.25(17) C(1)-C(2)-C(2A) 123.11(18) 
C(3)-C(2)-C(2A) 119.52(17) C(4)-C(3)-O(2) 123.93(18) 
C(4)-C(3)-C(2) 121.15(18) O(2)-C(3)-C(2) 114.93(17) 
C(3)-C(4)-C(5) 120.94(19) C(3)-C(4)-H(4) 119.5 
C(5)-C(4)-H(4) 119.5 C(10)-C(5)-C(4) 119.52(17) 
C(10)-C(5)-C(6) 121.90(17) C(4)-C(5)-C(6) 118.56(18) 
C(7)-C(6)-C(5) 112.14(17) C(7)-C(6)-H(6A) 109.2 
C(5)-C(6)-H(6A) 109.2 C(7)-C(6)-H(6B) 109.2 
C(5)-C(6)-H(6B) 109.2 H(6A)-C(6)-H(6B) 107.9 
C(6)-C(7)-C(8) 109.88(17) C(6)-C(7)-H(7A) 109.7 
C(8)-C(7)-H(7A) 109.7 C(6)-C(7)-H(7B) 109.7 
C(8)-C(7)-H(7B) 109.7 H(7A)-C(7)-H(7B) 108.2 
C(14)-C(8)-C(7) 113.98(16) C(14)-C(8)-C(9) 106.83(15) 
C(7)-C(8)-C(9) 109.54(16) C(14)-C(8)-H(8) 108.8 
C(7)-C(8)-H(8) 108.8 C(9)-C(8)-H(8) 108.8 
C(10)-C(9)-C(11) 114.49(16) C(10)-C(9)-C(8) 112.20(15) 
C(11)-C(9)-C(8) 111.28(15) C(10)-C(9)-H(9) 106.1 
C(11)-C(9)-H(9) 106.1 C(8)-C(9)-H(9) 106.1 
C(5)-C(10)-C(1) 117.91(17) C(5)-C(10)-C(9) 121.76(16) 
C(1)-C(10)-C(9) 120.10(16) C(9)-C(11)-C(12) 111.49(17) 
C(9)-C(11)-H(11A) 109.3 C(12)-C(11)-H(11A) 109.3 
C(9)-C(11)-H(11B) 109.3 C(12)-C(11)-H(11B) 109.3 
H(11A)-C(11)-
H(11B) 
108.0 C(13)-C(12)-C(11) 110.71(16) 
C(13)-C(12)-H(12A) 109.5 C(11)-C(12)-H(12A) 109.5 
C(13)-C(12)-H(12B) 109.5 C(11)-C(12)-H(12B) 109.5 
H(12A)-C(12)-
H(12B) 
108.1 C(17)-C(13)-C(12) 115.86(16) 
C(17)-C(13)-C(14) 101.05(15) C(12)-C(13)-C(14) 110.14(16) 
C(17)-C(13)-C(18) 105.00(16) C(12)-C(13)-C(18) 111.09(17) 
C(14)-C(13)-C(18) 113.36(16) C(8)-C(14)-C(15) 121.82(16) 
C(8)-C(14)-C(13) 112.11(15) C(15)-C(14)-C(13) 104.03(15) 
C(8)-C(14)-H(14) 105.9 C(15)-C(14)-H(14) 105.9 
C(13)-C(14)-H(14) 105.9 C(14)-C(15)-C(16) 100.72(16) 
C(14)-C(15)-H(15A) 111.6 C(16)-C(15)-H(15A) 111.6 
C(14)-C(15)-H(15B) 111.6 C(16)-C(15)-H(15B) 111.6 
H(15A)-C(15)-
H(15B) 
109.4 C(16A)-C(16)-C(15) 117.20(18) 
C(16A)-C(16)-C(17) 112.62(18) C(15)-C(16)-C(17) 105.38(16) 
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C(16A)-C(16)-H(16) 107.0 C(15)-C(16)-H(16) 107.0 
C(17)-C(16)-H(16) 107.0 O(1)-C(17)-C(13) 128.5(2) 
O(1)-C(17)-C(16) 124.1(2) C(13)-C(17)-C(16) 107.38(16) 
C(13)-C(18)-H(18A) 109.5 C(13)-C(18)-H(18B) 109.5 
H(18A)-C(18)-
H(18B) 
109.5 C(13)-C(18)-H(18C) 109.5 
H(18A)-C(18)-
H(18C) 
109.5 H(18B)-C(18)-
H(18C) 
109.5 
O(2)-C(19)-H(19A) 109.5 O(2)-C(19)-H(19B) 109.5 
H(19A)-C(19)-
H(19B) 
109.5 O(2)-C(19)-H(19C) 109.5 
H(19A)-C(19)-
H(19C) 
109.5 H(19B)-C(19)-
H(19C) 
109.5 
C(2')-C(1')-C(10') 124.3(3) C(2')-C(1')-H(1') 117.9 
C(10')-C(1')-H(1') 117.9 C(1')-C(2')-C(3') 116.8(2) 
C(1')-C(2')-C(2A') 132.4(4) C(3')-C(2')-C(2A') 109.3(3) 
C(1')-C(2')-C(2A*) 113.2(4) C(3')-C(2')-C(2A*) 128.1(3) 
C(2A')-C(2')-C(2A*) 31.2(2) C(4')-C(3')-O(2') 131.9(4) 
C(4')-C(3')-O(2*) 114.8(4) O(2')-C(3')-O(2*) 21.5(3) 
C(4')-C(3')-C(2') 120.7(2) O(2')-C(3')-C(2') 106.4(4) 
O(2*)-C(3')-C(2') 124.4(4) C(3')-C(4')-C(5') 121.0(2) 
C(3')-C(4')-H(4') 119.5 C(5')-C(4')-H(4') 119.5 
C(4')-C(5')-C(10') 120.39(19) C(4')-C(5')-C(6') 117.7(2) 
C(10')-C(5')-C(6') 121.84(18) C(5')-C(6')-C(7') 112.41(18) 
C(5')-C(6')-H(6'1) 109.1 C(7')-C(6')-H(6'1) 109.1 
C(5')-C(6')-H(6'2) 109.1 C(7')-C(6')-H(6'2) 109.1 
H(6'1)-C(6')-H(6'2) 107.9 C(6')-C(7')-C(8') 109.51(18) 
C(6')-C(7')-H(7'1) 109.8 C(8')-C(7')-H(7'1) 109.8 
C(6')-C(7')-H(7'2) 109.8 C(8')-C(7')-H(7'2) 109.8 
H(7'1)-C(7')-H(7'2) 108.2 C(14')-C(8')-C(7') 113.65(16) 
C(14')-C(8')-C(9') 106.73(15) C(7')-C(8')-C(9') 110.38(16) 
C(14')-C(8')-H(8') 108.7 C(7')-C(8')-H(8') 108.7 
C(9')-C(8')-H(8') 108.7 C(10')-C(9')-C(11') 115.27(17) 
C(10')-C(9')-C(8') 112.66(16) C(11')-C(9')-C(8') 109.99(16) 
C(10')-C(9')-H(9') 106.1 C(11')-C(9')-H(9') 106.1 
C(8')-C(9')-H(9') 106.1 C(5')-C(10')-C(1') 116.8(2) 
C(5')-C(10')-C(9') 121.78(17) C(1')-C(10')-C(9') 121.1(2) 
C(12')-C(11')-C(9') 112.56(19) C(12')-C(11')-
H(11C) 
109.1 
C(9')-C(11')-H(11C) 109.1 C(12')-C(11')-
H(11D) 
109.1 
C(9')-C(11')-H(11D) 109.1 H(11C)-C(11')-
H(11D) 
107.8 
C(11')-C(12')-C(13') 111.35(18) C(11')-C(12')-
H(12C) 
109.4 
C(13')-C(12')-
H(12C) 
109.4 C(11')-C(12')-
H(12D) 
109.4 
C(13')-C(12')-
H(12D) 
109.4 H(12C)-C(12')-
H(12D) 
108.0 
C(17')-C(13')-C(14') 101.14(17) C(17')-C(13')-C(12') 116.19(19) 
C(14')-C(13')-C(12') 110.03(17) C(17')-C(13')-
C(17A) 
105.22(18) 
C(14')-C(13')- 113.70(18) C(12')-C(13')- 110.35(19) 
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C(17A) C(17A) 
C(8')-C(14')-C(15') 121.75(17) C(8')-C(14')-C(13') 112.53(16) 
C(15')-C(14')-C(13') 104.33(16) C(8')-C(14')-H(14') 105.7 
C(15')-C(14')-H(14') 105.7 C(13')-C(14')-H(14') 105.7 
C(14')-C(15')-C(16') 100.11(18) C(14')-C(15')-
H(15C) 
111.8 
C(16')-C(15')-
H(15C) 
111.8 C(14')-C(15')-
H(15D) 
111.8 
C(16')-C(15')-
H(15D) 
111.8 H(15C)-C(15')-
H(15D) 
109.5 
C(16C)-C(16')-
C(15') 
116.2(2) C(16C)-C(16')-
C(17') 
114.0(2) 
C(15')-C(16')-C(17') 105.34(19) C(16C)-C(16')-
H(16') 
106.9 
C(15')-C(16')-H(16') 106.9 C(17')-C(16')-H(16') 106.9 
O(1')-C(17')-C(13') 128.5(3) O(1')-C(17')-C(16') 124.3(2) 
C(13')-C(17')-C(16') 107.14(18) O(2*)-C(19*)-
H(19G) 
109.5 
O(2*)-C(19*)-
H(19H) 
109.5 H(19G)-C(19*)-
H(19H) 
109.5 
O(2*)-C(19*)-
H(19I) 
109.5 H(19G)-C(19*)-
H(19I) 
109.5 
H(19H)-C(19*)-
H(19I) 
109.5 C(2B)-C(2A)-C(2) 115.30(19) 
C(2B)-C(2A)-
H(2A1) 
108.4 C(2)-C(2A)-H(2A1) 108.4 
C(2B)-C(2A)-
H(2A2) 
108.4 C(2)-C(2A)-H(2A2) 108.4 
H(2A1)-C(2A)-
H(2A2) 
107.5 N(1)-C(16A)-C(16) 179.4(3) 
C(13')-C(17A)-
H(17A) 
109.5 C(13')-C(17A)-
H(17B) 
109.5 
H(17A)-C(17A)-
H(17B) 
109.5 C(13')-C(17A)-
H(17C) 
109.5 
H(17A)-C(17A)-
H(17C) 
109.5 H(17B)-C(17A)-
H(17C) 
109.5 
C(2B')-C(2A')-C(2') 145.0(7) C(2B')-C(2A')-
H(2A3) 
100.6 
C(2')-C(2A')-
H(2A3) 
100.6 C(2B')-C(2A')-
H(2A4) 
100.6 
C(2')-C(2A')-
H(2A4) 
100.6 H(2A3)-C(2A')-
H(2A4) 
104.3 
C(2B*)-C(2A*)-
C(2') 
120.8(5) C(2B*)-C(2A*)-
H(2A5) 
107.1 
C(2')-C(2A*)-
H(2A5) 
107.1 C(2B*)-C(2A*)-
H(2A6) 
107.1 
C(2')-C(2A*)-
H(2A6) 
107.1 H(2A5)-C(2A*)-
H(2A6) 
106.8 
C(2A)-C(2B)-
H(2B1) 
109.5 C(2A)-C(2B)-
H(2B2) 
109.5 
H(2B1)-C(2B)-
H(2B2) 
109.5 C(2A)-C(2B)-
H(2B3) 
109.5 
H(2B1)-C(2B)-
H(2B3) 
109.5 H(2B2)-C(2B)-
H(2B3) 
109.5 
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C(2A*)-C(2B*)-
H(2B7) 
109.5 C(2A*)-C(2B*)-
H(2B8) 
109.5 
H(2B7)-C(2B*)-
H(2B8) 
109.5 C(2A*)-C(2B*)-
H(2B9) 
109.5 
H(2B7)-C(2B*)-
H(2B9) 
109.5 H(2B8)-C(2B*)-
H(2B9) 
109.5 
N(1')-C(16C)-C(16') 178.0(3)   
  
Symmetry transformations used to generate equivalent atoms. 
                                                            
Table 4: Anisotropic displacement parameters (Å
2
 x 10
3
). The anisotropic 
displacement factor exponent takes the form: -2 gpi
2
 [ h
2
 a*
2
 U11 + ... + 2 h k a* b* 
U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                                
O(1) 42(1) 39(1) 60(1) -6(1) -11(1) 3(1) 
O(2) 39(1) 29(1) 45(1) -10(1) -6(1) -3(1) 
O(1') 79(1) 56(1) 69(1) -6(1) -3(1) -41(1) 
O(2') 28(2) 59(4) 49(4) 7(3) 18(2) 3(2) 
O(2*) 30(2) 77(5) 42(3) -17(2) 14(2) -3(2) 
N(1) 86(2) 49(1) 68(2) -27(1) -31(1) 7(1) 
N(1') 36(1) 76(2) 69(2) 16(1) -8(1) -10(1) 
C(1) 33(1) 30(1) 31(1) 1(1) -8(1) -6(1) 
C(2) 40(1) 28(1) 28(1) 0(1) -8(1) -8(1) 
C(3) 40(1) 24(1) 32(1) -1(1) -2(1) -7(1) 
C(4) 31(1) 27(1) 36(1) -2(1) -2(1) -6(1) 
C(5) 31(1) 30(1) 32(1) -2(1) -3(1) -9(1) 
C(6) 31(1) 35(1) 55(1) -12(1) -12(1) -4(1) 
C(7) 32(1) 34(1) 43(1) -11(1) -6(1) -8(1) 
C(8) 31(1) 26(1) 30(1) -2(1) -4(1) -9(1) 
C(9) 31(1) 30(1) 28(1) -2(1) -5(1) -6(1) 
C(10) 31(1) 26(1) 28(1) -2(1) -3(1) -6(1) 
C(11) 31(1) 35(1) 44(1) -10(1) -7(1) -6(1) 
C(12) 31(1) 36(1) 41(1) -6(1) -9(1) -3(1) 
C(13) 32(1) 29(1) 29(1) -1(1) -3(1) -5(1) 
C(14) 33(1) 28(1) 24(1) -2(1) -4(1) -8(1) 
C(15) 38(1) 29(1) 36(1) -4(1) -7(1) -7(1) 
C(16) 43(1) 27(1) 32(1) -2(1) -7(1) -7(1) 
C(17) 40(1) 34(1) 29(1) -2(1) -4(1) -5(1) 
C(18) 41(1) 39(1) 32(1) 0(1) 2(1) -9(1) 
C(19) 36(1) 36(1) 62(2) -15(1) 1(1) -5(1) 
C(1') 47(1) 47(1) 46(1) -2(1) 6(1) 8(1) 
C(2') 44(2) 71(2) 66(2) 15(1) 15(1) 14(1) 
C(3') 26(1) 85(2) 47(1) 22(1) -1(1) -2(1) 
C(4') 32(1) 54(1) 36(1) 4(1) -8(1) -10(1) 
C(5') 28(1) 43(1) 32(1) -4(1) -6(1) -5(1) 
C(6') 35(1) 34(1) 62(1) -15(1) 5(1) -9(1) 
C(7') 29(1) 27(1) 55(1) -7(1) 0(1) -2(1) 
C(8') 26(1) 25(1) 34(1) -5(1) -6(1) -1(1) 
C(9') 33(1) 29(1) 31(1) -7(1) -5(1) -2(1) 
C(10') 30(1) 41(1) 27(1) -5(1) -7(1) 2(1) 
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C(11') 47(1) 29(1) 51(1) -5(1) 4(1) 3(1) 
C(12') 61(2) 28(1) 55(1) -10(1) 5(1) -9(1) 
C(13') 39(1) 29(1) 38(1) -4(1) -5(1) -7(1) 
C(14') 30(1) 32(1) 31(1) -4(1) -6(1) -7(1) 
C(15') 27(1) 39(1) 50(1) 1(1) -7(1) -5(1) 
C(16') 35(1) 61(2) 41(1) 9(1) -12(1) -17(1) 
C(17') 52(1) 48(1) 39(1) -3(1) -6(1) -22(1) 
C(19') 31(3) 83(6) 68(6) 14(4) -7(4) -28(4) 
C(19*) 37(3) 66(4) 60(5) 13(4) -18(4) -23(3) 
C(2A) 48(1) 33(1) 42(1) -5(1) -15(1) -10(1) 
C(16A) 53(1) 29(1) 46(1) -7(1) -15(1) 0(1) 
C(17A) 52(1) 44(1) 38(1) 5(1) -9(1) -8(1) 
C(2A') 31(2) 77(3) 75(3) -44(3) -13(2) -6(2) 
C(2A*) 43(2) 59(3) 41(2) 12(2) -13(2) -3(2) 
C(2B) 48(1) 53(2) 71(2) -16(1) -24(1) -12(1) 
C(2B') 40(2) 59(3) 63(3) -12(2) -16(2) -6(2) 
C(2B*) 60(3) 77(3) 71(3) -24(3) 2(3) -12(3) 
C(16C) 33(1) 60(2) 47(1) 13(1) -16(1) -14(1) 
    
Table 5: Hydrogen coordinates ( x 10
4
) and isotropic displacement parameters (Å
2
 x 
10
3
). 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(1) 8392 -1245 6418 38 
H(4) 13665 -3729 6915 39 
H(6A) 12742 -1322 8351 47 
H(6B) 14076 -1050 7339 47 
H(7A) 12572 1530 7030 43 
H(7B) 12801 1474 8115 43 
H(8) 10006 727 8714 35 
H(9) 9688 1563 6759 36 
H(11A) 7228 347 8341 44 
H(11B) 7006 716 7252 44 
H(12A) 6931 3552 7328 43 
H(12B) 5547 2963 8246 43 
H(14) 9795 3732 7540 34 
H(15A) 11434 4364 8506 41 
H(15B) 10209 3671 9480 41 
H(16) 9406 6492 8220 41 
H(18A) 7614 3175 10102 60 
H(18B) 7498 1506 9679 60 
H(18C) 5868 2923 9892 60 
H(19A) 14888 -5225 5466 69 
H(19B) 14569 -7075 5505 69 
H(19C) 14406 -6243 6489 69 
H(1') 9626 -225 1430 63 
H(4') 9908 5197 1751 49 
H(6'1) 6845 5776 2254 55 
H(6'2) 6932 4790 3274 55 
H(7'1) 4942 4234 2008 47 
H(7'2) 4221 4857 3082 47 
H(8') 5533 2265 3720 35 
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H(9') 6120 1186 1811 38 
H(11C) 7580 -1288 2400 56 
H(11D) 7134 -596 3454 56 
H(12C) 5173 -2289 3473 60 
H(12D) 4728 -1353 2504 60 
H(14') 3410 1641 2569 37 
H(15C) 1534 3735 3426 48 
H(15D) 1916 2902 4443 48 
H(16') 311 1623 3189 54 
H(19D) 11705 5708 296 91 
H(19E) 13732 5460 81 91 
H(19F) 12616 5517 1176 91 
H(19G) 11911 6162 529 79 
H(19H) 13911 5725 448 79 
H(19I) 12609 5850 1491 79 
H(2A1) 10192 -4247 4889 48 
H(2A2) 9234 -5194 5844 48 
H(17A) 2889 624 5158 69 
H(17B) 4905 156 4776 69 
H(17C) 3761 -1262 5057 69 
H(2A3) 12972 622 -38 70 
H(2A4) 13639 1405 706 70 
H(2A5) 11852 285 -217 59 
H(2A6) 13435 804 41 59 
H(2B1) 6861 -3151 5999 81 
H(2B2) 7344 -3760 4924 81 
H(2B3) 7826 -2065 5109 81 
H(2B4) 14814 -364 986 80 
H(2B5) 14406 -1014 72 80 
H(2B6) 13334 -1434 1146 80 
H(2B7) 12890 -1168 1232 106 
H(2B8) 14027 -1423 153 106 
H(2B9) 12110 -1755 437 106 
    
Table 6: Dihedral angles [
o
] 
                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
                                                  
C(10) - C(1) - C(2) - C(3) -0.1(3) 
C(10) - C(1) - C(2) - C(2A) -176.09(19) 
C(19) - O(2) - C(3) - C(4) -13.4(3) 
C(19) - O(2) - C(3) - C(2) 166.32(19) 
C(1) - C(2) - C(3) - C(4) 0.8(3) 
C(2A) - C(2) - C(3) - C(4) 176.95(19) 
C(1) - C(2) - C(3) - O(2) -178.87(17) 
C(2A) - C(2) - C(3) - O(2) -2.7(3) 
O(2) - C(3) - C(4) - C(5) 177.83(18) 
C(2) - C(3) - C(4) - C(5) -1.8(3) 
C(3) - C(4) - C(5) - C(10) 2.1(3) 
C(3) - C(4) - C(5) - C(6) -176.39(19) 
C(10) - C(5) - C(6) - C(7) -19.6(3) 
C(4) - C(5) - C(6) - C(7) 158.81(18) 
C(5) - C(6) - C(7) - C(8) 50.6(2) 
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C(6) - C(7) - C(8) - C(14) 174.77(17) 
C(6) - C(7) - C(8) - C(9) -65.6(2) 
C(14) - C(8) - C(9) - C(10) 171.08(14) 
C(7) - C(8) - C(9) - C(10) 47.2(2) 
C(14) - C(8) - C(9) - C(11) -59.17(19) 
C(7) - C(8) - C(9) - C(11) 176.93(16) 
C(4) - C(5) - C(10) - C(1) -1.4(3) 
C(6) - C(5) - C(10) - C(1) 177.08(19) 
C(4) - C(5) - C(10) - C(9) -175.85(17) 
C(6) - C(5) - C(10) - C(9) 2.6(3) 
C(2) - C(1) - C(10) - C(5) 0.4(3) 
C(2) - C(1) - C(10) - C(9) 174.99(17) 
C(11) - C(9) - C(10) - C(5) -144.74(18) 
C(8) - C(9) - C(10) - C(5) -16.7(2) 
C(11) - C(9) - C(10) - C(1) 40.9(2) 
C(8) - C(9) - C(10) - C(1) 168.96(16) 
C(10) - C(9) - C(11) - C(12) -174.11(16) 
C(8) - C(9) - C(11) - C(12) 57.4(2) 
C(9) - C(11) - C(12) - C(13) -54.1(2) 
C(11) - C(12) - C(13) - C(17) 168.04(17) 
C(11) - C(12) - C(13) - C(14) 54.2(2) 
C(11) - C(12) - C(13) - C(18) -72.3(2) 
C(7) - C(8) - C(14) - C(15) -54.2(2) 
C(9) - C(8) - C(14) - C(15) -175.35(16) 
C(7) - C(8) - C(14) - C(13) -178.27(16) 
C(9) - C(8) - C(14) - C(13) 60.60(19) 
C(17) - C(13) - C(14) - C(8) 177.37(15) 
C(12) - C(13) - C(14) - C(8) -59.6(2) 
C(18) - C(13) - C(14) - C(8) 65.6(2) 
C(17) - C(13) - C(14) - C(15) 43.89(17) 
C(12) - C(13) - C(14) - C(15) 166.91(16) 
C(18) - C(13) - C(14) - C(15) -67.93(19) 
C(8) - C(14) - C(15) - C(16) -172.78(16) 
C(13) - C(14) - C(15) - C(16) -45.08(18) 
C(14) - C(15) - C(16) - C(16A) 154.63(19) 
C(14) - C(15) - C(16) - C(17) 28.47(19) 
C(12) - C(13) - C(17) - O(1) 35.5(3) 
C(14) - C(13) - C(17) - O(1) 154.5(2) 
C(18) - C(13) - C(17) - O(1) -87.5(3) 
C(12) - C(13) - C(17) - C(16) -143.90(17) 
C(14) - C(13) - C(17) - C(16) -24.92(19) 
C(18) - C(13) - C(17) - C(16) 93.16(18) 
C(16A) - C(16) - C(17) - O(1) 49.6(3) 
C(15) - C(16) - C(17) - O(1) 178.50(19) 
C(16A) - C(16) - C(17) - C(13) -131.00(18) 
C(15) - C(16) - C(17) - C(13) -2.1(2) 
C(10') - C(1') - C(2') - C(3') 0.7(4) 
C(10') - C(1') - C(2') - C(2A') 165.2(4) 
C(10') - C(1') - C(2') - C(2A*) -165.1(3) 
C(19') - O(2') - C(3') - C(4') -1.0(8) 
C(19') - O(2') - C(3') - O(2*) -43.2(19) 
C(19') - O(2') - C(3') - C(2') 167.5(5) 
C(19*) - O(2*) - C(3') - C(4') -13.1(9) 
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C(19*) - O(2*) - C(3') - O(2') 133(3) 
C(19*) - O(2*) - C(3') - C(2') 169.9(6) 
C(1') - C(2') - C(3') - C(4') -1.7(4) 
C(2A') - C(2') - C(3') - C(4') -169.6(4) 
C(2A*) - C(2') - C(3') - C(4') 161.7(3) 
C(1') - C(2') - C(3') - O(2') -171.7(4) 
C(2A') - C(2') - C(3') - O(2') 20.3(5) 
C(2A*) - C(2') - C(3') - O(2') -8.4(6) 
C(1') - C(2') - C(3') - O(2*) 175.2(5) 
C(2A') - C(2') - C(3') - O(2*) 7.2(7) 
C(2A*) - C(2') - C(3') - O(2*) -21.5(7) 
O(2') - C(3') - C(4') - C(5') 168.2(5) 
O(2*) - C(3') - C(4') - C(5') -176.0(5) 
C(2') - C(3') - C(4') - C(5') 1.1(4) 
C(3') - C(4') - C(5') - C(10') 0.6(3) 
C(3') - C(4') - C(5') - C(6') -177.5(2) 
C(4') - C(5') - C(6') - C(7') 156.6(2) 
C(10') - C(5') - C(6') - C(7') -21.4(3) 
C(5') - C(6') - C(7') - C(8') 50.9(3) 
C(6') - C(7') - C(8') - C(14') 175.97(17) 
C(6') - C(7') - C(8') - C(9') -64.2(2) 
C(14') - C(8') - C(9') - C(10') 169.39(16) 
C(7') - C(8') - C(9') - C(10') 45.4(2) 
C(14') - C(8') - C(9') - C(11') -60.5(2) 
C(7') - C(8') - C(9') - C(11') 175.54(18) 
C(4') - C(5') - C(10') - C(1') -1.6(3) 
C(6') - C(5') - C(10') - C(1') 176.5(2) 
C(4') - C(5') - C(10') - C(9') -174.52(19) 
C(6') - C(5') - C(10') - C(9') 3.5(3) 
C(2') - C(1') - C(10') - C(5') 0.9(4) 
C(2') - C(1') - C(10') - C(9') 173.9(3) 
C(11') - C(9') - C(10') - C(5') -143.1(2) 
C(8') - C(9') - C(10') - C(5') -15.7(3) 
C(11') - C(9') - C(10') - C(1') 44.3(3) 
C(8') - C(9') - C(10') - C(1') 171.62(19) 
C(10') - C(9') - C(11') - C(12') -173.77(18) 
C(8') - C(9') - C(11') - C(12') 57.5(2) 
C(9') - C(11') - C(12') - C(13') -52.4(3) 
C(11') - C(12') - C(13') - C(17') 165.3(2) 
C(11') - C(12') - C(13') - C(14') 51.2(3) 
C(11') - C(12') - C(13') - C(17A) -75.1(3) 
C(7') - C(8') - C(14') - C(15') -50.9(3) 
C(9') - C(8') - C(14') - C(15') -172.76(18) 
C(7') - C(8') - C(14') - C(13') -175.74(17) 
C(9') - C(8') - C(14') - C(13') 62.3(2) 
C(17') - C(13') - C(14') - C(8') 178.25(16) 
C(12') - C(13') - C(14') - C(8') -58.4(2) 
C(17A) - C(13') - C(14') - C(8') 66.0(2) 
C(17') - C(13') - C(14') - C(15') 44.3(2) 
C(12') - C(13') - C(14') - C(15') 167.69(19) 
C(17A) - C(13') - C(14') - C(15') -68.0(2) 
C(8') - C(14') - C(15') - C(16') -174.36(18) 
C(13') - C(14') - C(15') - C(16') -45.8(2) 
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C(14') - C(15') - C(16') - C(16C) 156.31(19) 
C(14') - C(15') - C(16') - C(17') 29.1(2) 
C(14') - C(13') - C(17') - O(1') 152.9(3) 
C(12') - C(13') - C(17') - O(1') 33.8(4) 
C(17A) - C(13') - C(17') - O(1') -88.6(3) 
C(14') - C(13') - C(17') - C(16') -24.6(2) 
C(12') - C(13') - C(17') - C(16') -143.6(2) 
C(17A) - C(13') - C(17') - C(16') 94.0(2) 
C(16C) - C(16') - C(17') - O(1') 51.0(3) 
C(15') - C(16') - C(17') - O(1') 179.5(2) 
C(16C) - C(16') - C(17') - C(13') -131.4(2) 
C(15') - C(16') - C(17') - C(13') -2.9(2) 
C(1) - C(2) - C(2A) - C(2B) -1.6(3) 
C(3) - C(2) - C(2A) - C(2B) -177.5(2) 
C(15) - C(16) - C(16A) - N(1) -174(100) 
C(17) - C(16) - C(16A) - N(1) -52(36) 
C(1') - C(2') - C(2A') - C(2B') -30.0(13) 
C(3') - C(2') - C(2A') - C(2B') 135.4(10) 
C(2A*) - C(2') - C(2A') - C(2B') -91.5(11) 
C(1') - C(2') - C(2A*) - C(2B*) -58.5(8) 
C(3') - C(2') - C(2A*) - C(2B*) 137.6(7) 
C(2A') - C(2') - C(2A*) - C(2B*) 76.6(8) 
C(15') - C(16') - C(16C) - N(1') 96(9) 
C(17') - C(16') - C(16C) - N(1') -142(9) 
                                         
Symmetry transformations used to generate equivalent atoms.  
